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Abstract 
 The human immunodeficiency virus accessory protein Vif protects the viral 
genome from the mutational activity of APOBEC3 subfamily DNA cytosine deaminases 
by facilitating their proteasomal degradation, thereby preserving viral infectivity. A 
comprehensive understanding of the components of the Vif-APOBEC3 interaction is 
therefore important for consideration of the potential for novel antiretroviral approaches 
aimed at modulating this critical host-pathogen interaction. Here, we establish 
APOBEC3F among the seven subfamily members as a valid model for the study of the 
APOBEC3-Vif interaction. By utilizing this model as a starting point, we further define 
the APOBEC3-Vif interaction sites in each protein and the downstream ubiquitin 
acceptor sites modified en route to APOBEC3 degradation, in the process deriving 
broader insights into the nature of the interactions between different APOBEC3 proteins 
and Vif. In contrast with the diversiform APOBEC3-Vif interactions proposed in the 
extant literature, we find that the interaction of Vif with different APOBEC3 proteins 
likely proceeds through a conserved helix-helix interaction. Even if one were to 
successfully block this interaction for therapeutic purposes, however, the virus may 
develop accessory mechanisms of APOBEC3 evasion to bypass the intervention. While 
we find that this can occur, present evidence suggests that such alternatives may be 
insufficient to circumvent restriction in cells that naturally express multiple APOBEC3 
proteins. Thus, it may be possible to potentiate the action of multiple endogenous 
antiretroviral proteins to counteract human immunodeficiency virus infection by targeting 
a conserved interaction motif as described herein. 
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Preface 
 Human immunodeficiency virus type 1 (HIV), the causative agent of acquired 
immunodeficiency syndrome (AIDS), has sparked a global pandemic of staggering 
proportions. In 2011, 2.5 million new infections against 1.7 million deaths brought the 
total number of people living with HIV to more than 34 million on top of approximately 
30 million dead since 1981 (UNAIDS, 2010a, b, 2012). While advances in antiretroviral 
therapy have commuted the automatic death sentence imposed by the virus in the early 
years of the pandemic, HIV infection remains fundamentally incurable. Approaches to 
managing the associated disease burden now focus on three main areas - preventing 
infection, extending extant therapies to those who cannot readily access them and 
searching for new methods to combat the virus. 
 As in all of medicine, prevention is the cornerstone of good health. When 
prevention fails, current antiretroviral regimens can effectively quarantine the virus 
indefinitely, but these drugs must be taken continuously and are limited both by their 
side-effects and by the ability of HIV to acquire resistance mutations that may render a 
given drug class ineffective. Given these limitations, extensive resources are still directed 
toward basic research aimed at the discovery of new therapeutic options that might 
increase and improve the strategies available to clinicians or, in the ideal scenario, proffer 
a path to a cure. 
 Among these discovery-oriented endeavors, one of the most promising 
breakthroughs of the last decade has been the description of host restriction factors 
including APOBEC3G, TRIM5α, BST-2/tetherin and SAMHD1 [reviewed in (Harris et 
  2 
al., 2012; Malim and Bieniasz, 2012)]. These host restriction factors are cellular proteins 
that have innate antiviral activities that must be counteracted by HIV to facilitate viral 
spread, as opposed to host dependency factors, which are cellular proteins that the virus 
requires to complete its lifecycle. APOBEC3G is a DNA cytosine deaminase that 
introduces massive levels of mutation into the HIV genome that render the virus 
nonfunctional in the absence of the virus accessory protein Vif, which degrades 
APOBEC3G to prevent its antiviral functions (see Chapter 1). TRIM5α is a tripartite 
motif-containing family protein that recognizes the retroviral capsid, interrupting viral 
replication by stimulating premature uncoating and enhanced immune recognition, the 
effects of which can be counteracted by simple mutations in the viral capsid that ablate 
binding of TRIM5α (Pertel et al., 2011; Sayah et al., 2004; Stremlau et al., 2004; Towers 
et al., 2003). Mechanistically removed from the reverse transcription-centric nature of the 
first two factors, BST-2/tetherin is a GPI-anchored transmembrane protein that literally 
tethers HIV and other enveloped viruses to the cell surface to prevent their release and is 
counteracted by the degradative functions of the viral accessory protein Vpu - or, in 
related viruses, the viral Env or Nef proteins [(Neil et al., 2008; Van Damme et al., 2008) 
and reviewed in (Douglas et al., 2010)]. Finally, the latest restriction factor to be 
described is SAMHD1, a deoxynucleoside triphosphate triphosphohydrolase that 
maintains deoxynucleoside triphosphate levels in myeloid lineage cells at levels 
incompatible with viral replication and is counteracted by the lentiviral Vpx accessory 
protein (Berger et al., 2011a; Goldstone et al., 2011; Hrecka et al., 2011; Laguette et al., 
2011; Powell et al., 2011). 
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 Throughout evolutionary history, then, there has existed a conflict between 
retroviruses and the host defense proteins aimed at controlling their replication, many of 
which likely remain undiscovered. It is not known how these defenses evolved or how 
important they have been to the control of exogenous viruses over time, but they may be 
maintained, at least in part, for the purpose of controlling the endogenous retroelements 
most commonly encountered by a cell - those comprising half of its own genome. As 
stated above, however, these proteins collectively carry therapeutic promise since a 
retrovirus must carry out some action in order to counteract them, generally via the 
functions of accessory proteins. Where there is an interaction, then, there is a potential 
novel antiretroviral therapeutic target. 
 This dissertation focuses on the potential for interrupting the degradation of 
APOBEC3 subfamily proteins by the viral accessory protein Vif, which in turn may 
liberate APOBEC3 proteins to carry out their antiretroviral functions. In considering this 
possibility, it is important to make two key distinctions between APOBEC3 proteins and 
all extant drugs and known restriction factors. First, there are at least six APOBEC3 
proteins in addition to APOBEC3G, all of which have been shown under one condition or 
another to have anti-HIV activity (see Chapter 1). Effectively neutralizing Vif, then, 
would theoretically result in the potentiation of multiple antiretroviral proteins, yielding a 
sort of endogenous combinatorial antiretroviral therapy. Second, the mechanism of 
APOBEC3 restriction involves the introduction into the HIV genome of mutation levels 
incompatible with survival and spread. Once this genetic information is scrambled, it is 
difficult if not impossible for the virus to recover what was lost, and there are many such 
examples of viruses that have become "endogenized" in genomes over time through loss 
  4 
of function [reviewed in (Stoye, 2012)]. APOBEC3 proteins do not just inactivate or 
neutralize a viral particle like all other known antiretroviral drugs and naturally occurring 
restriction factors - they destroy the genome that makes the virus what it is. As such, it is 
at least hypothetically possible that bombarding HIV with these innate defense proteins 
may represent not only a novel therapy, but also a potentially curative approach. In 
considering this dissertation, it is my hope that the reader will recognize the basis for 
believing that such things, while hardly imminent, are possible. 
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Chapter 1: Introduction 
 
FOREWORD 
The text comprising this chapter is an updated amalgamation of the following references 
reproduced in sections with permission: 
  
 Albin JS and Harris RS. Interactions of host APOBEC3 restriction factors with  
 HIV-1 in vivo: implications for therapeutics.” Expert Reviews in Molecular 
 Medicine. 2010; 12 (e4): 1-26 
  
 Albin JS and Harris RS. APOBEC3 proteins and their roles in HIV proviral DNA 
 synthesis. Chapter 14 in Human Immunodeficiency Virus Reverse Transcriptase:  
 a 25-year Success Story. Ed. SF LeGrice, in press 
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Overview of APOBEC3 Proteins and Vif 
The human genome has a total of seven APOBEC3 DNA cytosine deaminase genes 
arrayed on chromosome 22 (A3A, A3B, A3C, A3D, A3F, A3G and A3H), the result of a 
series of tandem duplications that have expanded the locus throughout primate evolution 
(Conticello, 2008; LaRue et al., 2009; LaRue et al., 2008). This expansion, combined 
with evidence for strong positive selection among most of these APOBEC3 genes, 
suggests that a primary function of their protein products is defense of the genome 
against any number of retroelements encountered throughout evolution (Duggal et al., 
2011; OhAinle et al., 2006; Sawyer et al., 2004). The list of retroelements for which 
direct evidence of APOBEC3 restriction exists currently includes endogenous LTR and 
non-LTR retrotransposons as well as exogenous members of the Hepadnaviridae and 
Retroviridae families [e.g. (Bogerd et al., 2006b; Derse et al., 2007; Esnault et al., 2005; 
Esnault et al., 2006; Harris et al., 2003a; Löchelt et al., 2005; Mangeat et al., 2003; 
Muckenfuss et al., 2006; Navarro et al., 2005; Okeoma et al., 2007; Russell et al., 2005; 
Sheehy et al., 2002; Stenglein and Harris, 2006; Turelli et al., 2004)]. 
 Chief among the examples of viruses restricted by APOBEC3 proteins is the 
prototypical lentivirus human immunodeficiency virus type 1 (HIV-1, hereafter 
abbreviated HIV). In addition to gag, pol and env genes, lentiviruses possess several 
accessory genes that have integral roles in viral pathogenesis [recently reviewed by 
(Gramberg et al., 2009; Malim and Emerman, 2008)]. In HIV, these include two 
accessory genes involved in the regulation of viral gene expression and four additional 
accessory genes more directly involved in pathogenesis. One of these is vif, the virion 
infectivity factor, which is located in the center of the HIV genome overlapping the 3’ 
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end of pol and the 5’ end of the accessory gene vpr. Expressed from a partially spliced, 
Rev-dependent subgenomic mRNA (Garrett et al., 1991; Schwartz et al., 1991), the 
protein product is 192 residues, highly basic and 23 kDa in size (Kan et al., 1986; Lee et 
al., 1986; Sodroski et al., 1986). 
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HIV Vif and the Discovery of APOBEC3 Proteins 
Vif is required for productive infection in vivo and for infection of primary CD4+ T cells, 
monocytes, and macrophages ex vivo (Desrosiers et al., 1998; Gabuzda et al., 1992; 
Gabuzda et al., 1994; Strebel et al., 1987). This requirement, however, is variable in 
some human T cell lines (Fisher et al., 1987), allowing these lines to be grouped as 
‘permissive’ for the replication of Vif-deficient HIV (e.g. CEM-SS, SupT1) or 
‘nonpermissive’ (e.g. CEM, H9). When produced in permissive cells, virions from Vif-
deficient HIV have no quantitative or qualitative defects relative to wildtype virus except 
for the absence of the Vif protein itself. (Fisher et al., 1987; Strebel et al., 1987). When 
produced in nonpermissive cells, however, Vif-deficient HIV virions rarely complete 
reverse transcription (Courcoul et al., 1995; Goncalves et al., 1996; Simon and Malim, 
1996; Sova and Volsky, 1993). 
 Given the above, two scenarios were considered likely to explain the phenotype 
of Vif-deficient viruses on nonpermissive cells: (1) permissive cells contain an 
endogenous factor that complements the function lacking in a Vif-deficient virus or (2) 
nonpermissive cells contain a Vif-suppressible factor with antiviral restriction activity. 
To determine which hypothesis was correct, two groups tested the infectivity of virions 
produced from heterokaryons formed by the fusion of permissive and nonpermissive cells 
(Madani and Kabat, 1998; Simon et al., 1998). Under these conditions, the production of 
infectious virions would support the former hypothesis, while the production of 
noninfectious virions would support the latter. In fact, such heterokaryons formed from 
the fusion of permissive and nonpermissive cells produce virions with diminished 
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infectivity, indicating that nonpermissive cells contain a Vif-sensitive dominant 
restriction factor. 
 To identify the cellular factor suggested by cell fusion experiments, Sheehy et al. 
sought to isolate genes uniquely expressed in a nonpermissive cell line called CEM 
(Sheehy et al., 2002) by suppression subtractive hybridization, which simultaneously 
suppresses the recovery of transcripts common to CEM and its permissive derivative 
CEM-SS and enriches the recovery of transcripts that are more abundant in CEM. Among 
many sequences, a cDNA encoding APOBEC3G (A3G) was isolated, and engineering 
naturally permissive CEM-SS cells to express A3G rendered these cells nonpermissive 
for the replication of Vif-deficient but not wildtype virus. A3G therefore accounts for the 
nonpermissive phenotype of CEM, although a number of studies since then suggest that 
other APOBEC3 proteins may also contribute to the nonpermissive phenotype (Table 1-
1). Of particular note, passage of Vif-deficient HIV on permissive T cells stably 
transfected with A3G yields viral variants that grow efficiently in the presence of A3G 
but not in CEM cells (Haché et al., 2008), implying that other factors beyond A3G are 
also capable of restricting HIV in nonpermissive cells. 
 At approximately the same time, two other groups independently identified A3G, 
not for its antiviral activity but rather for its enzymatic activity, which provided a crucial 
clue about the mechanism by which A3G might restrict HIV. Jarmuz et al. identified 
A3G as part of a family of polynucleotide cytosine deaminases related to the mRNA-
editing enzyme APOBEC1, which edits the apolipoprotein B mRNA (Jarmuz et al., 
2002). The acronym APOBEC derives from APOBEC1 and stands for ‘apolipoprotein B 
mRNA editing, catalytic polypeptide’; human APOBEC3 proteins are designated 
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‘apolipoprotein B mRNA editing, catalytic polypeptide-like 3’ followed by the letter, A–
H, identifying the specific protein. Meanwhile, Harris and colleagues hypothesized, based 
on homology between APOBEC1 and the DNA mutator activation-induced deaminase 
(AID), which is involved in antibody diversification, that APOBEC1 and its homologues 
can act on DNA substrates. Indeed, APOBEC1, A3G, A3C and AID were all shown to 
mutate DNA (Harris et al., 2002; Petersen-Mahrt et al., 2002). 
 Putting the enzymatic and restrictive abilities of A3G together, several groups 
soon thereafter established that A3G restricts HIV by introducing massive numbers of C-
to-U transitions in the viral minus strand cDNA during reverse transcription in target 
cells (Harris et al., 2003a; Lecossier et al., 2003; Mangeat et al., 2003; Zhang et al., 
2003). These transitions may then either trigger the degradation of viral cDNA or impede 
reverse transcription (see below) to decrease overall reverse transcript accumulation or 
they may become fixed, manifesting as plus-strand G-to-A hypermutation that yields a 
presumably hypofunctional mutant virus (Figure 1-1A). To prevent this from happening, 
Vif links A3G in producer cells to an E3 ubiquitin ligase complex, thus facilitating its 
proteasomal degradation and permitting the production of relatively A3G-free virions that 
can successfully complete reverse transcription in target cells (Figure 1-1B). 
 While discussion to this point has focused on a basic description of the 
interactions between Vif and A3G, all of the six additional proteins in the APOBEC3 
subfamily – A3A, A3B, A3C, A3D, A3F and A3H – have been implicated at some point 
in the mutation and/or restriction of HIV under certain conditions. A summary of 
references with data concerning the restriction activity and Vif sensitivity of each 
APOBEC3 protein is provided in Table 1-1. 
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 While the results apparent in Table 1-1 do reflect a lack of consensus on the 
ability of certain APOBEC3 proteins to function against HIV, there are areas of 
agreement. Most notably, it is well accepted that A3F and, more prominently, A3G have 
strong activity against HIV, although a pair of recent reports have impugned the ability of 
stably expressed A3F to restrict the virus (in contrast with Chapters 2, 3, 5 and 6 of this 
thesis as well as Supplementary Chapter 2), leaving A3G as the only universally agreed 
upon APOBEC3 antagonist of HIV (Miyagi et al., 2010; Mulder et al., 2010). Beyond 
A3F and A3G, there is a second tier consisting of A3B and A3D where antiviral activity 
is generally reproducible in overexpression single-cycle infectivity assays but may not be 
apparent in a more physiologic spreading infection system. Recent results from our lab 
have supported a minor role for A3D in the restriction of HIV and a somewhat more 
robust role for this APOBEC3 protein in the hypermutation of the virus, but these studies 
failed to note an effect of A3B on HIV outside of 293T overexpression systems 
(Hultquist et al., 2011; Refsland et al., 2012). That said, the fact that A3B expression 
increases significantly in lymphoid tissue from acutely infected patients along with A3F 
and A3G (Li et al., 2009) combined with the previously reported correlation between 
A3B haplotypes and clinical indicators of disease may also suggest a role for this Vif-
insensitive protein in vivo [(An et al., 2009) and see below]. 
 A3H represents a special case since only two known allelic variants appear to 
encode a stable protein, and stability is required for its ability to effectively restrict HIV 
(Harari et al., 2009; OhAinle et al., 2008; Tan et al., 2009; Wang et al., 2011a). A3C has 
historically been something of an enigma among the APOBEC3 proteins, well-expressed 
in many cells and tissues but with no consistent phenotype of any kind, let alone a 
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reliable restrictive effect against HIV, despite its exquisite Vif sensitivity [(Refsland et 
al., 2010) and Table 1-1]. It should be noted, however, that A3C is quite active against 
simian immunodeficiency virus (Yu et al., 2004a). 
 In an attempt to bring some order to the often contradictory reports listed in Table 
1-1, our lab has recently published two studies assessing the restriction capacity of all 
seven APOBEC3 proteins in T cells, which offers the advantage of direct comparison in 
consistent systems as opposed to a patchwork of many systems in many hands with many 
divergent goals. By either stable expression of each of the APOBEC3 proteins in 
APOBEC3-deficient T cell lines or by the knockout or knockdown of endogenous 
APOBEC3 proteins in naturally nonpermissive cells, these studies have converged on 
four APOBEC3 proteins as the components of the repertoire relevant to the restriction 
and hypermutation of HIV in T cells – A3D, A3F, A3G and A3H (Hultquist et al., 2011; 
Refsland et al., 2012). 
 While some case can thus be made for the ability of six of seven human 
APOBEC3 proteins to dominantly restrict HIV in T cells, particularly A3D, A3F, A3G 
and A3H, there are few findings to support such a role for A3A. The caveat to this is that 
some authors have proposed A3A as a source of sequence diversification in HIV given its 
expression and apparent mutational activity in myeloid lineage cells (Koning et al., 2011; 
Koning et al., 2009; Refsland et al., 2010; Thielen et al., 2010). Some have even 
proposed A3A as the long-sought Vpx-suppressible myeloid cell restriction factor 
(Berger et al., 2010; Berger et al., 2011b; Peng et al., 2007), consistent with its role in the 
clearance of foreign DNA from myeloid cells (Stenglein et al., 2010). Nevertheless, there 
is presently a movement toward acceptance of the deoxyribonucleoside triphosphate 
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triphosphohydrolase SAMHD1 as “the” Vpx-suppressible suppressor of HIV reverse 
transcription in myeloid cells (Berger et al., 2011a; Goldstone et al., 2011; Hrecka et al., 
2011; Laguette et al., 2011; Powell et al., 2011). Whether A3A and SAMHD1 act in 
concert remains unknown. 
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Mechanisms of Restriction 
Restriction by APOBEC3 proteins is dependent on their expression in virus producing 
cells and on their encapsidation during virus assembly [(Harris et al., 2003a; Mangeat et 
al., 2003; Zhang et al., 2003) and Figure 1-1A-B]. This is thought to occur via an 
association of APOBEC3 proteins with the viral nucleocapsid protein via an RNA bridge 
(Alce and Popik, 2004; Bogerd and Cullen, 2008; Cen et al., 2004; Luo et al., 2004; 
Schafer et al., 2004; Svarovskaia et al., 2004; Zennou et al., 2004). In particular, this 
interaction may be facilitated by the cellular RNA 7SL, which is selectively packaged 
into HIV virions (Tian et al., 2007; Wang et al., 2007; Wang et al., 2008). The 
importance of RNA in facilitating the encapsidation of APOBEC3 proteins is further 
supported by the observation that mutations in the N-terminus of A3G that ablate RNA 
binding also ablate Gag interaction, encapsidation and, consequently, restriction (Friew et 
al., 2009; Huthoff et al., 2009; Huthoff and Malim, 2007; Navarro et al., 2005). In total, 
it is thought that 7 ± 4 molecules of A3G are packaged per particle and that as few as one 
may be measurably antiviral (Browne et al., 2009; Xu et al., 2007). 
 Once associated with the viral core, APOBEC3 proteins are positioned to exert 
their restrictive activities upon nascent reverse transcribed cDNA in target cells. 
Interpretations of the relative importance of different putative mechanisms of A3G 
inhibition of HIV may vary, but a broad point of unity in the field is that deamination is a 
major component of the restriction mechanism, as initially proposed [(Harris et al., 
2003a; Mangeat et al., 2003; Zhang et al., 2003) and see Deaminase-independent 
Restriction Mechanisms below as well as Supplementary Chapter 2]. Thus, we begin a 
consideration of the impact of APOBEC3 proteins on proviral DNA synthesis with a 
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more detailed rendering of the deamination process, focusing on the prototypical 
APOBEC3 protein A3G, but with the understanding that other APOBEC3 proteins are 
thought to work similarly. 
 
A3G Deamination and Hypermutation – The polynucleotide intermediates that occur in 
the course of HIV reverse transcription include the single-stranded RNA genome 
(ssRNA), a DNA:RNA heteroduplex following synthesis of the minus-strand cDNA 
templated by the plus-strand RNA genome, single-stranded DNA (ssDNA) resulting from 
RNase H degradation of the plus-strand ssRNA template after minus-strand synthesis, 
and double-stranded DNA (dsDNA) after completion of the plus-strand cDNA (Figure 1-
2A-D). Among these, A3G is capable of binding to both ssRNA and ssDNA (Iwatani et 
al., 2006; Yu et al., 2004b). Binding to ssRNA is thought to segregate A3G into 
enzymatically-inactive high molecular mass complexes (Chelico et al., 2006; Wedekind 
et al., 2006), and this may also be true of association between A3G and viral genomic 
ssRNA (Soros et al., 2007). In its low molecular mass form, however, A3G is capable of 
deaminating ssDNA substrates (Harris et al., 2003a; Iwatani et al., 2006; Suspène et al., 
2004; Yu et al., 2004b). This ssDNA specificity is reinforced by the observation that 
there are two gradients of 5’  3’ increasing levels of hypermutation in the viral genome, 
one from the primer binding site to the central polypurine tract and another from the 
central polypurine tract to the 3’ polypurine tract (Suspène et al., 2006; Yu et al., 2004b). 
Thus, there is a correlation between the most heavily deaminated regions of the viral 
genome and those regions of the minus-strand that remain single-stranded for the longest 
duration during reverse transcription. 
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 Some authors have noted an increased C-to-T transition rate in the viral plus-
strand as well, particularly with A3F (Albin et al., 2010a; Bishop et al., 2004; Liddament 
et al., 2004; Yu et al., 2004b). It is not clear whether these represent a modest ability of 
A3F to deaminate RNA, RNA:DNA heteroduplex or dsDNA templates or a more 
mundane phenomenon such as transient ssDNA states within the predominantly double-
stranded context in which the plus-strand generally exists. Regardless, there is no 
evidence for A3G activity on any non-ssDNA substrate, including free nucleosides 
(Iwatani et al., 2006; Suspène et al., 2004). 
 While A3G is termed a “deaminase”, it actually consists of two conserved 
deaminase motifs, N- and C-terminal. Between these, only the C-terminus is capable of 
deaminating ssDNA cytosine to uracil (Haché et al., 2005; Iwatani et al., 2006; Langlois 
et al., 2005; Navarro et al., 2005; Newman et al., 2005). The catalytically inactive N-
terminus, in contrast, is more important for binding to single-stranded nucleic acid 
substrates, an activity that mediates RNA-dependent oligomerization and encapsidation 
and that may also help orient A3G for processive deamination (Chelico et al., 2010; 
Friew et al., 2009; Gooch and Cullen, 2008; Huthoff et al., 2009; Huthoff and Malim, 
2007; Li et al.; Navarro et al., 2005). Although it has been proposed that monomeric 
A3G may also be capable of encapsidation, deamination and restriction (Opi et al., 2006), 
recent evidence suggests the particular mutant employed in this study, while monomeric, 
may not actually encapsidate, raising the question of whether its apparent ability to 
restrict represents a specific effect on HIV or a nonspecific poisoning of producer cells 
[(Friew et al., 2009; Shlyakhtenko et al., 2011) and Mueller & Harris Labs, unpublished 
data]. 
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 Deamination by A3G appears to occur in the 3’  5’ direction (Chelico et al., 
2006; Furukawa et al., 2009) and can proceed from 3 to at least 100 nucleotides along 
ssDNA substrates in the absence of any associated cofactors (Chelico et al., 2006). 
Although, as stated above, the C-terminal domain is required for actual catalysis, the 
inactive N-terminal deaminase domain is important for regulating the directionality and 
processivity of deamination (Chelico et al., 2010). Movement of the enzyme from one 
region of ssDNA to another may be achieved through some combination of random 
“jumping” motions to different segments (Chelico et al., 2006) and/or via intersegmental 
“transfers” in which the simultaneous binding of A3G to distinct ssDNA segments may 
facilitate its movement from one region to another (Nowarski et al., 2008). 
 The oligomeric form of A3G that mediates deamination in the context of infection 
is not entirely clear. Some in vitro data have implicated A3G monomers as the 
enzymatically active form (Nowarski et al., 2008), others dimers (Chelico et al., 2006; 
Shlyakhtenko et al., 2011). Atomic force microscopy studies that visualize A3G bound to 
ssDNA substrates have found a range of oligomeric forms, with a predominance of 
monomers and higher order oligomers (Chelico et al., 2010; Chelico et al., 2008), 
although more recent evidence derived from a refinement of this technique suggests a 
model in which unbound A3G, in agreement with the aforementioned prior studies, is 
predominantly monomeric, while bound A3G can take on a dimeric form with substantial 
components of monomers and higher order oligomers also apparent (Shlyakhtenko et al., 
2011). Although oligomerization of A3G does not appear to be required for deaminase 
activity (Chelico et al., 2010), the existence of these oligomeric forms may promote 
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enzyme processivity (Chelico et al., 2008) or the ability of A3G to “jump” or “transfer” 
to new substrates (Feng and Chelico, 2011; Nowarski et al., 2008). 
 Different APOBEC3 proteins exhibit different dinucleotide preferences for 
deamination, with A3G preferring 5’-CC-3’ dinucleotides (5’-GG-3’ on the plus-strand), 
often within a broader 5’-CCCA-3’ context (5’-TGGG on the plus-strand) [e.g. (Beale et 
al., 2004; Harris et al., 2003a; Harris et al., 2002; Mangeat et al., 2003; Yu et al., 2004b; 
Zhang et al., 2003)], and other APOBEC3 proteins including A3F typically showing 
varying degrees of preference for 5’-TC-3’ motifs (5’-GA-3’ on the plus strand) [e.g. 
(Bishop et al., 2004; Hultquist et al., 2011; Liddament et al., 2004; Zheng et al., 2004) 
and reviewed in (Albin, 2010)]. This complicates the attribution of hypermutation 
patterns to different APOBEC3 proteins. That is, while 5’-GG-3’ context mutations are 
most likely attributable to A3G since this is the sole APOBEC3 protein that displays a 
strong preference for this dinucleotide context, the 5’-GA-3’ context mutations could be 
introduced by any of several APOBEC3 proteins present and potentially active in primary 
T cells as well as by the myeloid-specific editing activity of A3A (Koning et al.; Koning 
et al., 2009; Refsland et al., 2010; Thielen et al., 2010). Since diverse authors have 
described substantial amounts of both 5’-GG-3’ and 5’-GA-3’ context hypermutation in 
patient-derived viral sequences [reviewed in (Albin, 2010)], the question of which 
APOBEC3 proteins contribute to the sequence diversification of HIV remains an 
outstanding and subtly complex issue in the field. Emergent data derived from gene 
targeting in the naturally nonpermissive cell line CEM2n suggests, however, that A3F 
and A3D likely contribute to 5’-GA-3’ context hypermutation on top of the 5’-GG-3’ 
context hypermutation characteristic of A3G activity (Refsland et al., 2012). 
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 The structural components of A3F and A3G that guide these context preferences 
have been mapped to loop sequences between the β4 strand and the α4 helix of active 
deaminase domains, which is thought to interact with ssDNA sequences 5’ of the target 
cytosine (Carpenter et al., 2010; Conticello, 2008; Kohli et al., 2009; Kohli et al., 2010; 
Langlois et al., 2005). The effect of these loop sequences may further be enhanced by a 
more N-terminal region corresponding to arginine residues along one of the predicted 
paths of ssDNA bound to the A3G C-terminus, although the exact placement of ssDNA 
on A3G remains controversial and, fundamentally, unknown (Carpenter et al., 2010; 
Chen et al., 2008; Holden et al., 2008). An additional study focusing on A3F and A3C 
further narrowed these determinants primarily to a single amino acid change within this 
same region (Langlois et al., 2005). Interestingly, these putative sequence recognition 
motifs are found adjacent to or extending into the conserved α4 helix where most known 
determinants of APOBEC3 susceptibility to Vif occur, with the most prominent single 
amino acid determinant of target sequence specificity in A3F also corresponding to the 
equivalent of A3G N-terminal amino acid D128, the best-known of these determinants of 
Vif susceptibility (Albin et al., 2010b; Bogerd et al., 2004; Mangeat et al., 2004; 
Schröfelbauer et al., 2004; Smith and Pathak, 2010; Xu et al., 2004; Zhen et al., 2010). 
Thus, while the ability of different deaminase domains among diverse APOBEC3 
proteins to mediate distinct processes – Vif binding, RNA binding, sequence recognition, 
etc. – implies that the structure of each will be somewhat different, determining the 
structure of the C-terminus of A3F may be particularly informative for understanding 
how this critical region influences the antiviral properties of APOBEC3 proteins and may 
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explain why some authors have noted a direct effect of Vif on the deaminase activity of 
A3G (Britan-Rosich et al., 2011; Santa-Marta et al., 2005). 
 On the other side of this interaction, a study utilizing nucleoside analogues as 
molecular probes for the DNA determinants recognized by A3G during the deamination 
process has suggested several important features of the target deamination hotspot itself 
beyond the aforementioned sequence specificity observations (Rausch et al., 2009). 
Insertion of an abasic site or alteration of the 2’ deoxyribose within a deamination hotspot 
are both potent inhibitors of deamination at a target cytosine, and ring positions 3 or 4 of 
the nucleotide base 5’ of the target cytosine may be particularly important for hydrogen 
bonding with A3G residues involved in substrate recognition. These data are consistent 
with the exquisite specificity of A3G for DNA substrates as well as the importance of 
active site aromatic residues for enzyme function (see below). 
 To date, seven structures of the catalytically active C-terminus of A3G have been 
solved by either NMR or X-ray crystallography (Chen et al., 2008; Furukawa et al., 
2009; Harjes et al., 2009; Holden et al., 2008; Li et al., 2012; Shandilya et al., 2010). 
These structures show that A3G has a concave active site with a floor containing critical 
hydrophobic residues likely involved in interaction with substrate bases, as also 
suggested by the above nucleoside analogue studies. Surrounding the outer edges above 
this concave active site are a number of positively charged residues that may orient 
ssDNA within the active site, although the exact path taken by ssDNA remains a point of 
controversy with competing “brim” (Chen et al., 2008) and “kink” (Holden et al., 2008) 
interaction models proposing somewhat different DNA binding paths. Barring a co-
crystal structure, ideally including the full-length enzyme, this debate may be difficult to 
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resolve, since molecular dynamics simulations have suggested that the DNA binding 
loops are flexible and that substrate binding may induce a conformational change in A3G 
(Autore et al., 2010). 
 
cDNA Degradation – In addition to the mutagenic implications of A3G action, early 
models of restriction proposed that A3G might trigger the degradation of viral cDNA 
through a base excision repair pathway [(Harris et al., 2003a; Harris et al., 2003b; 
Mangeat et al., 2003; Zhang et al., 2003) and Figure 1-2A]. Potential degradation was 
considered an important component of any explanatory model because prior observations 
had indicated that decreases in cDNA accumulation to roughly half of wildtype among 
early reverse transcription products with still more potent effects on late reverse 
transcription products was the primary phenotypic difference between Vif-deficient and -
proficient viruses (Sova and Volsky, 1993; von Schwedler et al., 1993). In this model, the 
presence of DNA uracils introduced by A3G would cause a uracil DNA glycosylase 
enzyme to excise the offending uracil, yielding an abasic site that would then be a target 
for cleavage by an AP endonuclease (Harris et al., 2003a; Harris et al., 2003b; Mangeat 
et al., 2003; Zhang et al., 2003). The first critical step in this proposed degradative 
pathway, uracil excision, is easily envisaged given the fact that UNG2 is packaged into 
HIV virions, and there is some evidence that this is important for the ability of HIV to 
repair uracil-containing cDNA (Chen et al., 2004; Mansky et al., 2000; Priet et al., 2005). 
Indeed, sequencing of proviruses with identical integration sites but different subsets of 
G-to-A mutations suggests that some uracilated minus-strand cDNAs do undergo repair, 
although the timing of this is unknown (Yu et al., 2004b). 
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 In contrast, others have found that the presence of UNG2 in virions may be 
detrimental to virus infectivity, presumably via cDNA degradation at the same abasic 
sites thought to lead to DNA repair in the aforementioned studies (Schröfelbauer et al., 
2005; Yang et al., 2007a). This view is not universally held, as others have reported that 
the presence of UNG2 or another uracil DNA glycosylase, SMUG1, is simply irrelevant 
to viral infectivity (Kaiser and Emerman, 2006; Langlois and Neuberger, 2008; Mbisa et 
al., 2007; Schumacher et al., 2008). It has even been proposed, somewhat 
counterintuitively, that heavy uracilation of viral cDNA may actually represent an 
adaptive strategy by which HIV can prevent autointegration (Yan et al., 2011). 
 Setting aside the role of UNG2 in determining the fate of uracilated cDNA for a 
moment, a separate but related question is what endonuclease(s) might cause the ultimate 
degradation of cDNA containing abasic sites as proposed. APE1 has been found to be 
packaged in virions along with UNG2 in a scenario perfectly supporting the base excision 
repair model of cDNA degradation as originally proposed, but we are unaware of any 
additional reports confirming this effect (Yang et al., 2007a). It is not clear that an active 
degradation mechanism would be necessary to result in decreased cDNA accumulation, 
however, as the mere existence of a number of abasic sites in the absence of a second 
strand to facilitate repair may simply impede the ability of reverse transcriptase to 
synthesize a second strand (Figure 1-2C). Reverse transcriptase is capable of inserting 
dAMP across from an abasic site, a phenomenon that may further be stimulated by Vif 
(Cancio et al., 2004), but this process appears to also reduce enzyme processivity (Cai et 
al., 1993). Thus, while it is clear that a fundamental aspect of A3-dependent restriction is 
the decreased accumulation of cDNA, whether this is the result of cDNA degradation, 
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deaminase-dependent decreases in reverse transcript synthesis, or an alternative 
mechanism such as one of the deaminase-independent models to be discussed below 
remains an open and interesting question. 
 
Summary of Deaminase-Dependent Mechanisms – The deaminase-dependent mutation of 
the HIV genome is a widely accepted mechanism by which A3G can inhibit the virus. 
The picture surrounding cDNA degradation, however, is somewhat less clear. It seems 
the crux of the argument is whether an abasic site is generated during reverse 
transcription since reverse transcriptase should not distinguish cDNA uracils from 
thymines (Klarmann et al., 2003). 
 The ssDNA specificity of APOBEC3 proteins has been taken to imply that the 
substrate for uracil DNA glycosylase activity should also be ssDNA. This ssDNA 
limitation, in turn, would narrow the available uracil DNA glycosylase enzymes to those 
with specificity for single-stranded DNA, namely UNG1/2 and SMUG1 in human cells, 
and as discussed above, there is little consensus on the involvement of these two enzymes 
in retroviral restriction. It is important to remember, however, that ssDNA, like ssRNA, is 
capable of taking on secondary and tertiary structures, sometimes with thoroughly 
impressive effects [e.g. (Breaker, 2004)]. Such cDNA folded back on itself, based on the 
extensive structure of the ssRNA regions of the viral genome first reverse transcribed 
[e.g. (Watts et al., 2009)], would likely represent an appropriate template for alternative 
uracil DNA glycosylases with double-stranded specificity such as TDG or MBD4 
(Krokan et al., 2002) without invoking the specter of unidentified enzymes, a particularly 
intriguing possibility given the interaction of MBD4 with relatives of the APOBEC3 
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enzymes (Rai et al., 2008). The assumption of single-strandedness as depicted in Figure 
1-2A and in many similar figures in prior reviews may therefore need to be revisited. 
 If the abasic site forms, it is a short leap to cleavage of the phosphodiester 
backbone, if such cleavage would in fact be necessary versus simple stalling of reverse 
transcriptase (Figure 1-2C). This could occur via enzymatic means as initially proposed, 
via APE1 or an alternative enzyme. Spontaneous cleavage may also be a viable but, to 
date, untested alternative hypothesis. For example, the deamination reaction itself 
releases ammonia, which may hypothetically create a locally basic environment in the 
viral core favoring destabilization of an abasic site. One could also imagine the apparent 
cDNA degradation observed experimentally as an artifact caused by sensitivity of an 
abasic site to the heat denaturation typical of the PCR procedures that have been utilized 
universally, to our knowledge, to amplify viral reverse transcripts for further analysis 
[e.g. (Borman et al., 1995; Courcoul et al., 1995; Goncalves et al., 1996; Simon and 
Malim, 1996; Sova and Volsky, 1993; von Schwedler et al., 1993)]. While we 
acknowledge that alternative routes to cDNA degradation are highly speculative, we 
propose that, given the lack of consensus on the exact mechanism by which cDNA 
accumulation is inhibited, it may be appropriate to consider less obvious answers to this 
important mechanistic question. 
 
Deaminase-independent restriction mechanisms – While the first papers describing the 
mechanism of A3G action focused on the implications of deamination for HIV 
restriction, multiple labs soon thereafter began to note that deaminase-independent 
mechanisms of restriction may also be at play. This was based on the simple observation 
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that overexpression of A3G containing mutations of conserved residues critical for 
deaminase activity such as the zinc coordinating residues and the catalytic glutamate of 
the conserved HxE/PCxxC motif might not fully ablate restriction (Bishop et al., 2006; 
Newman et al., 2005; Shindo et al., 2003). Although at odds with identical experiments 
published in the initial descriptions of A3G’s deaminase-dependent restriction activities 
(Mangeat et al., 2003; Zhang et al., 2003), this has grown to become a point of 
contention within the field. The details surrounding these proposed deaminase-
independent mechanisms fall into several categories, but these studies are united in the 
suggestion that the decreased accumulation of reverse transcripts characteristic of the 
nonpermissive phenotype is not due to cDNA degradation, but rather to the inhibition of 
cDNA synthesis in a manner not dependent on the introduction of uracils or abasic sites 
into viral cDNA. 
 
Physical Obstruction of Reverse Transcriptase – One mechanism by which deaminase-
independent restriction may occur is the simple obstruction of reverse transcriptase 
during cDNA synthesis as depicted in Figure 1-3A (Bishop et al., 2008; Holmes et al., 
2007; Iwatani et al., 2007). Per this model, A3G accumulates on viral genomic RNA and 
impedes the processivity of reverse transcriptase such that the reaction eventually falters. 
This mechanism is supported by several lines of evidence. First, A3G has RNA-binding 
activity (Chelico et al., 2006; Iwatani et al., 2006; Yu et al., 2004b). Second, in vitro 
reverse transcription reactions using A3G or a catalytically inactive A3G mutant inhibit 
the elongation of reverse transcriptase products (Iwatani et al., 2007). Finally, the length 
of minus-strand strong-stop cDNA derived from endogenous reverse transcription 
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reactions in particles – and thus presumably independent of any downstream catabolic 
pathway – inversely correlates with the amount of A3G or A3G catalytic mutant present 
(Bishop et al., 2008). 
 
Inhibition of tRNA Priming of Reverse Transcription – Another potential deaminase-
independent mechanism of inhibition proposed is the inhibition of tRNA priming during 
reverse transcription [(Guo et al., 2006; Yang et al., 2007b) and Figure 1-3A). Most of 
these observations were made using overexpressed wildtype A3G or A3F. To extend the 
observation of decreased reverse transcription to the lack of a deamination requirement, 
however, these authors employed deletion mutants as their inactive deaminases of choice. 
Despite the obvious implication that this priming deficiency may be due to A3G’s RNA 
binding activity, either via competition for the primer binding site or perhaps 
sequestration of the primer itself, this effect has specifically been proposed to be a result 
of the interaction between A3G and the HIV nucleocapsid protein (Guo et al., 2007). One 
potential problem with this particular study is that seeing the in vitro reverse transcription 
effect requires A3G:nucleocapsid ratios 10 times greater than those found in naturally 
restricted virions, but the authors propose that the actual A3G:nucleocapsid ratios present 
during the critical tRNA annealing step may be more in line with the enhanced relative 
levels of A3G they used. 
 
Inhibition of Strand Transfer and Integration – A third proposed mechanism of 
deaminase-independent inhibition by A3G is the inhibition of strand transfer events 
during reverse transcription (Figures 1-3B, 1-3D). One paper describes the inhibition of 
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both minus- and plus-strand transfers due to a deaminase-independent mechanism of 
A3G (Li et al., 2007), perhaps caused by the inhibition of RNase H processing via A3G 
binding to the DNA:RNA heteroduplex, although A3G appears to bind such 
heteroduplexes relatively weakly (Iwatani et al., 2006; Yu et al., 2004b). Another finds 
an effect primarily on plus-strand transfer in a deaminase-dependent fashion [(Mbisa et 
al., 2007) and Figure 1-2D). Discrepancies may be due in part to the different mutants 
used to render A3G catalytically inactive – truncation mutants in the former and point 
mutants in the latter. Similarly, there have been reports of an effect of A3G on HIV 
integration, but whether this process is deaminase-dependent (Mbisa et al., 2007) or at 
least partially deaminase-independent (Luo et al., 2007; Mbisa et al., 2010) is unclear. 
One interesting mechanistic note contained within one of these reports, however, is the 
finding that A3G appears to interfere with cleavage of the tRNA primer, creating aberrant 
ends that may contribute to the downstream inhibition of integration (Mbisa et al., 2007). 
Exactly how this may occur is unknown, but it echoes speculation on protection of the 
DNA:RNA heteroduplex (Li et al., 2007). 
 
Discrepancies Among Proposed Deaminase-Independent Mechanisms – Interpretations 
of deaminase-independent mechanisms of reverse transcription are as complicated as 
those of the cDNA degradation mechanisms above. One of the primary drawbacks of 
models focused on early reverse transcription products such as a physical blockage of 
reverse transcriptase or the inhibition of reverse transcriptase priming is that the 
inhibition of minus-strand strong stop cDNA is not universally observed under 
nonpermissive conditions (Li et al., 2004; von Schwedler et al., 1993), and when it is 
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observed, this effect may be overcome by priming with DNA rather than the natural 
tRNALys3 or by removing nucleocapsid from the reaction (Guo et al., 2006; Guo et al., 
2007; Li et al., 2007; Yang et al., 2007b). Moreover, even if one finds a defect in early 
RT products, a specific effect on tRNA priming may not be apparent either (Bishop et al., 
2008; Iwatani et al., 2007). 
 Rather, all authors agree that, whether early reverse transcription is impeded or 
not, late reverse transcription products are decreased. This may be consistent with those 
studies proposing effects on strand transfer. Alternatively, this could reflect a cumulative 
effect of deaminase-independent restriction mechanisms – at multiple steps, in multiple 
combinations with each other – or any mix of the above. It has even been proposed that 
A3G may interact directly with reverse transcriptase to mediate the inhibition of proviral 
cDNA synthesis (Wang et al., 2012) and, similarly, that Vif itself may be a component of 
reverse transcription complexes that directly facilitates cDNA synthesis (Carr et al., 
2008; Carr et al., 2006). 
 
Summary of Deaminase-Independent Restriction Mechanisms – A large body of evidence 
now supports a variety of deaminase-independent mechanisms of proviral DNA synthesis 
inhibition. That said, significant discrepancies remain in this literature as in the putative 
degradation of viral cDNA. The sheer diversity of the deaminase-independent restriction 
mechanisms described above could merely reflect the fact that RNA binding may be a 
critical component in all reactions. Alternatively, caution is generally appropriate when 
interpreting broadly positive results, as they may be explained by a pervasive artifact 
attributable to specific methods such as transient overexpression of a given protein. 
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 Apropos of pervasive artifacts, several papers now suggest that deaminase-
independent mechanisms may be overexpression artifacts [(Browne et al., 2009; Haché et 
al., 2008; Miyagi et al., 2010; Miyagi et al., 2007; Schumacher et al., 2008) and see 
Supplementary Chapter 2). That is, proponents of deaminase-independent restriction 
mechanisms universally rely on the transient overexpression of catalytic mutants to make 
their core functional arguments. When one stably expresses these mutants or titrates back 
the quantities transiently expressed, however, deaminase-independent restriction is 
largely absent. As of this writing, there are no published reports of the use of a stably 
expressed catalytic mutant in combination with a more reductionist approach such as the 
endogenous reverse transcription reaction. Moreover, despite the potential for more 
potent deaminase-independent restriction by other factors such as A3F (Holmes et al., 
2007), others and we have found that even A3F is incapable of substantial deaminase-
independent restriction of HIV when stably expressed [(Miyagi et al., 2010) and see 
Supplementary Chapter 2]. That said, it is possible that the induction of APOBEC3 
proteins might theoretically raise expression levels to the range of deaminase-
independent relevance (Hultquist et al., 2011; Koning et al., 2009; Refsland et al., 2010). 
 
  30 
Mechanism of Vif Neutralization of APOBEC3 Proteins 
Many mechanisms are plausible to explain how HIV Vif counteracts the restrictive 
capacity of APOBEC3 proteins such as A3G. Among published accounts, there is 
widespread support for the notion that Vif acts to inhibit APOBEC3 encapsidation 
primarily by marking APOBEC3 proteins for proteasomal degradation and thereby 
reducing the intracellular levels available for packaging into budding virions [(Conticello 
et al., 2003; Marin et al., 2003; Mehle et al., 2004b; Sheehy et al., 2003; Stopak et al., 
2003; Yu et al., 2003) and Figure 1-1B]. Specifically, Vif acts as the substrate specificity 
adapter within a cullin-RING ubiquitin ligase complex, where it interacts with cullin-5 
(CUL5) and elongin C (TCEB1, ELOC) as well as A3G to position the latter for 
polyubiquitination mediated by the ring-box protein 2 (RBX2/RNF7) bound to the 
opposite end of the CUL5 scaffold (Conticello et al., 2003; Kao et al., 2003; Marin et al., 
2003; Mehle et al., 2004b; Sheehy et al., 2002; Sheehy et al., 2003; Stopak et al., 2003; 
Yu et al., 2003). Functional stabilization of Vif also requires its interaction with the 
transcription factor CBFβ in the context of this complex. The specific mechanism 
involved remains unknown, but it may be as simple as stabilizing Vif steady state 
expression levels (Hultquist et al., 2012; Jäger et al., 2011; Zhang et al., 2011). By 
bringing A3G into proximity with the ubiquitin ligase complex, Vif thus facilitates the 
ubiquitination and eventual degradation of A3G through the proteasome. 
 A great deal of effort in the field has been expended toward the mapping of 
specific regions and residues in Vif required for anti-APOBEC3 function. A simplified 
synthesis of this literature is presented in Figure 1-4A. Regions of Vif required for 
interaction with other members of the E3 ubiquitin ligase complex are well-established. 
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Chief among these is the single conserved SLQYLA sequence of Vif, the BC box, which 
is required for interaction between Vif and ELOC [e.g. (Mehle et al., 2004a; Yu et al., 
2004c)]. Vif may also interact with ELOB, although the conserved PPLP sequence 
implicated in this activity appears to be multifunctional, as it has also been associated 
with Vif oligomerization and binding to A3G itself (Bergeron et al., 2010; Donahue et 
al., 2008; Yang et al., 2003; Yang et al., 2001). Upstream of the BC box but also in the 
C-terminal half of Vif is an HCCH zinc coordinating motif; these specific amino acids as 
well as other directly adjacent residues are required for Vif interaction with the CUL5 
scaffold but not A3G (Luo et al., 2005; Mehle et al., 2006; Xiao et al., 2007; Yu et al., 
2004c). 
 Functional interaction of Vif with A3G also requires a number of specific residues 
that, in contrast with those contacting components of the E3 ubiquitin ligase complex, are 
typically located in the N-terminal half of Vif. While this may appear straightforward, the 
simplified schematic provided in Figure 1-4A and the cognate schematic in Figure 1-4B 
depicting the Vif interaction site and other functionally important residues in A3G gloss 
over a much more complicated experimental reality. Most residues in Vif have been 
mutated at this point, many in several independent publications, with sometimes 
contradictory effects. A summary of this literature is provided in Table 1-2 in 
anticipation of Chapter 5. To summarize in broad terms, however, the present literature 
would suggest that the interaction of Vif with different APOBEC3 proteins, for example 
A3F and A3G, is different. That is, a unique complement of residues is required for 
interaction with each protein. Some are required for both, but since almost all mutants 
characterized to date are simple loss of function mutants, it is not clear whether these 
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regions represent common components of the A3F/A3G-Vif interaction or something less 
specific. For example, mutation of an amino acid required for overall protein stability 
might cause loss of Vif expression or gross changes in its structure, either of which may 
alter the neutralization of APOBEC3 proteins without being part of a normal interaction 
site. Similarly, changes at residues that interact with some other cellular component 
required for APOBEC3 neutralization such as CUL5 may be functionally 
indistinguishable from residues found in a common APOBEC3 interaction site in Vif. 
 Efforts to identify the Vif interaction site in APOBEC3 proteins have yielded a 
much more genetically restrained picture. As shown schematically in Figure 1-4B and in 
a full-length model structure of A3G in Figure 1-4C (Harjes et al., 2009), there are three 
prominent residues that, when mutated, can prevent functional interaction of Vif with 
A3G – DPD128-130, which are in the β4-α4 loop and the very beginning of the α4 helix 
in A3G (Bogerd et al., 2004; Huthoff and Malim, 2007; Lavens et al., 2010; Mangeat et 
al., 2004; Russell et al., 2009b; Schröfelbauer et al., 2004; Xu et al., 2004). Residues 
with similar phenotypes have also been identified in A3H (D121) and A3F (E289 and 
E324, see Chapters 3-5) and A3D and A3C (Albin et al., 2010b; Smith and Pathak, 
2010; Zhen et al., 2010). Unlike the N-terminal Vif-susceptibility residues in A3G, it was 
somewhat surprising when it was first reported that the Vif interaction region in A3F was 
not in the N-terminal deaminase domain as in A3G, but rather in the C-terminal 
deaminase domain (Russell et al., 2009b; Zhang et al., 2008). Given the aforementioned 
Vif literature, however, this represented still more evidence for the diversity of 
interactions between Vif and APOBEC3 proteins. As discussed in Chapters 3 and 5, 
however, our own work suggests that the linear separation of these Vif interacting regions 
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in A3F and A3G is misleading, since the two domains bound are phylogenetically related 
and, in fact, contain a single conserved structural motif that houses most of the 
APOBEC3 determinants of Vif susceptibility identified to date (Albin et al., 2010b). 
 This is a critical point since any attempts to block the interaction of APOBEC3 
proteins with Vif would benefit from having one, fixed cellular target at which to bind 
and prevent Vif interaction, thus theoretically hampering the ability of the virus to evolve 
resistance to the intervention (Harris and Liddament, 2004). Although no one has yet 
made public a small-molecule inhibitor of the APOBEC3–Vif interaction, a significant 
recent development has been the identification of RN-18, a small-molecule antagonist of 
HIV Vif (Nathans et al., 2008). Interestingly, RN-18 decreases Vif levels and thereby 
increases A3G (and A3F and A3C but not A3B) levels when these two are present 
together. This small molecule is also able to inhibit the growth of Vif-proficient HIV in 
cultured nonpermissive cells. Thus, while further research is necessary to understand the 
mechanism by which this and other putative inhibitors function, RN-18 has provided 
proof of principle that the APOBEC3–Vif axis can be targeted by small molecules and, 
more importantly, that multiple APOBEC3 proteins can be potentiated by a single 
intervention. 
 In summary, it is well-established that Vif mediates the degradation of APOBEC3 
proteins, thus obviating their potential antiviral functions. It bears mentioning, however, 
that evidence also exists suggesting that Vif can directly inhibit A3G encapsidation (Kao 
et al., 2003; Mariani et al., 2003; Sheehy et al., 2003). Such a mechanism need not 
require degradation as an end point. Furthermore, other reports indicate a Vif-dependent 
reduction in A3G expression (Kao et al., 2003; Stopak et al., 2003), and it is also possible 
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that Vif may function by directly inhibiting the catalytic activity of A3G (Britan-Rosich 
et al., 2011; Santa-Marta et al., 2005). These alternative mechanisms are not necessarily 
mutually exclusive, but an overarching message should be clear: preventing the 
encapsidation of A3G is crucial for the ability of Vif to preserve HIV infectivity. In fact, 
reducing the encapsidation of A3G by simply increasing particle production to titrate out 
the restriction factor is at least one mechanism by which HIV can resist restriction in the 
absence of Vif function [(Haché et al., 2008) and see Chapter 6]. 
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APOBEC3 Proteins In Vivo 
 Beyond restriction and Vif-sensitivity phenotypes, there is one key characteristic 
that is of some use in distinguishing among APOBEC3 proteins: the sequence context in 
which they typically mutate DNA cytosines to uracils (Table 1-1). A3G preferentially 
mutates cytosine residues that are preceded by another cytosine, with an even stronger 
preference for the context 5’-CCCA-3’ in minus-strand viral cDNA, where the 
preferentially targeted cytosine is underlined (Harris et al., 2003a; Mangeat et al., 2003; 
Yu et al., 2004b; Zhang et al., 2003). In plus-strand reverse-transcribed cDNA, this 
manifests as 5’-TGGG-3’ to 5’-TAGG-3’ mutations, or 5’-GG-3’ to 5’-AG-3’ in the less 
stringent dinucleotide context. Other APOBEC3 proteins, however, generally display a 
preference for the mutation of cytosines preceded by another base, most often thymine 
[e.g. (Bishop et al., 2004; Liddament et al., 2004; Wiegand et al., 2004; Zheng et al., 
2004)]. This results in 5’-TC-3’ to 5’-TU-3’ transitions, which manifest on plus-strand 
viral cDNA as 5’-GA-3’ to 5’-AA-3’ transitions. 
 The identification of these different sequence contexts is important for assessing 
which APOBEC3 proteins act on a given viral substrate in a context where multiple 
APOBEC3 proteins are expressed, such as in vivo. Furthermore, assessing these contexts 
helps one to appreciate how hypermutation can be detrimental to a virus. Aside from 
deleterious amino acid or other mutations that may occur in unique sequence contexts, 
any UGG codon encoding tryptophan is susceptible to the creation of a UAG or perhaps 
even a UAA stop, particularly in the presence of A3G. Similarly, the AUG start codon 
may place the wobble base in an APOBEC3-susceptible hotspot depending on the 
identity of the next base in the sequence, thus making the ablation of initiating 
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methionines another distinct possibility. Extensive mutation may also disrupt HIV 
genomic RNA secondary structures, which are important for the regulation of HIV gene 
expression (Watts et al., 2009). 
 Even prior to the discovery of APOBEC3 proteins, the tendency for HIV to 
acquire G-to-A mutations was evident (Janini et al., 2001; Vartanian et al., 1991; 
Vartanian et al., 1994) – a phenomenon analogous to the original observation of 
hypermutation in spleen necrosis virus (Pathak and Temin, 1990). These early reports 
generally noted a preferential sequence context for hypermutation of 5’-GA-3’ and, to a 
lesser extent, 5’-GG-3’, suggesting that, given what is now known, multiple APOBEC3 
proteins account for these early descriptions of hypermutation (Liddament et al., 2004). 
 While more recent analyses at times note stronger preferences for one context or 
another under a given condition (Kieffer et al., 2005; Pace et al., 2006; Piantadosi et al., 
2009), a theme uniting recent literature on the in vivo hypermutation of HIV is that it 
frequently occurs in both major dinucleotide contexts. One study indicates, for example, 
that hypermutated sequences separate roughly into thirds – sequences with hypermutation 
predominantly in a 5’-GA-3’ context, sequences with hypermutation predominantly in a 
5’-GG-3’ context, and sequences with hypermutation occurring in roughly equal 
proportions in each context (Land et al., 2008). Another reports the occurrence of 5’-GG-
3’ context mutations in approximately 95% of hypermutated sequences versus the 
occurrence of 5’-GA-3’ context mutations in approximately 60% of hypermutated 
sequences (Gandhi et al., 2008). Furthermore, mutations in both contexts frequently 
occur in the same cloned sequence. For example, 5’-GG-3’ hypermutations occur within 
95% of predominantly 5’-GA-3’ context clones (Gandhi et al., 2008), while another data 
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set shows a very slight preference for hypermutation in a 5’-GA-3’ context with a strong 
5’-GG-3’ component (Ulenga et al., 2008a). 
 It is reasonable to conclude, therefore, that multiple APOBEC3 proteins are active 
in vivo and that at least one of these is A3G with its strong 5’-GG-3’ context preference. 
The identities of the APOBEC3 proteins responsible for the reported 5’-GA-3’ 
hypermutations, however, remain unknown. Recent knockout and knockdown studies 
from our lab indicate that A3F and A3D are likely contributions to 5’-GA-3’ context 
hypermutation in naturally nonpermissive cells; it therefore stands to reason that these are 
also likely contributing to hypermutation in vivo (Refsland et al., 2012). This study did 
not, however, extensively address the potential for A3H to contribute to 5’-GA-3’ context  
hypermutation in naturally nonpermissive cells, and it stands in contrast with one report 
implicating A3C in target cell editing of HIV in the 5’-GA-3’ context (Bourara et al., 
2007). As indicated above, it is also possible that myeloid cell A3A may be a potent, 
inducible contributor to sequence diversification in the 5’-GA-3’ context (Koning et al., 
2011; Thielen et al., 2010). In any event, identification of the one true APOBEC3 
repertoire may be fundamentally impossible since both expression levels and genotypic 
differences are likely to contribute to the overall picture in any given patient as discussed 
below. 
 Regardless of which APOBEC3 proteins are actively hypermutating HIV, it is 
clear that their overall effect is significant. Estimates of the frequency of hypermutated 
sequences in vivo range from approximately 7% to 20% with wide variation in the 
proportions seen in any one individual (Gandhi et al., 2008; Kieffer et al., 2005; Land et 
al., 2008; Pace et al., 2006; Piantadosi et al., 2009). In fact, these figures almost certainly 
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underestimate the total proportion of proviral sequences mutated by APOBEC3 proteins. 
Since a sequence must typically reach a given threshold of G-to-A mutations to be 
defined as ‘hypermutated’, methods of quantifying hypermutants fail to account for 
sequences that have been mutated by APOBEC3 proteins at a lower level. Furthermore, 
extremely hypermutated sequences may fail to replicate and amplify by PCR while still 
potentially contributing to the overall mutational load of a viral population through 
recombination (Mulder et al., 2008). As discussed above, the deamination of cDNA 
cytosines may also create a substrate for the downstream degradation of the viral genome, 
which would further diminish the apparent proportion of viral genomes affected by 
APOBEC3 proteins. 
 
Adaptive potential of G-to-A mutations – A hallmark of HIV is its high mutation rate 
(Mansky and Temin, 1995), yet this mutation rate likely represents an equilibrium 
selected by the virus through evolution to optimize host immune evasion without 
collapsing into error catastrophe (Harris, 2008; Loeb et al., 1999). In this respect, 
APOBEC3 proteins are of interest not only for their ability to damage viral genomic 
integrity, but also for their potential ability to change the pace at which the virus may 
evolve. For example, several authors have written on the theoretical ability of APOBEC3 
proteins to introduce mutations into the viral genome that may confer resistance to 
antiviral drugs, promote immune evasion or even facilitate coreceptor switching 
(Berkhout and de Ronde, 2004; Bewick et al., 2011; Haché et al., 2006; Pillai et al., 
2008). 
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 The levels of mutation characteristic of hypermutation, on the face of it, would 
seem far too high to be of benefit to HIV. Yet current evidence suggests that there are 
multiple mechanisms by which HIV may harness the mutagenic power of APOBEC3 
proteins without suffering fatal consequences. The first of these centers on the concept of 
the fitness of a viral population versus that of any individual genome. If a particular viral 
genome encodes a Vif protein that is hypofunctional in its ability to counteract 
APOBEC3 proteins, an event that appears to happen at least 20% of the time (Albin et 
al., 2010a; Simon et al., 2005), processive deamination will introduce a large number of 
G-to-A mutations into the progeny of that viral genome. Frequently, these may be 
premature stop codons or mutations ablating the start codon of a given gene, as discussed 
above, yet recombination can allow the virus to resurrect hypermutated sequences into a 
functional genomic background (Mulder et al., 2008). Even when hypermutation is at full 
strength, then, the virus can utilize the expanded sequence space afforded by exposure to 
APOBEC3 proteins to acquire adaptive mutations. 
 Even when heavily affected by hypermutation, the virus retains at least two 
additional ways of averting certain death. One is purely stochastic in that it is possible for 
a gene to suffer heavy levels of hypermutation but still remain functional (Harris et al., 
2003a). A second is so-called purifying selection, a process by which the viral genomes 
represented at each stage of replication from integrated proviruses through packaged 
genomes are observed to be progressively less mutated, presumably due to loss of 
function at various stages of replication – for example, mutations in the viral U3 
promoter may select against the transcription of heavily mutated proviruses versus 
relatively intact counterparts (Russell et al., 2009a). 
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 Given the diverse mechanisms by which HIV may turn hypermutation to its own 
advantage, it may under certain conditions actually be beneficial for the virus to acquire 
mutations causing defects in Vif. For example, the presence of the hypofunctional Vif 
mutant K22H has been correlated with patients experiencing antiretroviral treatment 
failure, and these patients further display an enrichment for drug resistance mutations in a 
context consistent with A3G action (Fourati et al., 2010). While this would seemingly 
suggest that the potentiation of APOBEC3 proteins as a therapeutic strategy may be 
dangerous, others have found that, despite the potential contribution of A3G and other 
APOBEC3 proteins to drug resistance mutations, this effect is relatively modest and not 
necessarily a reason to avoid the therapeutic use of APOBEC3 proteins (Jern et al., 
2009). 
 It may also be possible for HIV to acquire sublethal levels of mutation from 
APOBEC3 proteins (Sadler et al., 2010), presumably through some residual 
encapsidation despite the presence of Vif, whether by chance or by viral design. This is 
echoed by a similar story in which cytotoxic T cell escape mutations consistent with A3G 
action were found early in infection, implying a role for A3G in providing the sequence 
diversity on which selection may act from even the earliest stages of infection (Wood et 
al., 2009). Indeed, even a Vif-proficient virus passaged in the presence of A3G can 
acquire a drug resistance mutation in a favorable dinucleotide context much more rapidly 
than the virus itself (Kim et al., 2010). It is thus at least theoretically possible that the 
virus could benefit from the presence of A3G and other APOBEC3 proteins at some 
level. Here, it is also important to reiterate the distinction between a viral population and 
an individual viral genome, as debilitated viruses may suffer mutation rates several times 
  41 
greater than their wildtype counterparts without necessarily impacting the overall titer of 
the population [e.g. (Haché et al., 2008)]. 
 
Clinical assessment of APOBEC3 impacts on HIV infection – While perhaps not entirely 
appropriate due to the clear in vitro effect of APOBEC3 proteins on cDNA accumulation, 
hypermutation is often taken as a surrogate for APOBEC3 activity in the evaluation of 
the potential clinical impact of APOBEC3 proteins with an eye toward their use as 
therapeutics. This approach has yielded a mixed picture for the potential efficacy of 
APOBEC3 proteins in vivo as summarized in Table 1-3. A number of publications 
support a positive correlation between hypermutation levels in patient sequences and 
reduced viremia and/or increased CD4+ T cell counts (Land et al., 2008; Pace et al., 
2006; Vazquez-Perez et al., 2009), but an equal number fail to find any association 
(Gandhi et al., 2008; Piantadosi et al., 2009; Ulenga et al., 2008a). Aside from the cDNA 
accumulation confounder, it is possible that this lack of clarity may further suffer from 
the fact that Vif is presumably largely functional in these patient-derived isolates. Thus, 
its ongoing suppression of APOBEC3 proteins may be sufficient to lower their apparent 
activity to a level difficult to assess. Unfortunately, the situation has turned out much the 
same when assessing APOBEC3 mRNA levels [(Amoedo et al., 2011; Biasin et al., 
2007; Cho et al., 2006; Jin et al., 2005; Reddy et al., 2010; Ulenga et al., 2008b; 
Vazquez-Perez et al., 2009) and reviewed in more detail in (Albin, 2010)]. Among recent 
positive data, however, an analysis of the effects of interferon induction in HIV/HCV 
coinfected human patients has shown a modest correlation between decreased viral load 
and the upregulation of A3F but not A3G (Pillai et al., 2012). 
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 The search for APOBEC3 polymorphisms of functional significance has achieved 
similarly modest success. Polymorphisms in A3H determine stability and restriction 
activity with the mutations associated with haplotypes II and V being the most relevant to 
HIV restriction (Cagliani et al., 2011; Harari et al., 2009; OhAinle et al., 2008; Tan et al., 
2009; Wang et al., 2011a). The most studied of these two, haplotype II, is present in 
roughly 50% of individuals of African descent, 10–18% of individuals of European 
descent and 3–4% of individuals of Asian descent (OhAinle et al., 2008), while a less 
stable but Vif-resistant haplotype I, which is more common in European and Asian 
populations, has been correlated with protection from HIV transmission (Cagliani et al., 
2011). Another common APOBEC3 polymorphism is an APOBEC3B deletion, which 
occurs in approximately 20% of the world’s population (Kidd et al., 2007). This deletion 
of APOBEC3B is relatively rare in African and European populations but common in 
East Asian (36.9%), Amerindian (57.7%) and Oceanic (92.9%) populations. 
Homozygosity for this deletion has previously been associated with enhanced 
susceptibility to HIV infection and a higher viral set point (An et al., 2009), but an 
additional study failed to find this effect in a separate cohort (Itaya et al., 2010). 
 As with other areas of APOBEC3 research, however, the most intensive efforts to 
date have been directed toward the search for polymorphisms in A3G, and although many 
have been found, the potential clinical implications are generally unclear [reviewed in 
(Albin, 2010)]. It has been suggested that one variant, A3G H186R, may be associated 
with an unfavorable course of infection (An et al., 2004; Reddy et al., 2010), but a 
smaller study focused on a population where the allele is less prevalent failed to observe 
these effects (Do et al., 2005). Nevertheless, the H186R variant of A3G is worthy of 
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further in vitro characterization in light of the recent finding that this change results in 
decreased processivity of the enzyme along ssDNA substrates and consequently 
decreased deaminase activity (Feng and Chelico, 2011). 
 It is important to point out, however, that most APOBEC3 proteins have evolved 
under positive selection, implying that the challenges posed by ancient and presumably 
divergent pathogens have resulted in the rapid evolution of these restriction factors 
(OhAinle et al., 2006; Sawyer et al., 2004). While this selective pressure may not have 
been applied by HIV given its relatively recent arrival in the human population, selection 
for APOBEC3 proteins better able to restrict other pathogens may have inadvertently 
selected cross-reactivity for the restriction of HIV. Thus, it is reasonable to predict that, 
despite the relative dearth of data presently available, variation at the genetic level will 
account for some effect on HIV in vivo. Furthermore, it is possible that ongoing selection 
by the HIV pandemic itself may result in the expansion of protective APOBEC3 alleles 
not yet identified. 
 CD4+ T cells are the primary reservoir of HIV infection in vivo, but relatively 
little is known about the APOBEC3 repertoire found in these cells. Among activated 
CD4+ T cells, the Th1 subset of helper T cells expresses greater levels of A3G and A3F, 
which are further enhanced by the autocrine action of IFNγ (IFNG) (Vetter et al., 2009). 
Greater expression, in turn, results in greater encapsidation of APOBEC3 proteins in HIV 
produced from these cells and consequently lower viral infectivity than in the Th2 subset 
of helper T cells, even for Vif-proficient viruses. In general, most APOBEC3 family 
proteins with the exception of A3A and, to a lesser extent, A3B appear to be expressed in 
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primary CD4+ T cells; among T cell subsets, however, A3G is expressed at somewhat 
higher levels than A3F (Koning et al., 2009). 
 Studies with primary myeloid lineage cells have also noted a prominent effect of 
interferon treatment on the ability of APOBEC3 proteins to restrict HIV, linking higher 
expression of A3G and A3A to the relative resistance of monocytes versus differentiated 
macrophages to infection (Peng et al., 2007). Another report indicates that A3G and A3F 
are responsible for preventing HIV from infecting immature dendritic cells, an effect 
which augments as dendritic cells mature and increase their A3G expression (Pion et al., 
2006). Expression of IFNα and, to a lesser extent, IFNγ have also been linked to 
increased APOBEC3 levels and to increased resistance to HIV infection; this 
upregulation of APOBEC3 proteins may effectively overwhelm normal Vif function and 
enable restriction of wildtype HIV in macrophages (Peng et al., 2007; Peng et al., 2006). 
Of note, IFNα may upregulate all APOBEC3 proteins in macrophages and dendritic cells 
with the possible exceptions of A3B and A3C, indicating that these are part of the normal 
interferon response in these cell types, although perhaps not in CD4+ T cells (Koning et 
al., 2009; Refsland et al., 2010). This upregulation is particularly astounding for A3A 
(Koning et al., 2009; Peng et al., 2007; Stenglein et al., 2010). Given the common 
expression of many APOBEC3 proteins in primary cell types and their potential 
interferon inducibility, it is tempting to speculate that the combination of different 
APOBEC3 proteins may yield emergent properties not readily apparent in the majority of 
in vitro studies to date, which almost exclusively focus on the effects of single 
APOBEC3 proteins (See also Chapter 6). 
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Table 1-1: Studies reporting restriction activity, susceptibility to Vif and mutational 
context preferences of APOBEC3 proteins with respect to HIV. 
 Restriction activity against 
HIVa 
Susceptibility to Vifb Dinucleotide 
preferencec 
A3A Active: (Aguiar et al., 2008; 
Goila-Gaur et al., 2007; Marin et 
al., 2008; Rose et al., 2005); note 
that two of these references 
involve fusion of A3A to a helper 
protein 
 
Not active: (Bishop et al., 2004; 
Bogerd et al., 2008; Bogerd et al., 
2006a; Bogerd et al., 2006b; Chen 
et al., 2006; Gooch and Cullen, 
2008; Hultquist et al., 2011; 
Kinomoto et al., 2007; Wiegand 
et al., 2004) 
Sensitive: (Marin et al., 
2008; Rose et al., 2005) 
 
 
 
 
 
Not sensitive: (Hultquist 
et al., 2011; Marin et al., 
2008) 
GA, substantial 
GG(Aguiar et al., 
2008; Stenglein 
et al., 2010) 
A3B Active: (Bishop et al., 2004; 
Bogerd et al., 2007; Bogerd et al., 
2006a; Bogerd et al., 2006b; 
Doehle et al., 2005a; Hakata and 
Landau, 2006; Hultquist et al., 
2011; Kinomoto et al., 2007; Rose 
et al., 2005; Yu et al., 2004a) 
 
Not active: (Haché et al., 2008; 
Hultquist et al., 2011; Refsland et 
al., 2012), note the distinction 
between spreading infection and 
293T overexpression systems 
Sensitive: no published 
reports 
 
 
 
 
 
 
Not sensitive: (Bishop et 
al., 2004; Doehle et al., 
2005a; Hultquist et al., 
2011; Rose et al., 2005; 
Yu et al., 2004a) 
GA: (Bishop et 
al., 2004; Doehle 
et al., 2005a) 
A3C Active: (Bishop et al., 2004; 
Bogerd et al., 2006a; Bogerd et 
al., 2006b; Kinomoto et al., 2007; 
Langlois et al., 2005; Marin et al., 
2008; Yu et al., 2004a) 
 
 
Not active: (Doehle et al., 2005a; 
Hultquist et al., 2011; Refsland et 
al., 2012; Rose et al., 2005; 
Wiegand et al., 2004; Zheng et 
al., 2004) 
Sensitive: (Chen et al., 
2009; Hultquist et al., 
2011; Langlois et al., 
2005; Marin et al., 2008; 
Pery et al., 2009; Zhang 
et al., 2008) 
 
Not sensitive: (Bishop et 
al., 2004; Yu et al., 
2004a) 
GA, substantial 
GG [nonspecific 
compared with 
others (Langlois 
et al., 2005; Yu et 
al., 2004a)] 
A3D Active: (Chen et al., 2009; Dang 
et al., 2008a; Dang et al., 2006; 
Hultquist et al., 2011; Kinomoto 
et al., 2007; Refsland et al., 2012; 
Zhang et al., 2008) 
 
Not active: (Haché et al., 2008) 
Sensitive: (Chen et al., 
2009; Dang et al., 2008a; 
Dang et al., 2006; 
Hultquist et al., 2011; 
Zhang et al., 2008) 
 
Not sensitive: no 
published reports 
GA, substantial 
GT(Dang et al., 
2006; Refsland et 
al., 2012) 
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 Restriction activity 
against HIVa 
Susceptibility to Vifb Dinucleotide 
preferencec 
A3F Active: (Bishop et al., 
2004; Liddament et al., 
2004; Wiegand et al., 
2004; Zheng et al., 2004) 
and many others; 
restriction by A3F is 
generally well accepted, 
and A3F is often used as a 
control with A3G 
 
Not active: (Miyagi et al., 
2010; Mulder et al., 2010) 
Sensitive: (Bishop et al., 
2004; Liddament et al., 2004; 
Wiegand et al., 2004; Zheng 
et al., 2004) 
 
 
 
 
 
 
Not sensitive: no published 
reports, although A3F may be 
generally less responsive to 
Vif than A3G [e.g. 
(Liddament et al., 2004)] 
GA: (Bishop et al., 
2004; Liddament et 
al., 2004; Wiegand 
et al., 2004; Zheng 
et al., 2004) 
A3G Active: (Harris et al., 
2003a; Mangeat et al., 
2003; Sheehy et al., 2002; 
Zhang et al., 2003) plus 
countless reports since 
 
 
 
Not active: no published 
reports 
Sensitive: (Conticello et al., 
2003; Mehle et al., 2004a; 
Mehle et al., 2004b; Sheehy 
et al., 2002; Sheehy et al., 
2003; Stopak et al., 2003; Yu 
et al., 2003) plus countless 
reports since 
 
Not sensitive: no published 
reports 
GG: (Harris et al., 
2003a; Liddament 
et al., 2004; 
Mangeat et al., 
2003; Yu et al., 
2004b; Zhang et al., 
2003) 
A3H Active: (Dang et al., 
2008a; Harari et al., 2009; 
Hultquist et al., 2011; Li et 
al., 2010; OhAinle et al., 
2008; Refsland et al., 
2012; Tan et al., 2009; 
Wang et al., 2011a) 
 
Not active: (Dang et al., 
2006; Kinomoto et al., 
2007; OhAinle et al., 
2006); multiple alleles and 
splice variants exist in the 
human population, not all 
of which are active or 
equally impacted by Vif, 
as briefly discussed in 
main text 
Sensitive: (OhAinle et al., 
2008; Tan et al., 2009)  
Partially sensitive(Hultquist et 
al., 2011; Li et al., 2010; 
Refsland et al., 2012) 
 
 
 
Not sensitive: (Dang et al., 
2008a; Harari et al., 2009; 
Wang et al., 2011a) 
GA(Harari et al., 
2009) 
aSingle-cycle activity here is defined as the suppression of infectivity relative to negative 
restriction controls of at least 50%. Spreading infection activity is defined as the 
substantial suppression of viral spread for the duration of the experiment shown. Some 
experiments involved the modification of APOBEC3 proteins by, for example, fusion to a 
helper protein. Where this occurs, restriction is counted as if the protein were wildtype. bAny data concerning the Vif sensitivity of modified APOBEC3 proteins as described 
above are disregarded in this table. cReferences for the dinucleotide preferences of APOBEC3 mutational activity are 
preferentially chosen from papers with data on mutation of the HIV genome. Studies on 
other substrates generally agree with those listed here, but variation among papers may 
occur.
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Table 1-2: Anti-APOBEC3 loss of function Vif mutants. 
Residue Conserved Inactive vs. A3G 
Inactive 
vs. A3F 
Inactive 
vs. A3C 
and 
A3D 
Active 
vs. 
A3G 
Active 
vs. 
A3F 
Refs 
E2 98%    A A 
(Yamashita 
et al., 
2008) 
W5 99% A A  A A 
(Simon et 
al., 1999; 
Tian et al., 
2006) 
Q6 99%    A A (Simon et al., 1999) 
V7 95%    A A 
(Russell 
and Pathak, 
2007) 
M8 81%    A A 
(Russell 
and Pathak, 
2007) 
I9 97%    A A 
(Russell 
and Pathak, 
2007) 
V10 99%    A A 
(Russell 
and Pathak, 
2007) 
W11 99% A A, R  A, R, L L 
(Mulder et 
al., 2010; 
Russell and 
Pathak, 
2007; 
Simon et 
al., 2005; 
Tian et al., 
2006; 
Yamashita 
et al., 
2008) 
Q12 99%  A  A A 
(Pery et al., 
2009; 
Russell and 
Pathak, 
2007; 
Simon et 
al., 1999) 
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Residue Conserved Inactive vs. A3G 
Inactive 
vs. A3F 
Inactive 
vs. A3C 
and 
A3D 
Active 
vs. 
A3G 
Active 
vs. 
A3F 
Refs 
V13 98%  A  A A 
(Pery et al., 
2009; 
Russell and 
Pathak, 
2007; 
Simon et 
al., 1999) 
D14 99%  A A, S A  
(He et al., 
2008; Pery 
et al., 2009; 
Russell and 
Pathak, 
2007; 
Zhang et 
al., 2008) 
R15 99%  A A, E A  
(He et al., 
2008; Pery 
et al., 2009; 
Russell and 
Pathak, 
2007; 
Zhang et 
al., 2008) 
M16 99%  A  A A 
(Russell 
and Pathak, 
2007; 
Simon et 
al., 1999) 
R17 88%  A Q A A 
(Pery et al., 
2009; 
Russell and 
Pathak, 
2007; 
Simon et 
al., 1999) 
I18 99%    A A 
(Russell 
and Pathak, 
2007; 
Simon et 
al., 1999) 
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Residue Conserved Inactive vs. A3G 
Inactive 
vs. A3F 
Inactive 
vs. A3C 
and 
A3D 
Active 
vs. 
A3G 
Active 
vs. 
A3F 
Refs 
W21 99% A A    
(Nagao et 
al., 2010; 
Tian et al., 
2006; 
Yamashita 
et al., 2008; 
Yamashita 
et al., 
2010) 
K22 46% E, H, D E  A, R A, D, R, E 
(Chen et 
al., 2009; 
Dang et al., 
2009; 
Fourati et 
al., 2010; 
Simon et 
al., 2005; 
Zhang et 
al., 2008) 
S23 98% Del Del  A A 
(Chen et 
al., 2009; 
Dang et al., 
2009; 
Simon et 
al., 1999) 
L24 97% Del, S Del, S  A A 
(Chen et 
al., 2009; 
Dang et al., 
2009; 
Nagao et 
al., 2010; 
Simon et 
al., 1999; 
Yamashita 
et al., 
2008) 
V25 98% Del Del, S  S  
(Chen et 
al., 2009; 
Dang et al., 
2009) 
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Residue Conserved Inactive vs. A3G 
Inactive 
vs. A3F 
Inactive 
vs. A3C 
and 
A3D 
Active 
vs. 
A3G 
Active 
vs. 
A3F 
Refs 
K26 99% A, D, R, Y, Q    
A, D, 
R, Y, 
Q 
(Albin et 
al., 2010a; 
Chen et al., 
2009; Dang 
et al., 
2009) 
H27 81%    Q Q (Albin et al., 2010a) 
H28 99%    A A 
(Nagao et 
al., 2010; 
Yamashita 
et al., 
2008) 
M29 85% A A    (Simon et al., 1999) 
Y30 78% A    A (Chen et al., 2009) 
S32 99% A, P A, P    
(Nagao et 
al., 2010; 
Simon et 
al., 2005; 
Yamashita 
et al., 2008; 
Yamashita 
et al., 
2010) 
R33 65% K    A A (Simon et al., 1999) 
K34 83% D D  A, R A, R 
(Dang et 
al., 2009; 
Simon et 
al., 1999) 
R36 61% K    A  (Chen et al., 2009) 
D37 59% G A A    
(Russell 
and Pathak, 
2007) 
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Residue Conserved Inactive vs. A3G 
Inactive 
vs. A3F 
Inactive 
vs. A3C 
and 
A3D 
Active 
vs. 
A3G 
Active 
vs. 
A3F 
Refs 
W38 99% A A    
(Nagao et 
al., 2010; 
Russell and 
Pathak, 
2007; Tian 
et al., 2006; 
Yamashita 
et al., 2008; 
Yamashita 
et al., 
2010) 
F39 51%    A A 
(Russell 
and Pathak, 
2007) 
Y40 99% A, H    A, H 
(Chen et 
al., 2009; 
He et al., 
2008; 
Nagao et 
al., 2010; 
Russell and 
Pathak, 
2007; 
Simon et 
al., 2005; 
Yamashita 
et al., 2008; 
Yamashita 
et al., 
2010) 
R41 83% A    A 
(Chen et 
al., 2009; 
He et al., 
2008; 
Russell and 
Pathak, 
2007; 
Zhang et 
al., 2008) 
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Residue Conserved Inactive vs. A3G 
Inactive 
vs. A3F 
Inactive 
vs. A3C 
and 
A3D 
Active 
vs. 
A3G 
Active 
vs. 
A3F 
Refs 
H42 98% A, N    A, N 
(Chen et 
al., 2009; 
He et al., 
2008; Pery 
et al., 2009; 
Russell and 
Pathak, 
2007; 
Zhang et 
al., 2008) 
H43 99% A, N    A, N 
(Nagao et 
al., 2010; 
Pery et al., 
2009; 
Russell and 
Pathak, 
2007; 
Yamashita 
et al., 2008; 
Yamashita 
et al., 
2010) 
Y44 86% A    A 
(Russell 
and Pathak, 
2007) 
E45 89% G G  A A 
(Russell 
and Pathak, 
2007; 
Simon et 
al., 2005) 
S46 88%    A A 
(Russell 
and Pathak, 
2007) 
T47 38% R    A A 
(Russell 
and Pathak, 
2007) 
N48 76% H A    A 
(Russell 
and Pathak, 
2007) 
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Residue Conserved Inactive vs. A3G 
Inactive 
vs. A3F 
Inactive 
vs. A3C 
and 
A3D 
Active 
vs. 
A3G 
Active 
vs. 
A3F 
Refs 
P49 99% A A    
(Russell 
and Pathak, 
2007) 
K50 49% A A    
(Russell 
and Pathak, 
2007) 
I51 55%    A A 
(Russell 
and Pathak, 
2007) 
S52 97%    A A 
(Russell 
and Pathak, 
2007) 
S53 99%    A A 
(Simon et 
al., 1999; 
Yamashita 
et al., 
2008) 
E54 98%    A A (Simon et al., 1999) 
V55 97%    S, A A 
(He et al., 
2008; Pery 
et al., 
2009) 
I57 98%    S, A A 
(He et al., 
2008; Pery 
et al., 
2009) 
P58 99%    A A 
(He et al., 
2008; 
Simon et 
al., 1999; 
Yamashita 
et al., 
2008) 
L59 94%    S, A S, A 
(He et al., 
2008; 
Simon et 
al., 1999) 
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Residue Conserved Inactive vs. A3G 
Inactive 
vs. A3F 
Inactive 
vs. A3C 
and 
A3D 
Active 
vs. 
A3G 
Active 
vs. 
A3F 
Refs 
L64 94% S S  A A 
(He et al., 
2008; Pery 
et al., 
2009) 
I66 89% S S  A A 
(He et al., 
2008; Pery 
et al., 
2009) 
Y69 99% A A A F  
(He et al., 
2008; 
Nagao et 
al., 2010; 
Pery et al., 
2009; 
Yamashita 
et al., 
2008) 
W70 99% A A  A A 
(He et al., 
2008; Pery 
et al., 2009; 
Tian et al., 
2006) 
L72 98% S, A S, A A   
(He et al., 
2008; Pery 
et al., 
2009) 
H73 69%    A A (Simon et al., 1999) 
T74 91%    A A 
(He et al., 
2008; 
Simon et 
al., 1999) 
E76 99%  A  A A 
(He et al., 
2008; 
Nagao et 
al., 2010; 
Yamashita 
et al., 
2008) 
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Residue Conserved Inactive vs. A3G 
Inactive 
vs. A3F 
Inactive 
vs. A3C 
and 
A3D 
Active 
vs. 
A3G 
Active 
vs. 
A3F 
Refs 
R77 83%    A A (He et al., 2008) 
W79 99%  A A A  
(He et al., 
2008; Tian 
et al., 2006; 
Yamashita 
et al., 2008; 
Yamashita 
et al., 2010; 
Zhang et 
al., 2008) 
H80 91%    A A (Simon et al., 1999) 
L81 98%  S  S, A A 
(Dang et 
al., 2010a; 
Simon et 
al., 1999) 
G82 99%  D  D  (Dang et al., 2010a) 
G84 99% D D, A  A  (Dang et al., 2010a) 
V85 92%    S S (Dang et al., 2010a) 
S86 99%    A A 
(Dang et 
al., 2010a; 
Simon et 
al., 1999; 
Yamashita 
et al., 
2008) 
I87 96%    A A 
(Dang et 
al., 2010a; 
Simon et 
al., 1999) 
E88 98%    A A (Dang et al., 2010a) 
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Residue Conserved Inactive vs. A3G 
Inactive 
vs. A3F 
Inactive 
vs. A3C 
and 
A3D 
Active 
vs. 
A3G 
Active 
vs. 
A3F 
Refs 
W89 99% A A  A A 
(Dang et 
al., 2010a; 
Tian et al., 
2006) 
R90 93%    D, A D, A 
(Dang et 
al., 2010a; 
Simon et 
al., 1999) 
K91 44%    D, A D, A 
(Dang et 
al., 2010b; 
Simon et 
al., 1999) 
R92 48%    D, A D, A 
(Dang et 
al., 2010b; 
Simon et 
al., 1999) 
R93 74%    D D (Dang et al., 2010b) 
Y94 98%    A A 
(Dang et 
al., 2010b; 
Yamashita 
et al., 
2008) 
S95 76%    A A (Dang et al., 2010b) 
T96 99% D, R D, R  A A 
(Dang et 
al., 2010b; 
Yamashita 
et al., 
2008) 
Q97 99%  R  A, R A 
(Dang et 
al., 2010b; 
Simon et 
al., 1999) 
V98 72%    S, A S, A 
(Dang et 
al., 2010b; 
Simon et 
al., 1999) 
D99 93%    K K (Dang et al., 2010b) 
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Residue Conserved Inactive vs. A3G 
Inactive 
vs. A3F 
Inactive 
vs. A3C 
and 
A3D 
Active 
vs. 
A3G 
Active 
vs. 
A3F 
Refs 
P100 99%    S, A S, A (Dang et al., 2010b) 
D101 42%    R R (Dang et al., 2010b) 
L102 91%    S S (Dang et al., 2010b) 
A103 99% D, R, Y D, R, Y  S, V S, V (Dang et al., 2010b) 
D104 99% A, R, Y A, R, Y  S A, S 
(Dang et 
al., 2010b; 
Nagao et 
al., 2010) 
Q105 88%    A A (Dang et al., 2010b) 
L106 99%    S S (Dang et al., 2010b) 
I107 99% R R  A A (Dang et al., 2010b) 
H108* 99% A A    
(Nagao et 
al., 2010; 
Yamashita 
et al., 
2010) 
Y111 97%    A A 
(Yamashita 
et al., 
2008) 
C114* 99% A, S A, S    
(Nagao et 
al., 2010; 
Simon et 
al., 2005) 
F115 99% S S    (Simon et al., 2005) 
S118 96%    A A 
(Yamashita 
et al., 
2008) 
R121 98%    A A (Simon et al., 1999) 
N122 49%    A A (Simon et al., 1999) 
T123 97%    A A (Simon et al., 1999) 
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Residue Conserved Inactive vs. A3G 
Inactive 
vs. A3F 
Inactive 
vs. A3C 
and 
A3D 
Active 
vs. 
A3G 
Active 
vs. 
A3F 
Refs 
R127 53% H    A A (Simon et al., 1999) 
I128 49% I    A A (Simon et al., 1999) 
C133* 99% A, S A, S    
(Nagao et 
al., 2010; 
Simon et 
al., 1999) 
G138 99% R R    (Simon et al., 2005) 
H139* 99% A A    (Nagao et al., 2010) 
G143 98% R R    (Simon et al., 2005) 
Y147 98%    A A (Simon et al., 1999) 
L148 99%    A A 
(Simon et 
al., 1999; 
Yamashita 
et al., 
2008) 
L150  P P    (Simon et al., 2005) 
P156 93%    A A (Simon et al., 1999) 
K157 78%    A A (Simon et al., 1999) 
Q158 65% K    A A (Simon et al., 1999) 
I159 39%    A A (Simon et al., 1999) 
K160 86%    A A (Simon et al., 1999) 
P161 98% A A  A A (Simon et al., 1999) 
P162 98% A A  A A 
(Simon et 
al., 1999; 
Yamashita 
et al., 
2008) 
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Residue Conserved Inactive vs. A3G 
Inactive 
vs. A3F 
Inactive 
vs. A3C 
and 
A3D 
Active 
vs. 
A3G 
Active 
vs. 
A3F 
Refs 
L163 98% A A  A A (Simon et al., 1999) 
S165 99%    A A 
(Yamashita 
et al., 
2008) 
V166 92%    A A (Simon et al., 1999) 
L169 99%    A A (Simon et al., 1999) 
T170 69%    A A (Simon et al., 1999) 
E171 99%  A  A A 
(Dang et 
al., 2010a; 
Yamashita 
et al., 
2008) 
D172 98%  A  A  (Dang et al., 2010a) 
R173 97%  A  A  (Dang et al., 2010a) 
W174 99%  A  A  (Dang et al., 2010a) 
N175 98%    A A (Dang et al., 2010a) 
T180 86%    A A (Simon et al., 1999) 
K181 60%    A A (Simon et al., 1999) 
M189 92%    A A (Simon et al., 1999) 
W190 84%    A A (Simon et al., 1999) 
Columns indicate the wildtype amino acid at each residue in a given study, its 
conservation among HIV isolates, loss of function mutations against A3G, A3F and A3D 
and A3C, aphenotypic mutations against A3G and A3F and the references reporting said 
mutants. Mutants are considered inactive if they demonstrate a loss of function of 
approximately 50% or greater relative to wildtype, with some deference given to the 
authors’ own interpretations. 
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Known zinc coordinating residues that affect interaction with CUL5 are indicated with an 
asterisk. References focusing on these and other residues required for interaction with 
other components of the E3 ligase complex are cited in the main text. Citations in this 
table derive from papers specifically seeking loss of function with respect to APOBEC3 
neutralization. 
 
Where two or more mutations are made simultaneously, a situation that typically occurs 
among contiguous residues, each point mutation is considered as though it were the only 
mutation present in the construct. The exception to this is the PPLP motif in (Simon et 
al., 1999), where the phenotypes of the individual amino acid changes in isolation are 
included in addition to the phenotypes associated with combination mutants. 
 
In (Yamashita et al., 2008) and in (Simon et al., 1999), growth in H9 cells is taken as 
intact anti-A3F and anti-A3G function. Loss of function in this cell line is not considered 
due to inability to distinguish A3F from A3G or other APOBEC3 proteins. 
 
Conservation derived from the 2011 Los Alamos National Laboratory HIV Sequence 
Database curated alignment for HIV subtypes (“All M Group A-K + Recombinants”). 
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Table 1-3. Summary of linkage studies between clinical indicators and 
hypermutation, APOBEC3 expression or APOBEC3 polymorphism. 
Study Cohort description Relationships reported 
Association with hypermutation   
(Pace et al., 2006) 136 Australians, largely male and 
Caucasian; all treatment-naive 
Reduced viremia 
attributable to 
hypermutation 
(Gandhi et al., 
2008) 
8 elite suppressors and 9 patients on 
highly active antiretroviral therapy 
Hypermutation 
comparable between the 
two groups with the 
exception of one elite 
suppressor who had 
significantly elevated 
hypermutation levels 
(Land et al., 
2008) 
215 Kenyan female sex workers and 25 
Kenyan women of similar 
socioeconomic status who were not 
commercial sex workers; all treatment-
naive 
Increased CD4+ cell 
counts in 17 patients with 
significant hypermutation 
Positive correlation 
between adenine content 
and CD4+ cell counts 
among 208 patients from 
whom counts were 
available 
(Ulenga et al., 
2008a) 
29 Senegalese female sex workers; all 
treatment-naive 
No correlation between 
hypermutation and 
viremia 
(Vazquez-Perez et 
al., 2009) 
45 HIV-infected, 37 HIV-exposed 
seronegative, and 26 healthy control 
patients; all treatment-naive 
Increased hypermutation 
in patients with low viral 
load 
(Piantadosi et al., 
2009) 
28 Kenyan women; all treatment-naive No correlation between 
percentage of 
hypermutated sequences 
and either viral load in 
chronic infection or 
CD4+ cell counts 
approximately 6 weeks 
postinfection 
No difference for either 
indicator between 
patients with and without 
hypermutated sequences 
 
(Amoedo et al., 
2011) 
17 Brazilian, perinatally-infected 
pediatric AIDS patients, most 
treatment-experienced 
No correlation between 
hypermutation levels and 
progressor/nonprogressor 
status 
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Study Cohort description Relationships reported 
Association with APOBEC3 expression   
(Jin et al., 2005) 6 uninfected individuals and 25 
infected individuals consisting of 8 
long-term nonprogressors and 17 
progressors; all treatment-naive 
Inverse correlation 
between A3G expression 
and viral load 
Positive correlation 
between A3G expression 
and CD4+ cell counts 
among the 25 infected 
individuals 
Higher A3G mRNA 
levels in long-term 
nonprogressors and 
uninfected individuals 
relative to progressors 
(Cho et al., 2006) 92 infected individuals (~2/3 African 
American and ~1/3 Caucasian) and 19 
uninfected individuals (~2/3 
Caucasian); infected individuals off 
treatment for at least three months 
Lower A3F and A3G 
mRNA levels in infected 
versus uninfected 
individuals 
No correlation between 
A3F or A3G mRNA 
levels and viral load or 
CD4+ cell counts 
(Biasin et al., 
2007) 
30 each of HIV-exposed seronegative 
individuals, HIV-infected individuals 
and uninfected individuals; all infected 
individuals on antiretroviral therapy 
Greater A3G protein 
levels in exposed 
seronegative individuals 
compared with healthy 
controls or infected 
individuals 
Cells from exposed 
seronegative individuals 
relatively resistant to ex 
vivo infection compared 
with healthy controls 
(Ulenga et al., 
2008b) 
Senegalese female sex workers – 16 
with a low viral set point and 14 with a 
high viral set point; all treatment-naive 
Inverse correlation 
between A3G or A3F 
mRNA levels after 
infection and viral set 
point 
(Vazquez-Perez et 
al., 2009) 
45 infected, 37 HIV-exposed 
seronegative and 26 healthy control 
patients; all treatment-naive 
Positive correlation 
between A3G mRNA 
and CD4+ cell counts in 
infected patients 
Negative correlation 
between A3G mRNA 
expression and viremia 
Higher A3G mRNA 
expression in exposed 
seronegative individuals 
compared with healthy 
controls 
(Pillai et al., 
2012) 
19 HIV/HCV coinfected patients 
receiving IFNα/ribavirin therapy 
Inverse correlation 
between interferon-
mediated upregulation of 
A3F but not A3G and 
viral load 
(Amoedo et al., 
2011) 
17 Brazilian, perinatally-infected 
pediatric AIDS patients, most 
treatment-experienced 
No correlation between 
A3F/G mRNA 
expression levels and 
progressor/nonprogressor 
status 
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Study Cohort description Relationships reported 
Association with APOBEC3 polymorphisms   
(An et al., 2004) Total of 3073 patients in six cohorts: 
1481 European Americans and 949 
African Americans broken into groups 
of seroconverters, seroprevalents and 
seronegatives among patients in the 
USA; 643 seroprevalent Swiss 
individuals 
7 polymorphisms 
identified in a subset of 
92 African American and 
92 European American 
patients 
H186R also identified in 
Do et al. (Ref. 105) more 
common in African 
Americans and correlates 
with loss of CD4+ cells 
and progression to AIDS 
in this group 
(Do et al., 2005) 245 HIV-infected slow progressors, 82 
HIV-infected rapid progressors and 446 
healthy subjects; all French Caucasians 
None of 29 
polymorphisms identified 
in A3G associated with 
rate of disease 
progression 
(Pace et al., 2006) 136 Australians, largely male and 
Caucasian; all treatment-naive 
22 polymorphisms 
identified 
No association between 
two closely examined 
polymorphisms and 
hypermutation levels 
(Valcke et al., 
2006) 
122 Canadian Caucasian males 6 polymorphisms 
identified 
C40693T intronic change 
associated with increased 
risk of infection 
(An et al., 2009) 4216 infected individuals from five 
longitudinal cohorts based in the USA 
Homozygous A3B 
deletion associated with 
increased risk of 
infection, faster 
progression to AIDS and 
increased viral set point 
No association detected 
in hemizygous 
individuals 
(De Maio et al., 
2011) 
Pediatric HIV infected cohort No association between 
H186R or C40693T A3G 
SNPs and progression to 
AIDS 
(Cagliani et al., 
2011) 
70 Italian HIV-exposed seronegative 
partners in serodiscordant relationships 
Association of A3H 
Haplotype I with 
preventing infection 
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Figure 1-1: APOBEC3 and Vif function. 
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Figure 1-1: APOBEC3 and Vif function. (A) Vif-deficient HIV infection using the 
prototypical APOBEC3 protein A3G as an example. In a ‘nonpermissive producer cell’ – 
that is, one that expresses the DNA cytosine deaminase A3G and/or other restrictive 
APOBEC3 proteins and does not support replication of Vif-deficient HIV –  gene 
expression of Vif-deficient HIV proceeds normally but, during assembly, A3G (pink 
circles) is encapsidated along with normal virion components. Virions with encapsidated 
A3G bud from a producer cell and enter a target cell normally. Reverse transcription, 
however, is blocked by the presence of A3G, either by the direct inhibition of cDNA 
synthesis or the degradation of uracil-containing cDNA, arising from cytosine 
deamination. Uracil-containing cDNA templates A on the viral plus-strand, resulting in 
G-to-A hypermutation. A direct A3G-mediated block to integration has also been 
proposed (not shown). (B) Vif-proficient HIV infection. To prevent encapsidation, Vif 
expressed from a Vif-proficient virus links A3G to an E3 ligase complex, which results in 
the ubiquitination of A3G and its eventual degradation in the proteasome. Alternatively, 
Vif may directly inhibit encapsidation, lower A3G expression and/or inhibit A3G 
catalytic activity (not shown). Subsequent release, entry, reverse transcription and 
integration are shown proceeding normally. 
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Figure 1-2: Steps of reverse transcription impacted by deaminase-dependent 
mechanisms of APOBEC3 restriction. 
A. Minus-Strand Strong Stop Synthesis
B. Minus-Strand Transfer & Minus-Strand Synthesis
C. Plus-Strand Strong Stop Synthesis
D. Plus-Strand Transfer & Plus-Strand Synthesis
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Figure 1-2: Steps of reverse transcription impacted by deaminase-dependent 
mechanisms of APOBEC3 restriction. Normal reverse transcription is depicted in the 
left column, while points at which APOBEC3 proteins may impede reverse transcription 
by deaminase-dependent mechanisms are depicted at the right. References are distributed 
throughout the main text. (A) APOBEC3 deamination of a target cytosine to uracil 
creates a substrate on which a uracil DNA glycosylase may act (blank oval), creating an 
abasic site that may be further processed by an unspecified AP endonuclease to degrade 
viral cDNA (blank circle). (B) Steps unaffected per published mechanisms of APOBEC3 
deaminase-dependent restriction. (C) Persistence of uracil in the viral minus strand is a 
mutagenic event that, among many possibilities, may introduce premature stop codons or 
ablate initiating methionine codons. Alternatively, persistence of an abasic site 
subsequent to APOBEC3-dependent deamination and processing by a uracil DNA 
glycosylase enzyme may impede synthesis of the plus-strand or, alternatively, result in 
the insertion of adenine across from the abasic site, yielding the same mutagenic event as 
minus-strand uracil persistence. (D) APOBEC3 deaminase-dependent aberrant RNase H 
processing of the tRNA primer may prevent liberation of the viral plus-strand for transfer 
to the 5’ end of the genome and subsequent priming of additional plus-strand synthesis. 
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Figure 1-3: Steps of reverse transcription impacted by deaminase-independent 
mechanisms of APOBEC3 restriction. 
A. Minus-Strand Strong Stop Synthesis
B. Minus-Strand Transfer & Minus-Strand Synthesis
C. Plus-Strand Strong Stop Synthesis
D. Plus-Strand Transfer & Plus-Strand Synthesis
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Figure 1-3: Steps of reverse transcription impacted by deaminase-independent 
mechanisms of APOBEC3 restriction. Normal reverse transcription is depicted in the 
left column, while points at which APOBEC3 proteins may impede reverse transcription 
by deaminase-independent mechanisms are depicted at the right. References are 
distributed throughout the main text. (A) Binding of APOBEC3 proteins to genomic 
RNA may impede the processivity of reverse transcriptase, preventing the completion of 
cDNA synthesis. Alternatively, the reverse transcription reaction may fail to prime in a 
manner dependent on APOBEC3 interaction with the viral nucleocapsid protein (gray 
circles). (B) APOBEC3 deaminase-independent aberrant RNase H processing of the 
template genomic RNA may fail to liberate the minus-strand strong stop cDNA to 
transfer to the 3’ end of the genome and prime additional minus-strand synthesis. (C) 
Steps unaffected per published mechanisms of APOBEC3 deaminase-independent 
restriction. (D) APOBEC3-dependent aberrant RNase H processing of the tRNA primer 
may fail to liberate the plus-strand for transfer to the 5’ end of the genome and 
subsequent priming of additional plus-strand synthesis. 
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Figure 1-4: Important domains in Vif and APOBEC3G. 
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Figure 1-4: Important domains in Vif and APOBEC3G. While many papers have 
identified residues critical to Vif function, only putative continuous interaction domains 
in Vif (A) and APOBEC3G (A3G) (B) are depicted here for the sake of clarity. 
Exceptions are made for two important lysines in Vif (K22 and K26) as well as the C-
terminal zinc-binding domain of Vif. Vif and A3G are internally to scale, but Vif is 
depicted at twice its actual size relative to A3G. HIV Vif residues shown are those found 
in the HXB2 reference sequence (accession number K03455). A3G corresponds to 
reference sequence NP_068594. (C) Important domains of A3G identified by genetic 
analysis are highlighted on a full-length model structure of APOBEC3G (A3G) (Harjes et 
al., 2009) with coloration carried out in Pymol. See main text for references and 
discussion. Side chains are shown for key regions, and the right panel represents a 
rotation of 180º about the y-axis. Red spheres, active-site zinc; green side chains 
(124YYFW127), encapsidation determinant (overlaps 126–127 start of Vif-binding region 
126FWDPDYQ132); red sidechain (D128), a key residue for Vif sensitivity; blue 
sidechains (129PDYQ132), the remainder of the putative Vif-binding site; yellow side 
chains (H65 & E67 and H257 & E259), the HxE of the pseudocatalytic and catalytic N- 
and C-terminal domains, respectively; orange side chains (96PC97 & C100 and 287PC288 & 
C291), the PCxxC of the active and pseudoactive N- and C-terminal domains, 
respectively. 
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Chapter 2: Long-term Restriction by APOBEC3F Selects Human 
Immunodeficiency Virus Type 1 Variants with Restored Vif Function 
 
Foreword 
 
This chapter is reproduced with permission from the following publication: 
 Albin JS, Haché G, Hultquist JF, Brown WL and Harris RS. “Long-term 
 restriction by APOBEC3F selects human immunodeficiency virus type 1 variants 
 with restored Vif function.” Journal of Virology. 2010; 84 (19): 10209-10219. 
 
The work described in this chapter is the continuation of a project initiated by a previous 
student, Guylaine Haché. She described the evolution of Vif-deficient isolates that bypass 
A3G by repairing an aberrant upstream open reading frame in the parent HIVIIIB strain, 
leading to enhanced viral production and thereby “tolerance” of the presence of A3G 
despite the persistent absence of Vif (Haché et al., 2009; Haché et al., 2008). 
 One observation to come of these studies was that repair of this aberrant upstream 
open reading frame was insufficient to permit growth in cell lines stably transfected with 
restrictive levels of A3F. We therefore set out to determine how viruses might bypass 
A3F by carrying out similar virus evolution studies starting from viral templates with a 
repaired upstream open reading frame and premature vpr stop codons. The function of 
Vpr deficiency in these and related studies remains obscure, but it is a common 
observation among viruses passaged in culture and may represent a culture-adaptive 
feature [e.g. (Nakaya et al., 1994) and see Chapters 5 and 6]. For example, inactivation 
of Vpr and its associated cell cycle arrest activity may keep infected cells alive longer to 
produce more virions. In any event, the Vpr status of the viruses described in this 
manuscript is, as we will show, irrelevant to their ability to neutralize A3F. 
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Summary 
Tandem stop mutations K26X and H27X in human immunodeficiency virus type 1 (HIV) 
vif compromise virus replication in human T cell lines that stably express the restriction 
factors APOBEC3F (A3F) or APOBEC3G (A3G). We previously reported that partial 
resistance to A3G could develop in these Vif-deficient viruses through a nucleotide 
A200-to-T/C transversion and a vpr null mutation, but these isolates were still susceptible 
to restriction by A3F. Here, long-term selection experiments were done to determine how 
these A3G-selected isolates might evolve to spread in the presence of A3F. We found 
that A3F, like A3G, is capable of potent, long-term restriction that eventually selects for 
heritable resistance. In 7/7 instances, the selected isolates had restored Vif function to 
cope with A3F activity. In two isolates, Vif Q26-Q27 and Y26-Q27, the resistance 
phenotype recapitulated in molecular clones, but when the selected vif alleles were 
analyzed in the context of an otherwise wildtype viral background a different outcome 
emerged. Although HIV clones with Vif Q26-Q27 or Y26-Q27 were fully capable of 
overcoming A3F, they were now susceptible to restriction by A3G. Concordant with 
prior studies, a lysine at position 26 proved essential for A3G neutralization. These data 
combine to indicate that A3F and A3G exert at least partly distinct selective pressures 
and that Vif function may be essential for the virus to replicate in the presence of A3F. 
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Introduction 
Human APOBEC3F (A3F) is a DNA cytosine deaminase that, like its prototypical 
relative APOBEC3G (A3G), restricts the infectivity of human immunodeficiency virus 
type 1 (HIV) in the absence of the viral accessory protein virion infectivity factor (Vif) 
(Bishop et al., 2004; Liddament et al., 2004; Sheehy et al., 2002; Wiegand et al., 2004; 
Zheng et al., 2004). Vif is thought to permit productive HIV infection by mediating the 
proteasomal degradation of A3G and A3F through recruitment of a ubiquitin ligase 
complex consisting of Elongins B and C, Cullin 5, and Rbx2 (Conticello et al., 2003; 
Liddament et al., 2004; Marin et al., 2003; Mehle et al., 2004a; Mehle et al., 2004b; 
Sheehy et al., 2003; Stopak et al., 2003; Wiegand et al., 2004; Yu et al., 2003; Yu et al., 
2004c; Zheng et al., 2004). In addition, several groups have suggested other mechanisms 
by which Vif may counteract APOBEC3 proteins, including directly inhibiting 
packaging, decreasing translation, and inhibiting deaminase activity (Kao et al., 2003; 
Mariani et al., 2003; Mercenne et al., 2009; Santa-Marta et al., 2005; Stopak et al., 
2003). 
 In contrast with HIV, direct and indirect observations indicate that many 
retroviruses do not need Vif to evade restriction by cellular APOBEC3 proteins. For 
instance, the lentivirus equine infectious anemia virus (EIAV) lacks a vif gene despite the 
existence of an extensive repertoire of equine APOBEC3 proteins (Bogerd et al., 2008; 
Zielonka et al., 2009), and among other types of Vif-deficient retroviruses, a number of 
alternative APOBEC3-resistance mechanisms have evolved. Foamy viruses use an 
auxiliary protein called Bet to neutralize APOBEC3 proteins (Löchelt et al., 2005; 
Russell et al., 2005). Human T cell leukemia virus type 1 (HTLV-1) avoids APOBEC3 
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encapsidation through its unique nucleocapsid protein (Derse et al., 2007). Analogously, 
murine leukemia virus (MLV) excludes certain APOBEC3 proteins from virions and 
cleaves encapsidated murine APOBEC3 (Abudu et al., 2006; Doehle et al., 2005b), while 
Mason-Pfizer Monkey Virus (MPMV) also avoids the encapsidation of its cognate rhesus 
macaque A3G (Doehle et al., 2006). 
 Overall, it appears that most retroviruses must possess a mechanism to evade the 
APOBEC3 proteins of their hosts, and this requirement does not always involve Vif. 
Even in the case of HIV, the most influential study to date to analyze the activity of 
primary isolates of Vif against A3F and A3G demonstrated that 10/40 genetically intact 
vif alleles tested were defective for the neutralization of one or both restriction factors 
(Simon et al., 2005). In addition to intact but defective vif alleles, diverse studies suggest 
the occurrence of vif alleles with gross genetic lesions to be quite common, ranging from 
3.4-31% of clones analyzed [e.g. 3.4% (Komoto et al., 2005), 5.8% (Zhang et al., 1997), 
6.3% (Simon et al., 2005), 10.2% (Yedavalli et al., 1998), 17.4% (Sova et al., 1995), 
21.1% (Yedavalli and Ahmad, 2001) or 31.1% (Tominaga et al., 1996)] and readily 
detectable in most studies in a sizeable fraction of patients analyzed [e.g. 0/50 (Hassaine 
et al., 2000), 6/55 (Wieland et al., 1994), 2/18 (Wieland et al., 1997), 3/14 (Rangel et al., 
2009), 2/9 (Zhang et al., 1997), 2/7 (Simon et al., 2005), 4/10 (Sova et al., 1995), 7/10 
(Yedavalli et al., 1998), 3/4 (Yedavalli and Ahmad, 2001) or 5/6 (Tominaga et al., 
1996)]. Our own analysis of 2,522 subtype B sequences from the Los Alamos National 
Laboratory HIV Sequence Database indicated approximately 4% of vif sequences contain 
one or more premature termination codons (data not shown; http://www.hiv.lanl.gov/). 
One may therefore conservatively estimate that, concordant with the overall proportion of 
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defective vif alleles estimated by Simon and colleagues, at least 20% of vif alleles are 
likely inactive against one or more APOBEC3 proteins (Simon et al., 2005). Beyond that, 
some unknown percentage will likely display suboptimal neutralizing activity relative to 
“wildtype” as also observed previously [e.g. (Marin et al., 2008; Simon et al., 2005)]. 
Combining these findings with the fact that HIV has had only decades in which to adapt 
to the human APOBEC3 repertoire while its Vif-encoding simian immunodeficiency 
virus (SIV) ancestors may have been coexisting with primate APOBEC3 repertoires for 
millions of years [e.g. (Gifford et al., 2008; Worobey et al., 2008)], it is important to 
consider the possibility that Vif function may not be the sole mechanism of resistance to 
APOBEC3 proteins available to HIV.  
 To address this, we have previously carried out long-term in vitro selection 
experiments in which we passaged HIV containing tandem stop codons at position 26 and 
27 of vif in the presence of A3G. These studies yielded viral variants that could spread 
effectively in the presence of A3G despite retention of these tandem stop codons; rather, 
all isolates had acquired a pyrimidine at nucleotide 200 and a stop codon in vpr (Haché et 
al., 2008). While the effect of the vpr null mutation remains unknown, the substitution of 
A-to-T/C at nucleotide 200 functions to optimize viral translation, resulting in increased 
particle production and a relative decrease in A3G encapsidation to levels tolerable to the 
viral population (Haché et al., 2009). However, we also observed that these T/C200 vif- 
vpr- variants were still susceptible to restriction by A3F and by the APOBEC3 repertoire 
in nonpermissive CEM cells (Haché et al., 2008). 
 We therefore set out to select variants of these viruses that might additionally 
resist A3F. Given the literature on the Vif-independent evasion of APOBEC3 proteins by 
  77 
the other viruses noted above as well what is known of the mechanisms of human 
APOBEC3-mediated restriction, we hypothesized that any of several possibilities might 
manifest: i) changes in nucleocapsid or viral nucleic acid structures that inhibit A3F 
encapsidation [e.g. references above and many addressing the mechanism of A3G 
encapsidation as discussed in (Chiu and Greene, 2008)]; ii) mutations in integrase or viral 
nucleic acid motifs that impede the effects of APOBEC3 proteins on integration [e.g. 
(Luo et al., 2007; Mbisa et al., 2007; Mbisa et al., 2010)]; iii) mutations in viral nucleic 
acid structures or nucleocapsid that impede APOBEC3 effects on reverse transcription 
[e.g. (Bishop et al., 2008; Guo et al., 2006; Iwatani et al., 2007; Li et al., 2007; Yang et 
al., 2007b)]; iv) nonspecific fitness-enhancing mutations [e.g. T/C-200 in (Haché et al., 
2008)]; or v) the restoration of functional vif alleles. 
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Results 
A3F selects for the restoration of Vif function – To determine how vif-deficient HIVIIIB 
may evolve to overcome restriction by A3F, we used four starting virus templates to 
initiate a total of 288 selection cultures across four independent experiments. In the first 
two experiments, we used viruses derived from molecular clones of our previous A3G-
resistant isolates to infect A3F-expressing CEM-SS cells [i.e. A3G-R2 is HIVIIIB T200 
vif-X26X27 vpr-W54X and A3G-R3 is T200 vif-X26X27 vpr-W18X (Haché et al., 
2008); Tables 2-1 and 2-2]. Within approximately 8-12 weeks of long-term continuous 
culture, a total of 7 resistant isolates out of 96 infected were obtained; representative 
isolates from Experiments 1 and 2 are described below and in Table 2-2. All attempts to 
select resistance from the parental A200 vif-X26X27 vpr+ or a C200 derivative of this 
parent in these and in two subsequent experiments were unsuccessful (data not shown). 
Immunoblotting showed that the A3F levels in stably transfected clones of CEM-SS and 
the naturally nonpermissive CEM and H9 cell lines are similar [Figure 2-1A and (Haché 
et al., 2008)]. A recent report further indicates that A3F expression levels in CEM are 
similar to those in primary CD4+ T cells, suggesting that the selective pressure applied in 
these studies is comparable to that exerted by A3F in primary cells (Refsland et al., 
2010). 
A3F-resistant isolates were passaged sequentially two additional times in A3F-
expressing CEM-SS cells. Replication curves from the third passage indicated that the 
resistant viruses spread with improved titer and kinetics in A3F-expressing cell lines with 
peaks generally occurring between 10 and 20 days post-infection as shown for 2 
representative isolates (Figure 2-1B). As anticipated, the putative A3F-resistant isolates 
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maintained the ability to replicate in A3G-expressing or vector control CEM-SS clones 
(Figures 2-1C and 2-1D). However, these viruses did not acquire the capacity to 
replicate in CEM (Figure 2-1E, below, and Discussion). In some instances, the growth 
curves of the parental virus (A200 Vif-K26-H27) are relatively weak due to high 
cytotoxicity, but this does not affect our overall interpretations or conclusions (e.g., 
Figure 2-1D). 
 To genotype the A3F-selected viruses, we amplified and cloned a region of the 
proviral genome encompassing vif and vpr, nucleotides 3,095-5,485 [GenBank accession 
EU541617 (Haché et al., 2008)]. We obtained a minimum of 10 sequences per isolate, 
and analysis revealed that the A3F-resistant isolates had changed nonsense vif codons to 
missense, while the vpr null mutations remained intact (Table 2-2 and data not shown). A 
composite analysis of the sequences derived from three A3F-resistant isolates showed a 
high hypermutation load averaging 2.4 G-to-A mutations per kilobase (Figure 2-2A-C). 
These mutations generally occurred with notable bias toward a 5’-GA-3’ dinucleotide 
context, which is characteristic of the deaminase activity of A3F attacking cDNA strand 
5’-TC-3’ motifs. However, substantial 5’-GG-3’ context hypermutations consistent with 
the action of A3G were also evident, particularly in A3F-resistant isolate 7 (Figure 2-
2C). These G-to-A mutations were likely the result of the low levels of endogenous A3G 
in CEM-SS cells [e.g. Figure 2-1A, see below and published quantifications (Koning et 
al., 2009; Refsland et al., 2010)]. The overall hypermutation levels in these isolates was 
also likely influenced by the existence of an initially mixed resistant population due to the 
sequential accumulation of the missense vif mutations, with codon 26 mutating first and 
codon 27 second. This order of events is suggested by the fact that the same X-to-Q 
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missense mutation at codon 26 was detected in isolate 7 alongside two different codon 27 
missense mutations, X-to-Q or X-to-W. From hereon, analyses will focus exclusively on 
two resistance-associated vif alleles encoding missense mutations at codons 26 and 27, 
vif-QQ and vif-YQ (Tables 2-1 & 2-2). 
 
Resistance to A3F occurs through Vif –  Based on our proviral DNA sequence analyses 
and the fact that numerous prior studies have shown that Vif can counteract A3F, we 
hypothesized that the resistance to A3F observed in our isolates would be conferred by 
the aforementioned missense mutations at vif codons 26 and 27. To test this hypothesis 
and eliminate the possibility that mutations elsewhere in the viral genome might 
contribute to A3F resistance, we incorporated the vif-QQ and vif-YQ alleles cleanly into 
their parent A3G-resistant molecular clone backgrounds and infected A3F-expressing 
CEM-SS cells with viruses produced from these molecular clones (Table 2-1). These 
viruses – HIVIIIB T200 vif-QQ (or vif-YQ) vpr- – displayed robust infectivity and kinetics 
on cells expressing A3F, A3G, or a vector control, as expected for a virus engineered to 
contain both A3G and A3F resistance mutations (Figures 2-3A-C). In addition, like the 
original A3F-resistant isolates, these molecular clones still failed to replicate in CEM 
cells despite their enhanced replicative capacity in the presence of A3F (Figure 2-3D, 
below, and Discussion). 
 
vpr deficiency does not explain the lack of resistant virus replication in CEM –  Given the 
ability of the selected viruses to grow in the presence of A3F or A3G, it was notable that 
they were still unable to spread in CEM cells that express these and three additional 
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APOBEC3 proteins (Refsland et al., 2010). We therefore turned to viral genotypes in 
search of a possible explanation. The nucleotide at position 200 was not likely to be 
responsible because the vast majority of HIV isolates already have a T or C at that 
position [e.g., (Haché et al., 2008) per the Los Alamos National Laboratory HIV 
Sequence Database]. The A200 in the parent HIVIIIB is presumably disfavored because it 
causes suboptimal translation, lower levels of viral particle production, and a relatively 
greater degree of A3G-dependent restriction (Haché et al., 2009; Haché et al., 2008). 
However, the function served by vpr inactivation in the parent A3G-resistant viruses is 
still unknown. 
 To address the possibility that an undescribed Vpr function might be required for 
these viruses to grow in the presence of multiple APOBEC3 proteins, we incorporated the 
selected vif alleles into HIVIIIB C200 vpr(+) molecular clones (Table 2-1). All viruses 
were replication-competent in vector control CEM-SS and SupT11 cell lines (data not 
shown). Like the Vpr-deficient vif-QQ and vif-YQ viruses in Figures 2-1E and 2-3D, 
however, Vpr-proficient viruses with the vif-QQ or vif-YQ alleles remained restricted by 
nonpermissive CEM and H9 cells (Figure 2-4A-B, data not shown, and see below for 
additional data with these molecular clones). In contrast, the wildtype vif-KH virus spread 
readily in these fully nonpermissive lines in both vpr+ and vpr- backgrounds (Figure 2-
4A-B and data not shown). We therefore concluded that the basis for the observed 
replication defect in naturally nonpermissive cell lines lay in the identity of the amino 
acids selected by A3F – vif-QQ or vif-YQ versus the wildtype vif-KH. 
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Variants of Vif selected by A3F are unable to effectively degrade A3G – To 
mechanistically characterize Vif-QQ and Vif-YQ, we assessed the ability of these Vif 
variants to neutralize A3F or A3G in single-cycle infectivity experiments at several levels 
of Vif expression. As predicted by the spreading infection phenotypes, the Vif variants 
selected by A3F were as efficient at enhancing viral infectivity and lowering intracellular 
A3F levels as the wildtype Vif-KH (Figure 2-5A). In contrast, the Vif variants selected 
by A3F did not restore infectivity in the presence of A3G, and they were markedly 
deficient in their ability to lower intracellular A3G levels (Figure 2-5B). This clear A3G 
susceptibility helped to explain why viruses with these vif alleles fail to spread in CEM or 
H9 (e.g. Figure 2-4) and why our original A3F-resistant isolates had significant 5’-GG-3’ 
context hypermutations – the original CEM-SS A3F lines have permissive but detectable 
levels of endogenous A3G [Figure 2-1A, Figure 2-2 and (Refsland et al., 2010)]. 
However, it remains possible that other APOBEC3 proteins expressed in CEM and H9 
beyond A3F and A3G may account for at least part of the continued restriction of A3F-
selected viruses in these cells [Discussion and (Refsland et al., 2010)]. 
 
The inability of the vif alleles selected by A3F to neutralize A3G maps to the identity of 
amino acid 26 – To test whether viruses with the vif alleles selected by A3F are deficient 
in their ability to neutralize A3G in spreading infections and, if so, to additionally 
determine the nature of the mutation responsible, we did a series of spreading infection 
experiments using a panel of full-length molecular clones with amino acid substitution 
mutations at vif codons 26 or 27 (i.e. wildtype HIVIIIB C200 viruses with the exception of 
vif; Table 2-1). Specifically, we compared viruses with K, Q, or Y at position 26 and H 
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or Q at position 27, and we used A3F or A3G expressing SupT11 clones because we 
recently found that this line is nearly devoid of endogenous APOBEC3 expression 
[(Refsland et al., 2010) and Figure 2-6A].  
We found that all combinations of Vif residues at positions 26 and 27 were able to 
spread in SupT11 cells expressing A3F and in SupT11 vector control cells (Figure 2-6B 
and data not shown). In contrast, only viruses encoding a lysine at position 26 of Vif were 
able to spread effectively in cells expressing A3G or in nonpermissive CEM or H9 cell 
lines (Figures 2-6C-D and data not shown). These data corroborate two recent Vif site-
directed mutation screens, which independently found that K26 is important for the 
neutralization of A3G (Chen et al., 2009; Dang et al., 2009). They are also consistent 
with the high conservation of K26 in sequences in the Los Alamos National Laboratory 
HIV sequence database, where 99.4% (2,507/2,522) of subtype B sequences encode 
lysine at position 26 [data not shown; http://www.hiv.lanl.gov/]. 
Given the correlation between the capacity of a particular Vif to degrade 
APOBEC3 proteins and the ability of viruses carrying those vif alleles to spread in the 
presence of APOBEC3 proteins, we further hypothesized that degradation is the 
predominant mechanism of Vif action at play in our spreading infection system. To test 
this hypothesis, we incorporated Vif BC Box mutations at positions 144-146 into both the 
wildtype and A3F-selected molecular clones. SLQ-to-AAA substitutions in this highly 
conserved region have been previously shown to interrupt interaction between Vif and 
Elongin C, thus attenuating the Vif-mediated degradation of APOBEC3 proteins [e.g. 
(Yu et al., 2003)]. We observed that viruses carrying these mutations are unable to spread 
in SupT11 cells stably transfected with A3F or A3G as well as naturally nonpermissive 
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CEM or H9 cells (data not shown). These data indicate that the interaction between Vif 
and Elongin C is required for A3F/G neutralization and, further, based on many prior 
studies, that degradation is an integral part of the mechanism. 
 
Additional long-term selection experiments in nonpermissive CEM cells select for a 
positive charge at Vif position 26 – To determine how the vif alleles selected by A3F 
might evolve to become resistant to the full nonpermissive APOBEC3 repertoire in CEM, 
we passaged vif-QQ viruses in these cells until resistant isolates arose. From 48 parallel 
cultures, 5 isolates emerged after 8-12 weeks of incubation. Second passage proviral 
DNA sequencing revealed that 3 isolates carried Q26R mutations while two more carried 
Q26K mutations; representative viruses from these selections are shown in Experiment 5 
of Table 2-2. Serial passage in CEM indicated that these isolates replicated with greater 
efficiency than the parent vif-QQ viruses, although Q26R viruses still tended to display 
attenuated replication kinetics (Figure 2-7).  
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Discussion 
The experiments described here are the first reported selections for HIV resistance 
to the restriction factor A3F. Our data show that A3F, like A3G, is capable of potent 
long-term restriction, extending to two the number of APOBEC3 proteins shown capable 
of selecting heritable resistance (Haché et al., 2008). The strength of A3F-mediated 
restriction in our spreading infection experiments combined with its ability to select 
resistance contrasts somewhat with the consistently weaker effects of A3F in single-cycle 
assays compared with A3G [e.g. (Bishop et al., 2006; Bishop et al., 2004; Holmes et al., 
2007; Liddament et al., 2004; Simon et al., 2005)]. The reason(s) for this disparity are not 
obvious, but the data presented here suggest that A3F may be an important part of the 
selective pressure that maintains Vif function in vivo. 
We presume that the isolates emerging from long-term selection experiments will 
have taken the easiest path to resistance. Given the current literature on APOBEC3 
proteins, we might have anticipated the selection of any number of Vif-independent 
resistance mechanisms to A3F as discussed in the Introduction, but we have only ever 
selected for the restoration of Vif function. If Vif-independent resistance to A3F is 
possible, then, the genetic barriers to evolving such mechanisms are apparently greater 
than the 1-2 mutational events required to restore Vif function in the alleles described 
here. Fitness costs to viruses acquiring these putative alternative resistance mutations 
may also influence the overall barrier to their development.  
Aside from the central observation that A3F selects for the restoration of Vif 
function, we identified K26 as an important residue for the Vif-mediated degradation of 
A3G but not A3F. This result is satisfying in light of recent site-directed mutagenesis 
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studies also showing that K26 is indeed required for A3G neutralization (Chen et al., 
2009; Dang et al., 2009), and it likely explains the notable presence of G-to-A mutations 
consistent with A3G action in our selected viral isolates (Figures 2-1A and 2-2). 
Molecularly, our characterization of the vif alleles selected by A3F is largely in 
agreement with these two reports in finding that viruses without the wildtype K26 lack 
the ability to efficiently degrade A3G, although they still continue to bind it (Figure 2-5B 
and data not shown). Thus, our data also support the notion that K26 is part of the Vif 
interaction surface that contacts A3G. 
In the process of characterizing the amino acid identity requirements at residue 
26, we also demonstrate for the first time that the evolution of vif in response to one 
APOBEC3 protein (A3F) may not result in a Vif variant with activity against another 
APOBEC3 protein (A3G; Figures 2-5 and 2-6). Thus, the selective pressures exerted on 
vif by each APOBEC3 protein are at least partially distinct. This conclusion is consistent 
with a growing body of mutagenesis data implying that the structural determinants of 
A3F and A3G binding sites within Vif can be both defined and in some instances 
separated genetically [reviewed in (Albin, 2010; Smith et al., 2009)].  
While we have not yet succeeded in selecting Vif function as a mechanism of 
A3G resistance, our observations should not be extrapolated to quantify the relative 
abilities of A3F and A3G to select for Vif function. For instance, the vif genotype of the 
parental virus is highly likely to influence the outcome. Furthermore, we do not wish to 
imply that Vif function is unimportant for overcoming restriction by A3G. Even in vitro, 
the A3G-selected mutations that we have previously reported are not as robust as 
wildtype Vif function. They fail to complement the A3F-selected Vif alleles when 
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replicated in naturally nonpermissive CEM and H9 cells as well as CEM-SS cells stably 
transfected with both A3F and A3G (Figures 2-1E, 2-3D and data not shown), and we 
have also observed that they may become overwhelmed when replicating on SupT11 
cells expressing higher levels of A3G but no other APOBEC3 proteins (data not shown).  
This is likely due to the nature of our previously characterized A3G-resistance mutations, 
which merely tolerate the presence of A3G better than the parental virus (Haché et al., 
2008). That a particular resistance mutation should be saturable by higher APOBEC3 
expression levels is perhaps not all that surprising, because even Vif-proficient viruses 
can be overwhelmed and restricted under conditions of APOBEC3 overexpression [e.g. 
(Peng et al., 2006; Sadler et al., 2010)]. Furthermore, we cannot rule out the possibility 
that other dominant acting APOBEC3 restriction factors in CEM and H9 beyond A3F 
and A3G may be at least in part responsible for the more potent restriction observed in 
these cell lines. Results of future long-term selection experiments, especially if the viral 
genotype and/or the cellular APOBEC3 levels differ from those described here, are likely 
to yield other informative outcomes. 
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Materials and Methods 
Plasmids – All novel constructs described were confirmed by DNA sequencing. A3F and 
A3G coding sequences are identical to those found in GenBank, NM_145298 and 
NM_021822, respectively. The pcDNA3.1-derived constructs used for the stable 
expression of untagged A3F and A3G have been described (Haché et al., 2008). 
pcDNA3.1-V5 and pcDNA3.1-A3F-V5 expression constructs containing a V5 epitope 
tag were made by digesting pcDNA3.1-3xHA or pcDNA3.1-A3F-3xHA (Stenglein and 
Harris, 2006) with XhoI/XbaI and ligating these with synthetic complementary 
oligonucleotides 5’-TC GAG GGA GTC GAG GGC GGC GGT AAG CCT ATC CCT 
AAC CCT CTC CTC GGT CTC GAT TCT ACG TAG T-3’ and 5’-CT AGA CTA CGT 
AGA ATC GAG ACC GAG GAG AGG GTT AGG GAT AGG CTT ACC GCC GCC 
CTC GAC TCC C-3’, which replaces the 3xHA coding sequence with one for the V5 
epitope. pcDNA3.1-A3G-V5 was derived by amplifying A3G from pcDNA3.1-A3G 
using primers 5’-NNN GAA TTC GAG CTC GGT ACC ACC ATG AAG CCT CAC 
TTC AG AAA C-3’ and 5’-NNN GTC GAC TCC GTT TTC CTG ATT CTG GAG 
AAT-3’, digesting with KpnI/SalI and ligating the purified product into pcDNA3.1-V5 
digested with KpnI/XhoI. 
 We codon-optimized HIVIIIB Vif and added nucleotides for a C-terminal HA 
epitope (GenScript USA). The translated Vif open reading frame is identical to GenBank 
EU541617 (Haché et al., 2008). VifIIIB-HA was excised from parental vector pU57 using 
BamHI/SalI and subcloned into a similarly cut pVR1012-derived plasmid provided by 
Dr. Xiao-Fang Yu (Johns Hopkins University, Baltimore). This BamHI/SalI-digested 
expression construct was religated to itself to create a vector control. pVR1012-VifIIIB-
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HA was modified by site-directed mutagenesis with Pfu polymerase (Stratagene) to 
create variants encoding QQ and YQ at positions 26 and 27 using primers 5’-T TGG 
AAG CGC CTC GTG CAG CAG CAT ATG TAC ATC TCC C-3’ and 5’-G GGA GAT 
GTA CAT ATG CTG CTG CAC GAG GCG CTT CCA A-3’ or 5’-ACT TGG AAG 
CGC CTC GTG TAT CAG CAT ATG TAC ATC TCC CGC-3’ and 5’-GCG GGA GAT 
GTA CAT ATG CTG ATA CAC GAG GCG CTT CCA AGT-3’. 
 Proviral constructs for wildtype HIVIIIB [GenBank EU541617 (Haché et al., 
2008)] and a vif-deficient derivative with tandem stop codons at positions 26 and 27 were 
obtained from Dr. Michael Malim (King’s College London, England). Derivative 
molecular clones with A3G-resistant virus 2 and A3G-resistant virus 3 (A3G-R2 and 
A3G-R3) mutations, as well as a vif-deficient HIVIIIB containing a cytosine at nucleotide 
200, have been described [(Haché et al., 2008) and Table 2-1]. Substitution of a given vif 
allele in these backgrounds was done by site-directed mutagenesis on a pCR4-Blunt 
(Invitrogen) plasmid containing the PCR amplified and cloned HIVIIIB vif/vpr region 
extending from nucleotides 3,095 to 5,485 [GenBank EU541617 (Haché et al., 2008), 
where +1 is the transcriptional start site]. Of note, the A3G-R3 used here is a variant of 
the published sequence containing an additional nucleotide deletion at position 5,285 in 
the vpr open reading frame downstream of the reported vpr W18X mutation (Haché et 
al., 2008). Mutated fragments were reintroduced into full-length molecular clones by 
subcloning the SwaI/SalI fragment from the shuttle vector into a similarly cut parental 
HIVIIIB proviral plasmid. A comprehensive listing of the molecular clone genotypes used 
in these studies is provided in Table 2-1. 
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Stable cell lines – CEM-SS cells stably expressing A3F, A3G or a vector control have 
been described (Haché et al., 2008). SupT1 was obtained from the AIDS Research and 
Reference Reagent Program (#100). SupT11 is a single-cell subclone of SupT1 isolated 
by limiting dilution. APOBEC3-expressing derivatives were made by electroporating 
with 20 µg linearized plasmid (250 volts, 950 µF; BioRad), selecting with 1.0 mg/ml 
G418 (Mediatech), and screening clones for APOBEC3 expression by immunoblotting 
using anti-A3F or anti-A3G antibodies (#11474 or #10201 from Drs. Michael Malim or 
Jaisri Lingappa, respectively, obtained through the AIDS Research and Reference 
Reagent Program). T cell lines were maintained in RPMI supplemented with 10% fetal 
bovine serum, penicillin/streptomycin, β-mercaptoethanol and, in some cases, 0.5 mg/mL 
G418. 
 
Virus stocks – Infectious virus was produced by transfecting 5 or 10 µg of proviral 
molecular clone plasmids into 293T cells at approximately 70% confluence in 10 cm 
dishes using Trans-IT (Mirus Bio) or Fugene 6 (Roche) transfection reagents. 2-3 days 
later, virus-containing supernatants were harvested and filtered through 0.45 µm filters. 
293T cells were maintained in DMEM supplemented with 10% fetal bovine serum and 
penicillin/streptomycin. 
 
Virus titration – Viruses derived from molecular clones were titered by infecting 50,000 
CEM-GFP reporter cells (Gervaix et al., 1997; Haché et al., 2008). Approximately three 
days later, cells were fixed in 4% paraformaldehyde, and GFP-positive infected cells 
were quantified using flow cytometry. A Beckman-Coulter Quanta MPL or a Becton-
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Dickinson FacsCalibur instrument was used for data collection, and FlowJo (Tree Star) or 
CellQuest (Becton-Dickinson) software was used for data analysis. Live cells were gated 
by forward versus side scatter (or by electronic volume versus side scatter when using the 
Quanta MPL), and the proportion of GFP-positive cells in this population was quantified. 
These percentages were then graphed against the volume of virus stock used, and linear 
regression was employed to determine the percentage of cells infected at a given volume 
of a particular virus stock. Calculations of multiplicity of infection (MOI) on CEM-GFP 
cells were derived from these percentages and used as a standard by which to normalize 
the quantity of infectious virus used to initiate infections. Quantification of resistant virus 
isolates differed from this protocol due to the limited amount of passaged supernatants 
available. In this case, titers were calculated from single infections of 25,000 CEM-GFP 
cells with 150 µL of virus saved on a given day in a total volume of 250 µL.  
 
HIV spreading infection experiments – Spreading infections were initiated by infecting 
50,000 cells of a given cell line in a total volume of 1 mL in one well of a 24-well plate at 
a CEM-GFP MOI of 0.01-0.05; MOI in a given experiment is indicated in the associated 
figure legend. Spreading infections were monitored by periodically using 150 µL of cell-
free supernatant to infect fresh target CEM-GFP cells at a concentration of 25,000 cells 
per 100 µL per well of a 96-well plate. At approximately 2-4 days post-infection, these 
cells were fixed in 4% paraformaldehyde and analyzed by flow cytometry as above. The 
original infected cultures were split and their media replenished as needed at each time 
point taken to prevent the overgrowth of infected cells. The accumulation of multiple 
cycles of infection in a spreading infection leads to some variability in the peaks of 
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replication, and clonal variation among the cell lines used in the experiments described 
introduces an additional variable (See Stable Cell Lines above for cell line derivation 
procedures). Nevertheless, general trends of growth/no growth for each virus on each cell 
line are apparent in the data shown here and in many additional experiments not shown. 
Additional observations of import are provided in the text or associated figure legend to 
supplement raw infectivity curves. Except where specifically indicated, the restriction of 
a given virus is indicated by increasingly flat replication curves. Viruses that spread 
effectively, in contrast, will generally yield a sharp infectivity peak followed by a decline 
as cells are killed by viral spread. 
 
Resistant virus selection procedures – Resistant viruses were selected by initiating 
spreading infections in a given cell line (e.g. CEM-SS clones stably transfected with 
A3F) as indicated above at an MOI of 0.05 or 0.03. Cell-free supernatants were 
periodically used to infect target CEM-GFP cells as above, and these CEM-GFP cultures 
were visually monitored for the outgrowth of notably more infectious viruses as 
evidenced by an increased proportion of bright GFP-positive cells. Cultures were split 
and fed as needed at each monitoring point to prevent the overgrowth of infected cells on 
which viral spread remained restricted until the emergence of resistance. Upon outgrowth 
of a virus displaying enhanced infectivity, cell-free supernatants were saved at each 
monitoring point for subsequent confirmatory passage. Passage of resistant isolates was 
then initiated using virus produced in the presence of A3F, and these passages were 
conducted as indicated above for a typical spreading infection. 
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Proviral DNA sequencing – Genomic DNA was extracted from target CEM-GFP cells 
infected at the end of the third passage of resistant virus isolates using Qiagen DNeasy 
kits. This gDNA was then used as template for the amplification of integrated proviral 
sequences using PCR with high fidelity Phusion polymerase (NEB) and primers 5’-
CAAGGCCAATGGACATATCA-3’ and 5’-CAAACTTGGCAATGAAAGCA-3’. PCR 
products were cloned into pJET (Fermentas), TOPO pCR4-Blunt or TOPO pCR-Blunt II 
(Invitrogen). Cloned viral fragments were recovered in TOP10 or DH10B Escherichia 
coli and plasmid DNA prepared with Qiagen or Clontech miniprep kits. Plasmids were 
then sequenced using universal or virus-specific primers. Sequences were compiled and 
analyzed using Sequencher software (Gene Codes Corp.). 
 
APOBEC3 immunoblotting experiments – T cell lines were grown to confluence, 
harvested, and lysed in approximately 50 µl of lysis buffer [25 mM HEPES pH 7.4, 150 
mM NaCl, 1 mM MgCl2, 50 µM ZnCl2, 10% glycerol and 1% Triton X-100 lysis buffer 
containing 50 µM MG132 (American Peptide) and complete protease inhibitor (Roche)] 
per 1 mL of cells. A 5x sample buffer consisting of 62.5 mM Tris pH 6.8, 20% glycerol, 
2% sodium dodecyl sulfate (SDS), 5% β-mercaptoethanol and 0.05% bromophenol blue 
was added to each lysate to a final concentration of 2x, and the mixture was boiled for 
approximately 10 minutes prior to loading. Proteins were fractionated by 10% SDS-
PAGE, transferred to a PVDF membrane, blocked in 4% milk dissolved in phosphate 
buffered saline (PBS) 0.01% Tween, incubated with rabbit anti-A3F (above), rabbit anti-
A3G (above) or mouse anti-Tubulin (Covance) and probed with a secondary horseradish 
peroxidase (HRP)-conjugated goat anti-rabbit or goat anti-mouse antibodies (BioRad). 
  94 
Blots were then developed using HyGlo chemiluminescent HRP antibody detection 
reagent (Denville Scientific) and exposed to film. Membranes were stripped using 62.5 
mM Tris pH 6.8, 2% SDS and 100 mM β-mercaptoethanol at 50ºC and washed in PBS 
0.01% Tween prior to sequential blocking and reprobing with each primary antibody 
after the first. 
 
Single-cycle infectivity assays – 250,000 293T cells/well were plated in a total volume of 
2 ml/well in 6-well plates. Approximately 24h later, each well was transfected using 
Trans-IT transfection reagent (Mirus Bio) with 200 ng of a vector control or an 
APOBEC3-V5 expression construct, a pVR1012 vector control or 50, 100 or 200 ng of a 
given Vif-HA expression construct supplemented as necessary to 200 ng total with the 
pVR1012 vector and 1.6 µg of the full-length replication-competent HIVIIIB C200 XX 
provirus (Table 2-1). Two days post-transfection, virus-containing supernatants were 
filtered through 0.45 µm filters and used to infect CEM-GFP cells in 96-well plates as 
above. Three days post-infection, these CEM-GFP cells were fixed and analyzed by flow 
cytometry as above. 
 In addition to particle infectivity, producer cell APOBEC3 expression levels were 
determined. Cells were lysed in 25 mM HEPES pH 7.4, 150 mM NaCl, 1 mM MgCl2, 50 
µM ZnCl2, 10% glycerol and 1% Triton X-100 lysis buffer containing 50 µM MG132 
(American Peptide) and complete protease inhibitor (Roche). Immunoblots were then 
prepared as described above, except primary mouse anti-V5 (Invitrogen), mouse anti-
HA.11 (Covance) or mouse anti-Tubulin (Covance) antibodies were used for protein 
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detection in conjunction with secondary HRP-conjugated goat anti-mouse (BioRad) 
antibodies. 
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Table 2-1: HIV molecular clone genotypes used in this study. 
Name 
HIVIIIB 
Nucleotide 
200 
vif 
Codons 
26-27 
vpr Other Mutations Reference 
A200 XX A XX + n/a Figure 1b-e; 3a-d 
C200 XX C XX + n/a Figure 4a-b; 5a-b; 6b-d; 7 
A200 KH A KH + n/a Figure 1b-e; 3a-d 
C200 KH C KH + n/a Figure 4a-b; 6b-d; 7 
C200 KH 
SLQ>AAA C KH + 
vif 144-146 
SLQ>AAA 
Figure 6 data not 
shown 
T200 XX 
vpr- 
(A3G-R2) 
T XX W54X gag (NC) R32K; pol (IN) silent Figure 1b-e; 3a-d 
T200 XX 
vpr- 
(A3G-R3) 
T XX W18X Del A5285 (vpr) Figure 1b-e; 3a-d 
T200 KH 
vpr- 
(A3G-R2) 
T KH W54X gag (NC) R32K; pol (IN) silent 
Figure 4 data not 
shown 
T200 KH 
vpr- 
(A3G-R3) 
T KH W18X Del A5285 (vpr) Figure 4 data not shown 
T200 QQ 
vpr- (A3F-
R7) 
T QQ W54X gag (NC) R32K; pol (IN) silent Figure 3a-d 
T200 YQ 
vpr- (A3F-
R5) 
T YQ W18X Del A5285 (vpr) Figure 3a-d 
C200 QQ C QQ + n/a Figure 4a-b; 6b-d; 7 
C200 QQ 
SLQ>AAA C QQ + 
vif 144-146 
SLQ>AAA 
Figure 6 data not 
shown 
C200 YQ C YQ + n/a Figure 4a-b; 6b-d 
C200 YQ 
SLQ>AAA C YQ + 
vif 144-146 
SLQ>AAA 
Figure 6 data not 
shown 
C200 KQ C KQ + n/a Figure 6b-d; 7 data not shown 
C200 QH C QH + n/a Figure 6b-d 
C200 YH C YH + n/a Figure 6b-d 
C200 RQ C RQ + n/a Figure 7 data not shown 
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Table 2-2: Summary of experiments selecting A3F- or CEM-resistant HIV variants. 
Expt Cell Line Parental HIVIIIB Genotype 
Resistant 
Isolate 
Name 
Selected vif 
26-27 
Genotype 
Amino 
Acid 26-27 
Changes 
Frequency 
by 
Sequencing 
  A200 KH vpr+ n/a AAA CAC KH n/a 
  A200 XX vpr+ n/a TAA TAG XX n/a 
1 CEM-SS F1 
T200 XX vpr 
W54X 
(A3G-R2) 
A3F-R3 CAA CAG QQ 11/13 
1 CEM-SS F1 
T200 XX vpr 
W18X 
(A3G-R3) 
A3F-R5 TAT CAG YQ 12/13 
2 CEM-SS F2 
T200 XX vpr 
W54X 
(A3G-R2) 
A3F-R7 CAA CAG CAA TGG 
QQ 
QW 
5/12 
2/12 
5 CEM C200 QQ vpr+ CEM-R1    AAA CAG KQ 5/5 
5 CEM C200 QQ vpr+ CEM-R2  CGA CAG RQ 3/3 
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Figure 2-1: Restriction of Vif-deficient HIV by A3F selects resistant virus variants. 
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Figure 2-1: Restriction of Vif-deficient HIV by A3F selects resistant virus variants. 
(A) A Western blot showing the expression of A3F and A3G in H9, CEM and the CEM-
SS-derived cell lines used in these studies. F1 and F2 = A3F-expressing CEM-SS; G1 
and G2 = A3G-expressing CEM-SS; V1 and V2 = CEM-SS transfected with a vector 
control. (B-E) Growth curves in the indicated cells for the following HIV isolates: Vif-
proficient (A200 KH), Vif-deficient (A200 XX), A3G-resistant [(T200 XX vpr- (A3G-
R2) and T200 XX vpr- (A3G-R3)] and representative A3F-resistant viruses derived from 
parent A3G-resistant viruses [T200 YQ vpr- (A3F-R5) and T200 QQ vpr- (A3F-R7) 
where vif genotypes are retrospectively indicated according to subsequent sequencing 
(Table 2-2)]. The starting MOI was approximately 0.02, and similar results were 
obtained using second CEM-SS A3F-expressing and vector control cell lines (data not 
shown). The low peaks observed for some A200 KH growth curves, particularly in panel 
2-1D, are due to the high cytotoxicity of this virus, which sometimes results in low 
apparent titers as infected cells are rapidly killed. In addition to the notably low A200 KH 
CEM-SS V1 curve, a growth curve for A200 KH in another CEM-SS vector line from 
this experiment, CEM-SS V3, is indicated by an arrow in 2-1D to visually demonstrate 
that the wildtype virus spreads in the absence of restrictive levels of APOBEC3 proteins. 
The x-axis is offset from zero in all curves to permit better visualization of viruses 
showing little or no growth. Throughout, open symbols indicate viruses lacking Vif 
expression; closed symbols indicate full-length vif alleles. Similarly, dashed lines are 
used for vpr- viruses, while solid lines are used for vpr+ viruses. 
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Figure 2-2: Hypermutation patterns in selected A3F-resistant isolates. The frequency 
of each base change is given for the clones described in Experiments 1 and 2 of Table 2-
2, as is the predominance of the dinucleotide context in which G-to-A mutations occur. 
Similar to previous authors, we note a substantial C-to-T transition rate in the presence of 
A3F in addition to the expected G-to-A hypermutations [e.g. (Bishop et al., 2004; 
Holmes et al., 2007; Liddament et al., 2004)]. The viruses selected also contain 
substantial 5’-GG-3’ to 5’-AG-3’ transitions, particularly in the case of A3F-resistant 
isolate 7, suggesting ongoing mutation by A3G in addition to A3F. 
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Figure 2-3: Restoration of the vif open reading frame accounts for phenotypic 
resistance to A3F-mediated restriction. 
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Figure 2-3: Restoration of the vif open reading frame accounts for phenotypic 
resistance to A3F-mediated restriction. Spreading infections at an MOI of 0.05 were 
initiated in CEM-SS cells stably transfected with A3F (A), A3G (B) or a vector control 
(C) as well as in nonpermissive CEM cells (D) using viruses derived from proviral 
molecular clones with the indicated genotypes. The mildly enhanced infectivity of A3G-
resistant viruses relative to their parent A200 XX viruses in A3F-expressing CEM-SS 
cells is sometimes observed in experiments such as the one shown that starts from a 
higher MOI (compare the lower MOI in Figure 2-1B with the higher MOI in Figure 2-
3A). In contrast, A3F-selected viruses consistently display robust peaks at any MOI in 
the presence of A3F. The peaks of A200 KH growth are indicated by arrows in 2-3A and 
2-3B to differentiate them from the descending T200 YQ vpr- (A3F-R5) curve and the 
superimposed T200 YQ vpr- (A3F-R5) peak, respectively. Similar results were obtained 
using proviral molecular clones corresponding to other selected isolates as well as 
additional CEM-SS clones stably transfected with A3F, A3G or a vector control (data not 
shown). 
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Figure 2-4: The identity of Vif amino acids 26 and/or 27 rather than Vpr status is 
critical for the ability to replicate on naturally nonpermissive cells. Spreading 
infection curves are shown for viruses with wildtype (KH), A3F-selected missense (QQ 
and YQ) and nonsense (XX) codons at positions 26 and 27 of vif in a Vpr-proficient 
context. Spreading infections were carried out from a starting MOI of 0.01 on CEM and 
H9 cells (A and B) as well as CEM-SS and SupT11 clones transfected with a vector 
control (data not shown). Different alleles of vif in Vpr-deficient contexts showed the 
same growth patterns on CEM and H9 as their Vpr-proficient counterparts (Table 2-1 
and data not shown). 
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Figure 2-5: Functional Vifs selected by A3F are deficient in their ability to degrade 
A3G. A titration experiment analyzing the infectivity of particles produced by the 
cotransfection of constant amounts of A3F-V5 (A) or A3G-V5 (B) in the presence of 
increasing amounts of Vif-HA. The identities of amino acids 26 and 27 are indicated for 
each Vif-expressing construct. Infectivity data represent the mean and SEM of three 
independent experiments where infectivity is determined relative to that of particles 
produced under the same cotransfection conditions in each experiment with a vector 
control in place of the APOBEC3 expression construct (not shown). Immunoblots shown 
are taken from one of these three experiments. While Vif-QQ and Vif-YQ are notably 
deficient in their ability to neutralize A3G relative to the wildtype Vif-KH, a mild effect 
is seen at higher levels of Vif expression, which achieves statistical significance by a 
paired two-tailed t test for Vif-QQ but not Vif-YQ (B and data not shown). V = Vif 
vector and A3F-V5 or A3G-V5 expression constructs cotransfected; these conditions 
were tested once in each experiment but are loaded in the immunoblots and plotted in the 
histograms three times each for direct visual comparison with the addition of each Vif. 
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Figure 2-6: A3F-selected vif alleles are nonfunctional for the neutralization of A3G 
but can be rescued by restoration of the wildtype K26 residue. 
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Figure 2-6: A3F-selected vif alleles are nonfunctional for the neutralization of A3G 
but can be rescued by restoration of the wildtype K26 residue. (A) Western blots 
showing expression levels of A3F and A3G in the SupT11-derived cell lines used in these 
experiments as well as in H9 and CEM cells. Spreading infection curves from a starting 
MOI of 0.01 are shown for wildtype (C200 KH), Vif-deficient (C200 XX) and A3F-
selected (C200 QQ and YQ) mutants as well as mutants completing the matrix of 
combinations of wildtype and selected residues at positions 26 and 27 of vif (C200 QH, 
YH and KQ) on SupT11 cells transfected with A3F (B) or A3G (C) as well as 
nonpermissive CEM cells (D). Results demonstrate that K26 is critical for the 
neutralization of A3G and the APOBEC3 repertoire found in CEM cells but not A3F. 
Results concordant with 2-6B-D were observed using additional SupT11-derived cell 
lines expressing A3F or A3G as well as SupT11 clones transfected with a vector control 
and H9 cells (data not shown). Higher peaks than that shown in 2-6B are usually 
observed with the C200 QQ virus (e.g. Figures 2-1 and 2-3 and data not shown); in 
addition to those curves and many not shown, the ability of C200 QQ to spread in the 
presence of A3F is indicated by the fact that it efficiently kills the culture in which it 
replicates (see the legend to Figure 2-1). 
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Figure 2-7: Long-term culture of A3F-resistant viruses in CEM cells selects for 
restoration of a positive charge at Vif residue 26. Passage of CEM-resistant viral 
isolates in CEM cells demonstrating their functional resistance to the nonpermissive 
phenotype of CEM. Phenotypic resistance of the selected alleles to the nonpermissive 
phenotype as encountered in CEM cells was also confirmed using viruses derived from 
molecular clones (Table 2-1 and data not shown). A summary of the sequence evolution 
observed in resistant isolates that were confirmed by second passage and for which 
sequence was available is given in Experiment 5 of Table 2-2. 
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Postscript 
 The takeaway from Chapter 2 is straightforward and neatly encapsulated in its 
title. That said, several points merit clarification. Only after completing this study did we 
understand that we had effectively stacked the deck against vif repair in our A3G 
selections since a lysine at position 26 is apparently the only option available for 
reversion in the presence of A3G (Figure 2-6). Efficacy of arginine may also be implied 
by the passages in naturally nonpermissive CEM cells (Figure 2-7), but R26-Q27 
mutants were not clearly superior to Q26-Q27 in lowering the steady state levels of 
cotransfected A3G (data not shown) or in mediating spread in cell lines stably expressing 
A3G alone (Judd F. Hultquist, data not shown). These findings corroborate those of Dang 
et al., where despite its conservative nature, the K26R mutation fails to restore Vif 
efficacy against A3G (Dang et al., 2009). This may imply that K26 is a site of a post-
translational modification that is somehow selectively critical to anti-A3G function, but 
we have not investigated this matter further. It is also possible that the K26R mutant may 
simply be a hypomorphic variant that more readily manifests in certain cells types than in 
others for any number of potential reasons. 
 Thus, while Vif anti-A3F function has a great deal of flexibility in reverting 
codons at positions 26 and 27, Vif anti-A3G function effectively has one, rare T-to-A 
transversion available to it. Despite the apparent contrast between the selective pressures 
applied by A3G and A3F, then, this phenomenon should not necessarily be taken as a 
direct comparison of the relative importance of A3F versus A3G for the maintenance of 
Vif function – but see Chapters 5-6. 
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Chapter 3: A Single Amino Acid in Human APOBEC3F Alters Susceptibility to 
HIV Vif 
 
Foreword 
 
This chapter is reproduced with permission from the following publication: 
 Albin JS, LaRue RS, Weaver JA, Brown WL, Shindo K, Harjes E, Matsuo H and 
 Harris RS. “A single amino acid in human APOBEC3F alters susceptibility to 
 HIV Vif.” Journal of Biological Chemistry. 2010; 285 (52): 40785-40792. 
 
Following the work described in Chapter 2, we surmised that, despite the field’s focus 
on A3G, further study of A3F may be more informative for our understanding of the 
APOBEC3-Vif interaction based simply on the fact that the genetic interaction between 
A3F and Vif was much clearer than that between A3G and Vif. Surprisingly, this has 
remained the case through several experimental iterations (see Chapters 5-6). 
 The natural next question, then, was to ask which portions of each protein are 
involved in this interaction. Since a highly influential alanine scanning mutagenesis paper 
had already identified putative A3F and A3G binding regions in Vif (but see Chapter 5 
and Supplementary Chapter 2), we opted to determine the Vif interaction site in A3F, 
which was only known in broad terms at this point based on chimera studies. 
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Summary 
 
Human APOBEC3F (huA3F) potently restricts the infectivity of HIV in the absence of 
the viral accessory protein virion infectivity factor (Vif). Vif functions to preserve viral 
infectivity by triggering the degradation of huA3F but not rhesus macaque A3F (rhA3F). 
Here, we use a combination of deletions, chimeras and systematic mutagenesis between 
huA3F and rhA3F to identify E324 as a critical determinant of huA3F susceptibility to 
HIV Vif-mediated degradation. A structural model of the C-terminal deaminase domain 
of huA3F indicates that E324 is a surface residue within the α4 helix adjacent to residues 
corresponding to other known Vif susceptibility determinants in APOBEC3G and 
APOBEC3H. This structural clustering suggests that Vif may bind a conserved surface 
present in multiple APOBEC3 proteins. 
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Introduction 
 
 Human APOBEC3 proteins including APOBEC3F (huA3F) and APOBEC3G 
(huA3G) are DNA cytosine deaminases that restrict the infectivity of HIV in target cells 
following virion incorporation in producer cells [recently reviewed by (Albin, 2010; 
Goila-Gaur and Strebel, 2008; Henriet et al., 2009)]. HIV overcomes this restriction 
activity by utilizing its accessory protein virion infectivity factor (Vif) to facilitate the 
degradation of APOBEC3 proteins in producer cells, thus preventing particle 
incorporation and restriction. 
 Previously, several groups identified specific changes in the N-terminal 
deaminase domain (NTD) of huA3G that affect the ability of HIV Vif to neutralize this 
restriction factor (Bogerd et al., 2004; Mangeat et al., 2004; Schröfelbauer et al., 2004; 
Xu et al., 2004). The first of these studies sought to determine the basis for the 
observation that the Vif proteins of the lentiviruses infecting different species neutralize 
the A3G proteins of their natural host species but not the A3G proteins of other species 
(Mariani et al., 2003). For example, African green monkey A3G (agmA3G) is susceptible 
to Vif from the simian immunodeficiency virus (SIV) that naturally infects Chlorocebus 
aethiops (agmSIV) but not to HIV Vif, while huA3G is susceptible to HIV Vif but not to 
agmSIV Vif. By substituting agmA3G residues into huA3G where the two differed, 
several groups identified D128 as a critical determinant of this species specificity 
(Bogerd et al., 2004; Mangeat et al., 2004; Schröfelbauer et al., 2004; Xu et al., 2004). 
Subsequent mutational analyses have confirmed that huA3G D128 and surrounding 
residues including D130 impact HIV Vif-mediated degradation (Huthoff and Malim, 
2007; Lavens et al.; Russell et al., 2009b). 
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 More recently, two reports showed that, in contrast with huA3G, huA3F is 
recognized at its C-terminal deaminase domain (CTD) by HIV Vif (Russell et al., 2009b; 
Zhang et al., 2008). One of these groups further narrowed the determinants of this 
recognition to amino acids 283-300, although individual amino acid changes critical for 
HIV Vif susceptibility were not identified in a manner analogous to the huA3G studies 
cited above. Thus, the residues of huA3F critical for the ability of HIV Vif to bind and 
degrade this restriction factor are presently unknown. 
 Here we identify a critical determinant of huA3F susceptibility to HIV Vif by 
comparing huA3F with the closely related but HIV Vif-resistant rhA3F (Virgen and 
Hatziioannou, 2007; Zennou and Bieniasz, 2006). Using chimeras between these 
orthologs as well as single-domain  studies, we confirm that Vif recognizes the CTD of 
huA3F. Through systematic replacement of selected C-terminal huA3F residues with 
their corresponding rhA3F residues, we further identify huA3F QE323-324EK as a 
critical determinant of this differential susceptibility. Additional mutagenesis between 
these two residues revealed that mutation of E324 to the rhA3F lysine or to alanine 
results in resistance to HIV Vif-mediated degradation. To determine the three-
dimensional context surrounding this residue, we created a model of the CTD of huA3F 
and found that E324 is a surface residue contained within the α4 helix that forms part of a 
broader surface shared with the linearly separate huA3F Vif interaction domain 
previously narrowed to residues 283-300 (Russell et al., 2009b). Importantly, this 
analysis also revealed that the huA3F residues corresponding to three known Vif 
susceptibility determinants, D128 and D130 in huA3G and D/E121 in human 
APOBEC3H (huA3H), also cluster at this helix. These studies combine to suggest that a 
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conserved structural surface is targeted by HIV Vif en route to APOBEC3 neutralization 
and degradation. 
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Results 
HIV Vif recognizes the huA3F C-terminal deaminase domain – Two previous reports 
have indicated that HIV Vif binds the CTD of huA3F  (Russell et al., 2009b; Zhang et 
al., 2008). To confirm and extend these results, we took two approaches. First, we created 
chimeras between huA3F and rhA3F, which share 87% identity and 92% overall 
similarity at the protein level (Figure 3-1A). This strategy takes advantage of the fact that 
rhA3F is resistant to HIV Vif while huA3F is sensitive to HIV Vif (Virgen and 
Hatziioannou, 2007; Zennou and Bieniasz, 2006). Therefore, by comparing the sensitivity 
of chimeric proteins to HIV Vif-mediated degradation, one can broadly infer whether a 
given chimera contains a site functionally recognized by HIV Vif. As shown in Figure 3-
1B, huA3F and the rhA3F/huA3F chimera containing the rhA3F NTD and the huA3F 
CTD retained high sensitivity to HIVIIIB Vif-mediated degradation on cotransfection of a 
given chimera with HIV Vif. In contrast, rhA3F and the huA3F/rhA3F chimera 
containing the huA3F NTD and the rhA3F CTD were insensitive to the presence of HIV 
Vif. To confirm these results, we cotransfected HA-tagged HIV Vif or SIV Vif with 
GFP-tagged single deaminase domains of huA3F or rhA3F, respectively, and assessed 
the stability of each domain. Both HIV Vif and SIV Vif destabilized the CTDs of huA3F 
and rhA3F, respectively, while the corresponding NTDs were relatively unaffected 
(Figure 3-1C). Thus, our data corroborate prior reports demonstrating that the A3F CTD 
is necessary and sufficient for Vif-mediated degradation (Russell et al., 2009b; Zhang et 
al., 2008). 
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A3F residues 323-324 affect the differential susceptibility of huA3F and rhA3F to HIV 
Vif – To more closely map the residues critical for functional neutralization of huA3F, we 
created a series of huA3F mutants containing 1-2 rhA3F residues at sites where these two 
differ within their CTDs. A schematic of the substitutions made is shown in Figure 3-2A. 
To test the Vif susceptibility of these mutants, we carried out single-cycle infectivity 
assays. As shown in Figure 3-2B, infectivity restoration upon the cotransfection of 
HIVIIIB Vif with most huA3F mutants was similar to that seen with wildtype huA3F. For 
the substitution QE323-324EK, however, Vif sensitivity was ablated (Figure 3-2B). 
These infectivity data correlated with producer cell huA3F levels, making this mutant 
phenotypically analogous to the control huA3G D128K. 
 Interestingly, neither of these substitutions is contained within the Vif binding 
region proposed by Russell et al. (Russell et al., 2009b), residues 283-300, while the 
substitutions that do fall within this region (NLT298-300KLA) have no apparent 
phenotype [Figure 3-2A-B and Discussion]. Furthermore, huA3F D313H, which 
corresponds to the change D130K in the evolutionarily related NTD of huA3G, has no 
apparent phenotype  [Figure 3-2A-B, Discussion and (25)]. 
 To confirm the intrinsic Vif-resistance of huA3F QE323-324EK and eliminate the 
possibility that the C-terminal V5 tag initially used might affect our observations, we 
carried out single-cycle titration experiments using increasing levels of Vif cotransfected 
with a constant amount of huA3F, huA3F QE323-324EK, huA3G or huA3G DPD128-
130KPK. As shown in Figure 3-2C, both huA3F QE323-324EK and huA3G DPD128-
130KPK retained similar restriction regardless of Vif levels. The Vif-resistance of both 
  116 
constructs was further confirmed by the intracellular stability of each in comparison with 
its wildtype control in the presence of Vif. 
 Because the single-cycle infectivity assays described to this point are vulnerable 
to potential overexpression artifacts [e.g. (Browne et al., 2009; Miyagi et al., 2007; 
Schumacher et al., 2008), we also sought to assess the Vif-resistance of the huA3F 
QE323-324EK construct in a more physiologic setting. To that end, we created 
derivatives of a previously-described APOBEC3-deficient T cell line, SupT11, stably 
transfected with untagged huA3F QE323-324EK or huA3G DPD128-130KPK to go with 
our previously described derivatives expressing wildtype huA3F or huA3G (Albin et al.; 
Refsland et al., 2010). The expression levels of huA3F and huA3G in each cell line used 
are shown in Figure 3-2D. We then initiated spreading infections at an MOI of 0.01 on 
these cell lines using Vif-deficient or wildtype IIIB or LAI-GFP viruses. All cell lines 
with the exception of the vector controls restricted the spread of Vif-deficient HIVIIIB and 
HIVLAI-GFP (data not shown). In contrast, both wildtype HIVIIIB and HIVLAI-GFP, which 
differ at 20/192 Vif amino acids, spread efficiently on cell lines expressing wildtype 
huA3F or huA3G (Figure 3-2E and data not shown). Despite this, similar levels of 
huA3F QE323-324EK or huA3G DPD128-130KPK restricted the spread of even these 
Vif-proficient viruses (Figure 3-2E and data not shown). We thus conclude that huA3F 
QE323-324EK, like huA3G DPD128-130KPK, is fully resistant to HIV Vif and fully 
capable of inhibiting virus replication. 
 
Reciprocal amino acid substitutions rhA3F EK323-324QE do not sensitize rhA3F to HIV 
Vif – To ask whether the reciprocal amino acid substitutions in rhA3F might render it 
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susceptible to HIV Vif in a manner analogous to the sensitization of agmA3G by the 
humanizing mutation K128D (Bogerd et al., 2004; Mangeat et al., 2004; Schröfelbauer et 
al., 2004; Xu et al., 2004), we carried out single-cycle infectivity and expression analyses 
as above using rhA3F and rhA3F EK323-324QE. Under these conditions, rhA3F EK323-
324QE showed no significant recovery in infectivity in the presence of HIV Vif over 
wildtype rhA3F (Figure 3-3). Thus, residues 323-324 are not exclusively responsible for 
the differential Vif sensitivity of rhA3F and huA3F. This observation is consistent with 
the emerging view that a larger surface on APOBEC3 proteins is recognized by Vif (See 
Discussion). 
 It is important to note that such separation of function experiments are not 
possible using SIVmac239 Vif, as this Vif neutralizes both huA3F and rhA3F (Zennou and 
Bieniasz, 2006). This parallels the results of several of the original papers characterizing 
huA3G D128K, which show that SIVmac239 Vif is able to neutralize both huA3G and 
rhA3G [ e.g. (Schröfelbauer et al., 2004; Xu et al., 2004)]. It is also consistent with our 
own studies suggesting that the Vifs of various species’ lentiviruses are optimized for 
recognition of their own host species’ APOBEC3Z3 proteins but often retain 
considerable activity against the APOBEC3Z3 proteins of other species (LaRue et al., 
2010). 
 
Mutation of huA3F E324 alone alters functional susceptibility to HIV Vif in the absence 
of a quantitative reduction in physical binding – To further characterize the changes at 
residues 323-324, we created huA3F mutants with single cognate rhesus substitutions at 
each position as well as single and double alanine mutations at these positions and 
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assessed their restriction activities and Vif susceptibilities as before. This analysis 
revealed that any huA3F variant lacking glutamate at position 324 is resistant to HIV Vif 
regardless of the identity of residue 323, which correlates with intracellular A3F levels 
(Figure 3-4A). We therefore conclude that residue 324 is a single amino acid determinant 
of huA3F HIV Vif susceptibility. 
 To determine whether mutation of E324 alters the quantitative binding of Vif to 
huA3F, we cotransfected HA-tagged Vif with V5-tagged huA3F and variants mutated at 
residues 323 and 324. We then immunoprecipitated HA-tagged Vif from these lysates 
and blotted for associated V5-tagged huA3F. Despite the resistance of huA3F E324 
variants to HIV Vif-mediated degradation, however, we found that mutation of this 
residue does not reduce coimmunoprecipitation with HIV Vif relative to wildtype 
(Figure 3-4B-C). These results were confirmed by reciprocal immunoprecipitation of the 
V5-tagged huA3F or huA3F E324K and blotting for cotransfected, untagged Vif in both 
RIPA and NP40 lysis buffers (data not shown). 
 
Determinants of HIV Vif recognition localize to the α4 helix of a susceptible deaminase 
domain – To visualize E324 in its three-dimensional context, we created a model of the 
CTD of huA3F based on a recent crystal structure of the huA3G CTD [PDB ID 3IR2, 
(Shandilya et al., 2010). As shown in Figure 3-5A-B, E324 is located on the surface of 
the α4 helix. Importantly, this region is also adjacent to the linearly separate stretch of 
amino acids previously implicated in the huA3F interaction with HIV Vif, residues 283-
300 (Russell et al., 2009b). We also noted, however, that several additional negatively 
charged residues occurred on or near the surface of this helix: D311, D313 and E316. On 
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aligning these residues to those found in other Vif-susceptible deaminase domains in 
Figure 3-5C, we noted that they each align to a previously-described APOBEC3 
determinant of Vif susceptibility (Bogerd et al., 2004; Huthoff and Malim, 2007; Lavens 
et al.; Mangeat et al., 2004; Russell et al., 2009b; Schröfelbauer et al., 2004; Xu et al., 
2004). D311 and D313 in huA3F correspond to D128 and D130 in the NTD of huA3G, 
while huA3F E316 corresponds to E/D121 in human APOBEC3H (huA3H). Thus, all 
known APOBEC3 determinants of Vif susceptibility cluster along the surface of the α4 
helix, and all are negatively charged. 
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Discussion  
 The studies described here are the first to identify a single amino acid determinant 
of the susceptibility of huA3F to HIV Vif. This represents an important advance in our 
understanding of the HIV Vif-huA3F interaction, the relevance of which is strongly 
supported by a large body of work demonstrating the potency of huA3F-mediated 
restriction of HIV [e.g. (Bishop et al., 2004; Liddament et al., 2004; Wiegand et al., 
2004; Zheng et al., 2004)]. Our own long-term viral evolution studies have also 
suggested that functional neutralization of huA3F by HIV Vif is required for the virus 
propagate in the presence of huA3F (Albin et al., 2010a). Thus, shielding the α4 region 
of huA3F described here from HIV Vif may represent a viable strategy for the 
development of novel pharmacotherapies for HIV infection [e.g. (Albin, 2010; Harris and 
Liddament, 2004)]. 
 Our work confirms prior reports that broadly localized Vif interaction to the CTD 
of huA3F [(Russell et al., 2009b; Zhang et al., 2008), Figure 3-1]. An additional recent 
report on the existence of a Vif-susceptible splice variant of huA3F composed largely of 
the CTD is also consistent with these data (Lassen et al., 2010). 
 Our identification of a single amino acid determinant of HIV Vif susceptibility in 
huA3F echoes several prior reports localizing Vif susceptibility in huA3G and huA3H in 
that the residue identified is a single negative charge localized to the surface of an 
APOBEC3 protein [(Bogerd et al., 2004; Mangeat et al., 2004; Schröfelbauer et al., 
2004; Xu et al., 2004), Figures 3-4 and 3-5]. E324 differs from these reports in one key 
respect, however, as a charge substitution was involved in all prior reports. For example, 
huA3G D128A has no phenotype, while D128K is Vif-resistant [e.g. (Bogerd et al., 
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2004; Huthoff and Malim, 2007; Schröfelbauer et al., 2004)]. The fact that both alanine 
and lysine substitutions at huA3F E324 ablate Vif susceptibility (Figure 3-4A) suggests 
that E324 is required either for overall stability of the broader Vif binding surface or for 
direct functional interaction with HIV Vif. Changes to this residue do not, however, 
affect the ability of huA3F to restrict HIV; in fact, none of the changes described in these 
studies affected restriction activity (e.g. Figures 3-2, 3-3, 3-4). 
 It is notable that E324 does not fall within the region previously found by Russell 
et al. to be critical for HIV Vif recognition of huA3F (Russell et al., 2009b). These 
residues, 283-300, encompass most of the α3 helix, which is structurally adjacent to α4 
and E324 and appears to form a common surface [Figure 3-5A-B and (Russell et al., 
2009b)]. It is therefore possible that E324 may cooperate with residues in α3 and/or α4 to 
create a stable surface recognized by HIV Vif, in which case mutational alteration of any 
critical component of this putative Vif interaction node may affect Vif sensitivity. 
Alternatively, Russell et al. used chimeras between huA3F and huA3G to map the huA3F 
Vif interacting region (Russell et al., 2009b). The C-terminal deaminase domains of 
huA3F and huA3G, however, are evolutionarily divergent Z2 and Z1 types, respectively 
(25). This means that chimeras in this domain will contain a relatively large number of 
amino acid substitutions versus wildtype. For example, only half of residues 283-300 are 
biochemically similar or identical between huA3F and huA3G. Thus, we think it likely 
that the structure of huA3F-huA3G chimeras in this region will be altered relative to 
huA3F, which may affect interaction with Vif. 
 In addition to suggesting the structural unity of our findings with those of Russell 
et al., our model of the huA3F CTD allowed us to make an important observation about 
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the nature of the region surrounding E324. Namely, both the α4 and the neighboring α3 
helix have a number of negatively charged surface residues (Figure 3-5A-B). This led us 
to align these surface residues with those in other Vif-susceptible APOBEC3 deaminase 
domains such as the huA3G NTD and huA3H, which showed that each negatively-
charged surface residue in the α4 helix of huA3F corresponds to a known  negatively 
charged determinant of Vif susceptibility in another APOBEC3 protein (Figure 3-5). 
Thus, while determining the identity of all the amino acid residues with which Vif 
interacts (i.e. the broader Vif binding surface in APOBEC3 proteins) will require a great 
deal of future genetic and structural study, it is intriguing that all known Vif susceptibility 
determinants map to the same structural motif. This implies a degree of structural 
conservation among APOBEC3-Vif interaction surfaces that would not be apparent from 
a simple linear comparison of these single amino acid determinants. 
 While the lack of functional interaction between Vif and huA3F E324 variants is 
clear, this appears to be due to a qualitative change in the nature of the Vif-huA3F 
interaction in E324 mutants since coimmunoprecipitation of huA3F E324 mutants with 
HIV Vif is unimpaired. Our data therefore support the potential for both qualitative and 
quantitative changes in huA3F binding to Vif that may alter susceptibility. In the absence 
of structural data, however, we are unable to explain the nature of the qualitative defect 
found in huA3F E324 mutants. It is possible that the qualitative defect in E324 mutants 
may involve a conformational change that prevents productive interaction with HIV Vif. 
Alternatively, mutation of E324 may impair the recruitment of other components of the 
E3 ligase complex by HIV Vif en route to degradation. It is also conceivable that E324 
mutants may have a functionally relevant, altered affinity for HIV Vif that is not readily 
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apparent by coimmunoprecipitation. 
 In summary, we have described here a single amino acid determinant of huA3F 
susceptibility to HIV Vif. This important advance in our understanding of the Vif-huA3F 
interaction echoes the single amino acid determinants previously identified in other 
APOBEC3 proteins, as all are negatively charged residues that may interact directly with 
the highly basic Vif protein. Importantly, the observation that all of these single amino 
acid determinants cluster along the α4 helix raises the exciting possibility that certain 
features of the APOBEC3-Vif interaction may be structurally conserved, which would 
facilitate the design of hypothetical single molecules which may simultaneously block the 
functional interaction of Vif with multiple APOBEC3 proteins. Indeed, while its exact 
mechanism of action remains unknown, the lead compound RN-18 provides proof of 
concept for just such a scenario (Nathans et al., 2008). 
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Materials and Methods 
Plasmid DNA construction and site-directed mutagenesis – All constructs were 
confirmed by DNA sequencing. huA3F and huA3G coding sequences correspond to 
those found in GenBank NM_145298 and NM_021822, respectively. rhA3F was 
provided by Dr. Theodora Hatziioannou (Aaron Diamond AIDS Research Center, New 
York) (Virgen and Hatziioannou, 2007; Zennou and Bieniasz, 2006). Substitutions of 
rhA3F residues into huA3F were based on alignment between huA3F and rhA3F 
reference sequences NM_145298 and NM_001042373.1. pcDNA3.1-V5, -huA3F-V5 and 
-huA3G-V5 have been described, and pcDNA3.1-huA3G-V5 D128K was similarly 
derived (Albin et al., 2010a).  A3F domain chimeras were made using overlapping 
PCR (LaRue et al., 2008). PCR products were digested with KpnI/XhoI and ligated into 
similarly cut pcDNA3.1-V5. Single-domains of huA3F and rhA3F were amplified using 
primers containing SacI/SalI sites and cloned into similarly cut pEGFP-N3 (Clontech). 
Full-length huA3F-GFP has been described (Stenglein and Harris, 2006); NTD = 
residues 1-191; CTD = residues 192-373. huA3F PE281-282LD, NLT298-300KLA, 
T303A and D313H were introduced into the pcDNA3.1-huA3F-3xHA  construct 
(Stenglein and Harris, 2006) by site-directed mutagenesis using Pfu polymerases 
(Stratagene). The 3xHA tag was subsequently replaced with a V5 tag (Albin et al., 
2010a). All other mutations were introduced directly into pcDNA3.1-huA3F-V5. 
 HIVIIIB and SIVmac239 Vif as well as a vector derived from pVR1012 have been 
described (Albin et al., 2010a; LaRue, 2010). An untagged, codon-optimized version of 
HIVIIIB Vif was made by PCR amplification and ligation of the coding region into the 
SalI/BamHI segment of the original construct. The codon-optimized translated Vif open 
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reading frames are those of HIVIIIB (GenBank EU541617) and SIVmac239 (GenBank 
AY588946). 
 Proviral plasmid HIVIIIB is a nucleotide A200C derivative of pIIIB (Albin et al., 
2010a). A Vif-deficient A200C HIVIIIB derivative containing a previously described 
deletion in vif made by overlap extension PCR was used in spreading infections (Gibbs et 
al., 1994). A Vif-deficient HIVIIIB derivative containing tandem stop codons at positions 
26-27 of vif was used for all single-cycle infectivity experiments and has been previously 
described (Albin et al., 2010; Haché et al., 2008). Wildtype and Vif-deficient HIVLAI-GFP 
were kindly provided by Dr. Mario Stevenson (University of Massachusetts, Worcester, 
MA). 
 
Cell lines –  293T cells were maintained in DMEM supplemented with 10% fetal bovine 
serum and, in some cases, penicillin/streptomycin. CEM-GFP reporter cells were 
maintained in RPMI supplemented with 10% fetal bovine serum, penicillin/streptomycin 
and β-mercaptoethanol (Gervaix et al., 1997; Haché et al., 2008). 
 
Stability of A3F chimeras in the presence of HIV and SIV Vifs – At 50% confluency in 6-
well plates, 293T cells were transfected using Trans-IT transfection reagent (Mirus Bio) 
with 100 ng A3-V5 and 25 ng Vif-HA. After 48 hours, cell lysates were harvested and 
resuspended in 2x sample buffer 25 mM Tris pH 6.8, 8% glycerol, 0.8% SDS, 2% β-
mercaptoethanol, 0.02% bromophenol blue, boiled for 10 minutes, and run on a 12% 
SDS-PAGE gel prior to transfer to a PVDF membrane (Millipore). Membranes were 
probed with mouse anti-V5 (Invitrogen), mouse anti-HA.11 (Covance) or mouse anti-α-
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tubulin (Covance) primary antibodies followed by incubation with horseradish 
peroxidase (HRP)-conjugated goat anti-mouse antibodies. Membranes were developed 
using HyGLO chemiluminescent HRP detection reagent (Denville Scientific) and 
exposed to film. Blots were stripped using 0.2 M glycine, 1.0% SDS, 1.0% Tween-20, 
pH 2.2 between sequential probing with primary antibodies. 
 
Single-cycle infectivity assays – 250,000 293T cells were plated in 2 mL DMEM in 6-
well plates. One day later, Trans-IT transfection reagent (Mirus Bio) was used to 
cotransfect these cells with 1.6 µg Vif-deficient HIVIIIB, 100 ng of a codon-optimized 
HIVIIIB Vif-HA expression construct (or 50-200 ng supplemented to 200 ng total with a 
vector control in Figure 3-2C) and 200 ng of a given APOBEC3-V5 construct. 
Approximately two days later, virus-containing supernatants were filtered through 0.45 
µm PVDF filters (Millipore) and 75 or 150 µL were used to infect 25,000 CEM-GFP 
reporter cells plated at a final total volume of 250 µL. At this time, 293T cells were 
resuspended with 1 mL phosphate buffered saline (PBS) and 500 µL were spun down and 
resuspended in 250 µL lysis buffer [25 mM HEPES pH 7.4, 150 mM NaCl, 1 mM 
MgCl2, 50 µM ZnCl2, 10% glycerol and 1% Triton X-100 supplemented with 50 µM 
MG132 (American Peptide) and complete protease inhibitor (Roche)] for analysis of 
APOBEC3 intracellular stability. Three days post-harvest, CEM-GFP reporter cells were 
fixed with 4% paraformaldehyde and analyzed by flow cytometry on a Beckman-Coulter 
Quanta MPL or a Becton-Dickinson LSR II to determine infectivity as measured by the 
percentage of GFP-positive cells. Relative infectivity was calculated by normalizing the 
infectivity of viruses produced in the presence of each APOBEC3 protein +/- Vif to the 
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infectivity of viruses produced in the presence of an APOBEC3 vector control +/- Vif in 
each experiment. Data shown represent the mean and SEM of the number of independent 
transfection-infection series indicated in the figure legend. 
 
Analysis of intracellular APOBEC3 stability – Cotransfected cells were lysed as 
described above, and aliquots were mixed with a 5x or 7.5x version of the sample buffer 
described to a final concentration of 2x and boiled for 10 minutes. Proteins were then 
separated by 10% SDS-PAGE and transferred to a PVDF membrane. Membranes were 
probed as described above and stripped using 62.5 mM Tris pH 6.8, 2% SDS and 100 
mM β-mercaptoethanol at 50°C prior to sequential blocking and reprobing. 
 
Analysis of intracellular APOBEC3 expression – APOBEC3-expressing and vector 
control derivatives of SupT11 as well as the model nonpermissive cell lines CEM and H9 
were grown to confluence in 10 cm dishes. 5x106 cells were then lysed in 250 µl and 
analyzed for huA3F or huA3G expression using antibodies #11474 or #10201 from Drs. 
Michael Malim or Jaisri Lingappa, respectively, obtained through the AIDS Research and 
Reference Reagent Program. 
 
Virus titration and spreading infections – Viruses were produced by plating 3.5x106 
293T cells in 10 cm dishes and one day later transfecting those cells with 5-10 µg of a 
given proviral plasmid using Trans-IT transfection reagent (Mirus Bio). Approximately 
two days post-transfection, supernatants were harvested, and different volumes were used 
to infect 150,000 CEM-GFP reporter cells at a constant total volume of 1 mL in 24-well 
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plates. Three days later, these CEM-GFP cells were fixed in 4% paraformaldehyde, and 
the total percentage of GFP-positive cells was quantified by flow cytometry as before. 
Linear regression was then employed to determine the volume of a given viral stock 
required to initiate infection at a CEM-GFP MOI of 0.01. 
 Spreading infections were initiated by infecting 150,000 cells of a given cell line 
at an MOI of 0.01 in a total volume of 1 mL in 24-well plates. Cultures were 
subsequently split and fed as necessary to prevent cell overgrowth. Viral spread was 
monitored by periodically harvesting 150 µL of supernatant from each culture and using 
it to infect 25,000 CEM-GFP cells at a final volume of 250 µL in 96-well plates. Three 
days post-infection, these CEM-GFP were fixed in 4% paraformaldehyde, and the 
percentage of GFP-positive cells was analyzed by flow cytometry on a Becton-Dickinson 
LSR II. 
 
Homology Modeling of the huA3F C-terminal Deaminase Domain – The A3F186-373 
model was generated using YASARA (Krieger et al., 2002) based on the crystal structure 
of A3G191-384 2K3A [PDB ID 3IR2, (Shandilya et al., 2010)]. Alignment with the 
A3G191-384 sequence (Figure 3-6) was iteratively optimized using related SwissProt 
and TrEMBL sequences, the predicted secondary structure and the structural information 
of the template. Knowledge-based and electrostatic interactions in unrestrained molecular 
dynamics with explicit solvent molecules were used to refine amino acid side chain 
geometry. Insertions were accounted for by a search of the Protein Data Bank for loop 
ends superimposable with model anchor points. Further optimization was achieved by 
placement of loops into their lowest energy conformations. 
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Coimmunoprecipitation – Coimmunoprecipitation of V5-tagged huA3F with HA-tagged 
HIV Vif or with HA-tagged Vif with mutation of the conserved BC Box residues 
SLQ>AAA that ablate Vif-mediated degradation was carried out by lysing cotransfected 
293T cells with RIPA buffer [50 mM Tris pH 8.0, 150 mM NaCl, 1% NP40, 0.5% 
sodium deoxycholate, 0.1% SDS supplemented with complete protease inhibitor 
(Roche)]. Lysates were then incubated with 2.5 µL of mouse anti-HA.11 at 4°C followed 
by the addition of 40 µL Dynabeads Protein G (Invitrogen). Immunoprecipitated 
complexes were isolated by magnetic separation, washed four times with PBS and eluted 
by addition of 30 µL of 5x sample buffer as above. SDS-PAGE and Western blotting 
were then carried out as before. Western blots were quantified by analysis with ImageJ 
software (Rasband, 1997-2009). Binding quantification represents the intensity of V5 
bands immunoprecipitated divided by the intensity of the corresponding lysate bands and 
normalized to the ratio found for huA3F in a given experiment. 
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Figure 3-1: Susceptibility of huA3F to HIV Vif maps to the huA3F C-terminal 
deaminase domain. (A) A schematic depiction of the chimeras used in Figure 3-1B. (B) 
A cotransfection experiment demonstrating the instability in the presence of HIV Vif of 
chimeras between rhA3F and huA3F that contain the huA3F CTD. (C-D) Cotransfection 
experiments demonstrating that the CTDs of huA3F and rhA3F are destabilized by HIV 
Vif or SIV Vif, respectively, while the corresponding NTDs remains highly expressed. 
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Figure 3-2: Substitution of rhA3F residues at positions 323-324 of huA3F results in 
phenotypic Vif resistance. 
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Figure 3-2: Substitution of rhA3F residues at positions 323-324 of huA3F results in 
phenotypic Vif resistance. (A) A schematic depiction of the CTDs of huA3F and rhA3F 
with key changes tested through site-directed mutagenesis for their effects on the Vif-
sensitivity of huA3F indicated as numbered from the first position changed in a given set. 
(B) Single-cycle infectivity data quantifying the effects of HIV Vif on the rescue of HIV 
infectivity. All mutants remained competent for restriction. Relative infectivity represents 
the mean and SEM of four independent experiments. Western blots demonstrating 
intracellular APOBEC3 and Vif expression levels are shown below blotting for V5 or 
HA, respectively, and are derived from the producer cells of one of these four 
experiments. (C) Single-cycle infectivity data demonstrating the continued restriction of 
HIV by untagged huA3F QE323-324EK and huA3G DPD128-130KPK in the presence 
of increasing amounts of Vif. Relative infectivity represents the mean and SEM of two 
independent experiments done in duplicate. The Western blots demonstrating the stability 
of Vif-resistant huA3F and huA3G variants in the presence of Vif correspond to one of 
these infectivity experiments. (D) Western blots showing the expression levels of huA3F, 
huA3G and their Vif-resistant variants in the cell lines used.  (E) Spreading infection 
curves demonstrating that wildtype HIVIIIB is restricted by Vif-resistant variants huA3F 
QE323-324EK and huA3G DPD128-130KPK but not the corresponding wildtype 
proteins. Similar results were obtained with three additional cell lines stably transfected 
with A3F, A3G or the Vif-resistant variants thereof as well as one additional vector 
control cell line (data not shown). Open symbols indicate vector control or huA3F- or 
huA3G-expressing cell lines. Closed symbols indicate cell lines expressing huA3F 
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QE323-324EK or huA3G DPD128-130KPK. The y-axis is offset from zero to permit 
visualization of curves yielding no detectable spread. 
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Figure 3-3: Substitution of human residues at positions 323-324 of rhA3F does not 
sensitize rhA3F to HIV Vif. Single-cycle infectivity experiments demonstrating that 
substituting the human residues at positions 323-324 of rhA3F does not sensitize this 
restriction factor to permit infectivity recovery in the presence of Vif. Data represent the 
mean and SEM of three independent experiments. Western blots corresponding to one of 
the single-cycle experiments shown demonstrate the correlation between intracellular 
stability of APOBEC3 variants and functional recovery in infectivity. 
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Figure 3-4: The identity of residue 324 is a primary determinant of the degradation 
sensitivity of huA3F to HIV Vif. 
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Figure 3-4: The identity of residue 324 is a primary determinant of the degradation 
sensitivity of huA3F to HIV Vif. (A) Single-cycle infectivity data quantifying the 
restriction and Vif-sensitivity phenotypes of single and double human-to-rhesus and 
human-to-alanine mutations at positions 323 and/or 324 of huA3F, where only mutations 
at position 324 ablate Vif-responsiveness. Data represent the mean and SEM of three 
independent experiments. Western blots corresponding to one of these experiments 
demonstrating that mutations at position 324 of huA3F result in resistance to Vif-
mediated degradation are shown below. (B) A representative experiment demonstrating 
the lack of effect of mutations at huA3F positions 323-324 on coimmunoprecipitation 
with HA-tagged Vif. The images shown are all taken from the same blot where the A3F 
and A3F No Vif lanes have been digitally juxtaposed with the experimental mutants. (C) 
Quantification of the results from a total of five independent experiments similar to and 
including that shown in Figure 3-4B. Relative binding represents the ratio of IP V5 
signal to cellular V5 signal normalized to the ratio found for A3F in a given experiment, 
which is set to 1.0. 
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Figure 3-5: A model structure of the C-terminal deaminase domain of huA3F. 
  138 
 Figure 3-5: A model structure of the C-terminal deaminase domain of huA3F. (A) 
A ribbon diagram depicting the CTD of huA3F. The region encompassing the huA3F 
equivalents of all known single amino acid determinants of Vif-sensitivity is shown in 
blue, with D311, D313 and E316 shown in orange and E324 in red. The region 
previously implicated in huA3F interaction with Vif (residues 283-300) is colored purple. 
(B) The predicted surface of the huA3F CTD. (C) An alignment of residues in the α4 
helix encompassing known determinants of Vif susceptibility. 
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Figure 3-6: Alignment of huA3G and huA3F used for structural modeling. An 
alignment of huA3G and huA3F including secondary structural elements used in making 
the model in Figure 3-5A-B is shown. 
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Postscript 
 The study described in Chapter 3 appears modest in its scope, a single residue 
story using a standard toolbox. It is my opinion, however, that Figure 3-5 represents an 
important insight that will resonate throughout the field as we come to understand more 
about the APOBEC3-Vif interaction, starting with Chapter 5 and someday including co-
crystal structures of complex components to complement the genetic and functional data. 
This chapter yielded the tool and the insight necessary to start to bring some sense of 
order to the otherwise complicated mutagenesis data on APOBEC3-Vif interactions 
(compare Table 1-2 with Chapter 5). 
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Chapter 4: Dispersed Sites of HIV Vif-dependent Polyubiquitination in the DNA 
Deaminase APOBEC3F 
Foreword 
 The data presented in this chapter derive from the following manuscript in 
revision. 
 Albin JS, Anderson JS, Johnson JR, Harjes E, Matsuo H, Krogan NJ and Harris 
 RS. “Dispersed sites HIV Vif-dependent polyubiquitination in the DNA 
 deaminase APOBEC3F.” in revision 
 
Chapter 3 described the genetic identification of the Vif interaction site in A3F. Aside 
from a Vif interaction site, there must also be ubiquitin acceptor sites in A3F in order for 
Vif to target the deaminase for proteasomal degradation. A previous study using A3G had 
suggested that these could be clearly narrowed to a set of four out of the 20 internal 
lysines in A3G (Iwatani et al., 2009). Based on the structural clustering of these targeted 
lysines, these authors proposed a novel model of APOBEC3-Vif interactions in which 
binding of Vif to one domain in a double-domain deaminase such as A3F or A3G orients 
the opposite domain for polyubiquitination. We therefore set out to determine whether 
polyubiquitinated lysines in A3F might be similarly identified and whether the Vif 
interaction model previously proposed would prove valid for A3F. 
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Summary 
APOBEC3F (A3F) and APOBEC3G (A3G) are DNA cytosine deaminases that potently 
restrict human immunodeficiency virus type 1 (HIV) replication when the virus is 
deprived of its accessory protein virion infectivity factor (Vif). Vif counteracts these 
restriction factors by recruiting A3F and A3G to an E3 ubiquitin ligase complex that 
stimulates their polybiquitination and proteasomal degradation. While previous efforts 
have identified a Vif-dependent recognition site in APOBEC3 proteins centered on the 
α4 helix of Vif-susceptible deaminases, less is known about the downstream ubiquitin 
acceptor sites that are targeted. A prior report aimed at identifying polyubiquitinated 
residues in A3G, however, proposed an antiparallel model of A3G interaction with the 
Vif-E3 ubiquitin ligase complex wherein Vif binding at one terminus of A3G orients the 
opposite terminus for polyubiquitination (Iwatani et al., 2009). To test the 
generalizability of this model, we carried out a complete mutagenesis of the lysine 
residues in A3F and used a complementary, unbiased proteomic approach to identify 
ubiquitin acceptor sites targeted by Vif. Our data indicate that internal lysines are the 
dominant ubiquitin acceptor sites in both A3F and A3G, but in contrast with the proposed 
antiparallel model, we find that the Vif-dependent polyubiquitination of A3F and A3G 
can occur at multiple acceptor sites dispersed along lysine-enriched surfaces of both the 
N- and C-terminal deaminase domains, suggesting alternative models for binding of 
APOBEC3 proteins to the Vif-E3 ubiquitin ligase complex and diminishing enthusiasm 
for the amenability of APOBEC3 ubiquitin acceptor sites to therapeutic intervention. 
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Introduction 
Human A3F and A3G are DNA cytosine deaminases capable of inhibiting HIV reverse 
transcription and integration, most prominently through their active C-terminal 
deaminase domains, which introduce massive levels of G-to-A mutations in the nascent 
provirus that contribute to incomplete reverse transcription and render hypermutated 
genomes hypofunctional [reviewed (Albin, 2010; Chiu and Greene, 2008; Malim, 2009)]. 
To achieve this restriction activity, A3F and A3G must encapsidate during viral budding 
in producer cells, but HIV typically circumvents this inhibitory APOBEC3 activity by 
utilizing its accessory protein Vif as a substrate receptor to link A3F and A3G to an E3 
ubiquitin (Ub) ligase complex consisting of CBFβ, ELOB and ELOC, CUL5 and RBX2, 
which results in the polyubiquitination (polyUb) and subsequent proteasomal degradation 
of these restriction factors [see recent papers (Jäger et al., 2011; Zhang et al., 2011) and 
references therein]. 
 Much effort has been devoted to identifying the determinants of the APOBEC3-
Vif interaction critical for this degradative process, including a variety of changes in Vif 
that result in the functional inactivation of its anti-APOBEC3 activity [e.g. (Russell and 
Pathak, 2007; Simon et al., 2005); reviewed in (Albin, 2010; Smith et al., 2009)]. On the 
APOBEC3 side of this direct, host-pathogen interaction, initial efforts suggested that the 
Vif binding sites in A3F and A3G were structurally distinct, occurring in the C-terminus 
of the former and in the N-terminus of the latter at unrelated residues (Bogerd et al., 
2004; Huthoff and Malim, 2007; Lavens et al., 2010; Mangeat et al., 2004; Russell et al., 
2009b; Schröfelbauer et al., 2004; Xu et al., 2004). However, independent studies 
indicated that these single amino acid determinants of Vif recognition typically occur 
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within a common region within a given susceptible APOBEC3 deaminase domain 
centered on the α4 helix, suggesting that a conserved structural determinant may be 
targeted by Vif [DPD128-130 in A3G (Bogerd et al., 2004; Huthoff and Malim, 2007; 
Mangeat et al., 2004; Schröfelbauer et al., 2004; Xu et al., 2004); E324 and E289 in A3F 
(Albin et al., 2010b; Smith and Pathak, 2010) and D/E121 in A3H (Zhen et al., 2010). 
 Less is known about the downstream Ub acceptor sites targeted for polyUb during 
the degradation process. Iwatani et al. have previously reported that four lysines in the C-
terminus of A3G are the Ub acceptor sites required for the Vif-mediated degradation of 
this enzyme (Iwatani et al., 2009). Combined with the aforementioned studies localizing 
the Vif interaction to the N-terminal half of the A3G, this led to the proposal of an 
antiparallel model of APOBEC3 binding to the Vif-E3 Ub ligase complex wherein Vif 
interacts with one deaminase domain, thereby orienting the second domain for polyUb by 
an activated E2~Ub conjugate at the opposite end of the CUL5 scaffold. 
 To test this model and potentially enhance our understanding both of APOBEC3 
binding to the Vif-E3 Ub ligase complex and of how these substrate acceptor sites might 
be utilized to block the degradation of APOBEC3 proteins, we set out to define the sites 
of polyUb in A3F. Consistent with results previously reported by Iwatani et al., we find 
that internal lysines are the dominant Ub acceptor sites in both A3F and A3G. Analysis of 
the specific residues available for functional polyUb, however, reveals that these are 
dispersed throughout both domains of A3F at lysine residues clustered on one side of 
model structures of the A3F N-terminal and C-terminal deaminase domains, opposite the 
Vif interaction site in the latter case. Furthermore, mutation of the lysine residues 
determined by Iwatani et al. to be the sites of polyUb in A3G confers only partial Vif 
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resistance. Consistent with these genetic data, mass spectrometric analysis reveals Vif-
dependent Ub modification of at least 6 sites in A3F and 10 sites in A3G localized to 
both the N- and C-terminal deaminase domains of each. We conclude, therefore, that the 
lysine residues available for Vif-dependent polyUb in human APOBEC3 proteins are 
diverse and unlikely to be leveraged for novel therapeutics. To explain this flexibility, we 
further propose an alternative model of APOBEC3 binding to the Vif-E3 Ub ligase 
complex. 
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Results 
The Sites of Vif-mediated polyUb in A3F are Distributed Throughout the Protein – The 
lysine codons in A3F cluster into three linear groups separated by unique EcoRI and 
BamHI sites. We first used serial mutagenesis to convert each of these groups from K-to-
R. Next, we joined the three regions together to make the panel of K-to-R mutants 
including a derivative completely devoid of lysines, A3F-19KR, and tested the restriction 
activity and Vif susceptibility of the resultant proteins in a single cycle of replication 
(Figure 4-1A). 
 The restriction activity of all A3F mutants was similar to that of the wildtype 
protein, and the K-to-R mutation of any single linear region resulted in A3F variants with 
Vif susceptibility similar to that of the wildtype protein as evidenced both by the recovery 
of infectivity and by the decrease in steady state A3F levels in the presence of Vif 
(Figure 4-1B). Similarly, the combination of any two linear regions of K-to-R mutants 
resulted in somewhat more resistant but still notably Vif-susceptible variants of A3F. 
Only the variant devoid of all lysines, A3F-19KR, was largely resistant to the effects of 
Vif. Taken together, these data indicate that at least one lysine residue in each linear 
region is available for Vif-mediated polyUb. We also noted that the putative Vif-resistant 
control protein, A3G-4KR, in which the polyUb residues previously described Iwatani et 
al. were changed to arginine, was only partially resistant to HIV Vif (Figure 4-1B). Thus, 
A3G may also contain alternative sites of polyUb. 
  
Multiple Internal Lysine Residues in the A3F N- and C-termini Are Suitable Substrates 
for Vif-dependent polyUb – To map the individual lysines in A3F available for polyUb, 
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we reverted each of the 19 R residues of A3F-19KR back to K and assessed the 
sensitivity of these mutants to Vif in comparison with the parent A3F-19KR in a single 
cycle of replication. Seven individual lysine reversions in A3F-19KR – R40K, R52K in 
Region 1; R209K in Region 2; and R334K, R337K, R355K, R358K in Region 3 – induce 
a statistically significant increase in infectivity in the presence of Vif over the parent 
lysine-free variant (Figure 4-2A-C). In addition to these seven residues, it is possible that 
others in each region might also be functional targets since we noted some variability 
from experiment to experiment in which R-to-K changes appeared to sensitize A3F-
19KR to Vif, the extent of which is indicated by the associated error bars. For example, 
A3F-19KR R185K appeared Vif-susceptible in the experiment from which the Western 
blots shown in Figure 4-4B derive but failed to yield a statistically significant increase in 
infectivity over A3F-19KR when averaged over three, independent experiments. This 
implies that, despite the preferential targeting of certain residues in A3F, the process of 
Vif-mediated polyUb may be sufficiently promiscuous to find alternative sites with lower 
efficiency when preferred options are not available. Such a semi-stochastic character is 
consistent with the distribution of more consistently targeted residues throughout both the 
N- and C-termini of A3F as well as the generally more efficient degradation of control 
mutants in which the lysine residues in all but one linear region have been changed to 
arginine, yielding six or seven potential targets of polyUb in that region rather than the 
one found in associated individual revertants. The degradative Vif-mediated polyUb of 
A3F is therefore not a structurally fixed Ub event such as those associated with 
regulatory functions or that previously described for A3G [e.g. (Batonnet et al., 2004; 
Das-Bradoo et al., 2010; Iwatani et al., 2009; Scherer et al., 1995; Wu et al., 2003; Zheng 
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et al., 2002)], but rather may be more accurately described as a flexible sampling of 
available substrates wherein at least seven residues throughout both the N- and C-termini 
of A3F can be polyubiquitinated despite binding of Vif at the protein C-terminus (Albin 
et al., 2010b; Russell et al., 2009b; Smith and Pathak, 2010; Zhang et al., 2008). 
 
Mass Spectrometric Identification of Lysine Acceptor Sites in A3F and A3G – Previous 
analyses have relied exclusively on genetic and biochemical techniques for the 
determination of Ub sites in A3G (Dang et al., 2008b; Iwatani et al., 2009; Shao et al., 
2010; Wang et al., 2011b). To acquire direct, relatively unbiased biophysical evidence for 
Ub of the lysine residues identified as functional targets in A3F and to determine whether 
sites in A3G beyond those previously identified might be modified by Ub, we subjected 
A3F and A3G to ubiquitin remnant profiling, a technique whereby a monoclonal 
antibody specific for the K-GG motif characteristic of trypsinized, Ub peptides is used to 
immunoprecipitate the Ub proteome in a cell lysate prior to mass spectrometric analysis 
(Xu et al., 2010). Peptides harboring Ub on residues 52, 234, 334, 352, 355 and 358 of 
A3F were highly enriched in the presence of Vif, indicating substantial modifications at 
the A3F C-terminus despite the binding of Vif to the same end of the protein (Figure 4-
3A). Moreover, despite a few minor discrepancies in the specific acceptor sites 
implicated by the mass spectrometric and genetic datasets, the results of these approaches 
largely overlap and collectively reinforce the notion that the modification of APOBEC3 
proteins is not restricted to a structurally rigid subset of lysine acceptor sites (see 
Discussion). 
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 For A3G, peptides corresponding to ubiquitination of five N-terminal and five C-
terminal residues were enriched in the presence of Vif (Figure 4-3B). These data again 
implicate residues of both the N- and C-termini as Ub acceptor sites and are further 
consistent with the inability of K-to-R mutations at the residues previously identified by 
Iwatani et al. to render A3G fully resistant to Vif (Figure 4-1B). Importantly, like the 
variation observed in the analysis of single K-to-R revertants in A3F-19KR, we found 
that the exact repertoire of modified sites as determined by mass spectrometry differed 
slightly from experiment to experiment. For example, a previous analysis of A3G by this 
same technique identified modification only at residues 297 and 303 among the four 
residues reported by Iwatani et al. while also finding no modification at residue 63 
(Figure 4-3B and see Discussion). 
 
Lysine Residues in A3F and A3G Cluster at Distinct Predicted Surfaces – To determine 
whether the susceptibility patterns observed in Figures 4-2 and 4-3 may have a structural 
basis, we created a model of the A3F N-terminus to complement the C-terminus model 
previously reported (Albin et al., 2010b). This yielded the surprising finding that in both 
the N- and C-termini, the lysine residues in A3F typically cluster at one surface, which in 
the case of the C-terminus is opposite to the surface strongly implicated in the interaction 
with Vif (Figure 4-4A-B). Thus, the placement of lysines within A3F is consistent with 
the promiscuous ability of the Vif-E3 ligase complex to promote polyUb at multiple 
residues in A3F since these residues are, broadly speaking, structurally comparable. It is 
important to note, however, that structural data are not yet available to make a robust 
model of full-length A3F. When the Ub acceptor sites implicated in Figure 4-3B are 
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visualized on our previously-described full-length model of A3G, however, we observe a 
similar structural clustering of lysine residues at a surface opposite that bound by Vif 
(Figure 4-4C). 
 
Lack of evidence for polyUb at sites other than internal APOBEC3 lysines – Although 
our results above as well as those of Iwatani et al. provide positive evidence for internal 
lysines as the predominant sites of polyUb in APOBEC3 proteins, others have previously 
reported that either Vif itself or the N-terminus of A3G may be important sites of polyUb 
en route to A3G degradation (Dang et al., 2008b; Shao et al., 2010; Wang et al., 2011b). 
The results of Dang et al. implicating autoUb of Vif as the functionally relevant 
modification for A3G degradation may reflect the targeting of lysine residues in the C-
terminal tag of the otherwise lysine-free A3G variant used [(Dang et al., 2008b; Iwatani 
et al., 2009) and consistent with sequencing of constructs we received from Dr. Yong-
Hui Zheng, Michigan State University]. To functionally address the possibility that A3F 
or A3G may be N-terminally modified, however, we sought to create variants that would 
be predicted to be resistant to N-terminal modification. 
 Changing residue two of A3F and A3G from K to P, G or V favors cleavage of 
the initiating methionine to create a new N-end [e.g. (Varshavsky, 2011)]. Among 
potential N-terminal residues, the imino group of P is biochemically distinct and likely 
resistant to N-terminal Ub since, unlike all other amino acids, artificial fusion of Ub to an 
N-terminal P yields a bond resistant to the action of the deubiquitinating enzymes present 
in yeast and in mammalian cell lysates [e.g. (Bachmair et al., 1986; Gonda et al., 1989)]. 
The resistance of P to N-terminal acetylation also obviates potential complications 
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associated with the ability of this modification promote degradation (Hwang et al., 2010), 
while G and V are subject to modification by N-terminal acetylases distinct from those 
predicted to act on wildtype A3F and A3G [e.g. (Arnesen, 2011)]. We therefore predicted 
that changing the second APOBEC3 amino acid to P, G or V should alter the Vif 
sensitivity of the resultant variant if Vif regulates APOBEC3 proteins via modifications 
of the APOBEC3 N-terminus. We observed, however, that changes to the second amino 
acid of APOBEC3 proteins do not substantially alter their Vif susceptibility in a single 
cycle of replication (Figure 4-5). Combined with positive evidence for the Ub of internal 
lysines, we therefore conclude that the APOBEC3 N-terminus is not a major target of Vif 
function. 
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Discussion 
 We present here genetic and biophysical evidence for the polyUb of multiple 
internal lysines distributed throughout both the N- and C-termini of A3F and A3G 
(Figures 4-1, 4-2, 4-3). The robust flexibility of the Vif-E3 ligase complex to promote 
the polyUb of APOBEC3 proteins at a wide range of acceptor sites is consistent with an 
active sampling of APOBEC3 lysines by the associated E2~Ub conjugate. Such a 
sampling model is further consistent with the observation that single R-to-K reversions in 
A3F-19KR context are generally less efficient in sensitizing A3F-19KR to Vif relative to 
control mutants in which all the available substrates of a given region are lysines, 
particularly in Region 1 (Figure 4-2A). This relatively indiscriminate process makes 
intuitive sense since the default mode for Vif should be to rapidly degrade APOBEC3 
proteins with no apparent need for tight regulation of the kind mediated by more selective 
Ub events [e.g. (Batonnet et al., 2004; Das-Bradoo et al., 2010; Iwatani et al., 2009; 
Scherer et al., 1995; Wu et al., 2003; Zheng et al., 2002)]. 
 Consistent with the promiscuous modification of A3F lysines, we observe that 
mutation of the residues previously reported by Iwatani et al. as the sole functional 
targets of Vif-mediated polyUb in A3G render the protein only partially Vif-resistant, 
while many N- and C-terminal lysines in A3G are modified in the presence of Vif 
(Figures 4-1A and 4-3B). We therefore think it likely that the antiparallel Iwatani et al. 
model previously proposed for APOBEC3 polyUb does not accommodate all of the data 
(Figure 4-6A). It is possible that the model proposed by Iwatani et al. may be partially 
correct since the A3G-4KR mutant is notably less susceptible to Vif than wildtype A3G, 
and we do note the presence of some susceptible lysine residues in the A3F N-terminus 
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(Figures 4-1B and 4-2A-B). Nonetheless, the reversion of multiple lysines in the A3F C-
terminus can also render A3F-19KR sensitive to Vif, demonstrating extensive flexibility 
in the ability of RBX2-activated E2~Ub conjugates to reach dispersed sites. 
 Rather than the rigid antiparallel model of APOBEC3 polyUb proposed by 
Iwatani et al., it is more likely that APOBEC3 proteins bind Vif in an angled or 
perpendicular orientation that would expose to activated E2~Ub the entirety of the lysine-
rich surfaces predicted to be opposite the Vif binding sites in A3F and A3G (Figure 4-
6B). It is also possible that multimeric forms of APOBEC3 proteins or of the E3 Ub 
ligase complex might yield results similar to ours, although we have no evidence to 
directly support such a model. 
 We noted that there was some variability in which specific R-to-K reversions in 
A3F-19KR sensitized the protein to Vif from experiment to experiment (Figure 4-2), 
while linear regional mutants with multiple sidechains available for polyUb were 
consistently Vif-sensitive (Figures 4-1 and 4-2). Similarly, independent, unbiased mass 
spectrometric analyses of A3G indicated some variation in the specific residues modified. 
For example, focusing just on the four residues functionally implicated by Iwatani et al., 
residues 297, 303 and 334 were identified in one experiment (Figure 4-3B), while only 
residues 297 and 303 were identified in a second and neither experiment produced any 
evidence for the modification of residue 301. We interpret these data to mean that the 
Vif-mediated polyUb of APOBEC3 proteins is a semi-stochastic affair in which the 
associated E2~Ub conjugate is able to sample multiple available sidechains for polyUb. 
As a result, changing the residues most efficiently targeted for modification may simply 
force the modification of less efficiently targeted sidechains, consistent with data from 
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other fields indicating that components of the E3 Ub ligase complex may display 
substantial structural flexibility [e.g. (Deshaies and Joazeiro, 2009; Liu and Nussinov, 
2009, 2010, 2011)]. 
 Similarly, there were several discrepancies between the specific residues likely 
modified according to genetic versus biophysical approaches (Figures 4-2 and 4-3). 
Three A3F residues – 40, 209 and 337 – were found to be significantly targeted in the 
genetic data but were not identified by mass spectrometry, while the opposite was true of 
residue 234. This may reflect the fact that the wildtype protein used for mass 
spectrometry simply has more residues available for polyUb and that, consequently, the 
wildtype protein is preferentially modified at those residues common to the genetic and 
mass spectrometric datasets. Alternatively, the structures of A3F and A3F-19KR may 
differ slightly despite their similar restriction activities (Figures 4-1 and 4-2). It is also 
possible that further experiments may find additional residues modified that are not 
apparent in the data presented here, as we have observed with A3G. Regardless, the 
overarching message remains clear: many residues in both the N- and C-terminal 
domains of both A3F and A3G are suitable substrates for polyUb. 
 In summary, we report here that the Ub acceptor sites in A3F and A3G are 
distributed throughout the protein, suggesting that the conjugated E2 enzyme(s) recruited 
by the Vif-E3 ligase complex are more flexible in their substrate targeting potential than 
previously proposed and that blocking the modification sites themselves will not be a 
viable strategy for the therapeutic stabilization of APOBEC3 proteins. It will be 
interesting, as more structural data become available, to find whether the apparent 
clustering of lysines at surfaces distinct from those at which Vif interacts is a general 
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feature of the APOBEC3-Vif interaction. It may be that the positively-charged Vif 
protein achieves efficient degradation of APOBEC3 proteins, in part, by binding to 
negatively charged regions of susceptible deaminase domains such as the α4 helix and 
thereby positioning distinct, lysine-rich surfaces for efficient polyUb in the context of the 
fully assembled E3 Ub ligase complex. 
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Materials and Methods 
Plasmids – Wildtype A3F and A3G coding sequences are identical to those found in 
GenBank entries NM_145298 and NM_021822 and previously reported [e.g. (Albin et 
al., 2010a)]. APOBEC3 expression constructs were expressed in pcDNA3.1-derived 
vectors with a C-terminal V5 tag as previously described (Albin et al., 2010a); in all V5 
constructs except the Vif interaction mutants A3F QE323-324EK and A3G D128K, 
however, the inherent tag lysine was mutated to arginine to prevent artifactual tag Ub 
such as that previously described (Iwatani et al., 2009). K-to-R mutants were made by 
sequential site-directed mutagenesis and subcloning; A3G-20KR was graciously provided 
by Dr. Yong-Hui Zheng (Dang et al., 2008b) and cloned into our lysine-free V5 vector. 
The Vif-deficient HIVIIIB proviral construct and IIIB Vif-HA expression construct were 
as previously described (Albin et al., 2010a). All constructs were verified by sequencing 
and restriction digestion. 
 
Cell lines – HEK293T cells were maintained in DMEM medium supplemented with 10% 
fetal bovine serum and penicillin-streptomycin. CEM-GFP reporter cells were obtained 
from the AIDS Research and Reference Reagent Program (Gervaix et al., 1997) and 
maintained in RPMI medium supplemented with 10% fetal bovine serum, penicillin-
streptomycin and β-mercaptoethanol. 
 
Single-cycle infectivity protocol – Single-cycle infectivity experiments were carried out 
as previously described (Albin et al., 2010a). 250,000 HEK293T cells were plated into 2 
mL of supplemented DMEM in 6-well plates. The following day, cells were transfected 
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with 200 ng of either a vector control or an A3-V5 expression construct, 100 ng of a Vif-
HA expression construct, and 1.6 µg of replication competent, Vif-deficient HIVIIIB 
provirus using Trans-IT transfection reagent (Mirus Bio). Two days after transfection, 
transfected cells were harvested and lysed as described below, and virus-containing 
supernatants were filtered through 0.45 µm filters and used to infect CEM-GFP cells in 
96-well plates. Three days post-infection, target CEM-GFP cells were fixed with 4% 
paraformaldehyde and analyzed by flow cytometry for viral infectivity on a FACSCanto 
flow cytometer (BD Biosciences). 
 
Western blot analysis – HEK293T cells transfected as described above were washed in 
PBS and lysed in 250 µL of a lysis buffer composed of 25 mM HEPES (pH 7.4), 150 mM 
NaCl, 1 mM MgCl2, 50 µM ZnCl2, 10% glycerol and 1% Triton X-100 and supplemented 
with 50 µM MG132 and complete protease inhibitor (Roche). A 5x sample buffer 
consisting of 62.5 mM Tris pH 6.8, 20% glycerol, 2% sodium dodecyl sulfate, 5% β-
mercaptoethanol, and 0.05% bromophenol blue was added to each cell lysate to a 2x 
concentration, and the mixture was boiled for 5-10 minutes and subjected to fractionation 
by 10% SDS-PAGE and transfer to PVDF membranes. Primary antibodies utilized 
include mouse anti-V5 (Invitrogen), mouse anti-HA.11 (Covance), and mouse anti-
tubulin (Covance). Between probing with different primary antibodies, membranes were 
stripped with 62.5 mM Tris pH 6.8, 2% SDS, and 100 mM β-mercaptoethanol at 50°C 
and washed in PBS 0.01% Tween. 
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Mass spectrometry – HEK293T cells were labeled using a SILAC approach (Ong et al., 
2002). Cells were cultured in either “light” SILAC media containing the normal 
complement of amino aids or “heavy” SILAC media wherein lysine was replaced with 
13C6-lysine. FBS was dialyzed in both light and heavy media formulations to remove free 
unlabeled amino acids. Four 15 cm plates of light media each were transfected with 2.5 
µg Vif-Strep and 2.5 µg of either A3F-V5 or A3G-FLAG. An additional four 15 cm 
plates of 293T cells cultured in heavy media each were also transfected with 2.5 µg 
pcDNA4 vector and 2.5 µg either A3F-V5 or A3G-FLAG. Cells were detached from the 
plate with 10 mM EDTA in PBS, spun down, and snap frozen. The frozen cell pellets 
were lysed in buffer containing 8M urea, 0.1M Tris pH 8.0, 150 mM NaCl, and a 
combination of protease inhibitors (Complete tablet, Roche). Protein concentration was 
measured by Bradford assay (QuickStart 1x Reagent, Bio-Rad). 50 mg protein lysate 
from equal portions of light and heavy culture conditions for A3F-V5 or A3G-FLAG, 
respectively, were combined and then subjected to reduction with 4 mM TCEP for 30 
minutes at room temperature, alkylation with 10 mM iodoacetamide for 30 minutes and 
room temperature in the dark, and overnight digestion with 250 µg of trypsin (Promega) 
at room temperature. Treated lysates were subsequently desalted using SepPak C18 
cartridges (Waters), lyophilized for two days and immunoprecipitated using an antibody 
specific for the K-GG motif characteristic of trypsinized, Ub-modified peptides 
(UbiScan, Cell Signaling Technology). Immunoprecipitates were then desalted using C18 
STAGE tips (Thermo Scientific), evaporated, and analyzed in duplicate with a two-hour 
gradient on an Orbitrap Elite Mass Spectrometer (Thermo Scientific). The reverse phase 
gradient was delivered by an Easy nLC 1000 liquid chromatography system (Thermo 
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Scientific) from 5% to 30% acetonitrile in 0.1% formic acid. Columns used were a 100 
µm x 2 cm pre-column packed with 5 µm ReproSil Pur C18 particles and a 75 µm x 10 
cm analytical column packed with 2 µm ReproSil Pur C18 particles (Thermo Scientific). 
The Orbitrap Elite continuously collected data in data-dependent acquisition mode, 
acquiring a full scan in the orbitrap at 120,000 resolution followed by collision-induced 
fragmentation of the top 20 most intense peaks from full scan in the ion trap. Dynamic 
exclusion was enabled to exclude repeated fragmentation of peaks for 30 seconds. Charge 
state screening was enabled to reject fragmentation of unassigned or singly charged 
species. Results were analyzed using the MaxQuant software package (Cox and Mann, 
2008). 
 
Homology modeling of the A3F N- and C-terminal deaminase domains – Modeling of the 
A3F CTD has been described previously (Albin et al., 2010b). The A3F NTD model 
including residues 1–190 was generated using YASARA (Krieger et al., 2002) with the 
crystal structure of A3G191–384 2K3A (PDB 3IR2) as a template (Shandilya et al., 
2010). Alignment with the template sequence was iteratively optimized using SwissProt 
and TrEMBL sequences, the predicted secondary structure and the three dimensional 
structure of the template. Refinement of the model was carried out using knowledge-
based and electrostatic interactions in unrestrained molecular dynamics with explicit 
solvent molecules. Insertions were accounted for by searching the Protein Data Bank for 
superimposable loop ends with model anchor points and optimized for energy 
minimization. 
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Figure 4-1. The sites of functional Vif-mediated polyUb in A3F are distributed 
throughout the protein. 
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Figure 4-1. The sites of functional Vif-mediated polyUb in A3F are distributed 
throughout the protein. (A) A schematic showing the K-to-R variants of A3F tested in 
Figure 4-1B. (B) Single-cycle infectivity of Vif-deficient viruses produced in the 
presence of the indicated A3F-V5 variant +/- transcomplementation by Vif-HA. 
Infectivity data represent the mean and SEM of four independent experiments; here as in 
all singe-cycle infectivity experiments conducted, infectivity is normalized to the 
infectivities of virus produced in the presence of an APOBEC3 vector control -/+ Vif. 
Statistics were derived by carrying out one-tailed, paired T tests comparing the infectivity 
of virus produced in the presence of each APOBEC3 construct -/+ Vif. ** = p < 0.05; *** 
= p < 0.01. Western blots showing the steady state levels of Vif-HA and A3-V5 are 
derived from the producer cells from one of the experiments conducted. 
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Figure 4-2. Multiple internal lysine residues in A3F are suitable substrates for 
functional Vif-dependent polyUb. 
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Figure 4-2. Multiple internal lysine residues in A3F are suitable substrates for 
functional Vif-dependent polyUb. (A-C) Single-cycle infectivity of individual single 
lysine revertants in an A3F-19KR background in the absence or presence of Vif where 
data represent the mean and SEM of three independent experiments with associated 
Western blots showing producer cell steady state levels of Vif-HA and A3-V5 derived 
from one of these experiments. Statistics represent two-way ANOVA with Dunnett’s 
post-test comparing the infectivity recovery of each single amino acid revertant 
(Vif+/Vif-) to that of the A3F-19KR control. * = p < 0.1; ** = p < 0.05; *** = p < 0.01.  
Controls that appear in multiple panels of this figure (e.g. A3F in A, B and C) are 
regraphed and reblotted for visual comparison with the mutants of each individual region; 
all data shown in this figure are the result of one large experiment repeated three times 
and presented visually as three parts. 
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Figure 4-3. Mass spectrometry indicates Ub of multiple internal lysine residues in 
the N- and C-termini of both A3F and A3G. (A-B) Diagrams showing Ub-modified 
residues in A3F (A) or A3G (B) and their associated fold enrichment in the presence of 
Vif. + Indicates that some of the peptides detected indicating modification of the 
associated residues were so rare in the absence of Vif as to preclude calculation of a fold-
enrichment; in this case, the number represents the fold enrichment from those peptides 
for which is was calculable. ++ is used for residues where all of the peptides indicating 
modification of a particular residue precluded calculation of a fold-enrichment. 
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Figure 4-4. Lysine residues in the N- and C-termini of A3F and A3G cluster at 
distinct predicted surfaces. (A) A model of the A3F N-terminal deaminase domain 
rotated 180° about the y-axis. (B) A model of the A3F C-terminal deaminase domain 
rotated 180° about the y-axis. (C) A previously-described model of full-length A3G 
rotated 180° about the y-axis (Harjes et al., 2009). Orange indicates residues implicated 
by Figures 4-2 and 4-3, while yellow indicates residues implicated by one or the other; in 
(C), A3G residues implicated by Iwatani et al. and also identified in Figure 4-3B are 
orange, while additional residues not implicated by Iwatani et al. are yellow. Lysine 
residues not significantly implicated by either data set are gray; Vif interaction residues 
are red (Albin et al., 2010; Albin et al., 2010b; Smith and Pathak, 2010).
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Figure 4-5. Changes at the APOBEC3 N-terminus do not alter Vif susceptibility. (A-
B) Single-cycle infectivity experiments demonstrate the Vif sensitivity of A3F, A3G and 
lysine-free variants thereof to Vif when the second amino acid is altered as shown. 
Infectivity data represent the mean and SEM of four independent experiments. 
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Figure 4-6. An alternative model of APOBEC3 binding to the Vif-E3 ligase complex. 
(A) The antiparallel model previously proposed by Iwatani et al. in which binding of Vif 
at one deaminase domain orients an APOBEC3 protein for polyUb at its second 
deaminase domain (Iwatani et al., 2009). (B) An alternative, angled/perpendicular model 
for A3F binding to the Vif-E3 ligase complex in which binding of Vif to a lysine-poor 
surface orients the lysine-rich surfaces of A3F for polyUb. 
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Postscript 
 This manuscript is presently in revision. While we report specific ubiquitin 
acceptor sites that are more likely targeted than others in A3F and A3G, the broader point 
suggested by our data is that there is little structural rigidity associated with the ability of 
an E2-Ub conjugate to find a suitable substrate in E3 ubiquitin ligase complex-associated 
A3F. It will therefore be of interest to those in the field to know that the model proposed 
by Iwatani et al., despite its appeal, does not hold for other APOBEC3 proteins – or 
perhaps even for A3G itself. Our data may further be of use in the functional evaluation 
of any future co-crystal structures of the full APOBEC3-Vif-E3 ubiquitin ligase complex 
since the clustering of lysines at surfaces distinct from those at which Vif binds implies a 
distinctive topology that we anticipate with be borne out structurally. 
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Chapter 5: Evidence for a Conserved Structural Feature in HIV Vif that Interacts 
with APOBEC3 Proteins 
Foreword 
 This chapter is a working draft of the following manuscript in preparation: 
 Albin JS, Refsland EW, Ikeda T, Holten JR, Anderson JS and Harris RS.  
 “Evidence for a Conserved Structural Feature of HIV Vif that Interacts with 
 APOBEC3 Proteins.” In preparation 
 
The data herein are an extension of Chapter 3 in which we seek to identify the specific 
amino acids in Vif that interact with the known single amino acid determinants of Vif 
susceptibility found in the α4 helix of human APOBEC3 proteins. While we are still 
pursuing confirmatory evidence, we believe the data in this chapter support a novel 
conception of the APOBEC3-Vif interaction. That is, the residues that we have identified 
suggest that the interaction of HIV Vif with human APOBEC3 proteins, rather than being 
three different interactions depending on the substrate APOBEC3 as currently conceived, 
is defined by a common core contact with a region of Vif containing a conserved GxxxG 
helix-helix interaction motif, a concept we have dubbed the Trinity Hypothesis. 
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Summary 
The human immunodeficiency virus virion infectivity factor (Vif) links APOBEC3 
cytosine deaminases to an E3 ubiquitin ligase complex to mediate their proteasomal 
degradation and thereby protect viral genomic integrity from the mutations created by 
these restriction factors. The APOBEC3-Vif interaction is thus an attractive potential 
target for the development of small molecule therapeutics that might liberate APOBEC3 
proteins to inhibit HIV. Our knowledge of the molecular details of the interactions of 
APOBEC3 proteins with Vif, however, remains limited. Here, we report the results of 
genetic selection experiments in which we have evolved compensatory changes in Vif 
that counteract the Vif-resistant APOBEC3 variations of the α4 helix. Together, these 
data identify a putative α-helix in HIV Vif containing a GxxxG helix-helix interaction 
motif and three conserved glycine residues in a stretch of 11 amino acids that mediate 
compensatory changes in Vif to counteract Vif-resistant APOBEC3 proteins. Thus, we 
propose an antiparallel helix-helix interaction between the APOBEC3 α4 helix and a 
putative glycine-rich helix in HIV Vif as the common structural core of APOBEC3-Vif 
interactions. 
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Introduction 
 When APOBEC3 proteins are encapsidated into budding HIV virions in producer 
cells, they can inhibit HIV reverse transcription in target cells by introducing massive 
levels of C-to-U transitions into minus-strand viral cDNA during reverse transcription. 
[e.g. (Harris et al., 2003a; Mangeat et al., 2003; Zhang et al., 2003)]. The net effect of 
this is decreased viral cDNA accumulation and the integration of hypermutated, and 
presumably hypofunctional, proviruses. To prevent encapsidation and thereby prevent the 
deleterious effect of APOBEC3 proteins on the viral genome, the HIV accessory protein 
virion infectivity factor (Vif) links APOBEC3 proteins to an E3 ubiquitin ligase complex, 
facilitating the polyubiquitination and proteasomal degradation of these restriction factors 
(Conticello et al., 2003; Marin et al., 2003; Mehle et al., 2004b; Sheehy et al., 2003; 
Stopak et al., 2003; Yu et al., 2003). 
 While the APOBEC3-Vif interaction has garnered substantial interest due to its 
potential as a novel antiretroviral therapeutic target, our understanding of the interactions 
between APOBEC3 proteins and Vif remains limited. Many structures of the A3G C-
terminus have been published, and although these are useful for modeling other 
APOBEC3 proteins, the A3G C-terminus itself is not targeted by Vif (Chen et al., 2008; 
Furukawa et al., 2009; Harjes et al., 2009; Holden et al., 2008; Li et al., 2012; Shandilya 
et al., 2010). More recently, a crystal structure of the Vif-susceptible APOBEC3 protein 
A3C has been reported along with extensive mutagenesis identifying novel components 
of the Vif recognition region applicable to A3C, A3D and A3F, and our own 
collaborative efforts have contributed to a crystal structure of the A3F C-terminus 
[(Kitamura et al., 2012; Bohn et al., in preparation) and see Supplementary Chapter 1]. 
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 Genetically, several single amino acid determinants that can render APOBEC3 
proteins Vif-resistant have been identified by comparative mutagenesis of innately Vif-
resistant and Vif-susceptible cytosine deaminase domains, including but not limited to 
D128 and D130 in A3G (Bogerd et al., 2004; Huthoff and Malim, 2007; Lavens et al., 
2010; Mangeat et al., 2004; Schröfelbauer et al., 2004; Xu et al., 2004), D121 in A3H 
(Zhen et al.) and E289 and E324 in A3F [(Albin et al., 2010b; Russell et al., 2009b; 
Smith and Pathak) and see Chapter 3]. These studies have generally been interpreted as 
implying the existence of distinct Vif interaction regions in different APOBEC3 proteins 
since, in the case of A3G and A3F, the Vif interaction residues are linearly distinct, being 
found in the N- or C-terminal deaminase domains of these double domain APOBEC3 
proteins, respectively (Russell et al., 2009b; Smith and Pathak, 2010). If one considers 
the APOBEC3 proteins phylogenetically, however, a pattern emerges in which all of 
these critical determinants structurally cluster on or adjacent to the α4 helix of a Vif-
susceptible cytosine deaminase domain (Albin et al., 2010b). Thus, it is possible that Vif 
recognizes a common structural determinant in APOBEC3 proteins centered on this 
conserved helix. 
 Progress on the Vif side of this interaction has been hampered by the difficulty of 
purifying quantities of Vif amenable to structural study. To date, published structural 
assessments of Vif are limited to a short Vif peptide of the conserved BC box co-
crystallized with Elongin C (Stanley et al., 2008), NMR characterization of Vif assembly 
with the E3 ubiquitin ligase complex (Bergeron et al., 2010) and mass spectrometric 
characterization of crosslinked multimeric forms of Vif (Auclair et al., 2007). It is 
possible that the recent discovery of Vif cofactor CBFβ may soon improve this situation 
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given the potential to purify greater quantities of the notoriously difficult viral accessory 
protein by coexpression (Jäger et al., 2011; Zhang et al., 2011), but for the moment, 
much work remains to be done toward understanding the structural features that translate 
into Vif function. 
 In contrast, a number of genetic studies on the functionality of various Vif 
mutants against A3F, A3G or both has yielded, in recent years, an abundance of data 
summarized in Table 1-2 (Albin et al., 2010a; Chen et al., 2009; Dang et al., 2010a; 
Dang et al., 2010b; Dang et al., 2009; Fourati et al., 2010; He et al., 2008; Mulder et al., 
2010; Nagao et al., 2010; Pery et al., 2009; Russell and Pathak, 2007; Simon et al., 1999; 
Simon et al., 2005; Tian et al., 2006; Yamashita et al., 2008; Yamashita et al., 2010; 
Zhang et al., 2008). An attempt to illustrate some of these data in broad strokes is 
provided in Figure 1-4, wherein one can identify certain regions such as amino acids 14-
DRMR-17 and 74-TGERDW-79 as critical for interaction with A3F, others such as K26 
and 40-YRHHY-44 as critical for interaction with A3G and others such as amino acids in 
the range of 55-72 as critical for interaction with both APOBEC3 proteins. Taken as a 
whole, this implies that the APOBEC3-Vif interaction is structurally complex since 
disparate parts of Vif are associated with the ability to neutralize one or more APOBEC3 
proteins. 
 Even such attempts at distillation are perhaps less informative than one might 
imagine, however, because all of the aforementioned studies identified only loss of 
function mutants that could be the result of any number of nonspecific changes to Vif 
structure rather than an actual, direct interaction. The phenotypic data themselves are at 
times contradictory (Table 1-2), and there are instances in which even well-established 
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features of current conceptions of the APOBEC3-Vif interaction break down. For 
example, vif genes with mutations of amino acids 14-DRMR-17 are generally accepted as 
selectively susceptible to A3F but not A3G [e.g. (Russell and Pathak, 2007)], yet 
alteration of this same region to 14-SEMQ-17 on the basis of comparative sequence 
analysis between HIV and SIV Vifs permits the functional neutralization of the HIV Vif-
resistant proteins rhA3G and human A3G D128K by an otherwise unaltered HIV Vif 
(Schröfelbauer et al., 2006). Mutations in other regions such as 40-YRHHY-44, which 
selectively displays strong loss of function versus A3G under conditions of transient 
overexpression may nevertheless fail to yield similar phenotypes in a more physiologic 
spreading infection system [(Russell et al., 2009a) and Supplementary Chapter 2, but 
contrast with (Yamashita et al., 2008)], raising the question of whether such regions are 
as critical as they initially appeared (Russell and Pathak, 2007). 
 Despite the diversity of Vif interactions with APOBEC3 proteins implied by 
Table 1-2, the placement of most of the known single amino acid determinants of Vif 
susceptibility within a single, defined structural feature of APOBEC3 proteins strongly 
implies that the seemingly distinct interactions of Vif with APOBEC3 proteins must have 
some feature in common. Moreover, this common feature must depend on interaction 
with negatively charged residues of the α4 helix since all of the known single amino acid 
determinants of Vif susceptibility in this region can render an APOBEC3 protein Vif-
resistant via a negative-to-positive charge change. If a specific residue in Vif directly 
interacts with one of these critical amino acid determinants, then, one would predict that 
viruses adapted to growth in the presence of these Vif-resistant APOBEC3 proteins 
should acquire compensatory net-negative charge changes that permit functional 
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interaction with the newly positively charged interaction node in a given APOBEC3 
protein, a concept illustrated in Figure 5-1A. 
 To define such directly interacting residues, we have adapted Vif-proficient HIV 
molecular clone-derived viruses of defined sequence to growth in the presence of the Vif-
resistant APOBEC3 proteins A3F QE323-324EK, rhesus macaque A3F (rhA3F), A3G 
DPD128-130KPK or rhA3G and determined the vif genotypes of the resultant adapted 
virus cohorts. Surprisingly, the vif changes accumulated through this process displayed a 
strong propensity to scatter throughout the gene, with some isolates displaying no 
discernible changes in vif, potentially implying the existence of alternative, Vif-
independent mechanisms of APOBEC3 neutralization available to HIV (see Chapter 6). 
Within vif, however, we identified compensatory changes capable of preserving viral 
infectivity in the presence of APOBEC3 proteins resistant to the degradative effects of 
the parental Vif, namely changes G71D and G82D, which allow HIV Vif to overcome the 
Vif-resistance mutations A3F E324K and A3G D130K, respectively. 
 On comparing sequences, we noted that the phylogenetic equivalents of these 
residues in APOBEC3 proteins are separated by the same 11 amino acid distance found 
between the corresponding compensatory mutations in Vif. Moreover, this 11 amino acid 
stretch of Vif carries in it a 71-GxxxG-75 helix-helix interaction motif, which when 
modeled as a helix places four, conserved, glycine-negatively charged residue pairs at 71, 
75, 78 and 82 on the same surface of Vif available for interaction with the APOBEC3 α4 
helix. 
 Taken together, our data implicate a conserved, antiparallel helix-helix contact 
between the APOBEC3 α4 helix and a putative glycine-rich Vif helix as a shared feature 
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of APOBEC3-Vif interactions. These data represent the first identification of directly 
interacting residues involved in the APOBEC3-Vif interaction and provide insight into 
the structural basis of this interaction that has to date eluded structural study. Perhaps 
more importantly, our data suggest that the extensive array of interactions described by 
Table 1-2 can be distilled into a single target that may be highly susceptible to 
therapeutic intervention. 
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Results 
HIV can adapt readily to growth in the presence of Vif-resistant APOBEC3 proteins – 
The Vif proteins produced by the lentiviruses infecting a given species are thought to be 
specially adapted to neutralize the APOBEC3 repertoire of that species (Bogerd et al., 
2004; LaRue, 2010; Mangeat et al., 2004; Mariani et al., 2003; Schröfelbauer et al., 
2004; Xu et al., 2004). As a consequence, lentiviral replication is typically restricted by 
APOBEC3 proteins from non-cognate species since Vif has not evolved for activity 
against the novel host APOBEC3 repertoire. We have previously validated this 
phenomenon using rhesus macaque A3F and A3G as well as derivatives of human A3F 
and A3G that have been engineered to resist Vif through the incorporation of specific 
rhesus macaque residues into the Vif interaction site of the human protein, QE323-
324EK in A3F and DPD128-130KPK in A3G [(Albin, 2010; Hultquist et al., 2011) and 
see Materials and Methods]. In principle, then, infection of these cell lines with the 
human APOBEC3-adapted HIV Vif acts as an inverse mimic of the APOBEC3-Vif-
dependent components of a cross-species transfer event analogous to those transmissions 
from primate to human that have given rise to the HIV epidemic. 
 Given time to evolve sequence diversity, however, the transfer of a given virus 
such as HIV to a novel host species should be possible despite APOBEC3-dependent 
barriers since the novel host APOBEC3 repertoire will select variants from among 
transmitted genotypes that effectively neutralize the novel APOBEC3 repertoire. 
Moreover, the compensatory changes acquired in vif should theoretically correspond to 
alterations in the APOBEC3 interaction site in Vif that corresponds to the Vif interaction 
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sites in APOBEC3 proteins that have been either engineered to resist HIV Vif or that are 
natively HIV Vif-resistant. 
 To model this situation, we elected to carry out graded selection experiments that 
would allow sequence diversity to accumulate from defined molecular clone backgrounds 
while actively selecting for compensatory changes by gradually increasing exposure to 
any of four Vif-resistant APOBEC3 proteins. APOBEC3 expression levels in the cell 
lines used are shown in Figure 5-1B-C, and the overall strategy is depicted schematically 
in Figures 5-1E-F. In brief, we infected permissive SupT11 derivatives stably transfected 
with a vector control with viruses derived from molecular clones of defined sequence, 
HIVIIIB and HIVLAI-GFP, and gradually passaged these viruses through a series of co-
cultures between the SupT11-vector cells and one of four novel species APOBEC3 
conditions – A3F QE323-324EK, rhA3F, A3G DPD128-130KPK and rhA3G – before 
ending each round on a culture purely of cells stably transfected with a Vif-resistant 
APOBEC3 protein. The exact combinations of virus and cell line are depicted 
schematically in Figure 5-1E, where each prong represents a 24-well plate in which 22 
wells were used for selection and two wells were used for positive and negative controls 
– virus maintained on the original permissive cell line and an uninfected well of co-
cultured cells, respectively – and the cycles described are depicted schematically in 
Figure 5-1F. 
 In total, we completed three rounds of selection. Isolates were saved from 100% 
nonpermissive cultures at the end of each round based on indicators of improved 
replication such as enhanced CEM-GFP infectivity, increased syncytia formation or 
increased cell death as described in Materials and Methods. These viruses were then 
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subjected to a total of three subsequent, MOI-controlled confirmatory passages on fresh 
Vif-resistant nonpermissive cells of the kind on which they were originally selected; all 
viruses saved for subsequent passages were saved exclusively from cell lines of the type 
on which they were originally selected. The total number of adapted viruses as confirmed 
through the fourth and final passage of saved isolates present at the end of each round of 
selection as well as fourth-passage spreading infection curves of representative viruses 
adapted to the indicated condition are shown in Figure 5-2A-D. As expected, the number 
of adapted isolates gradually increased over time for each selection condition, suggesting 
that our system is capable of generating both sequence diversity and selective pressure 
for the maintenance of adapted genotypes. 
 
Cross-resistance patterns among viruses adapted to Vif-resistant APOBEC3 proteins 
show limited specificity – In addition to confirming the adapted phenotype of selected 
viruses, the fourth and final passage on cells nonpermissive to the parental viruses from 
which our isolates derive was utilized for two additional purposes – to phenotype adapted 
isolates when exposed for the first time to novel Vif-resistant APOBEC3 proteins to 
which they had not been previously adapted and to save infected genomic DNA for 
sequence characterization of the vif alleles present in each adapted virus population. A 
nearly comprehensive rendering of these sequence and cross-resistance characteristics for 
each isolate derived from the A3F QE323-324EK and A3G DPD128-130KPK as well as 
the rhA3F and rhA3G conditions is provided in Tables 5-1 through 5-8. 
 Phenotypically, most isolates from the fourth passage of viruses adapted to human 
A3F QE323-324EK or to rhA3F displayed strong cross-resistance to each other as shown 
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for representative isolates in Figures 5-3A-B and 5-3I-J and indicated in Tables 5-1 and 
5-2 and 5-5 and 5-6. These viruses also often displayed improved growth in the presence 
of human A3G DPD128-130KPK and rhA3G, although these phenotypes were generally 
weaker on the former cell lines, often yielding low peaks at late time points in the 
experiment (Tables 5-1-2 and 5-5-6 and Figure 5-3C-D). 
 A true appreciation for the extent of such cross-resistance was not feasible for the 
A3G DPD128-130KPK and rhA3G combinations because rhA3G is relatively poorly 
restrictive to Vif-proficient HIV; unaltered HIVIIIB viruses and, to a lesser extent, HIVLAI-
GFP will usually peak on rhA3G-expressing cells by approximately 2-3 weeks post-
infection when starting from low MOI (data not shown). Generally speaking, however, 
viruses adapted to growth in the presence of A3G DPD128-130KPK were quite proficient 
at growth in the presence of rhA3G, but the reverse was not true (Tables 5-3 and 5-4 and 
5-7 and 5-8 and Figures 5-3G-H and 5-3K-L). This is likely due to the poorly restrictive 
phenotype displayed by rhA3G; in this case, it is possible that mundane fitness 
enhancement or other nonspecific changes in the virus could enable enhanced replication 
in the presence of rhA3G without readily translating into growth in the presence of A3G 
DPD128-130KPK, which is strongly restrictive in our spreading infection system. 
 Surprisingly, when we exposed viruses adapted to A3G DPD128-130KPK to the 
strongly restrictive A3F QE323-324EK and rhA3F cell lines, these viruses often 
displayed robust growth phenotypes similar to those observed on their parent cell lines, 
indicating a lack of specificity in the adaptive features acquired by these viruses through 
sequential passage relative to viruses similarly passaged in A3F QE323-324EK- or 
rhA3F-expressing cells (Tables 5-3 and 5-4 and 5-7 and 5-8 and Figures 5-3E-F). 
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A3F QE323-324EK and rhA3F show strong selection for a common mutation despite 
prima facie evidence that vif mutations do not explain the adapted phenotypes of all 
viruses – To better characterize the vif genes present in the viruses adapted to our various 
Vif-resistant APOBEC3 conditions, we isolated genomic DNA from at or near the peaks 
of the fourth confirmatory passage from 1-2 cell lines for each virus and amplified the 
vif-vpr region of each virus as previously described (Albin et al., 2010a). We then 
purified and sequenced these PCR products. These data are presented in several formats 
to facilitate digestion and allow full access to the selection dataset for cross-referencing 
as desired. Tables 1-1 through 1-8 list the vif genotype of each adapted isolate next to its 
phenotypic scoring, while Figures 5-4 through 5-11 show alignments for the vif genes 
derived from each combination of starting virus template (HIVIIIB or HIVLAI-GFP) and 
selective condition (A3F QE323-324EK, A3G DPD128-130KPK, rhA3F or rhA3G). 
 A global overview of the mutations selected by each of our conditions is 
presented in Figures 5-12 and 5-13, where we have plotted the total number of isolates 
from a given selective condition carrying a particular mutation on the y-axis against each 
position in the Vif coding sequence on the x-axis. In viewing the data this way, one 
observes that, while several mutational hotspots occur when viruses are adapted to A3F 
QE323-324EK, mostly notably G71D and, to a lesser extent, E/D117K/N in isolates 
derived from both HIVIIIB and HIVLAI-GFP templates and E45D and G185R derived from 
HIVIIIB or HIVLAI-GFP templates, respectively, there are few patterns to the mutations 
selected by A3G DPD128-130KPK (Figure 5-12A-B). The potential exceptions of 
interest are the most common change in three isolates derived from both IIIB and LAI-
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GFP templates, G82D, as well as changes at residue 15 in the 14-DRMR-17 region that 
has been previously implicated in allowing HIV Vif to overcome rhA3G and A3G 
D128K (Schröfelbauer et al., 2006). Similarly, among our rhesus selection conditions, we 
see a strong selection for the G71D change, particularly among HIVIIIB-derived isolates, 
and essentially no pattern at all among viruses adapted to rhA3G, although once again 
there is one virus containing a change at residue 15 in the 14-DRMR-17 region (Figure 
5-13A-B). 
 Thus, while our selection protocol produced many changes in vif, perhaps the 
most surprising result in these data is the relative lack of consensus mutations in vif 
associated with each selective combination with the exception of G71D with A3F 
QE323-324EK and rhA3F. In fact, a total of 11 HIVLAI-GFP-derived viruses adapted to 
A3F QE323-324EK, four HIVIIIB-derived viruses adapted to A3G DPD128-130KPK, six 
HIVLAI-GFP-derived viruses adapted to A3G DPD128-130KPK, 10 HIVLAI-GFP-derived 
viruses adapted to rhA3F, three HIVIIIB-derived viruses adapted to rhA3G and 11 HIVLAI-
GFP-derived viruses adapted to rhA3G carried no clear mutations in vif (Tables 5-1-8). 
The latter two of these may conceivably be explained by the relative dearth of selective 
pressure imposed by rhA3G, which is generally only weakly restrictive to HIV Vif-
proficient viruses (see Figure 5-3 above). That said, most of these isolates with the 
exception of several inactivating mutations found among the HIVIIIB-derived viruses 
adapted to A3G DPD128-130KPK did maintain intact vif open reading frames. This 
strongly implies that HIV can acquire accessory mutations outside of vif that can 
synergize with Vif or even act independently, as it would seem for the inactivating 
mutations noted, to counteract APOBEC3 proteins in the absence of Vif. While we have 
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noted a number of vpr truncations in the viruses selected, consistent with our prior reports 
selecting adaptive Vif-independent changes, the cell lines used in the studies described in 
Chapter 5 and Chapter 6 were chosen specifically because their levels of APOBEC3 
expression restrict the growth of such vpr-deficient variants [(Albin et al., 2010a; Haché 
et al., 2008) and data not shown)]. Anticipating that other Vif-independent mutations 
might allow HIV to adapt to the presence of APOBEC3 proteins, however, we carried out 
similar selection experiments with Vif-deficient viruses in parallel with the studies 
described here. The results of these studies, described in Chapter 6, implicate HIV Env 
in phenocopying the anti-APOBEC3 effects of Vif, demonstrating unambiguously that 
Vif-independent adaptation to APOBEC3 proteins is possible. 
 
Selected adapted vif alleles neutralize Vif-resistant APOBEC3 proteins – In considering 
which mutations to further analyze, the obvious choices for A3F QE323-324EK and 
rhA3F derivatives were G71D, E45D, E/D117K/N and G185R. Among other prominent 
peaks, R92K was excluded since it typically occurs as a minor allele (Tables 5-1 and 5-
2). M189I was also excluded because both this change and G185R also affect the coding 
sequence of the overlapping vpr open reading frame, with R12K being caused by Vif 
G185R and E17K being caused by Vif M189I. It is possible that these may confound 
analysis in a proviral context, but it is not clear to what extent the vpr open reading frame 
remains intact in our passaged viruses since loss of vpr is a common consequence of 
long-term passage in culture (Nakaya et al., 1994) and, anecdotally, there are many 
obvious premature stop codons in vpr picked up by our sequencing reads aimed at vif 
(data not shown). Thus, these mutations may represent G-to-A noise in a neutrally 
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evolving open reading frame. Nevertheless, we were intrigued by the emerging theme of 
glycine changes among our adapted viruses and so opted to retain G185R for further 
analysis. 
 Surprisingly, there were almost no major peaks of sequence evolution evident 
among viruses adapted to A3G DPD128-130KPK (Figure 5-3B). This relative lack of 
selection for changes in vif may indicate that the changes to the Vif interface caused by 
amino acids DPD128-130KPK are gross alterations. Alternatively, the interaction of Vif 
with these residues may be partially indirect. Finally, it may simply be that having two 
mutations independently capable of rendering A3G Vif-resistant created a level of 
stringency too great for our selection system to handle, as this might require two 
mutations in close proximity despite the proposed cumulative effects of changes at D130 
and D128 in rendering A3G Vif-resistant (Huthoff and Malim, 2007). 
 Despite the relative lack of activity in vif genes adapted to Vif-resistant variants of 
A3G, we were interested in two changes found among the these viruses. Two viruses 
contained changes at R15, which was of interest both because these changes were also 
evident in preliminary clonal sequencing of viruses adapted to rhA3G (data not shown) 
and because R15 falls within the 14-DRMR-17 region that has been previously mutated 
to overcome Vif-resistant variants of A3G (Schröfelbauer et al., 2006). More 
importantly, though, the sole peak among A3G DPD128-130KPK-adapted viruses was 
G82D. Like G71D, this is a charge change consistent with neutralization of an aberrant 
positive charge in Vif-resistant A3G variants. Moreover, we noticed that the 11 amino 
acids separating G71 from G82 in Vif is equivalent to the 11 amino acids separating the 
phylogenetic equivalents of A3F E324 and A3G D130 [A3F D313, (Albin et al., 2010b)]. 
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Finally, we noted that the 71-GxxxG-75 sequence of Vif is a common helix-helix 
interaction motif that facilitates interhelical hydrogen bonding, which would be 
consistent with an interaction between negatively charged residues of the wildtype α4 
helix and either the glycine peptide backbone or the Cα-H itself as previously reported 
[e.g. (Kleiger et al., 2002; Lorieau et al., 2010)]. A depiction of these linear alignments is 
shown in Figure 5-14A-C for each set of APOBEC3-Vif interactions, and the helical 
wheel representation shows that this region of Vif, when modeled as a helix, places all of 
the relevant glycine residues on the same surface along with D78, which itself is aligned 
to APOBEC3 glycine residues. Thus, each of these residues is predicted to occur on the 
same helical surface and to be available for interaction with the negatively charged 
APOBEC3 surface (Figure 5-14D). We therefore hypothesized that G71D and G82D act 
in the context of an antiparallel helix interacting with the APOBEC3 α4 helix. 
 To test our hypothesis, we carried out single-cycle infectivity analyses of Vif 
G71D versus wildtype A3F, A3F E324K and rhA3F and of Vif G82D versus A3G and 
A3G D130K. As shown in Figure 5-15A, G71D displayed a slight loss of function in the 
neutralization of wildtype A3F but gained modest activity against A3F E324K and 
rhA3F, consistent with a role for G71 in direct interaction with A3F E324. These results 
were corroborated by spreading infection data demonstrating that the G71D mutation 
facilitates viral growth in the presence of both rhA3F and A3F QE323-324EK, albeit less 
robustly in the latter case, commensurate with efficiency with which G71D is selected in 
each condition (Figure 5-15C-B). At the opposite end of the putative helix-helix 
interaction, interpretation is somewhat complicated by the fact that the D130K change 
alone is only partially Vif-resistant. That said, G82D in either HIVIIIB or HIVLAI-GFP 
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genetic backgrounds shows both enhanced degradation of A3G D130K relative to 
wildtype and enhanced infectivity recovery relative to wildtype (Figure 5-15D). Our data 
are therefore consistent with G71 and G82 acting as anchors on either end of a helix-helix 
interaction common to both A3F and A3G, indicating that the interaction of Vif with 
APOBEC3 proteins is, at least in this respect, structurally conserved. Analysis of 
additional mutants is ongoing. 
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Discussion 
 Here, we present the results of genetic selection experiments aimed at determining 
what residues in Vif interact with the single amino acid determinants of Vif susceptibility 
located in the APOBEC3 α4 helix. Despite the fact that our data suggest an antiparallel 
helix-helix interaction as the core of the Vif interaction with the conserved APOBEC3 α4 
helix, there are several lines of evidence that suggest the overall interaction is much more 
complex. First, a large and growing body of literature has characterized many single 
amino acid changes distributed predominantly throughout the N-terminus of Vif that can 
render it nonfunctional against one APOBEC3 protein or another (see Table 1-2). While 
many of these, based on their sheer diversity, likely represent gross structural distortions 
of the protein, the broader point that many regions of Vif can affect the APOBEC3-Vif 
interaction is clear. 
 While the emergence of G71D is the clearest single result in the selection data and 
this mutant works very effectively at neutralizing rhA3F in spreading infections, we have 
found its phenotype more limited in cells expressing A3F QE323-324EK. This may, 
counterintuitively, be consistent with the notion that the 11 amino acids spanning 71-82 
form a glycine-rich helix that interacts with the APOBEC3 α4 helix. GxxxG motifs 
typically mediate tight packing of the associated helices, yet this is not likely possible for 
the A3F QE323-324EK mutant since, even if Vif can acquire a negative charge to 
interact with the target lysine, the bulk of the interacting side chains would impede the 
broader interaction. Indeed, we have tested one molecular clone based on a selected virus 
that carries both G71D and G75E, which is much more efficient at spreading in A3F 
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QE323-324EK cells than G71D alone (data not shown). This may suggest the need for a 
longer sidechain at the other end of the GxxxG motif to stabilize the interaction. 
 With respect to A3G, we have found that G82D can neutralize the A3G D130K 
change in a single-cycle infectivity assay, suggesting a second direct interaction at the 
opposite end of the putative helix. The spreading infection phenotypes of this mutant are 
also of interest for at least two reasons. First, the G82D mutant is deficient for the 
neutralization of wildtype A3F [data not shown and (Dang et al., 2010a)]. This may 
further be consistent with an interaction between G82 and D313 in A3F (the equivalent of 
A3G D130) since, in G82D context, these charges would repel each other. A similar loss 
of function phenotype does not, however, occur with G82D in the context of wildtype 
A3G as one might predict, indicating that, even if this putative helix represents a 
commonly held APOBEC3-Vif interaction motif as we propose, there must be 
modifications to that core interaction in different APOBEC3 proteins that result in some 
variation. 
 The G82D change was not selected using cells expressing A3G D130K, but rather 
DPD128-130KPK. We have not observed an effect either in single-cycle or in spreading 
infection to date of G82D on this double mutant, indicating that the D128K change alone 
must be capable of continuing to act as a dominant interrupter of the APOBEC3-Vif 
interaction despite apparent neutralization of A3G D130K itself. It is possible that G82D 
alone proffers some modest advantage to viruses in culture without itself facilitating 
complete adaptation to A3G DPD128-130KPK in accordance with the relatively weak 
selection for its occurrence observed. Indeed, we postulate that the D128K change may 
be the reason we observe such little selection for any sort of change in A3G, as this 
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implies any of several possibilities: 1) D128K may grossly alter the Vif interaction 
surface. We think this relatively unlikely since we would not likely select G82D at all if 
this were the case, but it is possible. 2) The effect of A3G D128K on interaction with Vif 
may be indirect, implicating some binding partner facilitating interaction at this residue. 
In particular, it is interesting to note that W127 directly adjacent to D128 is critical for 
A3G binding to RNA (Friew et al., 2009; Huthoff et al., 2009; Huthoff and Malim, 
2007). Thus, there is likely RNA bound locally around D128. In the context of the 
wildtype residue, this may not be problematic for Vif since the negatively charged RNA 
backbone and D128 would repel each other and permit G84 (a fourth glycine if one 
extends the interaction surface past G82D and into predicted APOBEC3 loop space) to 
interact with D128 – or perhaps to interact with the RNA backbone itself. Placing a lysine 
at D128, however, would create a strong charge interaction between residue 128 and the 
adjacent RNA that could shield the residue from interaction with Vif. This conception is 
consistent with the strong loss of Vif function against both A3F and A3G associated with 
the G84D mutation [(Dang et al., 2010a) and data not shown]. In any event, it is clear 
that A3G D128K strongly dominantly inhibits interaction with Vif despite extensive 
efforts to select a compensatory change. 
 In summary, we have described here the first evidence for a direct interaction 
between any two points in APOBEC3 proteins and Vif. Intriguingly, one may draw a line 
between these two points to identify a GxxxG helix-helix-interaction motif, both residues 
of which affect the interaction of A3F with the Vif-resistant derivative A3F QE323-
324EK. We therefore propose that the core of the APOBEC3-Vif interaction is a helix-
helix interaction between the α4 helix of APOBEC3 proteins that includes most of the 
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known single amino acid determinants of Vif susceptibility (Albin et al., 2010b) and a 
glycine-rich helix in Vif extending from amino acids 71-82. This represents an important 
advance in our understand of how APOBEC3 proteins and Vif recognize each other and 
provides important insights for further explorations both structural and genetic of bona 
fide direct interactions between APOBEC3 proteins and Vif that may be targeted 
therapeutically. 
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Materials and Methods 
Plasmids – Human A3F and A3G are identical to sequences NM_145298 and 
NM_021822, respectively, and have been previously described, as have the Vif-resistant 
variants A3F QE323-324EK and A3G DPD128-130KPK. Rhesus A3F and A3G were 
provided by Dr. Theodora Hatziioannou (Aaron Diamond AIDS Research Center, New 
York) and cloned into a pcDNA3.1-derived 3xHA vector as previously described 
(Hultquist et al., 2011); the coding sequences are identical to NM_001042373.1 and 
AY331716.1. Note that although the equivalent of human A3G D130 is aspartate in our 
rhesus A3G, other variants include asparagine at that residue (e.g. NM001198693.1). We 
have utilized lysine in the rhesus-based human construct A3G DPD128-130KPK 
described here since lysine displays the strongest Vif-resistant phenotype at residue 130 
and also allows for the clear identification of a putative compensatory charge change 
(Huthoff and Malim, 2007). V5-tagged derivatives of rhA3F and rhA3G were made by 
subcloning from the 3xHA vector as previously described (Albin et al., 2010b). Specific 
point mutants were made by QuickChange site-directed mutagenesis (Stratagene). Full-
length proviral HIVIIIB and HIVLAI-GFP plasmids have been described previously (Albin et 
al., 2010b); the HIVIIIB sequence used is identical to that deposited as EU541617 except 
for an A200C nucleotide change to interrupt an aberrant upstream open reading frame in 
the parent virus (Haché et al., 2009; Haché et al., 2008). For proviral mutant plasmids, 
mutations were made in TOPO shuttle vectors containing the Vif-Vpr region of each 
provirus and then subcloned back into the full-length proviral context via the unique 
SwaI/SalI sites in HIVIIIB or PshAI/SalI sites in HIVLAI-GFP. All constructs were verified 
by sequencing and diagnostic restriction mapping. 
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Cell lines –  The APOBEC3-expressing cell lines used in this study have been described 
previously (Albin et al., 2010a; Albin et al., 2010b; Hultquist et al., 2011). In brief, 
SupT11 cells were electroporated with linearized pcDNA3.1-derived plasmids encoding 
the indicated APOBEC3 protein, and single-cell clones were isolated by limiting dilution 
and G418 selection for integrated constructs. Expression levels for all cells were 
determined by lysing 5x106 cells in 250 µL of a lysis buffer consisting of 25 mM HEPES 
(pH 7.4), 150 mM NaCl, 1 mM MgCl2, 50 µM ZnCl2, 10% glycerol and 1% Triton X-
100 and supplemented with 50 µM MG132 and complete protease inhibitor (Roche), 
boiling portions of these lysates in a 5x sample buffer consisting of 62.5 mM Tris pH 6.8, 
20% glycerol, 2% sodium dodecyl sulfate, 5% β-mercaptoethanol, and 0.05% 
bromophenol blue at a final concentration of 2x and fractionating proteins by SDS-
PAGE. Following transfer, PVDF membranes were blocked with 4% milk in PBS-0.01% 
Tween, and samples were probed for A3G (#10201 from Dr. Jaisri Lingappa via the 
AIDS Research and Reference Reagent Program), A3F (#11474 from Dr. Michael Malim 
via the AIDS Research and Reference Reagent Program), hemagglutinin (HA.11, 
Covance) or tubulin (Covance) expression followed by appropriate secondary antibodies 
(anti-rabbit or anti-mouse from BioRad and Jackson, respectively). Between primary 
antibody probings, membranes were stripped at 50°C in a solution consisting of 62.5 mM 
Tris pH 6.8, 2% SDS, and 100 mM β-mercaptoethanol. 
 
Cell culture – T cell lines were maintained in RPMI medium supplemented with 10% 
fetal bovine serum, penicillin/streptomycin and β-mercaptoethanol. 293T cells were 
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maintained in DMEM medium supplemented with 10% fetal bovine serum and 
penicillin/streptomycin. 
 
Definition of adapted viruses –  The selection protocol was carried out as described in the 
text and as depicted in Figure 5-1. Adapted viruses were initially selected for 
confirmatory passage based on any of three qualitative characteristics indicating 
potentially enhanced replication relative to the uninfected control well on each plate and 
to the characteristics of neighboring viral cultures – infectivity on CEM-GFP reporter 
cells, qualitatively greater syncytia formation or qualitatively enhanced cell death. An 
adapted phenotype in subsequent passages was ultimately defined by the following 
criteria: i) Adapted viruses must be blindly identified as phenotypically adapted by the 
aforementioned characteristics at the end of each round of selection subsequent to the 
first in which they were identified. ii) Adapted viruses must rise above background peak 
parental infectivity within 21 days during confirmatory passage on cultures composed 
exclusively of cells expressing the Vif-resistant APOBEC3 protein to which the given 
virus was initially adapted, showing at least 2% absolute CEM-GFP infectivity for 
viruses adapted to A3F QE323-324EK or A3G DPD128-130KPK or at least 5% for 
viruses adapted to rhA3F or rhA3G. iii) Adapted viruses must peak in second and third 
MOI-controlled confirmatory passages following the round of selection in which they 
were initially identified on at least one of two selective cell lines used and must remain 
above 1% infectivity for at least one additional time point outside of their peaks. iv) 
Adapted viruses must peak in a fourth confirmatory passage on at least 2/4 cell lines used 
within 21 days as defined in (i). 
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Spreading infections – 150,000 cells per 1 mL were plated in 24-well plates and infected 
with a volume of virus corresponding to the MOI in a given figure legend. Viral spread 
was subsequently monitored by periodic harvest of 150 µL of culture supernatant, which 
was then used to infect 100 µL of 25,000 CEM-GFP reporter cells in 96-well plates. 
Approximately 3-5 days post-infection, CEM-GFP reporter cells were fixed and 
subsequently analyzed by flow cytometry, with the percentage of GFP+ cells in each well 
taken as an indicator of infectivity. Parent cultures were periodically split and fed to 
prevent cell overgrowth. 
 
Viral genotyping – To identify the vif sequences associated with adapted viruses, half of 
the CEM-GFP reporter cells infected at or near the peak of infectivity during fourth 
confirmatory passage were seeded into 500,000 uninfected CEM-GFP (the other half 
being those fixed for flow cytometry). Several days later, gDNA was harvested from 
these seeded cultures using the PureGene gDNA isolation method, genomic DNA was 
subjected to treatment with DpnI to remove any viral plasmid DNA that may have 
survived the many passages and manipulations to that point, and 550 ng were used as 
template in a touchdown PCR reaction to amplify the vif-vpr region as previously 
described (Albin et al., 2010a). PCR products were visualized in ethidium bromide 
stained agarose gels, and bands were extracted and purified (Epoch or Fermentas gel 
extraction kits) for subsequent sequencing of PCR products per service instructions 
(Genewiz). 
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Single-cycle infectivity and Vif sensitivity determination – Single-cycle infectivity 
experiments were carried out by seeding 250,000 293 T cells in 6-well plates. The 
following day, these were transfected using Trans-IT transfection reagent (Mirus Bio) 
with 1.6 µg Vif-deficient proviral plasmid, 200 ng of an APOBEC3-V5 construct and 0, 
50 or 100 ng of a Vif-HA construct. Two days post-infection, supernatants were purified 
through 0.45 µm filters and used to infect CEM-GFP reporter cells; three days later, these 
CEM-GFP reporter cells were fixed in 4% paraformaldehyde and analyzed by flow 
cytometry. Producer cells were also harvested at the same time as CEM-GFP infection by 
washing in PBS and then lysing in 250 µL lysis buffer before analysis by Western 
blotting as above except with anti-V5 (Invitrogen), anti-HA.11 (Covance) or anti-tubulin 
(Covance) antibodies. 
  196 
Table 5-1: Fourth passage vif genotyping and phenotypic characterization of 
HIVIIIB-derived viruses adapted to growth in the presence of A3F QE323-324EK. 
Isolate vif genotype 
Growth 
on 
QE323-
324EK 
Growth 
on 
rhA3F 
Growth 
on A3G 
DPD128-
130KPK 
Growth 
on 
rhA3G 
Growth 
on 
CEM2n 
Round 
First 
Apparent 
Q1-A2 A149T, W174X + + + + - 2 
Q1-A3 E45D, M189I ++ ++ + - + 3 
Q1-B4 
G71D, 
G75E, 
V142I 
++ ++ + - - 3 
Q1-B5 I31V, G191R* ++ ++ + + + 2 
Q1-C1 nd + + + - - 2 
Q1-C2 K26N, E45D, ++ + + - - 1 
Q1-C3 G71D, + nd nd nd nd 3 
Q1-C4 T180N + nd nd nd nd 3 
Q1-C5 I31V ++ ++ + - - 2 
Q1-D1 
H43Y, 
K50R, 
E117K 
++ + - - - 1 
Q3-A1 E45D, s116t, ++ + + - - 3 
Q3-B6 
G71D, 
M189I, 
G191E* 
++ +++ + + + 3 
Criteria 
- = No growth; for rhA3G, peaks one time point or later than vector 
+ = Weak growth such as failure to peak on one of the cell lines expressing A3F QE323-
324EK or delayed peaks in the last two time points (~3 weeks); for rhA3G, peaks at or 
before vector 
++ = Growth with peaks at the middle two time points (~2 weeks); no criteria for rhA3G 
+++ = Growth with peaks within the first two time points (~1 week); no criteria for 
rhA3G 
nd = Not determined, typically due to shortage of isolate viruses with which to initiate 
infection 
*Indicates mutation that introduces a stop codon in the overlapping vpr open reading 
frame 
Lower case vif genotypes indicate a minor population 
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Table 5-2: Fourth passage vif genotyping and phenotypic characterization of 
HIVLAI-GFP-derived viruses adapted to growth in the presence of A3F QE323-
324EK. 
Isolate vif genotype 
Growth 
on 
QE323-
324EK 
Growth 
on 
rhA3F 
Growth 
on A3G 
DPD128-
130KPK 
Growth 
on 
rhA3G 
Growth 
on 
CEM2n 
Round 
First 
Apparent 
Q4-A1 
G71D, 
s116t, 
K160R 
++ ++ + - na 2 
Q4-A2 D117N ++ nd nd nd na 2 
Q4-A3 nd + - - - na 3 
Q4-A4 
RL63-
64KM, 
G191E* 
++ ++ - - na 2 
Q4-B3 WT + nd nd nd na 1 
Q4-B4 D117N, L153I ++ ++ + + na 1 
Q4-C1 k92r, G185R ++ ++ - - na 2 
Q4-C2 G185R ++ ++ + - na 3 
Q4-C3 k92r ++ ++ - + na 1 
Q4-C4 WT ++ ++ ++ + na 1 
Q4-C5 nd ++ ++ + + na 1 
Q4-C6 WT ++ ++ ++ + na 3 
Q4-D1 G71D, G185R ++ ++ + + na 1 
Q4-D2 R19K ++ ++ + - na 2 
Q4-D4 k92r, M189K ++ +++ ++ + na 3 
Q11-
A1 WT ++ ++ - - na 2 
Q11-
A2 
R19K, 
K26E ++ ++ - + na 1 
Q11-
A3 WT + ++ - + na 2 
Q11-
A5 K92R ++ ++ + - na 3 
Q11-
A6 
g71d, 
G185R ++ ++ - - na 1 
Q11-
B1 L153I ++ ++ - - na 1 
Q11-
B2 WT ++ ++ + - na 3 
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Isolate vif genotype 
Growth 
on 
QE323-
324EK 
Growth 
on 
rhA3F 
Growth 
on A3G 
DPD128-
130KPK 
Growth 
on 
rhA3G 
Growth 
on 
CEM2n 
Round 
First 
Apparent 
Q11-
B3 g71d ++ ++ + - na 3 
Q11-
B4 k141r ++ ++ ++ + na 2 
Q11-
B5 
k92r, 
n175k, 
M189I 
++ ++ - nd na 2 
Q11-
B6 WT + ++ - + na 2 
Q11-
C1 D117N ++ ++ + + na 2 
Q11-
C2 
v98i, 
G191R* ++ ++ + - na 1 
Q11-
C3 G191R* ++ ++ + + na 3 
Q11-
C4 WT ++ ++ - - na 2 
Q11-
C5 WT ++ ++ + - na 1 
Q11-
C6 WT ++ ++ + - na 1 
Q11-
D1 
D117N, 
G185R ++ ++ - - na 2 
Q11-
D2 
g71d, 
g191e* ++ ++ + nd na 1 
Q11-
D3 WT ++ ++ - - na 1 
Q11-
D4 nd ++ nd nd nd na 1 
Criteria 
- = No growth; for rhA3G, peaks one time point or later than vector 
+ = Weak growth such as failure to peak on one of the cell lines expressing A3F QE323-
324EK or delayed peaks in the last two time points (~3 weeks); for rhA3G, peaks at or 
before vector 
++ = Growth with peaks at the middle two time points (~2 weeks); no criteria for rhA3G 
+++ = Growth with peaks within the first two time points (~1 week); no criteria for 
rhA3G 
nd = Not determined, typically due to shortage of isolate viruses with which to initiate 
infection 
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na = Not applicable; HIVLAI-GFP derivatives do not grow on CEM2n cells due to 
interruption of the nef open reading frame by GFP [e.g. (Chowers et al., 1994)]. 
*Indicates mutation that introduces a stop codon in the overlapping vpr open reading 
frame 
Lower case vif genotypes indicate a minor population 
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Table 5-3: Fourth passage vif genotyping and phenotypic characterization of 
HIVIIIB-derived viruses adapted to growth in the presence of A3G DPD128-
130KPK. 
Isolate vif genotype 
Growth 
on A3G 
DPD128-
130KPK 
Growth 
on 
rhA3G 
Growth 
on 
QE323-
324EK 
Growth 
on 
rhA3F 
Growth 
on 
CEM2n 
Round 
First 
Apparent 
D4-B2 G71D ++ + ++ ++ - 3 
D4-B6 G71D, G82D ++ + + ++ - 3 
D4-C2 D78E, L163S ++ - + + - 2 
D4-D2 
S32A, 
frameshift 
178 
++ - + + - 3 
D4-D3 L64S, W174X ++ - + + - 2 
D9-B2 K92R, P131L ++ + + + + 3 
D9-B3 W79X, G84X ++ + + + - 2 
D9-B4 frameshift 189 ++ - + + + 3 
D9-B5 F112I ++ + + + - 3 
D9-D2 C114R ++ - + + - 3 
Criteria 
- = No growth; for rhA3G, peaks one time point or later than vector 
+ = Weak growth such as failure to peak on one of the cell lines expressing A3G 
DPD128-130KPK or delayed peaks in the last two time points (~3 weeks); for rhA3G, 
peaks at or before vector 
++ = Growth with peaks at the middle two time points (~2 weeks); no criteria for rhA3G 
+++ = Growth with peaks within the first two time points (~1 week); no criteria for 
rhA3G 
nd = Not determined, typically due to shortage of isolate viruses with which to initiate 
infection 
*Indicates mutation that introduces a stop codon in the overlapping vpr open reading 
frame 
Minor populations not assessed in these sequences. 
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Table 5-4: Fourth passage vif genotyping and phenotypic characterization of 
HIVLAI-GFP-derived viruses adapted to growth in the presence of A3G DPD128-
130KPK. 
Isolate vif genotype 
Growth 
on A3G 
DPD128-
130KPK 
Growth 
on 
rhA3G 
Growth 
on 
QE323-
324EK 
Growth 
on 
rhA3F 
Growth 
on 
CEM2n 
Round 
First 
Apparent 
D14-
A1 P100S ++ - + ++ na 3 
D14-
A3 
G82D, 
G191R* ++ + ++ ++ na 3 
D14-
B5 WT + nd + ++ na 3 
D14-
C4 H127N ++ + ++ ++ na 3 
D14-
C5 nd + + + ++ na 3 
D14-
C6 WT ++ + +++ +++ na 3 
D15-
A2 
R15G, 
R50K, 
G82D, 
D117N 
++ nd + + na 3 
D15-
B1 WT + nd ++ nd na 3 
D15-
B2 R15W ++ + ++ ++ na 3 
D15-
B3 
R50K, 
E101K ++ nd ++ ++ na 3 
D15-
B4 WT + nd + ++ na 3 
D15-
B6 P100S ++ + ++ ++ na 3 
D15-
C1 WT + nd nd nd na 3 
D15-
C3 WT ++ nd nd nd na 3 
D15-
C5 nd + nd nd nd na 3 
D15-
D1 R121K ++ nd + nd na 3 
D15-
D2 H80Y ++ + ++ ++ na 3 
D15-
D3 
G60R, 
G191E* + nd + nd na 3 
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Criteria 
- = No growth; for rhA3G, peaks one time point or later than vector 
+ = Weak growth such as failure to peak on one of the cell lines expressing A3G 
DPD128-130KPK or delayed peaks in the last two time points (~3 weeks); for rhA3G, 
peaks at or before vector 
++ = Growth with peaks at the middle two time points (~2 weeks); no criteria for rhA3G 
+++ = Growth with peaks within the first two time points (~1 week); no criteria for 
rhA3G 
nd = Not determined, typically due to shortage of isolate viruses with which to initiate 
infection 
na = Not applicable; HIVLAI-GFP derivatives do not grow on CEM2n cells due to 
interruption of the nef open reading frame by GFP [e.g. (Chowers et al., 1994)]. 
*Indicates mutation that introduces a stop codon in the overlapping vpr open reading 
frame 
Minor populations not assessed in these sequences. 
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Table 5-5: Fourth passage vif genotyping and phenotypic characterization of 
HIVIIIB-derived viruses adapted to growth in the presence of rhA3F. 
Isolate vif Genotype Growth on rhA3F 
Growth on 
A3F QE323-
324EK 
Round First 
Apparent 
50-4(1)-A1 G71D, T74I ++ + 3 
50-4(1)-A6 G71D +++ +++ 2 
50-4(1)-B1 nd nd nd 3 
50-4(1)-B2 G71D +++ ++ 2 
50-4(1)-B3 G71D +++ +++ 3 
50-4(1)-B5 G71D, E117K +++ ++ 1 
50-4(1)-C1 nd ++ ++ 2 
50-4(1)-C2 R23S ++ - 3 
50-4(1)-C5 G71D +++ ++ 2 
50-4(1)-D1 G71D +++ +++ 3 
50-4(1)-D2 G71D, Q83R +++ +++ 3 
50-4(1)-D3 G71D +++ +++ 2 
50-4(1)-D4 G71D +++ +++ 2 
50-4(2)-A1 G71D, I128R ++ ++ 2 
50-4(1)-A4 G71D, Y111H, G191R* +++ ++ 2 
50-4(2)-A5 L59V, G71D, R127C ++ ++ 3 
50-4(2)-A6 G71D, E117K +++ ++ 3 
50-4(2)-B3 G71D, L81W +++ ++ 2 
50-4(2)-B5 G71D +++ +++ 1 
50-4(2)-B6 G71D +++ ++ 2 
50-4(2)-C2 R23S, I31V, E117K +++ + 3 
50-4(2)-C3 nd +++ ++ 2 
50-4(2)-C4 G71D +++ ++ 3 
50-4(2)-C5 S116L, I12L ++ + 3 
50-4(2)-C6 nd +++ ++ 2 
50-4(2)-D1 nd +++ ++ 3 
50-4(2)-D3 nd + - 3 
Criteria 
- = No growth 
+ = Weak growth such as failure to peak on one of the selective cell lines used or late 
peaks within the last two time points. 
++ = Growth with peaks by Day 13 post-infection 
+++ = Growth with peaks by Day 8 post-infection 
nd = Not determined, typically due to shortage of isolate viruses with which to initiate 
infection. 
Minor populations not assessed in these sequences. 
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Table 5-6: Fourth passage vif genotyping and phenotypic characterization of 
HIVLAI-GFP-derived viruses adapted to growth in the presence of rhA3F. 
Isolate vif Genotype Growth on rhA3F 
Growth on 
A3F QE323-
324EK 
Round First 
Apparent 
50-5(1)-A1 nd +++ ++ 2 
50-5(1)-A3 nd ++ ++ 3 
50-5(1)-A4 nd ++ ++ 2 
50-5(1)-A5 D117N ++ ++ 1 
50-5(1)-A6 WT + - 2 
50-5(1)-B1 WT ++ + 1 
50-5(1)-B4 WT ++ ++ 1 
50-5(1)-B6 nd ++ ++ 3 
50-5(1)-C1 G191E* ++ ++ 1 
50-5(1)-C4 nd ++ ++ 2 
50-5(1)-C5 nd ++ + 3 
50-5(1)-D1 nd ++ ++ 2 
50-5(1)-D2 I159M ++ ++ 2 
50-5(1)-D3 WT ++ ++ 1 
50-5(1)-D4 K92R ++ ++ 2 
50-5(2)-A1 WT ++ ++ 2 
50-5(2)-A2 R93K ++ ++ 2 
50-5(2)-A4 WT ++ ++ 3 
50-5(2)-A5 WT ++ + 3 
50-5(2)-B1 nd ++ ++ 1 
50-5(2)-B2 nd ++ ++ 2 
50-5(2)-B3 WT ++ ++ 3 
50-5(2)-B4 G191E* ++ ++ 2 
50-5(2)-B5 G71D, D78E ++ ++ 2 
50-5(2)-B6 WT ++ ++ 2 
50-5(2)-C1 WT ++ ++ 2 
50-5(2)-C2 nd ++ ++ 3 
50-5(2)-C3 nd ++ + 3 
50-5(2)-C4 nd ++ ++ 2 
50-5(2)-C5 nd nd nd 1 
50-5(2)-D1 nd nd nd 2 
Criteria 
- = No growth 
+ = Weak growth such as failure to peak on one of the selective cell lines used or late 
peaks within the last two time points. 
++ = Growth with peaks by Day 13 post-infection 
+++ = Growth with peaks by Day 8 post-infection 
nd = Not determined, typically due to shortage of viruses with which to initiate infection. 
Minor populations not assessed in these sequences. 
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Table 5-7: Fourth passage vif genotyping and phenotypic characterization of 
HIVIIIB-derived viruses adapted to growth in the presence of rhA3G. 
Isolate vif Genotype Growth on rhA3G 
Growth on 
A3G 
DPD/KPK 
Round First 
Apparent 
51-3(1)-A2 nd ++ - 2 
51-3(1)-A3 nd +++ ++ 1 
51-3(1)-A6 nd nd nd 2 
51-3(1)-A5 nd nd nd 3 
51-3(1)-B1 M8I, G71D +++ + 3 
51-3(1)-B2 R33K, G71D +++ + 2 
51-3(1)-B3 nd nd nd 1 
51-3(1)-B4 nd nd nd 3 
51-3(1)-B5 I18S, T188K* ++ + 3 
51-3(1)-B6 V98I ++ - 3 
51-3(1)-C6 I31S +++ + 3 
51-3(1)-D4 T67I, S95N +++ - 3 
51-3(2)-A1 K50N ++ - 3 
51-3(2)-A4 R17N nd nd 3 
51-3(2)-A6 M29I ++ - 3 
51-3(2)-B3 nd ++ + 1 
51-3(2)-B4 nd ++ + 1 
51-3(2)-B5 nd +++ - 2 
51-3(2)-B6 V85A nd nd 3 
51-3(2)-C3 nd nd nd 3 
51-3(2)-C4 I51T, L59Q +++ - 1 
51-3(2)-C5 WT ++ - 3 
51-3(2)-C6 WT ++ + 2 
51-3(2)-D2 WT ++ - 2 
51-3(2)-D3 nd ++ - 2 
Criteria 
- = No growth 
+ = Weak growth such as failure to peak on one of the selective cell lines used or late 
peaks within the last two time points. 
++ = Growth with peaks by Day 13 post-infection 
+++ = Growth with peaks by Day 8 post-infection 
nd = Not determined, typically due to shortage of isolate viruses with which to initiate 
infection. 
Minor populations not assessed in these sequences. 
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Table 5-8: Fourth passage vif genotyping and phenotypic characterization of 
HIVLAI-GFP-derived viruses adapted to growth in the presence of rhA3G. 
Isolate vif Genotype Growth on rhA3G 
Growth on 
DPD/KPK 
Round First 
Apparent 
51-5(1)-A2 WT +++ + 3 
51-5(1)-A3 Q136R + - 2 
51-5(1)-A4 nd +++ - 1 
51-5(1)-A5 nd + - 1 
51-5(1)-A6 nd +++ + 2 
51-5(1)-B1 D117V ++ + 3 
51-5(1)-C1 R4K ++ - 2 
51-5(1)-C2 R15G, R50K, G82D, D117N ++ ++ 2 
51-5(1)-C3 WT +++ + 2 
51-5(1)-C4 WT ++ + 2 
51-5(1)-C6 WT +++ ++ 1 
51-5(1)-D1 WT ++ + 1 
51-5(1)-D2 WT +++ ++ 2 
51-5(1)-D4 WT ++ + 3 
51-5(2)-A4 L59I ++ + 3 
51-5(2)-A5 WT ++ + 2 
51-5(2)-B2 G185R ++ + 2 
51-5(2)-B4 nd ++ - 2 
51-5(2)-B5 WT + - 2 
51-5(2)-B6 nd ++ - 2 
51-5(2)-C1 WT +++ - 3 
51-5(2)-C5 nd + - 3 
51-5(2)-C6 WT + - 1 
51-5(2)-D1 nd ++ - 1 
51-5(2)-D3 nd nd nd 3 
Criteria 
- = No growth 
+ = Weak growth such as failure to peak on one of the selective cell lines used or late 
peaks within the last two time points. 
++ = Growth with peaks by Day 13 post-infection 
+++ = Growth with peaks by Day 8 post-infection 
nd = Not determined, typically due to shortage of isolate viruses with which to initiate 
infection. 
Minor populations not assessed in these sequences. 
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Figure 5-1: Experimental approach to the genetic identification of residues in Vif 
that directly interact with the APOBEC3 α4 helix determinants of Vif susceptibility. 
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Figure 5-1: Experimental approach to the genetic identification of residues in Vif 
that directly interact with the APOBEC3 α4 helix determinants of Vif susceptibility. 
(A) A conceptual depiction of the experimental strategy using A3F as an example. 
Wildtype HIV Vif interacts with wildtype human A3F in the left panel, permitting viral 
spread. In the middle panel, a negative-to-positive charge change E324K renders A3F 
Vif-resistant, preventing viral spread. At the right, a compensatory negative charge in Vif 
restores functional interaction with A3F E324K, reversing the Vif-resistant phenotype 
and once again permitting viral spread. (B) SupT11-derived T cell lines used in this study 
that have been stably transfected with human A3F, A3F QE323-324EK, or a vector 
control as previously described (Albin et al., 2010b; Refsland et al., 2010). (C) SupT11-
derived T cell lines used in this study that have been stably transfected with human A3G, 
A3G DPD128-130KPK or a vector control, as previously described (Albin et al., 2010b; 
Refsland et al., 2010). (D) SupT11-derived T cell lines used in this study that have been 
stably transfected with rhesus macaque A3F-3xHA, rhesus macaque A3G 3x-HA or a 
vector control, as previously described (Hultquist et al., 2011). (E) A schematic showing 
the selection conditions used in this study in which each prong represents a 24-well plate 
with 22 selective cultures, an infected permissive cell culture and an uninfected culture. 
(F) A schematic depicting the co-culture selection strategy used in this chapter. 
Approximately 8-11 days separate each passage from the next. A “Round” of selection 
refers collectively to a set of step-wise passages from permissive to increasingly 
nonpermissive cultures as shown. Viruses were evaluated at Condition 4(a) for potential 
MOI-controlled, confirmatory passages, while portions of each culture were also cycled 
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back to the beginning of the process for another Round of selection as shown in 
Condition 4(b). 
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Figure 5-2: Successful selection for adapted viruses. (A) Histograms showing the total 
number of adapted isolates present at the end of each round of selection as determined in 
Materials and Methods for A3F QE323-324EK and A3G DPD128-130KPK. (B-C) 
Representative adapted viruses from the fourth passage of the A3F QE323-324EK and 
A3G DPD128-130KPK adapted viruses are shown relative to the parental molecular 
clone derived viruses and Vif-deficient derivatives of the same molecular clones. (D-F) 
As in A-B but with rhA3F and rhA3G. 
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Figure 5-3: Representative native and cross-resistance phenotypes of adapted 
viruses. 
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Figure 5-3: Representative native and cross-resistance phenotypes of adapted 
viruses. (A-D) Representative isolates originally adapted to A3F QE323-324EK and their 
growth on both a native adaptive cell line (A) and on cell lines expressing (B) rhA3F, (C) 
A3G DPD128-130KPK and (D) rhA3G. (E-H) Representative isolates originally adapted 
to A3G DPD128-130KPK and their growth on both a native adaptive cell lines (G) and 
on cell lines expressing (H) rhA3G, (E) A3F QE323-324EK and (F) rhA3F. (I-J) 
Representative isolates originally adapted to rhA3F and their growth on both a native 
adaptive cell line (J) and on cells expressing (I) A3F QE323-324EK. (K-L) 
Representative isolates originally adapted to rhA3G and their growth on both a native 
adaptive cell line (L) and on cells expressing (K) A3G DPD128-130KPK. Note that the 
fourth passages of viruses adapted to A3F QE323-324EK and A3G DPD128-130KPK 
were carried out as one experiment from MOI 0.02, while the fourth passage of viruses 
adapted to rhA3F or rhA3G were carried out as another, independent experiment from 
MOI 0.02. Thus, the control wildtype and Vif-deficient viruses replotted for the same cell 
line in the first two columns (e.g. panels A and E) are the same. 
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Figure 5-4: Alignment of HIVIIIB vif alleles selected by A3F QE323-324EK. All 
alignments prepared using SeqPublish: http://www.hiv.lanl.gov/content/sequence/ 
SeqPublish/seqpublish.html
IIIB_Vif    MENRWQVMIV WQVDRMRINT WKRLVKHHMY ISRKAKDWFY RHHYESTNPK ISSEVHIPLG DAKLVITTYW
Q1-A2       ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q1-A3       ---------- ---------- ---------- ---------- ----D----- ---------- ----------
Q1-B4       ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q1-B5       ---------- ---------- ---------- V--------- ---------- ---------- ----------
Q1-C2       ---------- ---------- -----N---- ---------- ----D----- ---------- ----------
Q1-C3       ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q1-C4       ---------- ---------- ---------- ---------- ----K----- ---------- ----------
Q1-C5       ---------- ---------- ---------- V--------- ---------- ---------- ----------
Q1-D1       ---------- ---------- ---------- ---------- --Y------R ---------- ----------
Q3-A1       ---------- ---------- ---------- ---------- ----D----- ---------- ----------
Q3-B6       ---------- ---------- ---------- ---------- ---------- ---------- ---------- 70
IIIB_Vif    GLHTGERDWH LGQGVSIEWR KKRYSTQVDP DLADQLIHLH YFDCFSESAI RNTILGRIVS PRCEYQAGHN
Q1-A2       ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q1-A3       ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q1-B4       D---E----- ---------- ---------- ---------- ---------- ---------- ----------
Q1-B5       ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q1-C2       ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q1-C3       D--------- ---------- ---------- ---------- ---------- ---------- ----------
Q1-C4       ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q1-C5       ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q1-D1       ---------- ---------- ---------- ---------- ------K--- ---------- ----------
Q3-A1       ---------- ---------- ---------- ---------- -----t---- ---------- ----------
Q3-B6       D--------- ---------- ---------- ---------- ---------- ---------- ---------- 140
IIIB_Vif    KVGSLQYLAL AALIKPKQIK PPLPSVRKLT EDRWNKPQKT KGHRGSHTMN GH*
Q1-A2       --------T- ---------- ---------- ---*------ ---------- ---
Q1-A3       ---------- ---------- ---------- ---------- --------I- ---
Q1-B4       -I-------- ---------- ---------- ---------- ---------- ---
Q1-B5       ---------- ---------- ---------- ---------- ---------- R--
Q1-C2       ---------- ---------- ---------- ---------- ---------- ---
Q1-C3       ---------- ---------- ---------- ---------N ---------- ---
Q1-C4       ---------- ---------- ---------- ---------- ---------- ---
Q1-C5       ---------- ---------- ---------- ---------- ---------- ---
Q1-D1       ---------- ---------- ---------- ---------- ---------- ---
Q3-A1       ---------- ---------- ---------- ---------- ---------- ---
Q3-B6       ---------- ---------- ---------- ---------- --------I- E-- 192
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Figure 5-5: Alignment of HIVLAI-GFP vif alleles selected by A3F QE323-324EK. 
LAI_Vif    MENRWQVMIV WQVDRMRIRT WKSLVKHHMY VSGKARGWFY RHHYESPHPR ISSEVHIPLG DARLVITTYW
Q4-A1      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-A2      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-A4      ---------- ---------- ---------- ---------- ---------- ---------- --KM------
Q4-A6      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-B3      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-B4      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-C1      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-C2      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-C3      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-C4      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-C6      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-D1      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-D2      ---------- --------K- ---------- ---------- ---------- ---------- ----------
Q4-D4      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-A1     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-A2     ---------- --------K- -----E---- ---------- ---------- ---------- ----------
Q11-A3     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-A5     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-A6     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-B1     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-B2     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-B3     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-B4     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-B5     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-B6     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-C1     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-C2     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-C3     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-C4     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-C5     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-C6     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-D1     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-D2     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-D3     ---------- ---------- ---------- ---------- ---------- ---------- ---------- 70
LAI_Vif    GLHTGERDWH LGQGVSIEWR KKRYSTQVDP ELADQLIHLY YFDCFSDSAI RKALLGHIVS PRCEYQAGHN
Q4-A1      D--------- ---------- ---------- ---------- -----t---- ---------- ----------
Q4-A2      ---------- ---------- ---------- ---------- ------N--- ---------- ----------
Q4-A4      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-A6      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-B3      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-B4      ---------- ---------- ---------- ---------- ------N--- ---------- ----------
Q4-C1      ---------- ---------- -r-------- ---------- ---------- ---------- ----------
Q4-C2      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-C3      ---------- ---------- -r-------- ---------- ---------- ---------- ----------
Q4-C4      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-C6      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-D1      D--------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-D2      ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q4-D4      ---------- ---------- -r-------- ---------- ---------- ---------- ----------
Q11-A1     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-A2     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-A3     ---------- ---------- -R-------- ---------- ---------- ---------- ----------
Q11-A5     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-A6     d--------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-B1     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-B2     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-B3     d--------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-B4     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-B5     ---------- ---------- -r-------- ---------- ---------- ---------- ----------
Q11-B6     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-C1     ---------- ---------- ---------- ---------- ------N--- ---------- ----------
Q11-C2     ---------- ---------- -------i-- ---------- ---------- ---------- ----------
Q11-C3     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-C4     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-C5     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-C6     ---------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-D1     ---------- ---------- ---------- ---------- ------N--- ---------- ----------
Q11-D2     d--------- ---------- ---------- ---------- ---------- ---------- ----------
Q11-D3     ---------- ---------- ---------- ---------- ---------- ---------- ---------- 140
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Figure 5-5 (continued): Alignment of HIVLAI-GFP vif alleles selected by A3F QE323-
324EK. 
LAI_Vif    KVGSLQYLAL AALITPKKIK PPLPSVTKLT EDRWNKPQKT KGHRGSHTMN GH*
Q4-A1      ---------- ---------R ---------- ---------- ---------- ---
Q4-A2      ---------- ---------- ---------- ---------- ---------- ---
Q4-A4      ---------- ---------- ---------- ---------- ---------- E--
Q4-A6      ---------- ---------- ---------- ---------- ---------- ---
Q4-B3      ---------- ---------- ---------- ---------- ---------- ---
Q4-B4      ---------- --I------- ---------- ---------- ---------- ---
Q4-C1      ---------- ---------- ---------- ---------- ----R----- ---
Q4-C2      ---------- ---------- ---------- ---------- ----R----- ---
Q4-C3      ---------- ---------- ---------- ---------- ---------- ---
Q4-C4      ---------- ---------- ---------- ---------- ---------- ---
Q4-C6      ---------- ---------- ---------- ---------- ---------- ---
Q4-D1      ---------- ---------- ---------- ---------- ----R----- ---
Q4-D2      ---------- ---------- ---------- ---------- ---------- ---
Q4-D4      ---------- ---------- ---------- ---------- --------K- ---
Q11-A1     ---------- ---------- ---------- ---------- ---------- ---
Q11-A2     ---------- ---------- ---------- ---------- ---------- ---
Q11-A3     ---------- ---------- ---------- ---------- ---------- ---
Q11-A5     ---------- ---------- ---------- ---------- ---------- ---
Q11-A6     ---------- ---------- ---------- ---------- ----R----- ---
Q11-B1     ---------- --I------- ---------- ---------- ---------- ---
Q11-B2     ---------- ---------- ---------- ---------- ---------- ---
Q11-B3     ---------- ---------- ---------- ---------- ---------- ---
Q11-B4     r--------- ---------- ---------- ---------- ---------- ---
Q11-B5     ---------- ---------- ---------- ----k----- --------i- ---
Q11-B6     ---------- ---------- ---------- ---------- ---------- ---
Q11-C1     ---------- ---------- ---------- ---------- ---------- ---
Q11-C2     ---------- ---------- ---------- ---------- ---------- R--
Q11-C3     ---------- ---------- ---------- ---------- ---------- R--
Q11-C4     ---------- ---------- ---------- ---------- ---------- ---
Q11-C5     ---------- ---------- ---------- ---------- ---------- ---
Q11-C6     ---------- ---------- ---------- ---------- ---------- ---
Q11-D1     ---------- ---------- ---------- ---------- ----R----- ---
Q11-D2     ---------- ---------- ---------- ---------- ---------- e--
Q11-D3     ---------- ---------- ---------- ---------- ---------- --- 192
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Figure 5-6: Alignment of HIVIIIB vif alleles selected by A3G DPD128-130KPK. 
IIIB_Vif    MENRWQVMIV WQVDRMRINT WKRLVKHHMY ISRKAKDWFY RHHYESTNPK ISSEVHIPLG DAKLVITTYW
D4-B2       ---------- ---------- ---------- ---------- ---------- ---------- ----------
D4-B6       ---------- ---------- ---------- ---------- ---------- ---------- ----------
D4-C2       ---------- ---------- ---------- ---------- ---------- ---------- ----------
D4-D2       ---------- ---------- ---------- -A-------- ---------- ---------- ----------
D4-D3       ---------- ---------- ---------- ---------- ---------- ---------- ---S------
D9-B2       ---------- ---------- ---------- ---------- ---------- ---------- ----------
D9-B3       ---------- ---------- ---------- ---------- ---------- ---------- ----------
D9-B4       ---------- ---------- ---------- ---------- ---------- ---------- ----------
D9-B5       ---------- ---------- ---------- ---------- ---------- ---------- ----------
D9-D2       ---------- ---------- ---------- ---------- ---------- ---------- ---------- 70
IIIB_Vif    GLHTGERDWH LGQGVSIEWR KKRYSTQVDP DLADQLIHLH YFDCFSESAI RNTILGRIVS PRCEYQAGHN
D4-B2       D--------- ---------- ---------- ---------- ---------- ---------- ----------
D4-B6       D--------- -D-------- ---------- ---------- ---------- ---------- ----------
D4-C2       -------E-- ---------- ---------- ---------- ---------- ---------- ----------
D4-D2       ---------- ---------- ---------- ---------- ---------- ---------- ----------
D4-D3       ---------- ---------- ---------- ---------- ---------- ---------- ----------
D9-B2       ---------- ---------- -R-------- ---------- ---------- ---------- L---------
D9-B3       --------*- ---*------ ---------- ---------- ---------- ---------- ----------
D9-B4       ---------- ---------- ---------- ---------- ---------- ---------- ----------
D9-B5       ---------- ---------- ---------- ---------- -I-------- ---------- ----------
D9-D2       ---------- ---------- ---------- ---------- ---R------ ---------- ---------- 140
IIIB_Vif    KVGSLQYLAL AALIKPKQIK PPLPSVRKLT EDRWNKPQKT KGHRGSHTMN GH*
D4-B2       ---------- ---------- ---------- ---------- ---------- ---
D4-B6       ---------- ---------- ---------- ---------- ---------- ---
D4-C2       ---------- ---------- --S------- ---------- ---------- ---
D4-D2       ---------- ---------- ---------- -------RRP RATE-AIQ*M DT
D4-D3       ---------- ---------- ---------- ---*------ ---------- ---
D9-B2       ---------- ---------- ---------- ---------- ---------- ---
D9-B3       ---------- ---------- ---------- ---------- ---------- ---
D9-B4       ---------- ---------- ---------- ---------- --------IE SEA
D9-B5       ---------- ---------- ---------- ---------- ---------- ---
D9-D2       ---------- ---------- ---------- ---------- ---------- --- 192
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Figure 5-7: Alignment of HIVLAI-GFP vif alleles selected by A3G DPD128-130KPK. 
LAI_Vif    MENRWQVMIV WQVDRMRIRT WKSLVKHHMY VSGKARGWFY RHHYESPHPR ISSEVHIPLG DARLVITTYW
D14-A1     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D14-A3     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D14-B5     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D14-C4     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D14-C6     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D15-A2     ---------- ----G----- ---------- ---------- ---------K ---------- ----------
D15-B1     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D15-B2     ---------- ----W----- ---------- ---------- ---------- ---------- ----------
D15-B3     ---------- ---------- ---------- ---------- ---------K ---------- ----------
D15-B4     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D15-B6     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D15-C1     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D15-C3     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D15-D1     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D15-D2     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D15-D3     ---------- ---------- ---------- ---------- ---------- ---------R ---------- 70
LAI_Vif    GLHTGERDWH LGQGVSIEWR KKRYSTQVDP ELADQLIHLY YFDCFSDSAI RKALLGHIVS PRCEYQAGHN
D14-A1     ---------- ---------- ---------S ---------- ---------- ---------- ----------
D14-A3     ---------- -D-------- ---------- ---------- ---------- ---------- ----------
D14-B5     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D14-C4     ---------- ---------- ---------- ---------- ---------- ------N--- ----------
D14-C6     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D15-A2     ---------- -D-------- ---------- ---------- ------N--- ---------- ----------
D15-B1     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D15-B2     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D15-B3     ---------- ---------- ---------- K--------- ---------- ---------- ----------
D15-B4     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D15-B6     ---------- ---------- ---------S ---------- ---------- ---------- ----------
D15-C1     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D15-C3     ---------- ---------- ---------- ---------- ---------- ---------- ----------
D15-D1     ---------- ---------- ---------- ---------- ---------- K--------- ----------
D15-D2     ---------Y ---------- ---------- ---------- ---------- ---------- ----------
D15-D3     ---------- ---------- ---------- ---------- ---------- ---------- ---------- 140
LAI_Vif    KVGSLQYLAL AALITPKKIK PPLPSVTKLT EDRWNKPQKT KGHRGSHTMN GH*
D14-A1     ---------- ---------- ---------- ---------- ---------- ---
D14-A3     ---------- ---------- ---------- ---------- ---------- R--
D14-B5     ---------- ---------- ---------- ---------- ---------- ---
D14-C4     ---------- ---------- ---------- ---------- ---------- ---
D14-C6     ---------- ---------- ---------- ---------- ---------- ---
D15-A2     ---------- ---------- ---------- ---------- ---------- ---
D15-B1     ---------- ---------- ---------- ---------- ---------- ---
D15-B2     ---------- ---------- ---------- ---------- ---------- ---
D15-B3     ---------- ---------- ---------- ---------- ---------- ---
D15-B4     ---------- ---------- ---------- ---------- ---------- ---
D15-B6     ---------- ---------- ---------- ---------- ---------- ---
D15-C1     ---------- ---------- ---------- ---------- ---------- ---
D15-C3     ---------- ---------- ---------- ---------- ---------- ---
D15-D1     ---------- ---------- ---------- ---------- ---------- ---
D15-D2     ---------- ---------- ---------- ---------- ---------- ---
D15-D3     ---------- ---------- ---------- ---------- ---------- E-- 192
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Figure 5-8: Alignment of HIVIIIB vif alleles selected by rhA3F. 
IIIB_Vif      MENRWQVMIV WQVDRMRINT WKRLVKHHMY ISRKAKDWFY RHHYESTNPK ISSEVHIPLG DAKLVITTYW
50-4(1)-A1    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(1)-A6    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(1)-B2    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(1)-B3    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(1)-B5    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(1)-C2    ---------- ---------- --S------- ---------- ---------- ---------- ----------
50-4(1)-C5    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(1)-D1    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(1)-D2    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(1)-D3    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(1)-D4    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(2)-A1    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(2)-A4    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(2)-A5    ---------- ---------- ---------- ---------- ---------- --------V- ----------
50-4(2)-A6    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(2)-B3    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(2)-B5    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(2)-B6    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(2)-C2    ---------- ---------- --S------- V--------- ---------- ---------- ----------
50-4(2)-C4    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(2)-C5    ---------- ---------- ---------- ---------- ---------- ---------- ---------- 70
IIIB_Vif      GLHTGERDWH LGQGVSIEWR KKRYSTQVDP DLADQLIHLH YFDCFSESAI RNTILGRIVS PRCEYQAGHN
50-4(1)-A1    D--I------ ---------- ---------- ---------- ---------- ---------- ----------
50-4(1)-A6    D--------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(1)-B2    D--------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(1)-B3    D--------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(1)-B5    D--------- ---------- ---------- ---------- ------K--- ---------- ----------
50-4(1)-C2    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(1)-C5    D--------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(1)-D1    D--------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(1)-D2    D--------- --R------- ---------- ---------- ---------- ---------- ----------
50-4(1)-D3    D--------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(1)-D4    D--------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(2)-A1    D--------- ---------- ---------- ---------- ---------- -------R-- ----------
50-4(2)-A4    D--------- ---------- ---------- ---------- H--------- ---------- ----------
50-4(2)-A5    D--------- ---------- ---------- ---------- ---------- ------C--- ----------
50-4(2)-A6    D--------- ---------- ---------- ---------- ------K--- ---------- ----------
50-4(2)-B3    D--------- W--------- ---------- ---------- ---------- ---------- ----------
50-4(2)-B5    D--------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(2)-B6    D--------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(2)-C2    ---------- ---------- ---------- ---------- ------K--- ---------- ----------
50-4(2)-C4    D--------- ---------- ---------- ---------- ---------- ---------- ----------
50-4(2)-C5    ---------- ---------- ---------- ---------- -----L---- -------L-- ---------- 140
IIIB_Vif      KVGSLQYLAL AALIKPKQIK PPLPSVRKLT EDRWNKPQKT KGHRGSHTMN GH*
50-4(1)-A1    ---------- ---------- ---------- ---------- ---------- ---
50-4(1)-A6    ---------- ---------- ---------- ---------- ---------- ---
50-4(1)-B2    ---------- ---------- ---------- ---------- ---------- ---
50-4(1)-B3    ---------- ---------- ---------- ---------- ---------- ---
50-4(1)-B5    ---------- ---------- ---------- ---------- ---------- ---
50-4(1)-C2    ---------- ---------- ---------- ---------- ---------- ---
50-4(1)-C5    ---------- ---------- ---------- ---------- ---------- ---
50-4(1)-D1    ---------- ---------- ---------- ---------- ---------- ---
50-4(1)-D2    ---------- ---------- ---------- ---------- ---------- ---
50-4(1)-D3    ---------- ---------- ---------- ---------- ---------- ---
50-4(1)-D4    ---------- ---------- ---------- ---------- ---------- ---
50-4(2)-A1    ---------- ---------- ---------- ---------- ---------- ---
50-4(2)-A4    ---------- ---------- ---------- ---------- ---------- R--
50-4(2)-A5    ---------- ---------- ---------- ---------- ---------- ---
50-4(2)-A6    ---------- ---------- ---------- ---------- ---------- ---
50-4(2)-B3    ---------- ---------- ---------- ---------- ---------- ---
50-4(2)-B5    ---------- ---------- ---------- ---------- ---------- ---
50-4(2)-B6    ---------- ---------- ---------- ---------- ---------- ---
50-4(2)-C2    ---------- ---------- ---------- ---------- ---------- ---
50-4(2)-C4    ---------- ---------- ---------- ---------- ---------- ---
50-4(2)-C5    ---------- ---------- ---------- ---------- ---------- --- 140
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Figure 5-9: Alignment of HIVLAI-GFP vif alleles selected by rhA3F. 
LAI_Vif       MENRWQVMIV WQVDRMRIRT WKSLVKHHMY VSGKARGWFY RHHYESPHPR ISSEVHIPLG DARLVITTYW
50-5(1)-A5    men------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(1)-A6    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(1)-B1    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(1)-B4    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(1)-C1    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(1)-D2    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(1)-D3    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(1)-D4    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(2)-A1    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(2)-A2    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(2)-A4    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(2)-A5    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(2)-B3    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(2)-B4    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(2)-B5    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(2)-B6    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(2)-C1    ---------- ---------- ---------- ---------- ---------- ---------- ---------- 70
LAI_Vif       GLHTGERDWH LGQGVSIEWR KKRYSTQVDP ELADQLIHLY YFDCFSDSAI RKALLGHIVS PRCEYQAGHN
50-5(1)-A5    ---------- ---------- ---------- ---------- ------N--- ---------- ----------
50-5(1)-A6    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(1)-B1    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(1)-B4    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(1)-C1    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(1)-D2    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(1)-D3    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(1)-D4    ---------- ---------- -R-------- ---------- ---------- ---------- ----------
50-5(2)-A1    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(2)-A2    ---------- ---------- --K------- ---------- ---------- ---------- ----------
50-5(2)-A4    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(2)-A5    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(2)-B3    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(2)-B4    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(2)-B5    D------E-- ---------- ---------- ---------- ---------- ---------- ----------
50-5(2)-B6    ---------- ---------- ---------- ---------- ---------- ---------- ----------
50-5(2)-C1    ---------- ---------- ---------- ---------- ---------- ---------- ---------- 140
LAI_Vif       KVGSLQYLAL AALITPKKIK PPLPSVTKLT EDRWNKPQKT KGHRGSHTMN GH*
50-5(1)-A5    ---------- ---------- ---------- ---------- ---------- ---
50-5(1)-A6    ---------- ---------- ---------- ---------- ---------- ---
50-5(1)-B1    ---------- ---------- ---------- ---------- ---------- ---
50-5(1)-B4    ---------- ---------- ---------- ---------- ---------- ---
50-5(1)-C1    ---------- ---------- ---------- ---------- ---------- E--
50-5(1)-D2    ---------- --------M- ---------- ---------- ---------- ---
50-5(1)-D3    ---------- ---------- ---------- ---------- ---------- ---
50-5(1)-D4    ---------- ---------- ---------- ---------- ---------- ---
50-5(2)-A1    ---------- ---------- ---------- ---------- ---------- ---
50-5(2)-A2    ---------- ---------- ---------- ---------- ---------- ---
50-5(2)-A4    ---------- ---------- ---------- ---------- ---------- ---
50-5(2)-A5    ---------- ---------- ---------- ---------- ---------- ---
50-5(2)-B3    ---------- ---------- ---------- ---------- ---------- ---
50-5(2)-B4    ---------- ---------- ---------- ---------- ---------- E--
50-5(2)-B5    ---------- ---------- ---------- ---------- ---------- ---
50-5(2)-B6    ---------- ---------- ---------- ---------- ---------- ---
50-5(2)-C1    ---------- ---------- ---------- ---------- ---------- --- 192
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Figure 5-10: Alignment of HIVIIIB vif alleles selected by rhA3G. 
IIIB_Vif      MENRWQVMIV WQVDRMRINT WKRLVKHHMY ISRKAKDWFY RHHYESTNPK ISSEVHIPLG DAKLVITTYW
51-3(1)-B1    -------I-- ---------- ---------- ---------- ---------- ---------- ----------
51-3(1)-B2    ---------- ---------- ---------- --K------- ---------- ---------- ----------
51-3(1)-B5    ---------- -------S-- ---------- ---------- ---------- ---------- ----------
51-3(1)-B6    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-3(1)-C6    ---------- ---------- ---------- S--------- ---------- ---------- ----------
51-3(1)-D4    ---------- ---------- ---------- ---------- ---------- ---------- ------I---
51-3(2)-A1    ---------- ---------- ---------- ---------- ---------N ---------- ----------
51-3(2)-A4    ---------- ------N--- ---------- ---------- ---------- ---------- ----------
51-3(2)-A6    ---------- ---------- --------I- ---------- ---------- ---------- ----------
51-3(2)-B6    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-3(2)-C4    ---------- ---------- ---------- ---------- ---------- T-------Q- ----------
51-3(2)-C5    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-3(2)-C6    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-3(2)-D2    ---------- ---------- ---------- ---------- ---------- ---------- ---------- 70
IIIB_Vif      GLHTGERDWH LGQGVSIEWR KKRYSTQVDP DLADQLIHLH YFDCFSESAI RNTILGRIVS PRCEYQAGHN
51-3(1)-B1    D--------- ---------- ---------- ---------- ---------- ---------- ----------
51-3(1)-B2    D--------- ---------- ---------- ---------- ---------- ---------- ----------
51-3(1)-B5    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-3(1)-B6    ---------- ---------- -------I-- ---------- ---------- ---------- ----------
51-3(1)-C6    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-3(1)-D4    ---------- ---------- ----N----- ---------- ---------- ---------- ----------
51-3(2)-A1    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-3(2)-A4    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-3(2)-A6    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-3(2)-B6    ---------- ----A----- ---------- ---------- ---------- ---------- ----------
51-3(2)-C4    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-3(2)-C5    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-3(2)-C6    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-3(2)-D2    ---------- ---------- ---------- ---------- ---------- ---------- ---------- 140
IIIB_Vif      KVGSLQYLAL AALIKPKQIK PPLPSVRKLT EDRWNKPQKT KGHRGSHTMN GH*
51-3(1)-B1    ---------- ---------- ---------- ---------- ---------- ---
51-3(1)-B2    ---------- ---------- ---------- ---------- ---------- ---
51-3(1)-B5    ---------- ---------- ---------- ---------- -------K-- ---
51-3(1)-B6    ---------- ---------- ---------- ---------- ---------- ---
51-3(1)-C6    ---------- ---------- ---------- ---------- ---------- ---
51-3(1)-D4    ---------- ---------- ---------- ---------- ---------- ---
51-3(2)-A1    ---------- ---------- ---------- ---------- ---------- ---
51-3(2)-A4    ---------- ---------- ---------- ---------- ---------- ---
51-3(2)-A6    ---------- ---------- ---------- ---------- ---------- ---
51-3(2)-B6    ---------- ---------- ---------- ---------- ---------- ---
51-3(2)-C4    ---------- ---------- ---------- ---------- ---------- ---
51-3(2)-C5    ---------- ---------- ---------- ---------- ---------- ---
51-3(2)-C6    ---------- ---------- ---------- ---------- ---------- ---
51-3(2)-D2    ---------- ---------- ---------- ---------- ---------- --- 192
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Figure 5-11: Alignment of HIVLAI-GFP vif alleles selected by rhA3G. 
LAI_Vif       MENRWQVMIV WQVDRMRIRT WKSLVKHHMY VSGKARGWFY RHHYESPHPR ISSEVHIPLG DARLVITTYW
51-5(1)-A2    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(1)-A3    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(1)-B1    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(1)-C1    ---K------ ---------- ---------- ---------- ---------- ---------- ----------
51-5(1)-C2    ---------- ----G----- ---------- ---------- ---------K ---------- ----------
51-5(1)-C3    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(1)-C4    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(1)-C6    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(1)-D1    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(1)-D2    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(1)-D4    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(2)-A4    ---------- ---------- ---------- ---------- ---------- --------I- ----------
51-5(2)-A5    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(2)-B2    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(2)-B5    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(2)-C1    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(2)-C6    ---------- ---------- ---------- ---------- ---------- ---------- ---------- 70
LAI_Vif       GLHTGERDWH LGQGVSIEWR KKRYSTQVDP ELADQLIHLY YFDCFSDSAI RKALLGHIVS PRCEYQAGHN
51-5(1)-A2    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(1)-A3    ---------- ---------- ---------- ---------- ---------- ---------- -----R----
51-5(1)-B1    ---------- ---------- ---------- ---------- ------V--- ---------- ----------
51-5(1)-C1    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(1)-C2    ---------- -D-------- ---------- ---------- ------N--- ---------- ----------
51-5(1)-C3    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(1)-C4    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(1)-C6    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(1)-D1    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(1)-D2    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(1)-D4    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(2)-A4    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(2)-A5    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(2)-B2    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(2)-B5    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(2)-C1    ---------- ---------- ---------- ---------- ---------- ---------- ----------
51-5(2)-C6    ---------- ---------- ---------- ---------- ---------- ---------- ---------- 140
LAI_Vif       KVGSLQYLAL AALITPKKIK PPLPSVTKLT EDRWNKPQKT KGHRGSHTMN GH*
51-5(1)-A2    ---------- ---------- ---------- ---------- ---------- ---
51-5(1)-A3    ---------- ---------- ---------- ---------- ---------- ---
51-5(1)-B1    ---------- ---------- ---------- ---------- ---------- ---
51-5(1)-C1    ---------- ---------- ---------- ---------- ---------- ---
51-5(1)-C2    ---------- ---------- ---------- ---------- ---------- ---
51-5(1)-C3    ---------- ---------- ---------- ---------- ---------- ---
51-5(1)-C4    ---------- ---------- ---------- ---------- ---------- ---
51-5(1)-C6    ---------- ---------- ---------- ---------- ---------- ---
51-5(1)-D1    ---------- ---------- ---------- ---------- ---------- ---
51-5(1)-D2    ---------- ---------- ---------- ---------- ---------- ---
51-5(1)-D4    ---------- ---------- ---------- ---------- ---------- ---
51-5(2)-A4    ---------- ---------- ---------- ---------- ---------- ---
51-5(2)-A5    ---------- ---------- ---------- ---------- ---------- ---
51-5(2)-B2    ---------- ---------- ---------- ---------- ----R----- ---
51-5(2)-B5    ---------- ---------- ---------- ---------- ---------- ---
51-5(2)-C1    ---------- ---------- ---------- ---------- ---------- ---
51-5(2)-C6    ---------- ---------- ---------- ---------- ---------- --- 192
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Figure 5-12: Mutational hotspots encountered in evolving vif for growth in the 
presence of A3F QE323-324EK or A3G DPD128-130KPK. (A) The frequency (y-axis) 
with which changes along the length of the vif open reading frame (x-axis) occurred in 
isolates evolved to grow in the presence of A3F QE323-324EK is shown. Hotspots are 
identified by the specific change encountered. (B) As in (A) but with viruses evolved to 
grow in the presence of A3G DPD128-130KPK. Minor populations assessed for A3F 
QE323-324EK-adapted viruses but not for A3G DPD128-130KPK-adapted viruses. 
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Figure 5-13: Mutational hotspots encountered in evolving vif for growth in the 
presence of rhA3F or rhA3G. (A) The frequency (y-axis) with which changes along the 
length of the vif open reading frame (x-axis) occurred in isolates evolved to grow in the 
presence of rhA3F is shown. Hotspots are identified by the specific change encountered. 
(B) As in (A) but with viruses evolve to grow in the presence of rhA3G. Minor 
populations not assessed. 
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Figure 5-14: A putative antiparallel helix in HIV Vif for interaction with the 
APOBEC3 α4 helix. 
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Figure 5-14: A putative antiparallel helix in HIV Vif for interaction with the 
APOBEC3 α4 helix. (A) A linear alignment of the putative antiparallel Vif helix with 
critical residues in A3F, A3D and A3C. Critical Vif-resistance (E324) and gain of 
function (G71) residues are bolded. (B) As in (A) but with A3G. (C) As in (A) but with a 
predicted compensatory mutation to counteract A3H D121K. Vif residues associated with 
a glycine-negatively charged amino acid pairing in this region are underlined throughout 
(D) Helical wheel representation of residues 71-82 in Vif derived from: 
http://rzlab.ucr.edu/scripts/wheel/wheel.cgi?sequence=ABCDEFGHIJLKMNOP&subm 
it=Submit. 
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Figure 5-15: Vif G71D and Vif G82D neutralize Vif-resistant APOBEC3 proteins. 
(A) A single-cycle experiment showing the infectivity and steady state levels of each 
APOBEC3 protein in the presence of either wildtype IIIB or G71D Vif. (B) Spreading 
infection data demonstrating the ability of HIVIIIB G71D to spread in rhA3F-expressing 
cells. (C) Spreading infection data demonstrating the more attenuated ability of HIVIIIB 
G71D to spread in cells expressing A3F QE323-324EK. (D) A single-cycle experiment 
showing the infectivity and recovery and steady state levels of A3G D130K in the 
presence of G82D versus wildtype IIIB and LAI Vifs. 
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Postscript 
 There are several aspects of this study that remain to be resolved before 
submission for publication, aside from higher MOI infections with molecular clone-
derived mutant viruses and repetition of single-cycle experiments involving broader 
panels of selected mutants. First, we are expanding our analysis to test the efficacy of 
certain vif alleles against other Vif-resistant APOBEC3 proteins. Specifically, the 
equivalent of A3F E324 is conserved in A3C and A3D and renders at least the former of 
these Vif-resistant – the latter being indeterminate primarily because A3D expresses quite 
poorly and is thus difficult to assess (see Supplementary Chapter 1). We will therefore 
test the efficacy of G71D vs. the Vif-resistant variants of A3C (E141K) and A3D 
(E337K). 
 Similarly, the single amino acid determinant of Vif susceptibility associated with 
A3H falls between those associated with A3F and A3G. We would therefore predict that 
the interacting residue in Vif should also fall between the ends associated with A3F and 
A3G, or in other words, somewhere between G71 and G82. We will consequently be 
testing Vif G75D for the ability to neutralize A3H haplotype II D121K. 
 Finally, because the strongest result in this dataset is that associated with G71D 
and the suppression of Vif-resistant forms of A3F, there are two explorations of this topic 
that we are pursuing. One is a simple biochemical characterization of the sidechains at 
residue 71 capable of counteracting A3F E324K, since this goes to specificity of the 
direct interaction. The other, perhaps more critical, component is biophysical evidence 
for the ability of the predicted peptide to take on a helical structure and interact with A3F. 
Toward that end, we are collaborating with the Harki and Matsuo laboratories at the 
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University of Minnesota to create stapled peptides and test their association with the 
soluble form of the A3F C-terminal deaminase domain described in Supplementary 
Chapter 1 by isothermal titration calorimetry. We anticipate that these complementary 
approaches will help to address any doubts that one might have about the existence of the 
proposed antiparallel helix and its direct interaction with the APOBEC3 α4 helix. 
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Chapter 6: Vif-independent Adaptation of HIV to Human APOBEC3 Proteins 
Foreword 
This is a working draft of a manuscript in preparation of the same name. 
 Albin JS and Harris RS. “Vif-independent Adaptation of HIV to Human 
 APOBEC3 Proteins.” in preparation. 
Whereas the adaptation experiments in Chapter 5 were designed to define the putative 
APOBEC3 interaction region of Vif corresponding to the Vif-interaction region located 
in the APOBEC3 α4 helix, the purpose of the experiments described in this chapter was 
to determine whether Vif-independent mechanisms of adaptation may be possible. This 
was an important possibility to consider in light of our prior efforts demonstrating proof 
of principle for just such an occurrence [(Haché et al., 2008) and Chapter 2]. Such 
mechanisms could be at play among some of the viruses described in Chapter 5, but to 
unambiguously investigate the potential for Vif-independent adaptation of HIV to 
APOBEC3 proteins, we felt it important to remove Vif from the equation. In Chapter 6, 
we therefore utilize parent viruses containing large, presumably irreparable deletions in 
their vif genes, as this bypasses any concerns about potential residual Vif activity that 
might contribute to the overall adapted phenotype. 
 Two additional important modifications were made before commencing these 
experiments to preemptively address problems that might arise based on our prior studies. 
First, the original HIVIIIB virus contains an aberrant upstream open reading frame 
adjacent to the primer binding site that interferes with viral production. When the virus 
interrupts this upstream open reading frame by reverting to one of the nucleotides 
presents in the overwhelming majority of patient isolates at position 200, increased viral 
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production titrates out encapsidated A3G in our fixed-expression cell lines (Haché et al., 
2009; Haché et al., 2008). While interesting, this does not constitute a specific mutation 
relevant to the virus as it exists in patients. We therefore utilized only parent molecular 
clones in which the upstream open reading frame in question had been repaired. Doing 
so, however, would mean that all the resultant viruses would have to do to bypass A3G, 
based on our previous studies, would be to inactivate their vpr gene, which happens 
readily in culture. We therefore utilized SupT11-derived cell lines for our selections, 
since we had previously found that their levels of APOBEC3 expression restrict viruses 
with a repaired upstream open reading frame and a truncated vpr gene (Chapter 2). 
 Although we started from viral templates that lacked, to the best of our 
knowledge, unfit variations of the kind encountered previously, we did find in the course 
of these studies a partial p6 duplication in our HIVLAI-GFP virus that was sometimes 
deleted by adapted isolates and also rediscovered the importance of Nef, which is 
replaced by GFP in the same HIVLAI-GFP virus, for growth on certain cell types. For those 
reasons and because of their generally weaker Vif-independent phenotypes, we 
deemphasize the HIVLAI-GFP wing of these studies. The HIVIIIB viruses used, however, do 
not suffer from any such defects of which we are aware. 
 Finally, we changed the selection protocol utilized in these studies to that 
described in Chapter 5 to encourage more sequence diversification by giving the virus a 
chance to replicate in permissive cells while gradually increasing the APOBEC3-
dependent selective pressure. This is closer in principle to the way drug resistance studies 
are typically performed than our former method of passaging viruses on fully 
nonpermissive cells from the start, which may be too stringent. 
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Summary 
The HIV accessory protein virion infectivity factor (Vif) mediates the polyubiquitination 
and proteasomal degradation of the DNA cytosine deaminase APOBEC3G (A3G), 
thereby preventing the mutational activity of this host restriction factor from adversely 
affecting viral infectivity. Prior reports have demonstrated, however, that the Vifs derived 
from patient isolates show a wide range of anti-APOBEC3 activity, implying that the 
virus must have some way of averting APOBEC3 proteins in those situations where Vif 
is hypofunctional. To determine whether HIV can acquire Vif-independent adaptive 
mutations that enhance viral infectivity despite the presence of APOBEC3 proteins, we 
carried out genetic selection experiments designed to isolate Vif-deleted viruses that 
might utilize alternate routes of APOBEC3 evasion. Our results demonstrate that HIV 
can readily adapt to growth in the presence of A3G-expressing cells by acquiring 
mutations in the env gene. Surprisingly, we found that these mutations, despite the 
adaptive advantage conferred to the virus, do not appear to substantially alter levels of 
A3G encapsidation. We therefore propose that the HIV envelope may mediate an 
accessory, packaging-independent mechanism for counteracting A3G as a complement to 
the Vif-dependent reduction in A3G encapsidation. 
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Introduction 
The human immunodeficiency virus type 1 (HIV) accessory protein virion infectivity 
factor (Vif) is required for the maintenance of viral infectivity in vivo, in primary T cells 
and in certain immortalized cell lines termed “nonpermissive” for Vif-deficient 
replication (Desrosiers et al., 1998; Fisher et al., 1987; Gabuzda et al., 1992; Gabuzda et 
al., 1994; Strebel et al., 1987). Since the discovery of APOBEC3G (A3G) as a dominant-
acting, Vif-suppressible restriction factor that can reconstitute the nonpermissive 
phenotype in otherwise permissive cells (Madani and Kabat, 1998; Sheehy et al., 2002; 
Simon et al., 1998), it has been generally assumed that the suppression of APOBEC3 
restriction factors is the primary role of Vif. This assumption is consistent with the 
accumulation of G-to-A hypermutation during the infection of primates with viruses 
containing mutations in the Vif BC box or zinc coordinating motifs required for 
recruitment of the fully functional E3 ubiquitin ligase complex that mediates A3G 
polyubiquitination and proteasomal degradation (Schmitt et al., 2010; Schmitt et al., 
2009). 
 Clinically-oriented studies on the potential roles of APOBEC3 proteins in vivo, 
however, suggest that the APOBEC3-Vif duality may be less straightforward than 
currently thought. A growing number of studies has yielded an increasingly unclear 
picture of whether or to what extent APOBEC3 proteins actively restrict HIV in vivo 
[(Amoedo et al., 2011; An et al., 2004; An et al., 2009; Biasin et al., 2007; Cagliani et 
al., 2011; Cho et al., 2006; De Maio et al., 2011; Do et al., 2005; Gandhi et al., 2008; Jin 
et al., 2005; Land et al., 2008; Pace et al., 2006; Piantadosi et al., 2009; Pillai et al., 
2012; Ulenga et al., 2008a; Ulenga et al., 2008b; Valcke et al., 2006; Vazquez-Perez et 
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al., 2009) and reviewed in (Albin et al., 2010b; Sheehy and Erthal, 2012)]. Despite this, 
several analyses of patient isolates have indicated that various subtypes of Vif as well as 
variants within subtypes display a wide range of anti-APOBEC3 activity, with as many as 
20% being defective for the neutralization of A3F, A3G or both (Albin et al., 2010a; 
Binka et al., 2012; Iwabu et al., 2010; Simon et al., 2005). Mundane explanations for this 
are possible. For example, some have found that the levels of A3F and A3H in primary 
cells are too low to effectively restrict HIV, thus obviating the need for a highly active 
Vif (Li et al., 2010; Mulder et al., 2010). Similarly, the virus may simply replicate in 
reservoirs where APOBEC3 levels are insufficient to greatly impact the overall health of 
the viral population. 
 That said, it is also possible that HIV may use accessory modes of APOBEC3 
neutralization to survive when Vif is hypoactive. Such accessory mechanisms of evasion 
may hypothetically also be useful to the virus during the early production of virions from 
any given cell since Vif may not yet have effectively lowered APOBEC3 steady state 
levels at that time. These possibilities have gone largely unexplored to date. Although we 
have previously reported that increased viral production may be one mechanism by which 
HIV can “tolerate” A3G in the absence of Vif (Haché et al., 2009; Haché et al., 2008), 
this proof of principle is not applicable to the virus in vivo since the adapted viruses in 
that study merely repaired a defect in the parent virus that is not generally found in 
natural isolates. 
 For at least two other restriction factors, it is clear that alternative mechanisms of 
neutralization can be activated when need be. For example, it is now known that HIV and 
related lentiviruses use three different gene products to counteract the restriction factor 
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tetherin: HIV uses Vpu (Neil et al., 2008; Van Damme et al., 2008), certain simian 
immunodeficiency viruses (SIV) use Nef (Gupta et al., 2009; Jia et al., 2009; Sauter et 
al., 2009; Zhang et al., 2009) and HIV-2 uses gp41 (Le Tortorec and Neil, 2009). 
Intriguingly, when Nef-deficient SIV is passaged in primates, gp41 can reacquire anti-
tetherin function (Serra-Moreno et al., 2011), suggesting that ancient or perhaps simply 
masked alternative functions of lentiviral gene products may be biologically relevant. 
Similarly, the accessory proteins Vpr and Vpx can each act separately in different 
lineages to inactivate the myeloid cell restriction factor SAMHD1 (Lim et al., 2012). 
 In both of these cases, the search for an alternative mechanism of restriction factor 
neutralization was propelled by the simple observation that the canonical viral defense  
(Vpu against tetherin, Vpx against SAMHD1) does not exist in closely related lentiviral 
species despite the fact that these viruses too must presumably encounter their host 
species’ innate defenses. In the study of APOBEC3 proteins, however, such possibilities 
have gone largely unaddressed since vif is conserved in every known lentivirus with the 
exception of equine infectious anemia virus. If Vif is frequently hypofunctional or even 
nonfunctional, however, it is reasonable to hypothesize that HIV may have redundant 
mechanisms for preserving its genome from cytosine deaminases.  
 To determine whether HIV can acquire Vif-independent means of counteracting 
APOBEC3 restriction factors, we carried out genetic selection experiments aimed at 
isolating viruses with large, irreparable deletions in vif that nevertheless spread in cell 
lines expressing A3G. Consistent with our studies involving Vif-proficient viruses in the 
presence of Vif-resistant APOBEC3 proteins (Chapter 5), we find that Vif-deleted 
viruses can readily adapt to growth in the presence of A3G and that this phenotype 
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translates to the partial neutralization of A3F and Vif-resistant derivatives of A3F and 
A3G as well. Importantly, however, these viruses are not capable of spreading in 
naturally nonpermissive cells that express multiple APOBEC3 proteins, which may 
suggest that the selected adaptive mechanism is limited in its ability to counteract 
multiple APOBEC3 proteins or higher levels of a single APOBEC3 protein. On 
sequencing representative strongly resistant viruses, we noted a number of changes 
spread throughout the viral genome, which when recombined into molecular clone 
backgrounds revealed a novel anti-A3G activity for HIV Env. Despite their ability to 
spread in the presence of A3G, however, these viruses did not appear to substantially 
alter their levels of encapsidated A3G, suggesting that Env mediates an anti-APOBEC3 
function capable of inactivating particle-associated A3G. Such a mechanism may 
represent an ancestral function of Env and may act in the present to neutralize any A3G 
that escapes Vif function. Understanding the mechanism by which Env functions with 
respect to the neutralization of APOBEC3 proteins will therefore be of great importance 
for our understanding of the interplay between lentiviruses and their host APOBEC3 
proteins. 
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Results 
Vif-deleted HIV can readily adapt to growth in the presence of A3G – To determine 
whether HIV can adapt to the presence of APOBEC3 proteins in the absence of Vif, we 
opted to utilize two viruses carrying large, presumably irreparable deletions in vif that 
would prevent vif repair of the kind previously observed when adapting viruses to 
APOBEC3 proteins [(Albin et al., 2010a) and Chapter 2]. The first of these, HIVLAI-GFP, 
was provided by Dr. Mario Stevenson (Miami University) and contains a 290 nucleotide 
in-frame deletion in vif as well as gfp in place of the nef open reading frame. The second 
carries a previously-described 230 nucleotide deletion and frameshift built into a variant 
of HIVIIIB from Dr. Michael Malim (King’s College London) that has been engineered to 
ablate an aberrant upstream open reading frame that otherwise adversely affects virus 
production (Gibbs et al., 1994; Haché et al., 2009; Haché et al., 2008). 
 A3G expression levels in the SupT11-derived A3G and A3G DPD128-130KPK 
cell lines used in this study are shown in Figure 6-1A; A3F expression levels are as 
shown in Figure 5-1B. In total, 88 cultures of Vif-deleted virus were subjected to 
selection in the combinations depicted in Figure 6-1B where each prong represents a 24-
well plate with 22 selective cultures, an uninfected cell line control and a permissive 
infected cell line control. The selection strategy itself is shown schematically in Figure 6-
1C. In brief, viruses were gradually passaged from permissive cultures to co-cultures 
made progressively more nonpermissive by increasing the proportion of cells expressing 
A3F or A3G, wherein approximately 8-11 days of viral replication intervened between 
each passage. At the end of each progression, a portion of Condition 3 cultures was 
passaged back to permissive conditions to undergo another round of selection as depicted 
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in Condition 4b, while another portion of Condition 3 cultures was passaged to 100% 
nonpermissive cells in Condition 4a for phenotypic assessment as indicated in Materials 
and Methods and, if indicated, saved for MOI-controlled confirmatory passages. 
 In total, cultures scored positive at Condition 4a were subjected to three additional 
passages from low MOI to confirm adapted phenotypes and purify their associated 
genotypes away from any residual unadapted viruses. The total number of adapted 
isolates present at the end of each round of selection as confirmed through fourth passage 
is depicted in Figure 6-1D. While we were readily able to isolate Vif-deleted viruses 
from cell lines expressing A3G, this was not the case for cell lines expressing A3F, 
echoing our prior selection studies in which viruses adapted to A3F universally repaired 
their vif genes while viruses adapted to A3G went though Vif-independent means to 
achieve growth [(Albin et al., 2010a; Haché et al., 2008) and see Discussion]. 
 
Adapted viruses can effectively neutralize A3G, A3F and Vif-resistant derivatives thereof 
–  Comprehensive phenotypic scoring of adapted viruses is presented in Tables 6-1 
through 6-3. Interestingly, and in contrast with our prior reports, most of these isolates 
that were well-adapted to growth in the presence of A3G displayed a weaker but 
appreciable adapted phenotype in cells expressing A3F as well as cells stably expressing 
Vif-resistant derivatives of A3F and A3G, QE323-324EK and DPD128-130KPK, 
respectively. Growth curves for four of these viruses are shown in Figure 6-2. 
Importantly, these viruses were not able to spread in naturally nonpermissive T cell lines 
such as CEM2n and they were generally delayed on our highest APOBEC3-expressing 
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lines relative to the lower-expressing clones, suggesting saturability of the putative Vif-
independent adaptive mechanism (data not shown). 
 Viruses adapted to growth in the presence of A3F displayed similar but slightly 
more attenuated phenotypes, which may indicate that the mechanism underlying these 
adapted phenotypes is similar but, for reasons unknown, less efficiently selected by A3F. 
This could reflect generally higher levels of expression in our A3F lines relative to our 
A3G lines when using naturally nonpermissive cells as a benchmark for expression. 
Alternatively, if the putative Vif-independent mechanism of action were to function at the 
level of deaminase activity, it has been proposed that the deaminase-independent effects 
of A3F may be more robust than those of A3G [(Holmes et al., 2007) and see 
Supplementary Chapter 2]. Given the low effective multiplicity of infection during the 
points at which an adapted variant first begins to spread within a mixed population, 
inefficacy against even weak deaminase-independent restriction mechanisms could 
account for some of the differential selection patterns between A3F and A3G. Regardless, 
given their clearer phenotypes, we opted to move forward only with viruses adapted to 
A3G. In particular, we chose HIVIIIB-derived viruses because these were almost 
universally phenotypically stronger than HIVLAI-GFP-derived viruses, perhaps due to nef 
deficiency in the latter. Moreover, we anticipated that the use of a single isogenic 
background would facilitate more valid comparisons among candidate adaptive 
mutations. 
 
Mutational profiles of A3G-adapted viruses suggest exposure to A3G – To identify 
potential adaptive mutations in our viral isolates, we subjected four of the phenotypically 
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strongest HIVIIIB-derived isolates (Figure 6-2) to clonal sequencing of their full genomes 
between the third and fourth confirmatory passages. As shown in Figure 6-3A, these 
isolates displayed extensive hypermutation in the 5’-GG-’3 dinucleotide context 
characteristic of A3G activity. Moreover, comparison of the levels of hypermutation 
found in different portions of the genome recapitulated the twin gradient pattern of 
hypermutation previously associated with A3G. Although we could not conclusively say 
from these data alone whether the adapted viruses were actively being hypermutated on 
an ongoing basis, it is clear that the isolates had been highly exposed to A3G, again 
validating the co-culture method employed. PCR analysis and sequencing also showed 
that the adapted viruses maintained their vif deletions, eliminating mundane explanations 
for enhanced growth in the presence of A3G such as contamination of the cultures with a 
wildtype virus (Figure 6-3B). 
 In analyzing the clonal sequences derived from this process, we noted a large 
number of apparently fixed mutations present in the genomes of the viruses chosen. In 
particular, 4/4 had inactivated their vpr genes, 4/4 had changes in env, 3/4 had changes in 
reverse transcriptase, 2/4 had changes in gag and 2/4 had altered their U3 promoter 
region. These mutations are depicted schematically in Figure 6-3C and in detail in 
Tables 6-4 through 6-7. 
 
Changes in env enable enhanced spread by Vif-deficient HIV in the presence of A3G –  
To address the possibility that the U3 promoter mutations picked up by two viruses might 
alter viral gene expression and thereby enhance viral production to titrate out A3G as we 
have previously observed, we used a previously-characterized LTR-GFP reporter system 
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to determine the relative levels of gene expression derived from these viruses (Haché et 
al., 2008). Cotransfection of these reporters containing the mutant U3 elements, however, 
failed to enhance GFP expression over the parent background (Figure 6-4A). 
 To characterize the potential contributions of other mutations in the viral genome, 
we made approximately 20 molecular clones comprising many mutations found together 
in a single viral gene as well as several combinations of these as they naturally occurred. 
On subjecting these molecular clones to spreading infection in A3G-expressing cells, 
however, we were surprised to note that only those viruses containing an altered env gene 
among the various genotypes tested were capable of enhanced spread in the presence of 
A3G (Figure 6-4B). 
 
Selected env mutations do not substantially alter gross levels of encapsidated A3G – All 
known retroviral mechanisms of APOBEC3 evasion with the exception of that associated 
with equine infectious anemia virus involve the prevention of APOBEC3 encapsidation, 
whether by an active mechanism such as Vif-mediated degradation or by passively 
avoiding APOBEC3 encapsidation (Abudu et al., 2006; Bogerd et al., 2008; Derse et al., 
2007; Doehle et al., 2006; Doehle et al., 2005b; Löchelt et al., 2005; Russell et al., 2005; 
Zielonka et al., 2009). To ask whether the envelope mutations selected by A3G act in a 
similar encapsidation-dependent manner, we infected SupT11-derived cell lines 
expressing the deaminase-deficient mutant A3G E259Q with molecular clone-derived 
viruses containing the env mutations gp120 A58V, gp120 P81T/gp41 T626M or gp120 
M475I/gp41 L565Q as well as the parent HIVIIIB Vifdel virus and Vif-proficient HIVIIIB. 
Because A3G E259Q does not effectively restrict HIV when stably expressed in T cell 
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lines, it can be used as a means for directly comparing the inherent A3G encapsidation 
potential among wildtype, Vif-deficient and other variants in an infectivity-independent 
fashion [(Browne et al., 2009; Haché et al., 2008; Miyagi et al., 2007; Schumacher et al., 
2008) and see Supplementary Chapter 2]. At 9 days post-infection, we harvested viral 
supernatants from each culture, infected CEM-GFP reporter cells with a portion of each 
supernatant and then froze the remainder. Following fixation and flow cytometry of 
CEM-GFP cells, the frozen supernatants were thawed and purified through 0.45 um 
filters, and volumes of virus of equal infectivity as normalized by CEM-GFP were 
pelleted through 20% sucrose cushions to isolate virus particles in a manner analogous to 
that which we have previously reported (Haché et al., 2008). As shown in Figure 6-5A, 
viruses carrying adaptive alleles of env encapsidate A3G at levels similar to that of the 
parent HIVIIIB env/vif(-) virus. Similar results were observed in parallel infections using 
two additional SupT11-derived cell lines expressing A3G E259Q as quantified in Figure 
6-5B. Despite their enhanced infectivity in the presence of catalytically active A3G, then, 
the adapted alleles of env do not appear to substantially alter the gross levels of A3G 
encapsidated relative to the parental HIVIIIB env/vif(-) virus. It is conceivable that the 
minor, statistically insignificant decreases observed may be functionally relevant, but we 
cannot at present offer data in support of such a notion. Furthermore, the mobility of 
encapsidated A3G under denaturing conditions was typical of that observed in the 
presence of wildtype Env, suggesting that intravirion proteolysis of A3G is not involved 
in the Env-dependent mechanism described here despite a proteolytic component to the 
mechanism by which murine leukemia virus averts mouse APOBEC3 (Abudu et al., 
2006). Despite the lack of a significant reduction in the amount of A3G encapsidated, the 
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most common mechanism by which diverse retroviruses bypass APOBEC3 proteins 
(Abudu et al., 2006; Derse et al., 2007; Doehle et al., 2006; Doehle et al., 2005b; Löchelt 
et al., 2005; Russell et al., 2005), virion mislocalization to a space outside the viral core 
remains a mechanistic possibility, as does altered deaminase activity of the encapsidated 
enzyme. 
 
Selected env mutations clusters to Layer 1 of the gp120 inner domain – To gain some 
structural insight into the potential functions of the mutations identified in our genetic 
selections, we mapped the mutations onto a known structure of gp120 containing the g41 
interaction domain (Pancera et al., 2010). Surprisingly, we found that the mutations 
selected cluster to loops on either side of helix 0 in Layer 1 of the gp120 inner domain in 
close proximity to residues of the gp41 interaction site. It is therefore possible that 
mutation of these conserved residues may alter the interaction of gp41 with gp120, 
although the mechanistic implications of this putative alteration are unclear. 
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Discussion 
 Here, we report the results of genetic selection experiments that have identified 
HIV Env as the mediator of a putative packaging-independent mechanism of A3G 
neutralization. This is unique among known instances of APOBEC3 evasion in 
retroviruses, as only the Vif-deficient lentivirus equine infectious anemia virus uses a 
similar, undefined packaging-independent anti-APOBEC3 mechanism (Bogerd et al., 
2008). 
 Previously, we have found that Vif-deficient HIV can tolerate the presence of 
A3G by enhancing its production to titrate out the encapsidated levels of A3G in fixed-
expression T cell lines (Haché et al., 2008). The mutations implicated in that study were a 
nucleotide change A200T/C and truncation of the vpr gene, the former of which is 
already present in most natural isolates and ablates an upstream open reading frame that 
interferes with viral translation and particle production (Haché et al., 2009). The function 
of vpr truncation remains unknown. 
 In the studies described in Chapter 6, we sought to revisit the theme of Vif-
independent adaptation to A3G to determine whether we might select changes that would 
further enhance our understanding of the restriction mechanism and shed light on the 
viability of targeting the APOBEC3-Vif interaction therapeutically. To do this, we 
designed our experiments to be somewhat different from those we had previously 
reported. In particular, we started with viruses that already had a pyrimidine at nucleotide 
200, like the vast majority of natural isolates, and that had gross deletions in vif that 
would prevent vif restoration as a mechanism of adaptation (Albin et al., 2010). 
Furthermore, we utilized SupT1-derived cell lines stably transfected with APOBEC3 
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proteins since we had previously determined that the levels of expression in these 
particular cell lines restrict T/C200, vpr(-) viruses and thus would force viruses to acquire 
mutations beyond the vpr truncations we had previously selected. Finally, we changed 
our selection protocol to a co-culture method that gradually increases the exposure of 
Vif-deficient viruses to APOBEC3 proteins, thereby more closely mimicking the 
methods typically used in drug resistance studies and allowing more sequence 
diversification prior to selection. 
 These modifications resulted in a somewhat distinct global picture of the study of 
HIV adaptation to APOBEC3 proteins compared with our previous findings. Rather than 
being rare events, we find that viruses can readily adapt the presence of APOBEC3 
proteins under the new conditions described. It is not clear exactly what barriers must be 
bypassed by the virus in vivo, and thus we cannot speak to whether a gradual versus an 
immediate block such as that typical of our former method is more relevant to viral 
evolution, but it certainly appears that, for the in vitro study of alternative mechanisms of 
viral adaptation, a gradual approach will produce more candidate isolates for evaluation. 
 The phenotypes of the resultant isolates are quite strong when pitted against any 
single APOBEC3 protein and are clearly Vif-independent as evidenced by robust growth 
on Vif-resistant variants of A3F and A3G (Figure 6-2). Despite these robust phenotypes, 
we found that the isolates themselves were incapable of spreading in naturally 
nonpermissive CEM2n cells that express multiple APOBEC3 proteins. This may indicate 
saturability of the adaptive mechanism. That is, while the adaptive mechanism may 
successfully bypass one APOBEC3 protein, the expression levels of the full APOBEC3 
repertoire in naturally nonpermissive cells may overwhelm the mechanism in question. 
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 The inability of the selected viruses to spread in naturally nonpermissive cells, 
while reinforcing the importance of Vif and the potential therapeutic targeting of the 
APOBEC3-Vif interaction, does not negate the potential mechanistic insights that might 
be gained by further elucidating the underlying Vif-independent mechanism. Toward that 
end, we carried out extensive sequence and molecular clone analyses of the selected 
viruses that yielded the surprising result that the mutations conferring an adapted 
phenotype map to the env gene (Figure 6-4B). As described in Chapter 2, there are 
many points at which one might anticipate the potential for Vif-independent adaptation to 
APOBEC3 proteins, but Env, admittedly, seemed quite unlikely prior to these studies 
since the current understanding of the mechanisms of APOBEC3 restriction would 
indicate that APOBEC3 proteins should never come into contact with the extracellular 
portions of Env implicated by our data. 
 Our working model, based on the placement of the selected mutations on a known 
gp120 structure and the proximity of the mutated residues to the gp41 interaction site, is 
that these env mutations function to increase gp120 shedding and thereby enhance signal 
transduction that somehow alters A3G activity, perhaps at the deaminase level. This 
would be consistent with the existence of a deaminase inhibitor in T cells (Thielen et al., 
2007) and is the most plausible alternative given the fact that the extracellular domain of 
gp120 should theoretically never come into contact with A3G. Such an explanatory 
model might also account for the stronger phenotypes associated with the adapted isolates 
themselves relative to the molecular clone viruses. For example, if the mechanism were 
mediated through soluble gp120 accumulation, then the soluble gp120 present when 
infecting with adapted isolate supernatants but not with molecular clone-derived viruses 
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might be phenotypically relevant. This is, however, merely a hypothesis, and although we 
are actively pursuing said hypothesis, we have no direct evidence for such a phenomenon 
at present. 
 While we do not currently understand the mechanism at play, the finding that a 
gene product even more ancient than Vif can mediate anti-APOBEC3 function may 
imply that such activities were ancestral accessory functions of Env prior to the rise of 
Vif. In the present day, the subject of how much soluble gp120 accumulates in patients is 
a subject of some controversy, but a moderate position based on patient-derived samples 
would place the concentration in the range of hundreds of pg/mL (Cummins et al., 2010; 
Klasse and Moore, 2004; Santosuosso et al., 2009). If this is the case, it may be that Env 
actively functions in vivo, but not in a non-pressurized culture system in the absence of 
disruptive mutations, to alter A3G function and thereby assist Vif in counteracting A3G 
in lymphoid tissues. These suppositions remain, however, highly speculative, and 
additional work will be required to determine the precise mechanism by which Env 
variants may function to permit enhanced viral growth in the absence of Vif. 
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Materials and Methods 
Plasmids – Coding sequences for the pcDNA3.1-derived plasmids used to make stably 
transfected A3F- or A3G-expressing cell lines are identical to those of NM_145298 and 
NM_021822, respectively. Mutations rendering either protein Vif-resistant or 
catalytically inactive were made my QuickChange site-directed mutagenesis (Stratagene) 
and have been described previously [(Albin et al., 2010b) and Supplementary Chapter 
2]. Full-length molecular clones of HIVIIIB and HIVLAI-GFP as well as Vif-deficient 
derivatives have been described previously (Albin et al., 2010b). The parent HIVIIIB used 
is identical to that of EU541617 with the exception of an A200C nucleotide change 
introduced to disrupt an upstream open reading frame that would otherwise inhibit viral 
production (Haché et al., 2008; Haché et al., 2009). Derivatives containing mutations 
found in passaged isolates were made by subcloning fragments out of the PCR clones 
described below and into clean molecular clone backgrounds. LTR-GFP constructs were 
made by site-directed mutagenesis of the plasmids previously reported (Haché et al., 
2008). All constructs were verified by sequencing and by diagnostic restriction digest. 
 
Cell lines – The APOBEC3-expressing cell lines used in these studies have been 
described previously. SupT11-derived cell lines expressing wildtype A3F or A3G were 
first reported in (Albin et al., 2010a) and also appear in (Albin et al., 2010b), where Vif-
resistant derivatives were first reported. SupT11-derived cell lines expressing 
catalytically inactive A3G are described in Supplementary Chapter 2. Briefly, SupT11 
cells were electroporated with linearized APOBEC3 expression plasmids, and clones 
were isolated by limiting dilution under G418 selection. APOBEC3 expression was 
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evaluated by using 250 µL of a lysis buffer consisting of 25 mM HEPES (pH 7.4), 150 
mM NaCl, 1 mM MgCl2, 50 µM ZnCl2, 10% glycerol, 1% Triton X-100, 50 µM MG132 
and complete protease inhibitor (Roche) to lyse 5x106 cells. Lysates were then mixed 
with a 5x sample buffer consisting of 62.5 mM Tris (pH 6.8), 20% glycerol, 2% sodium 
dodecyl sulfate, 5% β-mercaptoethanol and 0.05% bromophenol blue to a final 2x 
concentration of sample buffer. This mixture was boiled for 10 minutes prior to SDS-
PAGE, and fractionated proteins were transferred to PVDF membranes and blocked in 
4% milk dissolved in PBS 0.01% Tween. Blocked membranes were then probed with 
primary antibodies against A3F (#11474 from Dr. Michael Malim via the AIDS Research 
and Reference Reagent Program), A3G (#10201 from Dr. Jaisri Lingappa via the AIDS 
Research and Reference Reagent Program), or tubulin (Covance) followed by anti-rabbit 
or anti-mouse secondary antibodies (BioRad and Jackson) as appropriate. Prior to 
analysis of expression via each new antibody after the first, membranes were stripped at 
50°C in a buffer consisting of 62.5 mM Tris (pH 6.8), 2% SDS and 100 mM β-
mercaptoethanol. 
 
Cell culture – Suspension T cell lines such as SupT11 and CEM2n were maintained in 
RPMI with 10% fetal bovine serum, penicillin/streptomycin and β-mercaptoethanol. 
293T cells were cultured in DMEM with 10% fetal bovine serum and 
penicillin/streptomycin. 
 
Adapted viruses – The selection procedure associated with the isolation of adapted 
viruses is described in the main text in and Figure 6-1. Candidate isolates were identified 
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qualitatively for the enhancement of one of any three characteristics relative to 
neighboring wells and to positive and negative infection control wells on each plate when 
cultured on 100% nonpermissive cells: CEM-GFP infectivity, syncytia formation or cell 
death. Isolates identified were then subjected to a total of three MOI-controlled 
confirmatory passages. Throughout, criteria for being labeled an adapted virus were as 
follows: i) Any virus identified in a particular round of infection must be blindly 
identified by the same qualitative criteria on 100% restrictive cells at the end of all 
subsequent rounds of infection and must appear adapted in all subsequent confirmatory 
passages. ii) During confirmatory passage, adapted viruses must rise to greater than 2% 
CEM-GFP infectivity within 21 days and must remain above 1% for at least one 
additional time point. iii) During the MOI-controlled second and third passages, adapted 
viruses must confirm on at least one of two cell lines expressing the APOBEC3 protein to 
which the isolate was adapted. iv) During the MOI-controlled fourth passage, adapted 
viruses must confirm on at least two of four cell lines expressing the APOBEC3 protein 
to which the isolate was adapted. 
 
Spreading infections – Spreading infections were initiated by infecting 150,000 cells in 1 
mL per well in 24-well plates with a volume of virus corresponding to a multiplicity of 
infection (MOI) between 0.01 and 0.05 as determined by CEM-GFP infectivity and 
indicated in the legend associated with a given experiment. CEM-GFP infectivity for 
molecular clone-derived viruses was determined by infecting 100 µL of 25,000 CEM-
GFP cells per well in 96-well plates with increasing volumes of virus in a constant total 
volume of 250 µL; the volume of virus corresponding to a desired MOI was then 
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determined by linear regression. For passaged viruses where a single infectivity measure 
was available, a y-intercept of zero was used to carry out linear regression. Cultures were 
monitored periodically for the infectivity of their associated supernatants by infecting 
25,000 CEM-GFP reporter cells in 100 µL RPMI with 150 µL of virus supernatant. 
Approximately 3-5 days later, CEM-GFP cells were fixed in 4% paraformaldehyde and 
analyzed by flow cytometry. Parent cultures were periodically split and fed to prevent 
cell overgrowth. 
 
Viral genotyping – Viral genotypes were determined by analysis of sequences taken at or 
near the peak of viral spread during the third confirmatory passage. Half of infected 
CEM-GFP cultures in 96-well plates as used for standard monitoring (see above) were 
seeded into 500,000 uninfected CEM-GFP cells; several days later, genomic DNA was 
prepared from these seeded cultures using the PureGene genomic DNA isolation method. 
Genomic DNA was then treated with DpnI, and 550 ng of treated genomic DNA was 
used as the template for a touchdown PCR reaction amplifying fragments of 
approximately 1 kb each with the exception of the 2.2 kb vif-vpr region. PCR products 
were then gel-purified (Epoch or Fermentas gel extraction kits), cloned using CloneJet 
PCR cloning kits (Fermentas) and sequenced. Sequences were aligned and analyzed 
using Sequencher software (Gene Codes). 
 
LTR-GFP reporter experiments – 293T cells were seeded in six-well plates at 250,000 
cells per 2 mL per well. The following day, wells were transfected with 225 ng of 
plasmids in which the expression of GFP is dependent on the activity of a given 
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associated LTR (Haché et al., 2008), 25 ng of a constitutively-expressing dsRed control 
plasmid and 250 ng of pcDNA3.1 vector plasmid to a total of 500 ng per well. Two days 
post-transfection, transfected cells were washed in PBS and analyzed by flow cytometry 
for total GFP fluorescence per total dsRed fluorescence. 
 
A3G encapsidation – Spreading infections were initiated by infecting SupT11 cells stably 
transfected with the deaminase-deficient mutant A3G E259Q [e.g. (Schumacher et al., 
2008) and Supplementary Chapter 2] with wildtype or Vifdel HIVIIIB or with Vifdel 
derivatives carrying selected mutations in env. Nine days post-infection, supernatants 
were harvested from these cultures and used to infect CEM-GFP reporter cells prior to 
freezing the remaining supernatant. Following fixation of CEM-GFP and analysis by 
flow cytometry, frozen supernatants were thawed, filtered through 0.45 µm filters and 
normalized by volume according to their CEM-GFP infectivities. Virions were then 
centrifuged through 20% sucrose cushions, and pelleted viruses were resuspended in the 
5x sample buffer described above. Western blotting for A3G (#10201 from Dr. Jaisri 
Lingappa via the AIDS Research and Reference Reagent Program) and for p24 
(antibodies purified from hybridoma 183-H12-5C from the AIDS Research and 
Reference Reagent Program) was carried out as above, and images were quantified using 
ImageJ software. 
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Table 6-1: Phenotypic characterization of fourth passage, HIVIIIB-derived, Vif-
deficient A3G-adapted viruses. 
Isolate Growth on A3G 
Growth on 
A3G 
DPD/KPK 
Growth on 
A3F 
Growth on 
A3F 
QE323-
324EK 
Round 
First 
Apparent 
WT IIIB ++ - ++ - na 
IIIB Vifdel - - - - na 
C6-A1 ++ + + + 3 
C6-A2 ++ + + + 3 
C6-A3 ++ + + + 3 
C6-A4 ++ + + + 3 
C6-A5 ++ + + + 3 
C6-A6 + + + + 3 
C6-B2 + + + + 3 
C6-B3 + + + + 3 
C6-B4 + + + + 3 
C6-B6 + + - + 3 
C6-C1 ++ + + + 3 
C6-C2 ++ + + + 3 
C6-C4 + + - - 3 
C6-C5 ++ ++ + + 3 
C6-C6 + + + + 3 
C6-D1 ++ + + + 3 
C6-D4 ++ ++ + + 2 
C7-A2 ++ + - + 2 
C7-A3 ++ + + + 2 
C7-A4 ++ + + + 2 
C7-A5 + + - - 3 
C7-B1 + + nd nd 2 
C7-B2 ++ + + + 2 
C7-B3 + + - + 3 
C7-B4 ++ + + + 2 
C7-B5 + + - + 2 
C7-C1 + + - - 2 
C7-C2 + + + + 2 
C7-C3 ++ + + + 2 
C7-C5 + + + + 3 
C7-C6 ++ + - - 2 
C7-D1 + + + + 3 
C7-D2 ++ + + + 2 
C7-D3 + + - + 3 
C7-D4 ++ ++ + + 2 
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Criteria 
+ = Peaks at the last three time points (~3-4 weeks post-infection) or failure to peak on 
one or more cell lines used for each APOBEC3 expression condition 
++ = Peaks at middle two time points (~1-2 weeks post-infection), peaks on at least ¾ 
A3G-expressing lines used; some viruses do not peak on the highest-expressing lines (C6 
for A3G) 
+++ = Peaks at first two time points (~1 week post-infection) 
nd = Not determined, generally due to shortage of adapted virus to initiate infection. 
na = Not applicable. 
Note: “Peak” is defined not as the literal highest peak post-infection, but rather as the first 
peak of height at or comparable to the highest. Many isolates, likely due to being Vpr-
deficient, will stay at high levels of CEM-GFP infectivity once they are up because they 
are less proficient at killing cells. Where there is disagreement (e.g. the peak on the 
highest level of A3G is more likely to be + versus ++ for the lowest levels of A3G), 
viruses are scored according to an overall impression of when viral growth is first 
occurring. 
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Table 6-2: Phenotypic characterization of fourth passage, HIVLAI-GFP-derived, Vif-
deficient A3G-adapted viruses. 
Isolate Growth on A3G 
Growth on 
A3G 
DPD/KPK 
Growth on 
A3F 
Growth on 
A3F 
QE323-
324EK 
Round 
First 
Apparent 
WT LAI-
GFP +++ - ++ - na 
LAI-GFP 
Vifdel - - - - na 
C8-A1 + nd nd nd 3 
C8-A2 + + - - 3 
C8-B3 + - + - 2 
C8-B5 + - - - 2 
C8-C1 + - nd - 2 
C8-C2 ++ + + - 2 
C8-D3 + - nd - 2 
C9-A2 ++ + + - 2 
C9-A3 ++ - nd nd 2 
C9-A4 ++ + - - 2 
C9-A5 + - - - 2 
C9-B1 + - + - 2 
C9-B2 + + nd nd 2 
C9-B3 ++ + + nd 3 
C9-B4 + - nd nd 2 
C9-B5 ++ + - - 1 
C9-C1 ++ + - - 2 
C9-C3 + - - - 3 
C9-C4 + - nd nd 3 
C9-C6 ++ + + - 2 
C9-D1 ++ + + + 3 
C9-D3 + + - - 3 
Criteria 
+ = Peaks at the last three time points (~3-4 weeks post-infection) or failure to peak on 
one or more cell lines used for each APOBEC3 expression condition 
++ = Peaks at middle two time points (~1-2 weeks post-infection), peaks on at least 3/4 
A3G-expressing lines used; some viruses do not peak on the highest-expressing lines (C6 
for A3G) 
+++ = Peaks at first two time points (~1 week post-infection) 
nd = Not determined, generally due to shortage of adapted virus to initiate infection. 
na = Not applicable. 
Note: “Peak” is defined not as the literal highest peak post-infection, but rather as the first 
peak of height at or comparable to the highest. Many isolates, likely due to being Vpr-
deficient, will stay at high levels of CEM-GFP infectivity once they are up because they 
are less proficient at killing cells. Where there is disagreement (e.g. the peak on the 
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highest level of A3G is more likely to be + versus ++ for the lowest levels of A3G), 
viruses are scored according to an overall impression of when viral growth is first 
occurring. 
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Table 6-3: Phenotypic characterization of fourth passage, HIVIIIB-derived, Vif-
deficient A3F-adapted viruses. 
Isolate Growth on A3G 
Growth on 
A3G 
DPD/KPK 
Growth on 
A3F 
Growth on 
A3F 
QE323-
324EK 
Round 
First 
Apparent 
WT IIIB ++ - ++ - na 
IIIB Vifdel - - - - na 
B6-A6 + + + + 3 
B6-B2 + + + + 3 
B6-C3 + + + + 3 
B6-C6 + + + + 3 
B6-D3 + + + + 3 
B8-B6 + + + + 3 
B8-C1 + + + + 3 
B8-C2 + + + + 3 
B8-C6 + + + + 3 
Criteria 
+ = Peaks at the last three time points (~3-4 weeks post-infection) or failure to peak on 
one or more cell lines used for each APOBEC3 expression condition 
++ = Peaks at middle two time points (~1-2 weeks post-infection), peaks on at least 3/4 
A3G-expressing lines used; some viruses do not peak on the highest-expressing lines (C6 
for A3G) 
+++ = Peaks at first two time points (~1 week post-infection) 
nd = Not determined, generally due to shortage of adapted virus to initiate infection. 
na = Not applicable. 
Note: “Peak” is defined not as the literal highest peak post-infection, but rather as the first 
peak of height at or comparable to the highest. Many isolates, likely due to being Vpr-
deficient, will stay at high levels of CEM-GFP infectivity once they are up because they 
are less proficient at killing cells. Where there is disagreement (e.g. the peak on the 
highest level of A3G is more likely to be + versus ++ for the lowest levels of A3G), 
viruses are scored according to an overall impression of when viral growth is first 
occurring. 
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Figure 6-1: Approach and successful isolation of A3G-adapted, Vif-deleted viruses. 
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Figure 6-1: Approach and successful isolation of A3G-adapted, Vif-deleted viruses. 
(A) Western blots showing the A3G levels expressed in the cell lines used in this study. 
(B) Western blots showing the A3F levels expressed in the cell lines used in this study. 
(C) Schematic depicting the selection matrix used in this study in which each prong 
represents a 24-well plate with 22 selective cultures, one uninfected control culture and 
another control in which permissive cells were infected and the resultant viruses passaged 
continuously. (D) Schematic depicting the selection strategy employed as described in the 
main text. (E) Histograms demonstrating the number of adapted isolates present at the 
end of each round of selection as confirmed through a total of four confirmatory passages 
on 100% restrictive cells. 
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Figure 6-2: Phenotypes of adapted viruses. (A-D) Spreading infection curves show the 
fourth passage adapted phenotypes of the four isolates selected for sequence 
characterization. 
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Figure 6-3: Sequence characterization of the selected viruses. (A) Hypermutation of 
fragments isolates from the 5’ end of the genome. Contrast with levels found in 
fragments isolated from the 3’ end of the genome (C) for overall mutation levels 
consistent with A3G action. (B) Direct sequencing across the virus demonstrates stability 
of the vif deletion employed. (D) Schematic depiction of the HIV genome showing the 
occurrence of the consensus mutations in the four isolates sequenced. 
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Table 6-4: Vif-deficient A3G-adapted A isolate C6-A5 consensus sequence1. 
Nucleotide 
Change2 Context
3 Amino Acid Change4 Database
5 Molecular Clones6 
T2386G CAT CCG GCA RT P97P n/a n/a 
G2610A TTT AAA AAA RT R172K 98% R; 1% K R 
T2724G CTG TGG AGG RT L210W 95% L; 1% W L 
C5135T CCA TAG AGG Vpr Q11X n/a n/a 
ins5347.1A AGG CGT TAC T Vpr Frameshift n/a n/a 
T5693G GAA TAG AGG Vpu Y29X n/a n/a 
C5939T GAT GTT AAA gp120 A58V 98% A A 
delT8984 GGGACTTTCC U3 NFκB II del8984 
79% T; 21% 
del 
(varying 
size) 
T8984 
 
 
                                                
1 Viral isolate names refer to the (Cell line)-(24-well Plate Coordinate) from which an 
adapted virus was isolated. 
2 Nucleotides are numbered as for wildtype pIIIB (EU541617.1) from the transcriptional 
start site. 
3 Context is given as the affected and immediate flanking codons; the mutant nucleotide 
is underlined. Changes are included only if they occur in at least 4/5 clonal sequences. 
4 Abbreviations: MA = p17 matrix; NC = p7 nucleocapsid; RT = reverse transcriptase; 
LTR = long terminal repeat. All amino acids are numbered from the start codon of their 
respective open reading frames with the exception of pol, which is numbered from the 
initial pol RT codon following the transframe gag-pro (equivalent to codon 588 
numbered from the gag start codon). 
5 Indicates the predominant amino acid or nucleotide frequencies at a given position per 
the Los Alamos National Laboratory HIV Sequence Database’s 2010 Premade 
Alignments analyzed in Jalview. Omitted for silent changes. 
6 Molecular clones HIVIIIB, HIVLAI-GFP, HIVNL4-3 and HIVHXB2 are collectively referred to 
unless otherwise noted. 
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Table 6-5: Vif-deficient A3G-adapted B isolate C6-D4 consensus sequence. 
Nucleotide 
Change Context 
Amino Acid 
Change 
Database 
Distribution 
Molecular 
Clones 
G1503A ACT ATT AAG NC V390I 57% V; 21% I V 
AG1712-
1713TC CCT CAA GAG 
p6 
PE459-
460PQ 
61% A; 31% 
E E
7 
C1750A ACT CAC TCT p6 P472H 70% P; 7% S P 
T2157C AAA GCT AAA RT V21A 99% V V 
G5097T ACA TAG GAC Vif E171X n/a n/a 
C5300T CAA TAA CTG Vpr Q66X n/a n/a 
C6007A AAC ACA CAA gp120 P81T 99% P P 
C7643T CAC ATG ACC gp41 T626M 
93% M; 5% 
L; 1% T 
IIIB/HXB2 
T; LAI-
GFP/NL4-3 
M 
 
                                                
1 Interpretation for HIVLAI-GFP is complicated by the fact that this virus carries a 12 aa 
duplication from the -1 to +11 positions of p6 (448-459). Sequencing of the p6 region 
from a greater number of adapted viruses than shown here demonstrated that some A3G-
adapted HIVLAI-GFP isolates had deleted this duplication (data not shown). 
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Table 6-6: Vif-deficient A3G-adapted C isolate C7-A2 consensus sequence. 
Nucleotide 
Change Context 
Amino Acid 
Change 
Database 
Distribution 
Molecular 
Clones 
G562A CGT AAA TCA MA R76K 53% K; 40% R R 
G2318A TTA ATA GAT RT V75I 98% V V 
G2993A GCA AAG CTA RT E300K 97% E E 
G3088A CAG AAA CAG RT K331K n/a n/a 
C4939A GAA TAT GCT Vif S118Y n/a n/a 
del5215-
5228 AT_ 12nt _TA 
Vpr 
del5215-
5228 
n/a n/a 
T5486C GTT TGC TTC Tat C37C n/a n/a 
G7191A GAT ATA AGG gp120 M475I 92% M; 6% I M 
T7460A CAT CAG TTG gp41 L565Q 61% L; 37% M L 
T7734C AAG AAC GAA gp41 N656N n/a n/a 
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Table 6-7: Vif-deficient A3G-adapted D isolate C7-D4 consensus sequence. 
Nucleotide 
Change Context 
Amino Acid 
Change 
Database 
Distribution 
Molecular 
Clones 
G4654A AAA AAA TTA Vif R23K 98% S 
LAI-
GFP/HXB2 
S; 
IIIB/NL4-3 
R 
G5157A GAA TAG ACA Vpr W18X n/a n/a 
A5312C TTT CTC CAT Vpr I70L n/a n/a 
C6002T GAC CTC AAC gp120 P79L 99% P P 
A7042C AAC CTG TGG gp120 M426L 
83% M; 6% 
R,L M 
A7091C GGA CCA ATT gp120 Q442P 
30% N; 
20% Q; 9-
7-6% V-I-
L 
Q 
C8988T NFκB II GCTG NFκB I U3 C8988T 
79% C; 1% 
T; 1% A C 
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Figure 6-4: Mutations in env account for the adapted phenotype. (A) Histograms 
showing LTR-driven GFP expression relative to a dsRed control for two mutants 
identified in our selections, a known A200 hypomorph (Haché et al., 2009; Haché et al., 
2008) and the parent C200 wildtype promoter. Data represent the mean and SEM of three 
independent experiments performed in duplicate. (B) Representative spreading infection 
curves showing that selected env mutations can overcome stably expressed A3G. 
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Figure 6-5: A3G encapsidation in selected env mutants. (A) Western blot showing the 
levels of A3G encapsidated by molecular clones of the indicated genotypes spreading at 
nine days post-infection on a SupT11 cell line stably expressing A3G E259Q. (B) 
Quantification of A3G encapsidation in adapted env backgrounds. A3G and p24 band 
intensities were quantified using ImageJ. Data represent the mean and standard deviation 
of A3G encapsidated per p24 for each virus on each of three, independent cell lines 
expressing A3G E259Q with the exception of envB, which was characterized on only two 
of these cell lines. One-way ANOVA with Dunnett’s post test using the envWT/vif(-) 
virus as the control condition indicated a significant difference only between the control 
and envWT/vif(+) viruses. ** = p < 0.01 
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Figure 6-6: Selected env mutations cluster to loops on either side of helix 0 in layer 1 
of the gp120 inner domain. Crystal structure 3JWO and summary of gp41-interactive 
residues (red) are derived from (Pancera et al., 2010). Different colors correspond to 
distinct isolates. Not all residues changed are to be found in extant structures. 
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Postscript 
 There are several major unresolved issues that must be addressed in this study. 
First, we fundamentally do not know the mechanism by which Env counteracts A3G. 
Although an alteration to the amount of A3G encapsidated would be the most likely 
mechanism that one might predict, this appears not to be the case per our present data. 
One alternative possibility is that Env may alter the deaminase activity of particle-
associated A3G, which is a plausible mechanistic basis that we are actively investigating. 
Another potential mechanism of Env function may be to alter the way in which the virus 
can spread by cell-to-cell contact, perhaps bypassing A3G in the process. To address this 
possibility, collaborators are presently investigating the cell-cell spread of the Env 
mutants described in this study. Finally, virion mislocalization remains a possibility since 
the localization of A3G outside of the viral core may render it unable to exert its antiviral 
effects. 
 Basic characterization of the env alleles selected is also ongoing. Specifically, 
selection for changes at highly conserved residues near the gp41 interaction site in gp120 
implies the potential for an altered interaction between these two extracellular 
components. Although we do not know what the nature of such an alteration may be, it is 
possible that mutation of these conserved residues may weaken the interaction between 
gp41 and gp120, perhaps leading to increased levels of soluble gp120 in culture. Thus, 
we are investigating the levels of intact gp120:gp41 complexes among the selected 
mutants in comparison with the parent Env. 
 Finally, there are several experiments pertaining to the generalizability of the 
ability of the Env mutants selected to counteract A3G. All of the cell lines stably 
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transfected with A3G in this chapter are derivatives of SupT1. It will therefore be 
important to determine whether the same phenotype is displayed by some of our cell lines 
derived from different parents such as CEM-SS. Beyond that, it is clear at this point that 
the env mutant molecular clones are not phenotypically equivalent to the passaged 
isolates from which they derive, an observation that similarly holds true for the viruses 
described in Chapter 5. We do not presently understand this, but several possible 
explanations merit exploration. For example, it may be that accessory mutations in the 
natural isolates aid Env in neutralizing A3G; to address this, we will need to analyze 
molecular clones with combinations of multiple selected mutations built back in to clean 
molecular clone backgrounds. It may also be that a substance in the passaged isolates 
important for the neutralization of A3G accumulates over time. This could be, for 
example, soluble gp120 if there is a partial disruption to the interaction between gp120 
and gp41. Such possibilities can be addressed by spreading infections using cultures 
pretreated with killed viral isolates, among other potential approaches. 
 In summary, many challenges remain in the elucidation of the mechanism by 
which the viruses described here function to bypass APOBEC3 proteins. We do not at 
present have data to support a mechanistic model that fully explains the phenotypes of 
our passaged isolates. Despite these challenges, the localization of APOBEC3-adaptive 
changes to an open reading frame other than vif is very important in that it suggests that 
we will need to consider the potential for accessory mechanisms of APOBEC3 evasion in 
implementing potential APOBEC3-related therapies. 
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Chapter 7: Conclusions and Discussion 
 
 The bulk of the data presented in this thesis describes a stepwise progression 
through the determination of important components required for the Vif-mediated 
neutralization of APOBEC3 proteins. In particular, the data may be conceived of as 
addressing five key questions: 1) Which APOBEC3 protein may best serve as a model for 
Vif-mediated neutralization? 2) Where in this APOBEC3 protein does Vif interact? 3) 
What are the downstream ubiquitination sites within this APOBEC3 protein required for 
its ultimate proteasomal degradation? 4) Where in Vif does this APOBEC3 protein 
interact? 5) If one could prevent Vif from facilitating the degradation of APOBEC3 
proteins, how might the virus adapt? These questions and their respective answers per the 
work presented here are described visually in a schematic of the Vif-associated E3 
ubiquitin ligase complex shown in Figure 7A-B. In viewing the data through this lens, 
the reader may appreciate how the various components of this dissertation unite in the 
central goal of addressing how one might go about the therapeutic utilization of 
APOBEC3 proteins. 
 
Chapter 2: Long-term restriction by APOBEC3F selects human immunodeficiency virus 
type 1 variants with restored Vif function – Prior to the study described in Chapter 2, we 
had carried out experiments aimed at determining whether HIV might be able to adapt to 
growth in the presence of A3G without Vif, thus implicating potential alternative 
pathways around APOBEC3 proteins that might yield insight into the mechanism of 
restriction and into the therapeutic potential of APOBEC3 proteins (Haché et al., 2008). 
These studies utilized a parent HIVIIIB containing tandem stop codons in vif to ablate 
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expression of the viral accessory protein, and despite extended passage in the presence of 
T cells stably expressing A3G, rare adapted variants of these viruses never altered these 
tandem stop codons, indicating that HIV might be capable of acquiring Vif-independent 
resistance to APOBEC3 proteins. In this specific case, adapted viruses acquired a 
noncoding nucleotide change A200T/C and a defective vpr open reading frame, the 
former of which enhances viral particle production to effective titrate out the levels of 
encapsidated A3G and allow the virus to survive at a population level while still being 
heavily exposed to A3G (Haché et al., 2009). 
 One caveat to the major result of the aforementioned study, however, is that the 
viruses selected in these studies were not capable of growing in cells stably expressing 
A3F or in naturally nonpermissive CEM cells expressing multiple APOBEC3 proteins. 
We therefore carried out a companion series of experiments aimed at further adapting the 
A3G-selected viruses to also grow in the presence of A3F. These efforts yielded the 
surprising finding that, in contrast with our A3G studies, passage in the presence of A3F 
always resulted in strong selection for reversion of the tandem stop codons in vif to a 
variety of sense codons (Table 2-2). Thus, we were able to readily detect genetic 
interaction between A3F and Vif but not between A3G and Vif, suggesting that Vif is 
absolutely required for neutralization of A3F but not A3G. This may be taken to further 
imply that the A3F-Vif interaction may be a superior model for the study of the 
APOBEC3-Vif interaction, as would prove to be the case in the years following (Figure 
7-1). 
 The exact nature of the reverted stop codons in vif turned out to be important for 
the interpretation of our selection studies. That is, the vif alleles selected by A3F proved 
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incapable of neutralizing A3G (Figure 2-5). A3F therefore exerts selective pressure for 
the maintenance of HIV Vif function distinct from that thought to be exerted by A3G. 
While it is not possible to extrapolate perfectly to the in vivo situation based on our 
culture models, this result implies that A3F is an important component of the selective 
pressures that maintain Vif function in the context of natural infection. 
 When we sought to define the nature of this differential Vif efficacy, we found 
that the identity of residue 26 in Vif was critical for the ability of the accessory protein to 
neutralize A3G. Despite the fact that all tested identities of both residues 26 and 27 in Vif 
were capable of neutralizing A3F, a lysine was required at position 26 to neutralize A3G 
(Figure 2-6). This was consistent with two directed mutagenesis studies of Vif residues 
critical for anti-APOBEC3 function that came out shortly before our manuscript was 
published (Chen et al., 2009; Dang et al., 2009). The mechanism by which this amino 
acid functions in the selective neutralization of A3G is not known. We observed no 
appreciable difference in the ability of Vif with K26 versus other residues at position 26 
to coimmunoprecipitate A3G, and similar data were variable between the 
contemporaneous papers cited above. It is possible that this lysine could act as a site of 
autoubiquitination in Vif that could facilitate the degradation of bound APOBEC3 
proteins as proposed previously (Dang et al., 2008b), but based on our data presented in 
Chapter 4 indicating that internal lysines in both A3F and A3G are the critical ubiquitin 
acceptor sites involved in APOBEC3 degradation, this seems unlikely. Combined with 
the existence of many other residues critical for the neutralization of one APOBEC3 
protein but not another, then, this implies by default that K26 is somehow important for 
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the quality of the interaction between Vif and A3G but not other APOBEC3 proteins 
(Table 1-2). 
 In a broader context, Chapter 2 is part of a recent debate in the literature on the 
restrictive power of A3F (Miyagi et al., 2010; Mulder et al., 2010). The crux of the 
matter is just how important A3F and other APOBEC3 proteins are relative to A3G, and 
the data in this chapter are among the most redeeming in favor of A3F. If a level of stably 
expressed A3F similar to that in naturally nonpermissive cells forces the virus to revert 
vif or fail to propagate, then the level of the threat from a viral perspective should be 
clear. 
 Arguing against A3F, however, are data suggesting that its expression levels in 
primary cells are so low as to be nonrestrictive (Mulder et al., 2010). In this study, the 
authors utilized a Vif mutant thought to be selectively deficient for the neutralization of 
A3F. By comparing the unimpaired spread of the selectively deficient virus to that of a 
grossly deficient virus in primary cells, the authors concluded that the levels of A3F in 
primary cells must be too low to effectively restrict HIV. Certainly, this is possible and 
not at all an unimportant point to address, yet there are two important caveats to these 
data. First, there is no guarantee that the levels of A3F expressed in the primary cells used 
are indicative of the A3F levels present in vivo. While it is laudable to use primary cells, 
then, their ability to reflect in vivo conditions when placed in a culture dish is not 
guaranteed, nor is there any real evidence that there is one, true level of APOBEC3 
expression since individual differences frequently cover a wide range of expression if one 
reviews some of the expression data discussed in Table 1-1. It also bears mentioning that 
parallel studies in which a selectively susceptible allele of vif is used to probe the efficacy 
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of A3G in primary cells have not been carried out. It is therefore not known to what 
extent these ex vivo models are indicative of restriction by any APOBEC3 protein, let 
alone A3F. 
 Overall, we fundamentally do not and cannot know “the” APOBEC3 repertoire of 
any one individual. Alleles vary. Expression levels vary. Cell types vary. The overall 
immune system varies. The nature of the virus infecting that individual varies, etc. All of 
these things will affect the expression and potential of APOBEC3 proteins in vivo, and 
thus to extrapolate the results of a handful of ex vivo primary cell experiments to an in 
vivo fact of life seems a false sense of physiologic security. In this case, “can happen” 
may be the best one can or should do until such time as a clinical trial becomes feasible 
subsequent to infrastructural “can happen” work. 
 Regardless, the reversions described in this chapter, repair of the vif open reading 
frame in a manner specific to the neutralization of A3F with a Vif that itself is 
nonfunctional against A3G, remain impressive in comparison with the broader scope of 
our efforts to adapt HIV to various APOBEC3 proteins. Three years and thousands of 
spreading infection cultures later, none of us in the Harris lab has yet seen anything quite 
that simple and clear despite numerous efforts to show a genetic interaction between A3G 
and vif. In following this lead by extending study of the APOBEC3-Vif interaction to 
A3F on top of A3G and other APOBEC3 proteins, we have gained important insights 
into shared and distinct features of these interactions. 
 
Chapter 3: A single amino acid in human APOBEC3F alters susceptibility to HIV Vif –  
Based on the clarity of the genetic interaction observed in Chapter 2, we next sought to 
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determine where Vif interacts with A3F, as prior efforts in the field had focused only on 
critical Vif interaction residues in A3G or on loss of function mutants in Vif defective for 
the neutralization of one of more APOBEC3 proteins. To do this, we utilized the species 
specificity of the interaction between APOBEC3 proteins and Vif. That is, HIV Vif is 
capable of neutralizing human A3F but not rhesus macaque A3F (Virgen and 
Hatziioannou, 2007; Zennou and Bieniasz, 2006). By systematically substituting rhesus 
residues into the human protein where the two differ, we might thus be able to determine 
which determinants in A3F are critical for functional recognition by Vif, a strategy 
employed successfully with human A3G and African green monkey A3G (Bogerd et al., 
2004; Mangeat et al., 2004; Schröfelbauer et al., 2004; Xu et al., 2004). 
 Adhering to this method, we were able to determine that A3F E324 is a critical 
determinant of A3F interaction with Vif. In contrast with other reported single amino acid 
determinants of Vif susceptibility (D128 and D130 in A3G, D/E121 in A3H), residue 324 
need not acquire a positive charge to render the protein Vif-resistant (Bogerd et al., 2004; 
Huthoff and Malim, 2007; Mangeat et al., 2004; Schröfelbauer et al., 2004; Xu et al., 
2004; Zhen et al., 2010). Rather, either a charge change at E324 or simply neutralizing 
the sidechain by mutation to alanine each renders A3F Vif-resistant (Figure 3-4). This 
demonstration of a positive requirement strongly implies that A3F E324 is a residue that 
directly interacts with Vif. This may also be the case for the other single amino acid 
determinants of Vif susceptibility, but it is difficult to assess direct interactions versus 
broader changes to the interaction surface caused by a mutation using the toolboxes 
employed by these authors. 
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 Contemporaneous with the publication of our manuscript, another group using a 
different comparative approach identified A3F E289 as a similar determinant of Vif 
interaction, and mapping of these residues onto our model structure of the A3F C-
terminus reveals that these residues are structural neighbors at the extreme C-terminal 
ends of the α3 and α4 helices (Smith and Pathak, 2010). This, combined with our 
inability to detect a quantitative difference in Vif binding between Vif-sensitive and Vif-
resistant proteins, suggests that the residues identified in these respective efforts are part 
of a broader interaction surface (Supplementary Chapter 1). A recently reported 
structure of A3C with associated mutagenesis demonstrates the existence of just such a 
surface, perhaps explaining in part the variability in coimmunoprecipitation efficacy seen 
among different authors (Kitamura et al., 2012). It may therefore be difficult to strictly 
correlate loss of anti-APOBEC3 function by mutation in either protein with loss of 
coimmunoprecipitation, although more sensitive, biophysical measures of association 
may shed light on this problem. 
 As demonstrated in Chapter 5, this straightforward finding yielded an important 
genetic tool that that we have since used to leverage insights well beyond this single 
amino acid. The basis for Chapter 5, however, was first reported in the manuscript 
associated with Chapter 3. That is, prior efforts aimed at mapping the determinants of 
Vif susceptibility in APOBEC3 proteins had emphasized the diversity of APOBEC3-Vif 
interactions (Bogerd et al., 2004; Huthoff and Malim, 2007; Lavens et al., 2010; Mangeat 
et al., 2004; Russell et al., 2009b; Schröfelbauer et al., 2004; Xu et al., 2004; Zhen et al., 
2010). We noted, however, that in comparing the phylogenetic equivalents of all of the 
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that a pattern began to emerge. While all single residue changes were linearly distinct, 
mapping them onto our model structure of the A3F C-terminal deaminase domain 
revealed that these residues, in addition to all being negatively charged, exist on the 
surface of the α4 helix, which itself forms part of a broader negatively charged surface 
with α3. Thus, we were able to determine that there is a structural commonality to the Vif 
interaction region of APOBEC3 proteins underlying the seemingly divergent results 
emerging from various mapping studies. This raises the possibility that one might 
intervene therapeutically at one structural point to facilitate restriction by multiple 
APOBEC3 proteins, a point to which we return in our discussion of Chapter 5. 
 On the face of it, this seems logical. Vif is likely a flexible protein based on its 
apparent intrinsically disordered nature, but it would still be quite a lot for the 
approximately 90 amino acids that comprise the N-terminus that most studies implicate in 
APOBEC3 recognition to adapt to at least three different APOBEC3 interactions – A3F 
(and A3C and A3D, which typically behave as A3F does), A3G and A3H (Auclair et al., 
2007; Jäger et al., 2011; Reingewertz et al., 2010; Zhang et al., 2011). Yet consensus in 
the field prior to this study and up to the present day would hold that this is exactly what 
happens. Whether the data described in Chapter 5 will achieve moderation of this view 
only publication and time will tell, but those data strongly reinforce our suspicions about 
how Vif and APOBEC3 proteins interact based on a simple comparison of the critical 
residues found in different APOBEC3 proteins. 
 While an attractive model, however, it bears mentioning that there are many large 
gaps in our understanding of the APOBEC3-Vif interaction. On the APOBEC3 side of 
the interaction, the most prominent of these is what defines a Vif-susceptible deaminase 
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domain. Why are there no known instances of Vif recognition of a Z1-type deaminase 
domain? Why does Vif recognize one Z2, for example the A3F C-terminus, but not 
another such as the A3F N-terminus? An interesting and important genetic problem 
moving forward, then, will be to build on the α4 hook to expand out and define the 
broader elements that make up a Vif-susceptible deaminase domain – how to make the 
insensitive sensitive, and how to reliably predict novel Vif-resistance mutations. Such 
efforts will also facilitate future attempts at defining directly interacting residues in Vif 
corresponding to functionally altered APOBEC3 sites in a manner analogous to Chapter 
5. 
 
Chapter 4: Dispersed sites of HIV Vif-dependent polyubiquitination in the DNA 
deaminase APOBEC3F –  Following Vif binding to an APOBEC3 protein, the next step 
in the degradation process is the polyubiquitination of downstream acceptor sites. This 
study sought to determine where such sites in A3F might occur with an eye toward 
testing the validity of a model proposed by a previous paper focusing on A3G (Iwatani et 
al., 2009). In this model, binding of Vif to one cytosine deaminase domain orients the 
other for polyubiquitination at well-defined internal lysine acceptors, which is 
therapeutically significant in that it implicates a second potential target for intervention 
by preventing polyubiquitination of a given APOBEC3 protein rather than directly 
interrupting the interaction with Vif. 
 To address this model, we mutated all of the lysine residues in A3F to arginine 
and then systematically reverted single amino acids or several groups of amino acids. 
This yielded the surprising finding that A3F can be effectively polyubiquitinated in the 
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presence of Vif at a minimum of six distinct sites, and that these sites are dispersed 
throughout the length of the protein (Figure 4-1 and 4-2). Similarly, we demonstrated 
that the four lysines previously reported to be modified do not fully ablate A3G 
neutralization by Vif when changed to arginine, suggesting that alternative targets can be 
utilized (Figure 4-1). 
 To confirm the modification of these multiple residues in A3F and A3G, we 
collaborated with the Krogan lab at the University of California, San Francisco, which 
specializes in mass spectrometric methods. Using a technique in which all modified 
substrates are purified by binding to an anti-K-GG antibody to detect the isopeptide 
bonds typical of ubiquitination, they were able to confirm modification of many residues 
in A3F and in A3G distributed throughout both the N- and C-termini (Figure 4-3). The 
polyubiquitination of APOBEC3 proteins in the presence of Vif, then, appears to be a 
somewhat more structurally flexible process than previously thought. 
 Importantly, these mass spectrometry data represent the first direct evidence for 
the modification of any specific residue in A3F or A3G by Vif. Previous efforts have 
utilized a more traditional biochemical approach in which one cotransfects an APOBEC3 
protein with or without Vif and a tagged ubiquitin, immunoprecipitates the APOBEC3 
protein and then blots for ubiquitin, typically yielding a high molecular weight smear 
thought to indicate polyubiquitinated APOBEC3 substrate (Dang et al., 2008b; Iwatani et 
al., 2009; Shao et al., 2010; Wang et al., 2011b). This method leaves much to be desired, 
however, since one cannot know specifically whether the smear represents APOBEC3 
proteins, associated coimmunoprecipitates (e.g. Vif) or some combination of the two. It is 
particularly concerning, given this sort of experimental design, that Vif has been shown 
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to autoubiquitinate itself [e.g. (Jäger et al., 2011; Mehle et al., 2004a)]. A more 
appropriate approach might be to blot for the APOBEC3 protein itself in this situation, 
but we have failed to detect a reliable APOBEC3-specific western blot signal of 
appropriate molecular weight under these conditions (data not shown). In any event, the 
mass spectrometry data are unambiguous and dovetail well with the genetically 
determined sites of modification. 
 Despite the apparently random linear distribution of targeted residues in our 
genetic and biophysical datasets, if one turns again to a structural understanding, the data 
begin to make sense. Surprisingly, the models of A3F and A3G available to us, which are 
based on a crystal structure of the A3G C-terminus, suggest that the lysine residues in 
these APOBEC3 proteins typically cluster to a common surface of the protein opposite 
the Vif interaction region [Figure 4-4 and (Shandilya et al., 2010)]. It is therefore 
possible that Vif, a highly basic protein, has evolved to recognize the negatively charged 
surface of APOBEC3 proteins located at and around the α4 helix, thereby positioning 
lysine-rich surfaces for downstream polyubiquitination (Figure 4-6). Such a model is 
consistent with the ability of the Vif-associated E3 ubiquitin ligase complex to target a 
wide range of residues since, in structural terms, these residues are of comparable 
accessibility. In the end, however, high resolution structures of the full APOBEC3-Vif-
E3 ubiquitin ligase complex will be necessary to determine whether these indirect 
inferences are valid. Regardless of whether the binding model is correct, however, it is 
undeniable that a wide range of lysines can be effectively modified in A3F and A3G in 
the presence of Vif. Therapeutic targeting of this step in the degradation process will 
therefore likely prove intractable. 
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 Chapter 5: Evidence for a conserved structural feature in HIV Vif that interacts 
with APOBEC3 proteins – Directed mutagenesis studies of the sort described in Table 1-
2 have suggested a variety of potential APOBEC3 interaction regions in Vif. If one sorts 
through these, several patterns emerge. First, regions that when mutated result in loss of 
function against A3F are often distinct from those that when mutated result in loss of 
function against A3G. This implies that there are aspects of the interaction between 
APOBEC3 proteins and Vif that are distinct from one APOBEC3 protein to another, and 
these selective deficiency regions are often presumed to represent the A3F- or A3G-
specific binding regions, of Vif [e.g. (Smith et al., 2009)]. 
 In reality, none of these studies has reported direct evidence for the interaction of 
any particular residue in Vif with any particular residue in A3F or A3G. While it may be 
true that mutation of a particular region results in loss of function and perhaps loss of 
immunoprecipitation, these readouts do not necessarily mean that one has mutated a 
directly interacting region, as it is impossible to distinguish such a scenario from one in 
which the mutations made have caused a broader change in Vif structure. Based on these 
studies, then, unambiguous identification of the regions of Vif that directly interact with 
the presumptive Vif-interacting regions of the α4 helix in APOBEC3 proteins cannot be 
achieved. 
 Introducing the Vif-resistance mutations of the α4 helix into their respective 
APOBEC3 proteins yields an APOBEC3 variant capable of restricting HIV despite the 
presence of Vif. If the residues of α4 directly interact with a given residue in Vif, then, 
passage of wildtype HIV in their presence should eventually select for a compensatory 
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mutation in vif that would restore functional interaction, a concept illustrated in Figure 5-
1. Such compensatory mutations represent superior evidence for direct interaction 
because they require a gain of function centered on a single point. There are, at least in 
theory, far fewer (perhaps as few as one) ways in which such a gain of function may 
occur, thereby limiting the myriad conceivable underlying mechanisms associated with 
loss of function mutations. 
 To test this, we chose Vif-resistant APOBEC3 proteins representative of changes 
at each end of the α4 helix, A3G DPD128-130KPK and A3F QE323-324EK. These 
choices carried an additional advantage for the identification of directly interacting 
residues in addition to be centered on a single point, namely their charge. That is, if a Vif-
sensitive residue in an APOBEC3 protein becomes Vif-resistant by changing charge from 
negative to positive, then a directly interacting residue in Vif ought to be able to 
compensate for this by changing its own charge to something negative. Moreover, the 
choice of residues at each end of the α4 helix held out the possibility that one might 
identify through compensatory mutations in Vif not only the mutations themselves, but 
also a broader region important for interaction with α4 and associated structural insights. 
 By sequentially passaging Vif-proficient HIV in the presence of these Vif-
resistant APOBEC3 proteins, we identified G71D and G82D as the most frequently 
occurring putative compensatory changes observed in viruses adapted to growth in the 
presence of A3F QE323-324EK and the related K324 rhesus macaque A3F or A3G 
DPD128-130KPK, respectively (Figures 5-12 and 5-13). The ability of G71D to 
functionally neutralize the E324K change was subsequently confirmed in single-cycle 
experiments and in spreading infections from clean molecular clone backgrounds (Figure 
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5-15). The G82D change was somewhat more difficult to assess, as this alone was only 
marginally selected for among A3G DPD128-130KPK-adapted viruses and did not 
display any appreciable effect against the selecting protein in our spreading infection or 
single-cycle systems (data not shown). We noted, however, that the G82D change itself 
was 11 amino acids away from G71D, which by linear alignment would place G82D 
opposite A3G D130 but not D128K. While the A3G D130K change is only partially Vif-
resistant, we noted an improved effect of Vif G82D against A3G D130 over wildtype, 
suggesting that this compensatory change corresponds to A3G D130 (Figures 5-14 and 
5-15). 
 As noted above, the 11 amino acids separating A3F E324 and D313 (the A3F 
equivalent of A3G D130) are equal to the 11 amino acids separating Vif G71 and G82. 
On closer inspection of this region, we further found that this 11 amino acid span 
contains a GxxxG helix-helix interaction motif and a total of four predicted linear pairs of 
a glycine with a negatively charged residue in the space of 11 amino acids, or five in 13 
amino acids if one extends into predicted APOBEC3 loop space preceding the α4 helix 
[e.g. (Kleiger et al., 2002; Lorieau et al., 2010)]. Moreover, helical wheel modeling of 
this region shows that the four linear pairs contained within Vif 71-82 align to the same 
putative helical surface. Taken together, this implies that, rather than being separate 
interactions, the interaction of Vif with the APOBEC3 α4 helix is defined by a 
conserved, glycine-rich helix in Vif wherein the sterically accessible glycine sidechains 
may permit hydrogen bonding with inapposite negatively charged residues on the 
interacting helix [e.g. (Kleiger et al., 2002; Lorieau et al., 2010)]. 
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 Ideally, one would want both structural and genetic validation of the details of the 
APOBEC3-Vif interaction. The structural gold standard for the determination of such 
directly interacting regions would be a co-crystal composed minimally of Vif and an 
APOBEC3 protein. Unfortunately, such a structure remains technologically unfeasible. In 
the studies described here, however, we report positive results derived from the genetic 
gold standard – selection experiments for the identification of compensatory vif 
mutations. These have two major advantages over a crystal structure. First, the 
phenotypic validity of the defined interaction region is built into the experiment, 
minimizing questions over the relevance of the sometimes spurious interfaces associated 
with structural methods. Moreover, because our genetic data define a known helix-helix 
interaction motif, we can reasonably predict the structural basis of the APOBEC3-Vif 
interaction and therefore advance efforts to rationally intervene at this target long before 
a crystal will be available. 
 As of this writing, we are expanding on these observations by going in two 
directions. First, we hypothesize that the putative αG helix is a conserved Vif interaction 
motif that binds the APOBEC3 α4 helix. If this is so, then we would predict that a 
compensatory mutation capable of overcoming A3H D/E121K should also be found in 
this region and that, since the α4 Vif-resistance mutation in A3H falls between the 
equivalents in A3F and A3G, said neutralizing residue in the putative Vif interaction 
helix should also fall between G71 and G82. Second, for definitive proof of the existence 
of this helix-helix interaction in the absence of a co-crystal structure, we are pursuing 
biophysical evidence for the differential binding of a synthetic peptide corresponding to 
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the putative αG helix to Vif-resistant versus Vif-sensitive variants of A3F based on the 
A3F CTD variant with enhanced solubility described in Supplementary Chapter 1. 
 Aside from the specific region identified, our results are also important proof-of-
concept for the notion of identifying directly interacting residues between Vif and 
APOBEC3 proteins by genetic selection. Based on the methods we have developed, one 
may extend selections to other recently-identified Vif-resistance mutations and thereby 
form an APOBEC3-Vif genetic interaction map over time in the absence of direct 
structural confirmation. Such efforts, in addition to potentially identifying new 
therapeutically targetable structural features, will be of great value in functionally 
assessing any co-crystal structures that the future may hold. 
 Stepping back from the details for a moment, it is important to emphasize that 
Chapter 3 and Chapter 5 unite in supporting the existence of conserved helices in each 
interaction partner facilitating the core of the APOBEC3-Vif interaction. This is not to 
say  that the interaction of Vif with each APOBEC3 protein is identical, as both the large 
body of loss-of-function evidence and the observation that related but distinct 
compensatory amino acids overcome the Vif-resistance mutations of the α4 helix indicate 
that variations do exist. Rather, one might envision this putative core helix-helix 
interaction as the fulcrum around which Vif may teeter-totter in finding its final 
APOBEC3 binding configuration. This hypothesis is summarized in Figure 7-2 in which 
we add to the data supporting compensatory mutations for Vif-resistant A3F and A3G the 
supposition that such a change will also exist to neutralize Vif-resistant A3H. The 
resultant “Trinity of APOBEC3-Vif interactions” conveys the overall message implicit in 
our data set against the background of the loss of function data summarized in Table 1-2: 
  286 
while distinct from each other in certain aspects, all APOBEC3-Vif interactions share a 
core identity not unlike the Christian concept of three manifestations of one god, the 
trinity, from which the schematic derives. 
 
Chapter 6: Vif-independent adaptation of HIV to human APOBEC3 proteins – The 
results of Chapter 5 demonstrate that it is possible for HIV Vif to adapt to Vif-resistant 
APOBEC3 proteins. Adaptation through vif supports the direct interaction between 
APOBEC3 proteins and Vif and suggests that pharmacologic inhibition of this interaction 
may select for direct compensatory mutations at the interaction site. Such data are an 
absolute prerequisite in support of the therapeutic potential of the APOBEC3-Vif 
interaction per a maxim attributable to the influential retrovirologist John Coffin – to 
paraphrase, “If it doesn’t select resistance, the drug’s no good” (Haché et al., 2008). 
 This is a generally valid way of considering drug targets wherein a small 
molecule inhibits a viral enzyme. If the small molecule doesn’t select some kind of 
resistance mutation within the open reading frame encoding the targeted enzyme, then 
either the drug is ineffective or it does not work the way it is supposed to. Either way, it 
will be ineffective at inhibiting the virus, for obvious reasons in the former case and 
because the virus may simply acquire a second-site suppressor not subject to inhibition 
by the drug itself in the latter. 
 In considering therapeutic intervention via restriction factors, we might propose 
an addendum to the aforementioned rule of thumb that is true for both viral enzymes and 
restriction factors but somewhat easier to grasp in the latter case: “If it doesn’t select 
direct resistance, the target’s no good.” In other words, we would expect an alteration to 
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the putative Vif binding site in APOBEC3 proteins to select direct compensatory 
mutations in vif since this is the only established interaction known to allow HIV to 
actively overcome APOBEC3 proteins. But what if HIV did not exclusively utilize Vif to 
bypass Vif-resistant APOBEC3 proteins? What if there were second site mutations 
capable of phenocopying Vif in the presence of APOBEC3 proteins? In addition to 
altering our mechanistic understanding of mechanisms by which APOBEC3 proteins 
restrict in a cell, such alternatives would likely be problematic for the use of APOBEC3 
proteins as therapeutics, as the virus might simply acquire mutations at a second site not 
subject to one’s intervention blocking the APOBEC3-Vif interaction and thus obviate the 
intervention itself. 
 It is clear from the results of Chapter 5 that the selected mutations in vif cannot 
fully account for the phenotypes of the viral isolates described since many isolates carried 
either no obvious mutations in vif or mutations in vif that subsequently proved incapable 
of neutralizing the Vif-resistant APOBEC3 protein with which they were selected (data 
not shown). Although we did not test every vif mutation for efficacy against the Vif-
resistant APOBEC3 protein that selected it, it is clear simply from the subset that we did 
that that most of these have marginal phenotypes at best, with the notable exception of 
mutations of the putative αG helix. These data strongly imply that HIV must be capable 
of acquiring alternative adaptive pathways around APOBEC3 proteins in much the same 
way that different lentiviruses utilize different genes to neutralize the restriction factor 
BST-2/tetherin [reviewed in (Douglas et al., 2010)]. 
 To unambiguously address the potential for Vif-independent mechanisms of 
adaptation to APOBEC3 proteins, we carried out selections of the kind described in 
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Chapter 5 using template viruses with gross, irreparable deletions in vif that would force 
the virus to act exclusively through second-site mutations in overcoming wildtype A3F or 
A3G, if such mutations should, in fact, exist. The result of these efforts is Chapter 6 
where we demonstrate that these deleted viruses can acquire Vif-independent strategies 
that effectively counteract APOBEC3 proteins, strategies that work, at least in part, 
through the viral env gene (Figure 6-4). 
 It is important to understand that ours is a field fundamentally based on a 
correlative observation – a Vif-suppressible protein is expressed in nonpermissive cells, 
and the ectopic expression that same protein can reconstitute the nonpermissive 
phenotype in otherwise permissive cells (Sheehy et al., 2002). This is not to say that the 
correlation is invalid, but rather that it may be incomplete. In the cases of other restriction 
factors, the potential for different viral gene products counteracting the same restriction 
factor was immediately obvious due to the absence of the gene in other, closely related 
viruses (Gupta et al., 2009; Jia et al., 2009; Le Tortorec and Neil, 2009; Lim et al., 2012; 
Neil et al., 2008; Sauter et al., 2009; Serra-Moreno et al., 2011; Van Damme et al., 2008; 
Zhang et al., 2009), yet the strong conservation of vif in lentiviruses with the exception of 
equine infectious anemia virus has led to the narrow assumption that Vif function is the 
sole mechanism by which Vif-encoding viruses bypass APOBEC3 proteins. Looking at 
the data, however, one finds that it is not so simple. The range of anti-APOBEC3 
potential among diverse Vifs is quite large, strongly implying that the virus may not 
always be able to depend on Vif to neutralize A3G and other APOBEC3 restriction 
factors (Albin et al., 2010a; Binka et al., 2012; Iwabu et al., 2010; Simon et al., 2005). If 
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this is the case, then how do these viruses carrying defective (from an APOBEC3 
perspective) vif alleles survive in vivo? 
 Mundane explanations for such phenomena abound. The levels of APOBEC3 
proteins expressed in vivo may be inadequate to fully restrict [e.g. (Mulder et al., 2010)]. 
Alternatively, the virus may depend in part on low APOBEC3 expression reservoirs, or 
the defective alleles in question may skew our collective view by being 
disproportionately derived from these hypothetical reservoirs. It is also possible that HIV 
could acquire simple fitness mutations to outrun the levels of APOBEC3 expression it 
encounters in vivo in much the same way that we’ve previously shown it can outrun A3G 
overexpressed in cell lines (Haché et al., 2008). All of these are possible, but it is also 
possible that HIV and other lentiviruses may have, at some point in their evolutionary 
history (and perhaps still), used alternate viral gene products to replace Vif function. 
 Our data supporting Env as an alternative anti-APOBEC3 factor, it may be fair to 
say, are quite literally the last mutations we would have expected to find in our 
selections. Since the extracellular portions of envelope never coexist with APOBEC3 
proteins as we know them, it makes little sense to those of us conditioned to think of 
direct binding interactions and complexes to imagine that envelope could be involved in 
APOBEC3 neutralization. In reality, though, this is not as far-fetched as it may at first 
seem. There is an entire literature on functions of soluble gp120, and combining that with 
the known existence of an inhibitor of deaminases in T cells (Thielen et al., 2007) and the 
apparent lack of a substantive effect on A3G encapsidation levels (Chapter 6), it is not a 
long leap to hypothesize signal transduction and subsequent inactivation of A3G as a 
mechanism of action. The trouble, of course, is proving it, and as of this writing, we are 
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unable to provide evidence speaking to a positive mechanism of action for Env in the 
neutralization of APOBEC3 proteins. It is possible that the very slight, statistically 
insignificant trend toward lower levels of A3G encapsidation might be functionally 
relevant, but it would be quite difficult to argue that such differences account for the 
phenotypes observed. Nevertheless, it is clear that a functional effect of Env, by whatever 
mechanism, does exist, and thus insight into said mechanism of Env neutralization of 
APOBEC3 proteins, as it becomes available, is likely to prove an important advance in 
our understanding of the APOBEC3 restriction mechanism. 
 
Final Summary – In closing, this dissertation describes a systematic approach to 
investigation of the interactions of human APOBEC proteins with HIV Vif. By breaking 
these interactions down into digestible individual components, we have added to the field 
several important insights. One is an assessment of the functionally targetable features in 
the interaction. Namely, the APOBEC3-Vif interaction itself is likely a suitable target, 
while downstream polyubiquitination events are not. A second is the finding that specific 
viral proteins other than Vif, Env in this case, can compensate for the absence of the viral 
accessory protein when the virus has no other option. Unfortunately, we do not as of this 
writing understand the mechanism by which this occurs, but it will be important moving 
forward to understand how envelope and potentially other viral genes might effectively 
adapt to counteract APOBEC3 proteins. 
 In favor of continuing down APOBEC3-oriented therapeutic routes, however, 
these exotic alternative mechanisms of evasion appear insufficient to fully complement 
Vif function in naturally nonpermissive cells (data not shown). The known alternatives, 
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while of great mechanistic interest, are therefore unlikely to change the overall potential 
of APOBEC3 proteins as novel antiretroviral therapeutics. That said, we are also actively 
attempting to evolve Vif-deficient viruses that can neutralize the APOBEC3 repertoire 
present in naturally nonpermissive cells; if such viruses can be evolved, they may 
undercut the viability of the APOBEC3-Vif interaction as a therapeutic target. 
 For the moment, however, it appears that Vif is required to neutralize APOBEC3 
proteins in the settings in which they normally occur – groups of several expressed in 
naturally nonpermissive cells. Importantly, we have identified common helix-helix 
interaction regions in APOBEC3 proteins and in Vif that appear to form the core of a 
common interaction that stands in stark contrast with the conventional wisdom in the 
field that Vif binds APOBEC3 proteins by several means. This common interaction 
region, while not yet fully validated, represents a highly attractive drug target for two 
reasons. One is that a single intervention may theoretically facilitate the antiviral 
activities of multiple APOBEC3 proteins. The second is more particular to the nature of 
the interaction. Because helix-helix interactions are a common means by which proteins 
contact each other, medicinal chemists have formed a wide variety of strategies for the 
creation of peptidomimetic small molecule scaffolds that can be tailored to the inhibition 
of specific protruding sidechains on a given target protein [reviewed in (Dewal and 
Firestine, 2011)]. If the Trinity Hypothesis is correct, then, it may form the basis for the 
rational design of APOBEC3-based therapeutics aimed at blocking the α4-αG 
interaction. 
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Figure 7-1: Schematic summary of the important findings reported in this 
dissertation. (A) A schematic depiction of the Vif-associated E3 ubiquitin ligase 
complex containing question marks associated with different components of the 
interaction. 1 = Suitable model APOBEC3 protein; 2 = Site of Vif interaction in that 
APOBEC3 protein; 3 = Downstream ubiquitin acceptor sites in that APOBEC3 protein; 4 
= Vif residue interacting with the α4 helix of APOBEC3 proteins; 5 = Secondary 
pathways of HIV adaptation to APOBEC3 proteins. (B) Answers to the questions posed 
in (A) as reported in this dissertation. 
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Figure 7-2: The Trinity Hypothesis. A schematic summary suggesting a common 
feature of the interaction between Vif and the α4 helix of Vif-sensitive APOBEC3 
proteins. 
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Supplementary Chapter 1: Additional Mutagenesis of the A3F C-terminal 
Deaminase Domain 
Foreword 
 In Chapters 3 and 4 of this thesis, a series of mutagenesis studies establishing the 
Vif interaction site in A3F as well as the potential sites of subsequent Vif-mediated 
polyubiquitination were described. This supplementary chapter reports several additional 
mutagenesis studies of the A3F C-terminus performed either in the course of the work 
described in the main chapters or as functional validation of a series of mutants that has 
recently resulted in the successful crystallization of the A3F C-terminus. 
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Conservation of E324 in related Z2 domains – APOBEC3 subfamily cytosine deaminase 
domains cluster into three phylogenetic groups, termed Z1, Z2 and Z3 (LaRue et al., 
2009). While there is no known instance of Vif recognition of a Z1 domain, certain Z2 
domains and the lone human Z3 domain are recognized by HIV Vif. The A3G N-terminal 
Vif recognition region is also part of a Z2 domain, while the A3G C-terminus is a Z1 
type. In the case of A3F, both the N- and C-terminal deaminases domains are Z2 types 
despite the fact that Vif functionally recognizes only the C-terminal A3F Z2. Thus, A3F 
is similar to both the single-domain A3C and the double domain A3D in being solely 
comprised of Z2 domains. 
 As shown in Figure SC1-1A, E324 is conserved in A3C and A3D. We therefore 
hypothesized that mutation of the corresponding residue in these proteins would similarly 
stabilize them in the presence of Vif. Consistent with this hypothesis, the analogous 
mutation E141K in the single-domain A3C substantially enhances its stability in the 
presence of HIV Vif (Figure SC1-1B). Proper assessment of A3D was not possible in 
this experiment due to inadequate expression of the parent wildtype protein for 
comparison, but the fact that both Vif and A3D E337K were both substantially better 
expressed together than the wildtype combinations implies that the analogous change in 
A3D also stabilizes the related A3D C-terminal Z3 deaminase domain (data not shown). 
The structurally analogous A3G mutant D143K was not assessed, but we did note that 
changing the linearly analogous K141 to a glutamate failed to sensitize the otherwise Vif-
resistant variant A3G D128K (data not shown). Thus, Vif recognition of the structural 
anchor point defined by A3F E324 is conserved in the related A3C Z2 domain and 
perhaps also in the A3D C-terminal deaminase domain, a matter currently under further 
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investigation as an extension of the data presented in Chapter 5. Interaction with the 
A3G N-terminal Z2 deaminase domain, however, appears at least partially distinct. 
 
Additional mutagenesis of the A3F α3 and α4 helices – The observation that most known 
single amino acid determinants of Vif susceptibility map to a structurally conserved helix 
(Chapter 3) combined with the lack of a notable decrease in coimmunoprecipitation of 
the functionally Vif-resistant A3F E324K variant by Vif implied that a broader surface, 
perhaps involving the α4 helix as further elucidated in Chapter 5, might be recognized 
by Vif. To test this hypothesis, we mutated the polar surface residues of the A3F α3 and 
α4 helices alone and in combination to alanine and assessed the physical association 
between these mutants and Vif. 
 As shown in Figure SC1-2A, mutation of the remainder of the α4 helix, 
excluding E324, failed to render A3F resistant to Vif. In contrast, mutation of the polar 
residues in the α3 helix to alanine yielded a Vif-resistant A3F variant with a phenotype 
similar to that of the E324A mutant. Thus, determinants of Vif susceptibility may be 
found in both the α4 helix and α3 helix of A3F. This is consistent with a 
contemporaneous report demonstrating that E289, an α3 structural neighbor of E324, is 
also a single amino acid determinant of A3F susceptibility to Vif (Smith and Pathak, 
2010). Although this report indicated that the E289A variant was still somewhat 
susceptible to Vif, the stronger phenotype observed in the helix mutants described here 
may indicate a cooperative effect of nearby surface residues such as R293. 
 We next asked whether physical association between A3F and Vif was interrupted 
by any of the helix mutants shown in Figure SC1-2A. Consistent with a role in Vif 
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binding, mutation of all polar surface residues in the A3F α4 helix except for E324 
resulted in a reproducible decrease in coimmunoprecipitation of A3F by Vif of 
approximately 50% despite the fact that this mutant was functionally Vif-sensitive 
(Figures A1-2B and A1-2C). Curiously, however, when E324A was added to this 
background, Vif association with A3F was restored to wildtype levels despite the 
functional resistance of this mutant (Figure SC1-2A), and association of the similarly 
functionally Vif-resistant α3 mutant with Vif was not notably altered. We lack a 
satisfactory explanation for this phenomenon, but it implies a potential nonequivalence 
between physical association and functional sensitivity. Another example of this 
disconnect is the Vif 40-YRHHY-44 region, wherein single amino acid changes at 
positions 40 and 43 among others yield strong loss of function phenotypes in single-cycle 
neutralization of A3G as well as loss of coimmunoprecipitation between Vif and A3G 
(see Table 1-2). Despite these strong single-cycle phenotypes, neither the H43N nor the 
Y40A mutants that we have tested in a proviral context are substantially impaired in their 
ability to spread in the presence of untagged, stably transfected A3G (See 
Supplementary Chapter 2). 
 Alternatively, it is possible that some technical aspect of the immunoprecipitation 
methods described in Chapter 3, such as the C-terminal tags on A3F (V5) and Vif (HA) 
may somehow alter the immunoprecipitation experiment despite the fact that they 
faithfully reproduce the functional Vif-A3F interaction as evidenced by more physiologic 
conditions such as single-cycle titration with untagged A3F and A3F QE323-324EK and 
spreading infection with the full-length provirus in the presence of cells stably transfected 
with untagged A3F or the QE323-324EK variant (Figure 3-2 and Chapter 5). We would 
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argue, however, that positive detection of an interaction is stronger evidence than loss 
thereof, and more to the point, we speculate that where papers in the field differ on gain 
or loss of immunoprecipitation [e.g. (Xu et al., 2004) vs. (Bogerd et al., 2004; Mangeat et 
al., 2004; Schröfelbauer et al., 2004) and (Chen et al., 2009; Dang et al., 2009) vs. (Chen 
et al., 2009; Dang et al., 2009) and Chapter 2 data not shown] these interpretations are 
largely a matter of degree. Most authors reporting loss of binding still detect some 
interaction, and anything from tag identity to buffer composition to the exact mutant 
employed could account for discrepancies in attempted quantification [e.g. (Chen et al., 
2009; Dang et al., 2009; Tian et al., 2006)]. The more important point, which we 
emphasize in our work, is functional interaction or lack thereof. 
 
Functional validation of mutants designated for structural study – As a collaboration 
with the Matsuo lab at the University of Minnesota and later also with the Schiffer lab at 
the University of Massachusetts, we have sought to mutagenize the A3F C-terminus to 
derive a version more amenable to structural study than the wildtype protein. Mutants 
were initially characterized for enhanced deaminase activity and/or its correlate protein 
solubility as has been previously reported [e.g. (Chen et al., 2008; Chen et al., 2007)]. 
These efforts led to a complement of deaminase activity enhancing mutations termed 
A3F 7x, containing mutations Y196D, C259A, F302K, W310K, Y314A, Q315A and 
F363D. To validate this mutant, we carried out single-cycle titrations of increasing 
amounts of Vif with a constant amount of A3F 7x and assessed the relative infectivities 
and A3F stability at each condition. To our surprise, not only was the A3F 7x more 
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restrictive than wildtype A3F, it was also somewhat more Vif-responsive than the 
wildtype protein (data not shown). 
 Within this A3F 7x mutant construct, we tested the effect of a number of 
additional candidate solubility mutations, some of which went on to be incorporated into 
subsequent generations of mutants made with the intention of rendering the A3F C-
terminus more soluble. As shown in Figure SC1-3A, these were inconsequential where 
the Vif interaction is concerned. Additional titration experiments of several intermediate 
mutants termed 7x, 9x and 11x’ also yielded no change in restriction and Vif sensitivity 
(Figure SC1-3B). 
 The final mutant, A3F 11x, which differs from 11x’ only at residue 363, has now 
been successfully crystallized by the Schiffer lab and will be submitted for publication in 
the near future. To test this mutant functionally, we again carried out restriction and Vif 
sensitivity single-cycle infectivity analyses, which demonstrated that A3F 11x is Vif-
sensitive and that this sensitivity can be blocked by the Vif-resistance mutation E324K 
first reported in Chapter 4 (data not shown). In that experiment, we included Vif G71D 
in an attempt to further validate the Vif interaction surface of the A3F 11x mutant. While 
the loss of function against Vif-responsive A3F 11x associated with the G71D mutation 
was more prominent in the 11x background than in the wildtype protein, the gain of 
function against A3F 11x E324K was less apparent, particularly by Western blot. It may 
be, therefore, that the A3F 11x variant is slightly altered in its Vif interaction region, 
consistent with the presence of changes in the α4 helix (YQ314-315AA). We are 
currently investigating whether reversion of these specific amino acids to wildtype may 
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improve the agreement between what we have observed in the wildtype protein in 
Chapters 3 and 5 and what we describe here in 11x context. 
 In summary, despite extensive coverage of surface residues in the A3F C-
terminus, critical determinants of Vif susceptibility are tightly localized to two structural 
neighbors, E324 of the α4 helix and E289 of the α3 helix. It remains possible, however, 
that less conservative mutations at certain residues and/or the mutation of regions not 
covered in my work may also affect the Vif-A3F interaction. 
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Figure SC1-1: Functional conservation of the Vif interaction site in A3C. (A) An 
alignment showing the conservation in residues of the α4 helix in A3F, A3C and A3D. 
(B) A Vif titration experiment in which cotransfection of a constant amount of A3C or 
A3C E141K with an increasing amount of Vif results in a decrease in steady state levels 
of the former but not the latter. 
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Figure SC1-2: Effect of alanine mutations at α3 and α4 surface residues on Vif 
susceptibility. 
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Figure SC1-2: Effect of alanine mutations at α3 and α4 surface residues on Vif 
susceptibility. (A) A3F containing alanine mutations at all of the polar surface residues 
in the indicated helix (α4 = S320, E316, D313, D311, +/- E324; α3 = E282, E286, E289, 
R293, +/- E324) were cotransfected with proviral and Vif-expression plasmids to assess 
the sensitivity of a given mutant to Vif-mediated degradation and infectivity recovery. 
(B) Immunoprecipitation experiments using the same collection of mutations analyzed in 
Figure SC1-2A. Procedures were as described in Chapter 3. (C) ImageJ quantification 
of the relative immunoprecipitation of the indicated A3F variants by Vif. Data derive 
from four independent experiments. 
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Figure SC1-3: Restriction capacity and Vif sensitivity of A3F mutants derived for 
structural study. 
R
el
at
iv
e 
In
fe
ct
iv
ity
huA3F 7x 9x 11x’
V Vif V Vif V VifV Vif
Vif-HA
A3-V5
Tub
0.25
0.5
0.75
1.0
1.25
Y2
01
D
Y2
01
K
RK
20
8-
20
9P
D
K2
05
N
Y2
11
D
Y2
11
K
W
23
3D
W
23
3K
V2
42
K
C2
53
A
W
25
7D
V2
42
D
F/
K3
02
D
W
/K
31
0D
K3
34
S
K3
52
Q
K3
55
D/
K3
58
D
F3
61
D
F3
61
K
A3
F
A3
F 
7x
A3
F 
QE
32
3-
32
4E
K
R
el
at
iv
e 
In
fe
ct
iv
ity
0.2
0.4
0.6
0.8
1.0
A3
F 
7x
Mutant Cotransfected -/+ Vif
A
B
  305 
Figure SC1-3: Restriction capacity and Vif sensitivity of A3F mutants derived for 
structural study. (A) Single-cycle infectivity of mutations made in A3F 7x context for 
the derivation of later generations of structural mutants. Methods were similar to those 
described in Chapters 2-5. (B) Vif titration experiments demonstrating the HIV 
restriction capacity and Vif susceptibility of the indicated generational mutants. 7x = 
Y196D, C259A, F302K, W310K, Y314A, Q315A and F363D; 9x = 7x plus K355D, 
K358D; 11x = 9x plus H247G, C248R. 11x’ in (B) has reverted D363 back to the 
wildtype F363. In both (A) and (B), data shown are the mean and standard deviation of 
duplicate infection events. 
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Supplementary Chapter 2: Catalytic Activity of APOBEC3F Is Required for HIV 
Restriction 
Foreword 
 This supplementary chapter includes data from the manuscript in preparation of 
the same name concerning the requirement for APOBEC3 catalytic activity in the 
restriction of HIV by A3F and A3G. 
 Albin, JS, Brown WL and RS Harris. “Catalytic activity of APOBEC3F is 
 required for HIV restriction.” in preparation 
The reader will recall that this requirement was taken for granted in assessing the 
encapsidation of A3G in Chapter 6, but some authors have proposed that catalytic 
activity may be dispensable for the ability of A3F to restrict. Here, we weigh in on this 
question using, for the first time, T cell lines engineered to stably expressed catalytically 
inactive A3F, thus bypassing the complications associated with transient overexpression. 
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Summary 
APOBEC3 proteins are DNA cytosine deaminases that restrict the replication of diverse 
retroelements, including human immunodeficiency virus type 1 (HIV) deficient in the 
counterdefense protein Vif. Among the seven human APOBEC3 proteins, the best 
studied restrictors of HIV are APOBEC3F (A3F) and APOBEC3G (A3G). The 
mechanism by which A3F and A3G restrict HIV, however, remains a subject of great 
interest. While most studies support a role for deaminase activity in the restriction of 
HIV, a number of reports have proposed accessory mechanisms of restriction that may 
function in one of several deaminase-independent fashions. Here, we address the capacity 
of A3F to restrict via deaminase-independent mechanisms by mounting spreading 
infections in T cells stably transfected with A3F, A3G or deaminase-deficient mutants 
E251Q and E259Q, respectively. While A3F E251Q induces a slight delay in the 
replication of Vif-deficient HIV relative both to the analogous A3G mutant E259Q and to 
APOBEC3-deficient cell lines, it is unable to cause long-term suppression of virus 
replication, unlike deaminase-proficient wildtype A3F and A3G. We therefore conclude 
that the primary mechanism of A3F-mediated restriction of HIV that forces the virus to 
maintain Vif function is deaminase-dependent. 
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 APOBEC3 proteins restrict HIV in the absence of the viral accessory protein Vif. 
Most authors agree that the deaminase activity of APOBEC3 proteins is an important part 
of the restriction mechanism, a model wherein the deamination of single-stranded minus-
strand cDNA during reverse transcription results in deleterious hypermutation of the viral 
genome and ultimately the inhibition of viral replication (Harris et al., 2003a; Mangeat et 
al., 2003; Yu et al., 2004b; Zhang et al., 2003). Despite this consensus, many authors 
have proposed diverse deaminase-independent mechanisms that may also operate in the 
restriction of HIV including direction physical inhibition of reverse transcriptase 
processivity by RNA-bound APOBEC3, inhibition of tRNA priming and the inhibition of 
strand transfer events (Bishop et al., 2006; Bishop et al., 2008; Guo et al., 2006; Holmes 
et al., 2007; Iwatani et al., 2007; Li et al., 2007; Luo et al., 2007; Mbisa et al., 2007; 
Mbisa et al., 2010; Newman et al., 2005; Shindo et al., 2003; Yang et al., 2007b). 
 More recently, several groups have reported that these deaminase-independent 
mechanisms may represent overexpression artifacts since, when one stably expresses an 
A3G catalytic mutant or titrates back the levels of transiently expressed protein, the 
restrictive effects of deaminase-deficient A3G prove incapable of achieving more than 
modest if any restriction of HIV (Browne et al., 2009; Miyagi et al., 2007; Schumacher et 
al., 2008). This same story has played out in less mechanistic detail with the related 
restriction factor A3F, which was initially proposed to have more prominent deaminase-
independent effects than A3G (Holmes et al., 2007). When utilized in a stable expression 
system, however, an A3F variant with mutations in the zinc-coordinating cysteines, 
C280S/C283S, failed to restrict HIV as had A3G catalytic mutants before it (Miyagi et 
al., 2010). Curiously, however, this report also failed to detect restriction by wildtype
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A3F stably expressed in HeLa cells, which contrasts with the restrictive activities we 
have found attributable to A3F in no fewer than 17 independently-derived T cell lines 
stably transfected with A3F (Albin et al., 2010a; Albin et al., 2010b; Haché et al., 2008; 
Hultquist et al., 2011). 
 To determine whether deaminase-deficient A3F is capable of restricting HIV in 
continuously cultured T cell lines, we stably transfected a permissive cell line, SupT11, 
with wildtype A3F, A3G or catalytic mutant derivatives thereof. We specifically elected 
to use mutants of the conserved catalytic glutamate in A3F (E251Q) or A3G (E259Q) 
since these show little or no discernible encapsidation defect relative to the wildtype 
protein [e.g. (Holmes et al., 2007; Schumacher et al., 2008) and Figure SC2-1]. 
Expression levels of A3F and A3G in all lines used were similar between wildtype and 
catalytic mutant lines (Figure SC2-2). We then initiated infections of all of these lines in 
parallel at MOIs of 0.01 and 0.05 with either wildtype HIVIIIB or a Vif-deficient 
derivative containing tandem stops at codons 26-27 of vif. Representative spreading 
infection curves are shown in Figure SC2-3. As shown, while stable expression of either 
A3F or A3G at levels comparable to those occurring in naturally nonpermissive cells 
restricts the spread of HIV for the duration of the experiment, Vif-deficient viruses peak 
within approximately two weeks on cell lines expressing catalytic mutant derivatives of 
A3F or A3G with a slightly longer delay induced by the former. Although we did not 
carry out these experiments any longer than is shown in Figure SC2-3, we have 
previously noted by using similar methods of infection with lines stably expressing A3F 
that this restriction can extend for long periods of time, preventing the spread of Vif-
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deficient HIV for at least three months in the absence of the acquisition of genetic 
resistance such as repair of the vif open reading frame (Albin et al., 2010a). 
 Despite the inability of catalytically inactive A3F and A3G to restrict on a par 
with the wildtype proteins, we did note a small but consistent delay in the spread of Vif-
deficient HIV relative to cells stably transfected with a vector control (data not shown). It 
is therefore formally possible that A3F may display some minor but appreciable 
deaminase-independent effects relative to A3G, as initially proposed (Holmes et al., 
2007). It is important to emphasize, however, is that this putative activity is incapable of 
inducing more than a modest delay and cannot account for the long-term duration of 
restriction that we have previously observed with A3F in the absence of genetic 
resistance (Albin et al., 2010a). 
 Others have proposed that the levels of A3F in primary cells may be incapable of 
restricting HIV (Mulder et al., 2010). In this study, the authors utilized a Vif mutant, 
W11R, that is capable of neutralizing A3G but not A3F to ask whether expression levels 
of the latter in ex vivo peripheral blood mononuclear cells from several donors are 
incapable of restricting viral spread. We were curious to test this mutant, however, 
because unrelated studies in our lab aimed at characterizing vif alleles that arise during 
long-term viral passages in the presence of APOBEC3 proteins had cast some doubt on 
the concept of selectively susceptible Vif mutants (see Chapter 5). Specifically, we had 
noted that mutants of the YRHHY region often implicated in the interaction of HIV Vif 
with A3G were largely replication-competent in the presence of stably expressed A3G 
despite their strong selectively susceptible single-cycle phenotypes [(Russell and Pathak, 
2007) and Albin & Harris, unpublished data]. Similarly, others had noted that long-term 
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passage of YRHHY mutants in naturally nonpermissive CEM cells fails to select for 
reversion of the mutated Vif residues, suggesting lack of selective pressure and, by 
extension, intact anti-A3G function in that spreading infection system (Russell et al., 
2009a). 
 To test the selective susceptibility of the W11R mutant as well as select passage-
derived mutants of the putative A3F- and A3G-interacting regions of Vif (14DRMR17 and 
40YRHHY44, respectively), we carried out spreading infections in the presence of A3F, 
A3G and naturally nonpermissive CEM2n cells using wildtype and Vif-deficient HIVIIIB 
as before as well as mutant W11R. In these experiments, we also included three mutants 
of the relevant regions that we had identified incidentally in unrelated long-term passage 
experiments: R15G, H43N and H43N/E117K. Mutation of each of these residues has 
been previously shown to ablate Vif anti-A3F (residues 11 and 15) or anti-A3G (residue 
43) activity in transient overexpression systems (see Table 1-2). Consistent with those 
overexpression data, each of the mutants predicted to be selectively susceptible to A3F 
was restricted by stable expression of A3F in SupT11 cells as well as by the levels of 
A3F expressed in naturally nonpermissive CEM2n cells but not by A3G (Figure SC2-4). 
In contrast, mutant H43N or H43N in combination with an additional passenger mutation 
E117K was capable of spreading efficiently with perhaps a modest delay in the presence 
of both A3G stably expressed in SupT11 cells as well as the levels of A3G expressed in 
CEM2n cells (Figure SC2-4). These results mirrored those we had previously observed 
with two independent mutants of the 14DRMR17 (D14A) and 40YRHHY44 (Y40A) regions 
at a time when we, too, were interested in probing the contributions of different 
APOBEC3 proteins in naturally nonpermissive cells using selectively susceptible Vif 
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variants (Albin and Harris, unpublished data). Together, our data suggest that, while 
mutants of the 14DRMR17 region are indeed selectively susceptible to A3F, the 
phenotypes associated with mutants of the 40YRHHY44 region are at least partially 
dependent on the experimental system used, showing strong effects in transient 
overexpression systems and poor effects in stable expression systems. This contrasts with 
mutants of Vif residue 26, which are consistently selectively defective for the 
neutralization of A3G in both transient and stable expression systems (Albin et al., 
2010a; Chen et al., 2009; Dang et al., 2009). 
 We therefore question whether the loss-of-function mutants previously identified 
as critical A3F- and A3G-binding regions are, in fact, A3F and A3G interacting regions. 
The inability of 40YRHHY44 mutants to faithfully reproduce their susceptibility 
phenotypes outside of transient overexpression systems suggests that their effects may be 
more complicated than a simple loss of anti-A3G activity. Moreover, while 14DRMR17 
mutants are phenotypically consistent in their loss of anti-A3F function, it is curious that 
mutation of this would-be A3F-selective region can result in the neutralization of A3G 
mutants containing alterations in the putative Vif binding residue D128K (Schröfelbauer 
et al., 2006). It is possible, therefore, that the losses of function associated with each 
region may represent something other than the simple loss of direct binding proposed. 
 Despite the unexpected growth of 40YRHHY44 mutants in the presence of 
restrictive levels of A3G, we confirmed in our system that the W11R mutant displays 
selective susceptibility to A3F. It may therefore be accurate that the levels of A3F in ex 
vivo samples from the donors previously described are unable to restrict HIV, although 
data concerning the ability of similar mutants selectively susceptible to A3G rather than 
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A3F were not reported (Mulder et al., 2010). Nevertheless, we note that both the W11R 
and the R15G mutants utilized in the present studies fail to spread in naturally 
nonpermissive cells. If one accepts these mutants as truly selectively susceptible to A3F, 
then, that would suggest that the levels of A3F present in naturally nonpermissive cells 
are sufficient to induce indefinite restriction of the kind we’ve previously reported via 
stable expression of A3F. In that case, it would seem appropriate to ask not whether A3F 
restricts in primary cells, but rather whether the expression of any APOBEC3 protein is 
adequate to prevent viral spread in primary cells, particularly in vivo. 
 In conclusion, we have shown here that the restriction of HIV by both A3F and 
A3G requires intact deaminase activity. This suggests that the predominant driving force 
for the maintenance of Vif function by the virus centers not on the comparatively minor 
effects potentially imposed by deaminase-independent mechanisms of restriction, but 
rather on the deaminase-dependent components previously described. We further note 
that not all Vif mutants thought to be selectively susceptible to one APOBEC3 protein or 
another yield similar phenotypes in transient overexpression and spreading infection 
systems. It is therefore possible that the ever-expanding literature on loss of function Vif 
mutants may be of limited utility in defining the regions of Vif that directly interact with 
A3F and A3G since, by nature, loss of function can indicate many things other than loss 
of direct binding [reviewed in (Albin, 2010; Smith et al., 2009)]. 
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Figure SC2-1: Encapsidation of A3F catalytic mutants. 293T cells were transfected 
with 200 ng of V5-tagged wildtype A3F, A3F E251Q or another deaminase-deficient 
A3F derivative, W277A, along with 1.6 µg Vif-deficient HIVIIIB. Producer cells and 
supernatants were harvested two days post-transfection, and supernatants were spun 
through 20% sucrose cushions and lysed. Western blots for particle-associated V5 and 
p24 as well as cell-associated V5 and tubulin are shown. 
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Figure SC2-2: APOBEC3 expression levels in the cell lines used in this study. (A) 
A3F levels found in SupT11 cells stably transfected with untagged A3F, A3F E251Q or a 
vector control in comparison with naturally nonpermissive lines CEM2n and H9. (B) 
A3G levels found in SupT11 cells stably transfected with untagged A3G, A3G E259Q or 
a vector control in comparison with naturally nonpermissive lines CEM2n and H9. 
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Figure SC2-3: Deaminase activity is required for restriction of HIV by both A3F 
and A3G. 
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Figure SC2-3: Deaminase activity is required for restriction of HIV by both A3F 
and A3G. Representative spreading infection curves infected at MOI 0.05 from one of 
three, independent experiments demonstrating the inability of catalytic mutants of A3F 
and A3G to efficiently restrict HIV. (A-B) Wildtype and Vif-XX variants of HIVIIIB on 
four independent cell lines expressing wildtype A3F. (C-D) Wildtype and Vif-XX 
variants of HIVIIIB on four independent cell lines expressing A3F E251Q. (E-F) Wildtype 
and Vif-XX variants of HIVIIIB on four independent cell lines expressing wildtype A3G. 
(G-H) Wildtype and Vif-XX variants of HIVIIIB on four independent cell lines expressing 
A3G E259Q. Note that each individual cell line is a stably transfected clone established 
by limiting dilution. Different cell lines expressing the same APOBEC3 protein are 
therefore susceptible to clonal variation but are graphed together to demonstrate that all 
cell lines qualitatively recapitulate growth versus no growth of a given virus. All viral 
cultures that peaked also subsequently killed all host cells in a given culture, whereas 
those that did not peak maintained healthy cell growth throughout. 
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Figure SC2-4: Mutation of the putative A3F-interacting region of Vif but not the 
putative A3G-interacting region of Vif yields viruses selectively susceptible to the 
predicted APOBEC3 protein. (A) Growth of wildtype, Vif-XX and the indicated Vif 
mutant derivatives of HIVIIIB in the presence of A3F. Results are representative of 2-3 
independent experiments on four independent cell lines. (B) Growth of wildtype, Vif-XX 
and the indicated Vif mutants in the presence of A3G. Results are representative of 2-3 
independent experiments on four independent cell lines. (C) Growth of wildtype, Vif-XX 
and the indicated Vif mutants in naturally nonpermissive CEM2n cells. Results are 
representative of three independent experiments. 
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